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Introduction: Many patients with brain tumours experience dysfunction in several 
cognitive domains. Given the limited survival times of the majority of patients with 
brain tumours, maintenance or improvement of quality of life is as important as 
increasing survival time. Impaired cognition has a negative impact on quality of life 
and as such, cognitive function is becoming an increasingly important endpoint in 
clinical trials in neuro-oncology. However, measuring cognition in patients with 
brain tumours is problematic for a number of reasons. Most intracranial tumours are 
initially treated with surgery and studies of neurosurgical morbidity often evaluate 
physical as opposed to cognitive domains, yet the latter can have a greater negative 
impact on the patient’s quality of life. This thesis therefore details cognition in brain 
tumour patients at the time of presentation (pre-operatively) and examines the effects 
of surgical intervention on cognitive function. Of particular interest is the potential 
utility of inspection time, a computer-based measure of the brain’s information 
processing efficiency, as a measure of brain slowing as a result of the tumour and as 
an indicator of response to surgical intervention. 
Methods: The study is based on a cohort of 118 newly-presenting patients with a 
supratentorial brain tumour who were to have surgery (biopsy or resection). Each 
patient was administered a comprehensive battery of cognitive tests prior to surgery 
(baseline). The battery comprised inspection time testing, other standardised 
cognitive measures and assessment of mood, quality of life and functional status. 
Post-operatively, each patient repeated the inspection time test in addition to a 
selected number of the other tests administered at baseline. For comparison, a group 
of patients admitted for elective spinal surgery (n = 85) were also tested pre- and 
post-operatively. A group of healthy volunteers provided a second control group by 
being tested twice (n = 80).
iii
Results: The brain tumour cohort were significantly impaired by comparison with 
both control groups at baseline (pre-operatively) on the majority of the cognitive 
measures, including inspection time. Baseline inspection time scores were 
significantly related to some scores on the EORTC Quality of Life Questionnaire in 
the brain tumour group, but not in the spinal surgery group. There was no significant 
difference between the brain tumour and spinal surgery groups in term of the levels 
of pre-operative anxiety and depression. 
The brain tumour cohort showed significantly greater relative deterioration on 
inspection time following surgery by comparison with both control groups. The brain 
tumour cohort also deteriorated significantly on several other measures post-
operatively by comparison with the healthy control group. 
Detailed analyses were carried out to determine the differential effects of tumour 
type, location, and type of surgery (biopsy or resection) on inspection time and other 
functions in the brain tumour group. 
Conclusions: Tumour-related cognitive impairment appears to be common in a 
heterogeneous group of brain tumour patients with a variety of different tumours 
located throughout the brain. Surgical intervention has a negative impact on function 
in brain tumour patients, although this deterioration may be transient. General 
slowing of visual information processing appears to be common to brain tumour 
patients and the inspection time task provides a feasible and useful method of 
assessment in brain tumour patients. The task is sensitive to tumour-related brain 
slowing and can provide a reliable assessment of response to surgery. Given the 
task’s advantages over more commonly-used cognitive measures, it could be usefully 
incorporated into cognitive tests batteries in neuro-oncology. 
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1 Brain Tumours and Cognition 
1.1 Brain tumours: an overview
1.1.1 Primary brain tumours
Primary brain tumours (i.e. tumours that originate in the cells of the brain
parenchyma) are fairly uncommon among adult cancer patients, with an approximate 
incidence of 8/100,000 per year, (Grant, 2004), accounting for around 2% of all 
cancers in adults (McKinney, 2004). In the United Kingdom, around 4400 people are 
newly diagnosed with a primary brain tumour each year and, given that survival is 
generally very poor and many primary tumour types are incurable, the diagnosis of a 
brain tumour inevitably has a devastating impact on every aspect of the patients’ life. 
The poor survival times generally associated with a diagnosis of a primary brain 
tumour means that a disproportionate number of years of life are lost to this disease 
when compared with many other more common cancers (McKinney, 2004).
1.1.1.1 Gliomas
Gliomas arise from the glial cells that form the connective tissue in the brain and 
comprise > 90% of all primary brain tumours. The incidence of gliomas is around 
five to ten per 100,000 general population (Behin et al., 2003) and around half of all 
brain tumours in adults can be classified as gliomas (Lezak et al., 2004). Cerebral 
gliomas as a group have a 5-year survival rate of only 18% (Grant, 2004). There are 
four main types of glioma: astrocytomas, oligodendrogliomas, ependymomas and 
mixed gliomas. These tumours are graded by the World Health Organisation (WHO)
according to the most malignant area identified in them and range from highly 
malignant (grade 3 or 4) to the less aggressive grades 1 or 2 (Fuller, 2008).
Malignant glial tumours are most commonly classified as anaplastic astrocytomas, 
anaplastic oligodendrogliomas or anaplastic oligoastrocytomas (WHO Grade 3 
2
tumours) or glioblastoma multiforme (GBM; WHO Grade 4 tumours). Anaplastic 
astrocytomas and glioblastoma multiforme are unfortunately the most common glial 
tumours in adults (DeAngelis, 2001). Treatment for these aggressive tumours tends 
to be palliative and comprises surgical resection of as much tumour as is safely 
possible, followed by focused cranial irradiation. Concomitant chemotherapy may 
modestly prolong survival in some patients (Stupp et al., 2005) and Gliadel wafers 
can be placed at the tumour site during surgery to provide local chemotherapy in 
either newly diagnosed or recurrent malignant gliomas (Westphal et al., 2006). 
Despite these advances in treatments, median survival for GBM patients in 
Randomized Controlled Trials is only around 14 months, and for anaplastic 
astrocytoma patients is around 2 to 4 years (DeAngelis, 2001, Stupp et al., 2005).
However, survival times are variable and depend upon a number of different factors
including patient age and symptoms at diagnosis as well as tumour location and the 
extent of resection achieved during surgery. The mean age at onset is 53 years for 
GBM and 40 years for anaplastic astrocytoma (Behin et al., 2003).
Low-grade gliomas (LGG) comprise approximately 40% of all adult gliomas (Correa 
et al., 2007) and can be divided into three main subtypes – diffuse astrocytomas, 
oligodendrogliomas and mixed oligoastrocytomas. Low-grade gliomas are more 
common in the third and fourth decades of life and the mean age of occurrence is 35 
years for astrocytomas and 45 years for oligoastrocytomas (Behin et al., 2003). Like 
high-grade gliomas, these tumours infiltrate normal surrounding brain tissue.
However, low-grade gliomas are more slowly growing than their high-grade 
counterparts. The best way to manage patients with low-grade tumours has attracted
a great deal of debate, particularly given the fact that many patients are relatively 
symptom-free. Surgery may be carried out to confirm the radiological diagnosis and 
radiotherapy may be offered immediately, or deferred until such a time as the patient 
becomes symptomatic (Whittle, 2002). Almost all patients who present with a low-
grade glioma will experience tumour progression during the course of their disease, 
at which point the recurrent tumour will often have transformed into a more 
malignant subtype. Median survival time for patients diagnosed with a low-grade 
glioma is approximately 5 years (DeAngelis, 2001). However, survival times for 
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patients with low-grade gliomas vary considerably, with many younger patients 
surviving for much longer (Pignatti et al., 2002).
1.1.1.2 Meningiomas 
Meningiomas arise from the cells forming the external membranes that cover the 
brain (the meninges). They are the most common benign intracranial tumour and the 
second most common primary brain tumour in adults after gliomas, comprising 13-
26% of all primary intracranial tumours (Whittle et al., 2004). This tumour type is 
more common in older people and in women than in men (ratio 2:1). Ninety percent
of meningiomas are classified as WHO grade I and are benign. These tumours can 
often be cured with complete surgical removal since they tend not to invade the brain 
itself. However, depending on the extent of excision and WHO tumour grade, up to 
20% may recur within a 10 year period at which point further surgery and/or 
radiotherapy can frequently be offered to the patient (Whittle et al., 2004).
1.1.2 Secondary brain tumours
Secondary, or metastatic brain tumours originate from solid malignant tumours 
located in other organs in the body that have been transported into the central 
nervous system. The most common cause of cerebral metastases are tumours in the 
lung, followed by the breast, melanoma, gastrointestinal tract and kidney cancers 
(Patchell, 2003). Brain metastases are multiple in more than 50% of cases and are 
often treated with surgery followed by whole-brain radiotherapy, and occasionally 
chemotherapy if the primary tumour is sensitive to chemotherapy (Lezak et al., 2004, 
van den Bent, 2003). Even with this aggressive treatment, median survival time for 
patients with brain metastases is generally only between 4 and 6 months. However 
this does depend greatly upon the type and status of the systemic cancer, patient age 
and performance status (Nussbaum et al., 1996). 
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1.1.3 Risk Factors
The only confirmed risk factor for developing a brain tumour is prior exposure to 
ionising radiation (McKinney, 2004). A number of other environmental factors have 
been investigated as possible risk factors for brain tumours and these have included 
mobile phones, allergies, diet, tobacco and alcohol, chemical agents and prior head 
injury. However, there is no consistent evidence to suggest a link between any of 
these factors and subsequent development of a brain tumour (McKinney, 2004).
1.1.4 Common Symptoms
Behin et al. (2003) classify the most common presenting symptoms that lead to 
diagnosis of brain tumour into four main categories. The first of these is seizure, 
which may be partial or generalised. Seizures are more commonly a symptom of low 
grade, as opposed to high-grade glioma. The second category comprises progressive 
headache, nausea, vomiting and/or visual abnormalities that result from increased 
intracranial pressure. Thirdly, focal neurological deficits, dependent upon the 
tumour site, can reveal an underlying brain tumour. These deficits can include
impaired motor function, speech problems and/or visual field deficits. Lastly, 
cognitive impairment is often a sign of underlying tumour and is commonly observed 
in patients with tumours located in the frontal lobes (Behin et al., 2003).
Grant (2004) completed a Scottish audit of the symptoms recorded in 324 patients 
who had an imaging diagnosis of a single intracerebral lesion that was deemed most 
likely to be a glioma. Headache was the most common first symptom in this group of 
patients (23.5%) and, further, was present in 46.5% of patients at the time of 
admission to hospital. However, despite the high proportion of patients who 
experience headaches at some point, it is rare for headache to be the sole presenting 
symptom of a brain tumour. In fact, this was the case for only 10 of the 324 patients 
studied. Seizures were found to be the next most common presenting symptom, and 
were recorded in 21% of the patients studied. Focal symptoms are also common in 
patients with brain tumours and may include dysphasia, hemiparesis or diplopia. 
These focal signs are less likely to be the presenting symptom; however,
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approximately 80% of patients exhibited focal signs by the time of hospital 
admission and diagnosis. Furthermore, non-focal symptoms such as confusion and 
personality change are also commonly observed by the patient or their relatives but 
again, it is rare for this type of symptom to be the presenting one (Grant, 2004).
1.2 Brain tumours and cognitive function
Cognitive function covers the different processes by which sensory input is 
elaborated, transformed, stored, recovered and used. Lezak et al. (2004) liken the 
four major classes of cognitive functions to the computer processes of input, storage, 
processing and output. Therefore, receptive functions, are the ‘input’ functions that 
include the ability to select, acquire, classify and integrate information. Memory and 
learning are the ‘storage’ processes by which information is stored and retrieved. 
Thinking is the ‘processing’ function by which information is organised and 
expressive functions are the ‘output’ processes by which information is expressed, 
communicated and acted upon (Lezak et al., 2004). Thus, cognitive functions are 
those brain functions that are extremely highly-developed in human beings as 
compared to other mammals (Taphoorn and Klein, 2004). Gilroy (2000) divides 
cognitive function into nine primary domains and these include attention, 
concentration, visuospatial skills, language, memory, executive function and sensory 
and perceptive abilities. 
In addition to the aforementioned common symptoms described by Grant (2004), 
problems with cognitive functioning are frequently observed in patients with brain 
tumours, and have in fact been cited by Boake and Meyers (1993) as the most 
common neurologic problem associated with this disease. However, the diagnosis of 
a brain tumour is rarely made as a result of reduced cognitive functioning alone and,
more commonly, impairment in cognitive ability is recognised by the patient and/or 
relatives retrospectively (Tucha et al., 2000).
There exist a number of reasons for which studying the neurocognitive function of 
patients with brain tumours is important. Meyers and Brown (2006) highlight the fact
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that studying cognition in brain tumour patients enables us to determine exactly what 
cognitive problems exist prior to any treatment. This not only facilitates the use of 
effective interventions and guides treatment decisions, but also establishes a baseline
level of function by which the effects of treatment can be examined. 
Cognitive impairment in one or many aspects of function can have a significantly 
negative effect on an individual’s quality of life, preventing them from taking part in 
work, leisure and even activities of daily living. Reduced cognitive function not only 
affects the patient but can have a significantly negative impact on the patient’s carer. 
Therefore, in addition to measures of progression-free survival and objective 
response on CT or MRI scanning, cognitive functioning is becoming an increasingly 
important outcome measure in clinical trials in neuro-oncology since it can provide 
meaningful information with regard to the clinical status of the patient. Furthermore, 
measuring cognition in brain tumour patients can yield important information 
regarding side-effects and potential toxicity of selected treatments. Given the limited 
survival times for many brain tumour patients, cognitive assessment may also reveal 
a beneficial treatment to be one that stabilises or even slows the progression of 
worsening mental symptoms, regardless of whether or not overall survival is 
extended (Meyers and Hess, 2003). Thus, in-depth assessments of cognitive function 
are now often used in clinical trials, as well as the more commonly used measures of 
performance status, such as the Karnofsky Performance Scale (KPS). The KPS 
classifies patients according to their level of functional impairment and allows 
medical staff to score a patient in terms of their ability to carry out activities of daily 
living. However, in contrast with detailed cognitive assessment, the KPS, alongside 
many other measures of performance status, have been shown to have poor validity 
and reliability and do not relate significantly to measures of quality of life (Meyers 
and Brown, 2006).
Significant proportions of brain tumour patients have been found to experience 
cognitive impairment and the reported prevalence of cognitive disorder ranges from 
around 29% in low-grade glioma patients who have not received radiotherapy to as 
large a proportion as 90% in patients with diverse brain tumours (Tucha et al., 2000, 
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Klein et al., 2001). The variation in the reported prevalence of cognitive impairment
is the result of a number of factors including different groups of patients studied, 
different cognitive tests used, treatment factors and different normative data used to 
compare test scores (Gehring et al., 2008). Studies have been unable to elucidate 
exactly what causes the observed cognitive impairment in brain tumour patients but 
it is likely that these deficits arise as a result of a number of different factors. For 
example, cognitive function in brain tumour patients may be negatively affected by 
the tumour itself, by tumour-related epilepsy, by treatment factors, and/or by patient-
related factors such as age and anxiety or distress (Bosma et al., 2007). This chapter 
will discuss the studies that have examined cognition in brain tumour patients and 
will specifically consider: the effects of different tumour types on cognition; the 
effects of treatments such as medications, neurosurgery and radiotherapy; and will 
examine evidence to suggest that tumours in a particular location may result in 
specific cognitive deficits. The role of cognitive assessment in providing an 
indication of tumour progression will also be discussed alongside the specific 
problems that are inherently associated with measuring cognition in brain tumour 
patients. 
1.3 Tumour type and cognitive function
As highlighted above, brain tumours may be divided into different groups dependent 
on the cells from which they arise, how invasive they are and how aggressive they 
tend to be. Given that brain tumours are not a single disease and that different types 
of tumour affect the brain and surrounding tissues in different ways, many studies 
have focused on particular groups of brain tumour patients in order to determine the 
specific effects of different tumour types on cognitive function (Ek et al., 2005).
Determining the specific contribution of the brain tumour itself to cognitive 
impairment is problematic since many studies include patients whose scores on 
cognitive measures are confounded by several variables, including the potential
effects of radiotherapy and/or chemotherapy. However, some studies have attempted 
to examine the specific effect of the tumour itself on cognition, by assessing patients 
prior to any surgical or other intervention and comparing test scores with control 
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participants or with population norms. Much of this research has focused on the 
specific cognitive effects of high and low-grade gliomas. However, a smaller number 
of studies have addressed the cognitive effects of brain metastases and meningiomas. 
Each tumour subtype and the evidence regarding its effect on cognition will be
discussed in the following sections. 
1.3.1 High-grade gliomas 
The cognitive effects of these aggressive, malignant high-grade tumours have 
received the greatest attention and this may simply be because they are the most 
common tumour and thus patients are more readily available.
Salander et al. (1995), given the scarcity of literature in this area at the time, 
addressed the extent of possible cognitive impairment in patients with high-grade 
gliomas. Thirty consecutive patients were recruited into the study along with their 
partners who served as control participants. Patients completed a short, clinical
cognitive assessment test (Standardised Mini Mental State Examination, MMSE) at 
the time of discharge from the neurosurgical department and also 2 months post-
radiotherapy. The MMSE is a brief standardised tool used to measure cognitive 
function and is frequently used to assess patients with dementia (Brown et al., 2004). 
Five months after the initial assessment and following radiotherapy, those patients 
who were still alive and in good enough health, with no signs of tumour recurrence,
were tested on a more comprehensive battery of neurocognitive tests. The control 
group of partners also completed the test battery. The test battery was designed to 
emphasise measurement of memory function and included the Rivermead test, 
selective reminding and selected subtests from the Revised version of the Wechsler 
Adult Intelligence Scales (Digit Span, Digit Symbol, Arithmetic, Vocabulary and 
Picture Arrangement). Eleven patients from the original cohort of thirty completed 
the test battery and there emerged a clear trend. No significant differences were 
found on digit span, action memory or prospective memory. However, patients with 
high-grade gliomas located in either the frontal or temporal lobe exhibited 
impairment in long-term memory, as compared to short-term memory with long-term 
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recall, delayed recall and consistent long-term retrieval significantly poorer in the 
high-grade glioma group compared to the control group. This was despite the fact 
that all but one of the patients were considered “normal” at baseline, according to 
their MMSE scores and this therefore suggests that the MMSE may be insensitive to 
cognitive impairments in brain tumour patients. This is perhaps unsurprising given 
that many authors have found the measure to have a large ceiling effect (Hogervorst 
et al., 2002). However, since these patients completed the test battery after receiving 
radiotherapy to the brain, this makes it difficult to determine the relative contribution 
of the tumour itself to the observed cognitive impairment since radiotherapy effects 
may also have had some effect. The specific effects of radiotherapy on cognitive 
function will be addressed later in this chapter (see section 1.5.2). There were no 
significant differences between the high-grade glioma patients and the control group 
in terms of performance on tests that provide a measure of more global cognitive or 
intellectual abilities (Digit Span, Digit Symbol, Arithmetic, Vocabulary, and Ravens
Progressive Matrices). This suggests that long-term memory is significantly affected 
by the presence of a high-grade glioma and/or radiotherapy to treat the tumour, yet 
many other cognitive functions remain intact. However, there exist several 
methodological difficulties with this study that may question this conclusion. Only 
eleven patients completed the cognitive assessments on both occasions and,
therefore, whether these results may be generalised to the whole population of 
patients with high-grade gliomas is questionable. It is likely that the patients who 
completed both testing sessions were a highly select group, comprising the best 
functioning patients. The test battery reportedly lasted between 2 and 3 hours and 
this is likely to have been somewhat demanding for patients and as a result some test 
scores may have been artificially poor as a result of fatigue, poor motivation or 
stress. Although the authors accept that radiotherapy may have been the main cause 
of their findings, they claim that the observed memory impairment may also have 
resulted from the high-grade tumour itself. Had the authors tested patients before 
radiotherapy treatment had commenced, or compared the study group with a group of 
patients with low-grade tumours who had received early radiotherapy this would 
have allowed a better analysis of the relative effect of the high-grade glioma itself in 
contributing to cognitive dysfunction. 
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A number of other studies have also assessed the neurocognitive function of patients 
with high-grade brain tumours. Hahn et al. (2003) prospectively examined 
neuropsychological function and quality of life in adult patients with newly 
diagnosed primary high-grade gliomas. An initial testing session was carried out 
prior to, or shortly after, radiotherapy had commenced in order to eliminate
radiotherapy treatment effects and thus assess the impact of the tumour itself on 
cognition more effectively. A total of 68 patients, each of whom completed a battery 
of tests measuring different aspects of cognition, were recruited. The tests 
administered to each participant included the American Nelson Adult Reading Test 
as a measure of premorbid intelligence, Controlled Oral Word Association as a 
measure of verbal fluency, the Short-Memory Questionnaire, a 14 item self-report 
measure that records memory deficits on a 4 point scale, Trail Making Tests A and B 
as an assessment of speed, attention, sequencing, mental flexibility and motor 
function, and the Visual Reproduction subtest of the Wechsler Memory Scale
(Revised), among others. Thus, the test battery comprised assessments of several 
different aspects of cognition. In addition to several other analyses which will be 
discussed in detail later in this chapter, the authors examined the specific effect of 
tumour histopathology on cognitive function. Analyses, that accounted for the known 
effects of age on cognitive test performance, revealed statistically significant 
differences in the neuropsychological test performance of GBM patients (n = 30) and 
those with other gliomas (n = 38). However, further analysis revealed no significant 
univariate effects for each cognitive measure with the exception of Trail Making Test 
A, on which GBM patients performed significantly slower. The number of patients
with low-grade glioma (n = 18; 26%) included in the study was relatively small 
compared with the number of high-grade glioma patients (n = 50; 74%) and the 
patients in the “other” glioma group with which the GBM patients were compared 
included both high and low-grade glioma subtypes. Therefore, the impairment in 
cognitive functioning between high-grade glioma patients and LGG patients as a 
whole may be more extensive than this study suggests, given that GBM patients were 
considered separately from other high-grade glioma tumour types. 
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In a further study in this area, Kayl and Meyers (2003) compared the cognitive 
performance of patients with GBM and anaplastic astrocytoma. The post-surgical 
neuropsychological functioning of 24 patients with newly diagnosed GBM and 24 
patients with newly diagnosed anaplastic astrocytoma were analysed retrospectively. 
The two groups of patients were matched in terms of age, gender, education, tumour 
location and tumour volume and each patient had completed a detailed battery of 
cognitive tests following surgery but prior to commencing radiotherapy or 
chemotherapy. The test battery comprised a number of standardised tests assessing
several aspects of cognition as categorised by the authors themselves. The battery 
included assessment of intellectual functioning (7 WAIS –R subtests: Information, 
Digit Span, Arithmetic, Similarities, Comprehension, Block Design and Digit 
Symbol), memory (Buschke Selective reminding, Hopkins Verbal Learning Test, 
Benton Visual Retention Test), language and verbal fluency (Visual Naming, 
Controlled Oral Word Association, Token Test), motor function (Right and Left Grip 
Strength, Right and Left Grooved Pegboard) and executive functioning (Booklet 
Category Test, Trail Making Test Part A and B). No significant effect of tumour type 
(anaplastic astrocytoma vs. GBM) on test scores assessing any of these five cognitive 
domains was found. Further analysis suggested that patient age has a greater effect 
on test performance than tumour histology or tumour volume and the authors 
concluded that, according to this small study, those with more malignant disease do 
not suffer greater cognitive impairment than patients with less aggressive tumours. 
However, again, this study did not include any comparison of performance of 
patients with low-grade tumours, and the authors themselves highlight the fact that 
this may have influenced results to some degree. Additionally, given the relatively 
narrow age range of the participants (25 – 52 years) and the fact that the authors did 
not make any attempt to measure or control for the influence of differing levels of 
anxiety on test performance suggests that the study had low power to detect any 
differences between the groups. Moreover, since patients were recruited in the post-
operative period, this study is also unable to distinguish surgery effects from tumour 
effects on cognition, although it does eliminate the potential effects of radiotherapy. 
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Klein et al. (2001) also assessed the cognitive functioning of high-grade glioma 
patients in the post-surgical period before radiotherapy and/or chemotherapy 
treatments had been commenced. They aimed to overcome limitations associated 
with previous studies that demonstrated the presence of cognitive deficits in brain 
tumour patients before the start of radiotherapy (i.e. deficits that are more likely 
caused by the presence of the tumour itself) but did not recruit adequate control 
groups (Scheibel et al., 1996, Taylor et al., 1998). Klein et al. (2001) argue that 
studies examining cognition in brain tumour patients should be based upon 
comparisons with a control group of patients with a diagnosis of cancer that does not 
involve the central nervous system in order to control for the many unique stressors 
encountered by cancer patients. Given that cancer patients are likely to experience 
significantly increased feelings of anxiety and/or depression, this emotional 
disturbance could negatively impact upon their performance and lead to inflated 
estimates of the extent of cognitive impairment in this patient group. This study 
therefore assessed the neuropsychological functioning and the health-related quality 
of life of newly diagnosed high-grade glioma patients who had undergone surgery to 
obtain a histological diagnosis. The high-grade glioma patients (n = 68) were 
compared with 50 non-small cell lung cancer (NSCLC) patients on a battery of 
standardised tests designed to assess a wide range of cognitive functions including 
perception (Line Bisection Test, Facial Recognition Test, Judgement of Line 
Orientation and Letter-Digit Substitution Test), memory (Visual Verbal Learning 
Test, Working Memory Task) and attention and executive function (Stroop Colour 
Word Test, Categoric Word Fluency and Concept Shifting Task). General cognitive 
performance was also assessed by the Mini Mental State Examination (MMSE) and 
premorbid intelligence was measured using the Dutch Adult Reading Test. An 
impairment score was calculated for each individual, since the authors argue that 
considering only group means may obscure impairments at the individual level. 
Thus, test scores were converted to z-scores using the mean scores of the NSCLC 
patients as a reference in order to control for the impact of a cancer diagnosis. 
Subsequently, a mean overall composite z-score was calculated and impairment was 
defined as a score of two standard deviations below the mean score of the NSCLC 
group. For each individual high-grade glioma patient, the number of tests that met 
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this criterion was counted to obtain an overall impairment score. Since the authors 
also expected cognitive deficits to be present in the NSCLC group, the fifth 
percentile of this group was used as a cut-off for neuropsychological impairment. 
Both glioma and NSCLC patients were deemed cognitively impaired if they had 
scores that met these criteria on at least three of the cognitive tests administered. 
Based upon this method of analyses, there was found to be a general reduction in 
cognitive performance of the brain tumour patients when compared to the NSCLC 
patients, as follows. Firstly, the HGG patients had significantly lower scores on the 
MMSE. Moreover, 49% of the glioma group were classified as cognitively impaired,
on the basis of the aforementioned criteria, compared with 26% of the NSCLC group 
and this difference was statistically significant. Furthermore, when compared with a 
healthy control group, all glioma patients were found to be cognitively impaired, 
with 52% of the NSCLC group also falling into this category. By comparison with 
the NSCLC patients, the glioma patients were specifically impaired on some aspects 
of perception, memory and attentional and executive functioning. However, after 
correcting for differences in motor and visual functioning of the glioma group, 
significant impairment in memory function only was observed in the glioma group. 
This suggests that the cognitive differences between the two patient groups are 
largely the result of impaired vision and/or motor abilities in the glioma patients. 
However, only 37% of the high-grade glioma patient sample had a diagnosis of 
glioblastoma multiforme, yet this type of tumour accounts for the majority of high-
grade glioma diagnoses. Therefore, given that GBM patients tend to present with 
more severe symptoms, the findings of this study may actually underestimate the 
impact of high-grade gliomas on cognitive functioning. 
Bosma et al. (2007) aimed to map the neurocognitive functioning of patients with 
high-grade gliomas throughout the course of their disease, using data obtained as part 
of the aforementioned study by Klein et al. (2001). These authors evaluated the 
cognitive function of newly diagnosed high-grade glioma patients and also 
specifically examined the effect of tumour recurrence on cognition. Patients 
completed various neurocognitive tests at a baseline session after surgery but before 
radiotherapy and then again 8 months and 16 months later, where possible. The 
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neurocognitive tests that comprised the test battery provided measures of information 
processing and psychomotor function (Letter-Digit Substitution Test), attention
(Stroop Colour-Word Test and Categoric Word Fluency), verbal memory (Visual 
Verbal Learning Test), working memory (Working Memory Task) and executive 
functioning (Concept Shifting Test). Premorbid functioning was also controlled for
by means of the Dutch version of the New Adult Reading Test (DART). The HGG 
patients were divided into three groups for analysis: i) patients tested at baseline (n = 
36), ii) patients tested at baseline and 8 month follow-up only (n = 14) and 
iii) patients tested at baseline, 8 month and 16 month follow-up (n = 18). Bosma et 
al. (2007) found no statistically significant differences in neurocognitive 
performance at baseline between the three patients groups with different follow-up 
lengths. However, patients who had tumour recurrence during follow-up had 
significantly poorer information-processing capacity and psychomotor speed (as 
measured by the Letter-Digit Substitution Test) at baseline testing than did those 
patients without recurrence. Overall, between baseline and subsequent testing at 8 
months, there was a significant deterioration in information-processing, psychomotor 
speed, and attentional functioning (as measured by the Stroop Test and Categoric 
Word Fluency). Moreover, patients with tumour recurrence at 8 month follow-up 
performed significantly less well on tests of information processing, psychomotor 
speed and executive functioning than those without recurrence. However, after 
correcting for differences in drug use this effect was no longer observed. At 16 
month follow-up, patients with tumour recurrence had significantly worse 
psychomotor speed than did those without progression, and this difference could not 
be accounted for by differences in drug use, since the use of antiepileptic medication 
and dexamethasone was equally divided between the two groups. Bosma et al. 
(2007) therefore conclude that there is a marked decline in cognitive functioning in 
high-grade glioma patients throughout the course of their disease. The study also 
confirms the importance of cognitive deficit as a potentially negative prognostic 
factor in glioma patients (Curran et al., 1993) since patients who went on to develop 
earlier tumour recurrence performed significantly less well on psychomotor speed 
measures than those who did not experience tumour progression during the study.
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Therefore, although the exact role of a high-grade glioma as a cause of cognitive 
impairment has not been fully determined due to methodological difficulties 
associated with studying groups of brain tumour patients, it would appear that this 
group of patients do experience a wide range of difficulties in different domains of 
cognition. 
1.3.2 Low-grade gliomas 
Cognitive deficits in patients with a diagnosis of low-grade glioma have also been 
studied, although perhaps in less detail than their high-grade counterparts. Measuring 
and assessing the cognitive status of low-grade glioma patients is particularly 
important given that many patients have prolonged survival times (Correa et al., 
2007). The utility of carrying out detailed neuropsychological assessments as 
opposed to brief assessment, or neurological examination only in low-grade glioma 
patients has been emphasised in a study that found moderate or severe cognitive 
impairment in more than half of the patients in a cohort of 35 individuals with a low-
grade glioma, despite the fact that impairment was not detected by neurological 
examination and was not always reported by the patients themselves (Pahlson et al., 
2003). 
Given the scarcity of literature detailing the neuropsychological presentation of low-
grade glioma patients, particularly those with tumours of the astrocytic subtype,
Sweet et al. (1994) report a case series of six patients with low-grade astrocytoma 
who were not having active treatment at the time of enrolment into the study. Each 
patient completed assessments of intellectual function, cognitive efficiency, 
sustained attention, learning and memory, sensory/perceptual and visual/spatial 
abilities and language function. The authors report results for each participant 
separately, however, overall, it was found that each patient exhibited slight 
dysfunction, when compared with standardised scores, on some tests of cognition. 
The observed dysfunction was not nearly as significant as that demonstrated in 
studies of high-grade glioma patients and the mild deficits observed in this case 
series of patients were varied and did not routinely involve similar aspects of 
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cognitive functioning. Sweet et al. (1994) discuss possible reasons for which this 
group of patients perform relatively well neuropsychologically. They propose that,
since low-grade astrocytomas tend to infiltrate widely among normal brain cells and 
do not destroy brain tissue in the manner that is characteristic of a more solid mass of 
tumour, this may explain why cognitive abilities appear to remain grossly intact in a 
high percentage of these patients. However, there are a number of important 
limitations associated with the methodology employed in this study, notwithstanding 
the extremely small sample size. Impairment on the cognitive tests was determined 
by comparison with normative data and therefore no control group was recruited and 
matched on important variables such as age, sex, number of years of education and
premorbid ability, for example. Since no attempt was made to control for prior 
ability, the slight dysfunction observed in this study may be the result of lower 
premorbid ability in this small number of patients. Conversely, comparing the 
patients to a well-matched control group may have revealed that the impairment was 
actually more extensive than it appears. Moreover, since only six patients were 
recruited into this study, no definitive conclusion can be made with regard to the 
extent, and indeed the very presence of, cognitive impairment that results from a 
low-grade glioma. 
In a further study examining the role of the tumour as a cause of cognitive deficit,
Reijneveld et al. (2001) recruited two groups of low-grade glioma patients. They 
compared functional status, quality of life and the cognitive ability of patients who 
were suspected of having a low-grade glioma with that of those who had a proven
diagnosis, having undergone early surgery. The suspected low-grade glioma group 
had a radiological diagnosis but surgical treatment had been deferred until the 
tumour showed signs of progression on CT or MRI scanning. The study aimed to 
determine whether uncertainty about diagnosis had any negative impact on cognitive 
ability and/or quality of life, as it has been shown to in other patient groups. If this 
proved to be the case, it would suggest that early intervention in the form of surgery 
in these patients may be a better policy than a “watch and wait” one, given the 
controversy surrounding the best way to manage these patients (Whittle, 2004).
Twenty-four patients with a suspected low-grade glioma were recruited into the 
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study and completed various cognitive measures and an assessment of quality of life. 
The performance of the suspected low-grade glioma group was compared with data 
from a matched healthy control group and also with data obtained from patients who 
had undergone surgery to confirm the diagnosis of low-grade glioma (‘proven’). It 
was found that both low-grade glioma groups (suspected and proven) had
significantly poorer quality of life scores, as assessed by the self-report Short-Form 
Health Survey and Brain Cancer Module 20, than the healthy control group. 
Cognitive function was assessed using a battery of tests that included the Visual 
Verbal Learning Test, Working Memory Task, Letter-Digit Substitution Test, 
Categoric Word Fluency, Concept Shifting Tests, Stroop Colour Word Test and 
Working Memory Task. Both the suspected and proven LGG groups scored 
significantly worse on these measures by comparison with the healthy controls. 
However, patients with a suspected low-grade glioma performed significantly better 
overall than did those with a proven low-grade glioma. Specifically, patients with a 
proven glioma performed significantly less well on the psychomotor processing 
assessment than did the patients with a suspected glioma. Thus, this study suggests 
that impaired cognition is common to low-grade glioma patients and, given that 
impairments are evident in patients who have not yet had any intervention (i.e. 
surgery), the tumour itself likely plays some role in worsening cognition in this 
patient group. However, surgery may exacerbate any deficits that are present prior to 
intervention. The groups were well-matched in terms of demographic and clinical 
characteristics, including scores on commonly-used functional scales such as the 
Barthel Index and Karnofsky Performance Scale and had similar sized tumours (as 
measured by tumour diameter). However, the patients enrolled into this study all 
presented with epileptic seizures and were presumably treated with anti-epileptic 
drugs, although this is not documented. Given the aforementioned study by Bosma et 
al. (2007) who proposed that anti-epileptic drugs may play some effect on cognition, 
the cognitive deficits displayed by the low-grade glioma patients in this study may in 
fact be the result of prescribed drug use and not due to the presence of the tumour 
itself. 
18
However, further evidence that proposes the presence of tumour-related cognitive 
impairment in patients with a low-grade glioma comes from a study by Ek et al. 
(2005) who retrospectively assessed cognitive function in a sample of low-grade 
glioma patients. Twenty-four patients with either stable disease or slowly growing 
tumours were recruited and each patient was administered a detailed
neuropsychological examination. Cognitive measures that assess different domains 
were chosen to comprise a battery that could be completed in 1½ – 2 hours. The tests 
used included the Symbol Digit Modalities Test, Rey Auditory Verbal Learning Test 
various subtests from the Swedish version of the Wechsler Adult Intelligence Scale 
and Judgement of Line Orientation. In order to determine any possible patterns of 
cognitive dysfunction that may be present in the tumour group, the authors rated the 
patients according to the number of tests scores that were below normal limits (after 
correcting for age and education). A pattern of variation was found that resulted in 
separation of the patients into three subgroups with significant differences between 
the mean z-score. The first of these groups comprised patients who had a ‘global’
cognitive dysfunction and exhibited impairments in most domains that were 
assessed. The second group had slowed information processing-speed and also were 
impaired on between two and five of the other test domains. Patients in the third 
group generally performed well in most of the tests, including those of processing-
speed. Additionally, it is reported that the majority of patients classified into the third 
group on the basis of good cognitive performance were found to have the most 
favourable prognosis based on the histopathological subtype of low-grade glioma. 
This finding that cognitive function is more impaired in patients with a low-grade 
glioma with a less favourable prognosis (i.e. more aggressive subtypes) is in keeping 
with the belief that more aggressive tumours (in particular high-grade gliomas) result 
in more pronounced cognitive deficits. However, the surprising finding of this study 
was the extreme variation in cognitive ability in this group of patients, with some
patients showing severe disturbance yet others scoring within ‘normal’ limits. 
However, given that 17 of the patients recruited had received radiotherapy and a 
further 6 of those 17 also received chemotherapy, the differences in cognition may 
actually reflect differences in treatment, irrespective of the presence of the tumour
itself. The authors did not analyse the potential effects of these treatments on 
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cognitive test scores due to the small number of patients and this makes it difficult to 
determine the effect of the tumour itself on cognitive function. 
The majority of studies that address cognition in specific histological brain tumour 
groups are therefore unable to elucidate the exact contribution of the tumour as a 
cause of cognitive dysfunction due to treatment-related heterogeneity in the samples 
of patients recruited. Goldstein et al. (2003) highlight this issue and attempted to 
overcome this problem by recruiting patients prior to radiotherapy or chemotherapy.
They specifically investigated the effect of low-grade tumours on attention function 
in a sample of 55 patients, 41 of whom were described as having ‘superficial’
tumours and 14 of whom had what was referred to as a ‘deep’ tumour. 
Neuropsychological testing took place 6 weeks following surgical excision or biopsy 
of the tumour, if this had taken place. Each patient completed a battery of 
standardised tests that were designed to measure specific domains of attention. The 
tests included the Auditory Selection Test, Bells Test, Symbol Digit Modality Test 
(Oral Version), Wisconsin Card Sorting Test, Digit Span Test, Visual Memory Span 
Test, and the Paced Auditory Serial Addition Test. The low-grade patients were 
compared to a normal control group, matched for age (n = 63). The normal control 
group had better overall performance than the low-grade brain tumour patients
suggesting that these tumours have a negative impact on several different measures 
of attentional abilities. Moreover, the “deep” tumour group performed similarly to 
the other tumour patients on all the attentional measures, other than the Digits 
Forward task, on which they performed significantly less well. This study therefore 
suggests that low-grade brain tumours are particularly associated with impaired 
attentional ability, irrespective of the location of the tumour. However, this study 
differs from the aforementioned studies examining low-grade glioma patients in that 
it recruited any patients with low-grade brain tumours. Therefore, patients with
meningiomas and pituitary adenomas were also included in the study. Given that 
these tumours are generally less infiltrative than gliotic brain tumours; the inclusion 
of patients with these types of tumour limits the conclusions that can be made 
regarding the specific effects of low-grade gliomas. Moreover, the control group 
used in this study was somewhat inadequate given that they were not matched with 
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the brain tumour patients on key variables such as premorbid ability or sex and this 
also questions the conclusions drawn in this study. Moreover, a more reliable 
assessment of the role of the tumour itself in contributing to cognitive impairment 
could have been achieved had the patients been recruited prior to surgery, instead of 
post-operatively but prior to radiation therapy.
1.3.3 High- and Low-Grade Gliomas – Conclusions
Therefore, there are a number of important methodological issues and flaws that are 
frequently associated with studies that attempt to determine the relative contribution 
of high-grade and low-grade gliomas themselves to cognitive impairment. However
evidence consistently suggests that cognitive functioning in a variety of domains is 
impaired in many patients with both high and low-grade gliomas. Moreover, the 
impairments observed in high-grade glioma patients tend to be more severe than 
those measured in low-grade glioma patients. However, few studies specifically 
compare the two tumour groups explicitly. There exists a great variety in terms of the 
extent of impairment reported by different studies and this could be due to the 
presence of confounding variables such as differences in treatments between patients 
groups and methodological differences between studies, with different tests used and 
different means of classifying ‘impairment’.
1.3.4 Other tumour types
Although the majority of studies that examine tumour-related impairment in 
cognitive function have focused on the effects of high and low-grade gliomas, some
studies have addressed the specific cognitive effects of brain metastases and 
meningiomas.
Although it has been reported that 10 – 20% of all cancer patients will develop brain 
metastases, studies assessing quality of life and neurocognitive function in patients 
with metastatic brain tumours have rarely been carried out (Herman et al., 2003). 
Thus, a pilot study was conducted to address the feasibility of administering a 
21
detailed neurocognitive test battery to patients with brain metastases, given the 
limitations associated with assessment using the Mini-Mental State Examination in 
this patient group. The MMSE, although brief and relatively non-demanding, is less 
sensitive to mild impairment and is not really suitable for repeated assessments due 
to practice effects. Herman et al. (2003) recruited 30 adult patients with any newly 
diagnosed, existing or recurrent brain metastases and administered a five-part 
neurocognitive test battery to each patient. The tests that comprised the battery were 
all widely-used, standardised measures of cognition and included the Hopkins Verbal 
Learning Tests, Trail Making Parts A and B and Controlled Oral Word Association 
(COWA, a measure of verbal fluency). The results of this preliminary investigation 
showed that the group of patients with a brain metastasis were impaired on measures 
of recall and delayed memory. Impairment was defined as a score more than 1.5 
standard deviations from the mean of normal age-matched subjects for the Hopkins 
Verbal Learning Test or as a score below the tenth percentile for the normative 
population for the COWA and Trail Making tests. Specifically, 76% of patients 
exhibited significantly impaired recall and 70% displayed significant impairment in 
delayed memory. Although some patients were classified as impaired on other tests 
including Trail Making Tests A and B and the Controlled Oral Word Association 
test, the proportion who displayed impairment was much smaller than that seen for 
the tests of memory. The authors conclude that patients with brain metastases can 
tolerate a 30 minute neurocognitive test battery and that such measures should be 
added prospectively to clinical trials as an outcome measure in this patient group. 
However, it is important to consider the fact that the ‘control’ group data in this 
study was derived from normative data from age-matched subjects. Thus, no attempt 
to control for variables such as education, premorbid ability, sex and the potential 
effects on increased emotional distress on test performance was made, limiting the 
conclusions that can be drawn regarding the cognitive status of this patient group. 
However, the study does highlight the potential utility and importance of carrying out 
further studies that assess cognition in patients with metastatic brain tumours. 
In a similar study that tested the feasibility of carrying out neurocognitive measures 
and quality of life assessments in a group of patients with brain metastases, Regine et 
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al. (2004) report high compliance rates, with the majority of participants (> 90%) 
yielding valid data on a number of different cognitive assessments. The authors do 
not give any information detailing the specific tests administered or the actual scores 
obtained and therefore do not report the presence or otherwise of any impairments in 
this group but the study again paves the way for future research in this under-studied 
area.
The results of cognitive assessments of glioma patients cannot equally be applied to 
patients with meningiomas for a number of reasons. Namely, gliomas tend to be 
more invasive, and high-grade tumours in particular grow much more rapidly than 
meningiomas which tend to be benign, slow-growing and non-infiltrative. Therefore 
meningiomas could reasonably be expected to have different and potentially fewer 
effects on cognition. However, compared with gliomas, the cognitive effects of
meningiomas have received far less attention in terms of their effect on cognitive 
functioning. A number of case studies have frequently reported disturbances in 
memory, concentration and orientation in patients with frontal meningiomas in 
particular (Avery, 1971). However, although a small number of studies have 
systematically examined cognition in larger cohorts of patients with meningiomas, 
many report only the incidence of neurological disturbance on admission, prior to 
any intervention being made, in addition to detailing postoperative functional 
outcome and prognosis (Feder et al., 1989, Simoca et al., 1994, Torres et al., 2003). 
Neurological symptoms frequently reported to be present in meningioma patients 
include aphasia, confusion and disorientation and, according to these studies, these 
symptoms were present in between 25% and 62% of meningioma patients during the 
course of their disease. However, no formal cognitive testing is reported by these 
authors.
In one of the few studies that have systematically assessed cognition in this patient 
group, Tucha et al. (2003), prospectively examined pre- and post-operative 
functioning in patients with frontal meningiomas, giving a detailed account of the 
cognitive deficits in this group. Fifty-four such patients were recruited prior to 
surgery and completed a detailed battery of tests assessing aspects of memory, 
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attention and executive functions both pre and post-operatively. A group of 54 
healthy volunteers were administered the tests on two separate occasions to serve as 
a control group. The two groups were well-matched in terms of age, sex, handedness, 
intelligence, education level and the duration between first and second testing 
session. Tests included in the battery were Digit Span, Logical Memory, Visual 
Reproduction, Divided Attention Task, Trail Making Test Parts A and B, the Five 
Point Test and Complex Figure Test. Analyses detailing the effects of surgery on 
function are discussed in due course in this chapter (see section 1.5.1). Prior to 
surgery, significant differences in the performance of the meningioma group by 
comparison with the healthy control group were found. In particular, there was a 
significant preoperative impairment in working memory, fluency functions, tonic 
alertness, processing speed, shifting, divided attention, and flexibility in the 
meningioma patient group. However, no differences were observed in intellectual 
function, memory or visuoconstructive abilities. Therefore, this study suggests that 
the presence of the meningioma itself may cause significant impairments in several 
specific cognitive domains. It is one of few to detail cognition in brain tumour 
patients prior to any treatment (i.e. at presentation, before any surgical intervention) 
and therefore gives greater insight into the role of the tumour itself as a cause of 
cognitive impairment. 
1.3.5 Tumour Type and Cognition: Conclusions
There is little doubt that many patients with brain tumours suffer cognitive 
impairment and studies have shown a general trend towards these impairments being 
more pronounced in patients with more aggressive tumours (i.e. high-grade gliomas). 
However, deficits have consistently been recorded in studies of patients with low-
grade gliomas and also to some extent in patients with other, less common tumour 
types. However, further research into the cognitive function of meningioma and 
metastasis patients, in particular, is required. 
Although a number of factors are likely to play some role in contributing to these 
impairments, it does appear that the tumour itself causes cognitive deficits to some 
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extent. Screening for cognitive impairment prior to any treatment is particularly 
important as it not only allows for the most effective interventions to be offered to 
the patient but also provides a baseline level of function from which to assess the 
success of any subsequent treatment. 
1.4 Brain tumour location and cognition
The location of the tumour within the brain has also received attention as a possible 
cause of cognitive impairment in neuro-oncological patients with studies aiming to 
determine whether tumours located within specific brain areas result in impairment 
in specific cognitive domains. 
Early studies regarding the relationship between tumour location and cognitive 
impairment yielded mixed results, with some studies reporting poor verbal 
performance in patients with left-sided compared with right-sided tumours (Hom and 
Reitan, 1984), yet others reporting no such differences (Haaland and Delaney, 1981).
Subsequently, Scheibel et al. (1996) used age-corrected test scores to examine the 
influence of tumour lateralisation, amongst other variables, on cognitive function in a 
large cohort of glioma patients. Two-hundred and forty-five glioma patients were 
recruited, the majority of whom had a diagnosis of glioblastoma multiforme. Each 
patient completed a detailed neuropsychological test battery and it was found that 
performance on several of the measures was dependent upon lesion lateralisation (i.e. 
whether the tumour was located in the left or right hemisphere of the brain).
Specifically, patients with left hemisphere tumours had lower scores on measures of 
language, verbal learning and verbal intelligence, whereas patients with right-sided 
lesions had greater difficulty with visual-perceptual skills, as measured by a test of 
facial recognition. Although the study is limited by its retrospective nature, these
findings are of interest since the results of previous studies have not always found a 
significant relationship between lesion site and type of cognitive impairment. 
Subsequent studies in this area have reported, perhaps unsurprisingly, that patients 
with right-sided tumours score significantly worse than patients with left-sided 
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tumours on tasks that rely heavily on functions carried out by the right-hemisphere, 
such as the line bisection test and facial recognition (Klein et al., 2001). Additionally, 
left-sided tumours were found to have a deleterious effect on both attention and 
executive function, and this was reflected by longer scanning times in the Concept 
Shifting Test A, increased susceptibility to interference as exhibited by poorer Stroop 
Test performance and reduced fluency ability. Thus, this study provides further 
evidence to suggest that the hemispheric location of the tumour appears to have an 
effect on specific aspects of cognition.
Patients with a glioma located in the dominant hemisphere of the brain tend to have 
more cognitive deficits than do those with a non-dominant hemisphere tumour, a 
finding that was confirmed by Hahn et al. (2003) whose study is described in detail 
previously (see section 1.3.1). Their study also examined the effect of lesion 
lateralisation on cognitive test performance. The performance of the right and left 
hemisphere tumour groups were compared and a significant relationship between 
hemispheric tumour site and neuropsychological test performance was found. The 
participants in this study were left hemisphere dominant and univariate analyses 
revealed that these patients with left hemisphere tumours (i.e. in the dominant 
hemisphere) performed significantly less well than patients with tumours in the non-
dominant right hemisphere on the COWA test (a measure of verbal fluency), 2 and 7 
Continuous Performance Test (attention and reaction time), Victoria Stroop 
Latencies (cognitive flexibility) and on the delayed free recall, recognition, and 
consistency of long-term retrieval from the Levin Selective Reminding Test. The 
authors thus conclude that left-sided tumours have a negative effect on memory, 
verbal fluency and verbal learning functions. This finding also supports conclusions 
made by Hom and Reitan (1984) who report poorer verbal functioning of patients 
with tumours located in the left hemisphere and also correlates with the findings of 
the aforementioned studies (Scheibel et al., 1996, Klein et al., 2001).
Thus, evidence exists to suggest that tumour location has an effect on several aspects 
of cognitive function with dominant hemisphere lesions resulting in greater 
impairments compared to tumours located in the non-dominant hemisphere. 
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However, given that many patients, particularly those with a low-grade glioma,
frequently experience non-specific cognitive slowing and diffuse deficits that cannot 
simply be explained by tumour location, Bartolomei et al. (2006b) carried out an 
investigation to test the hypothesis that brain tumours interfere with normal brain 
function through the disruption of functional connectivity of brain networks. 
Previous studies have shown that cognitive function in healthy participants relies 
upon interactions between multiple discrete neural networks in the brain and 
complex functional interactions between different brain areas have been found using 
magnetoencephalography (MEG) or electroencephalography (EEG) signal analysis, 
even when the participant has not been asked to complete any cognitive task (Stam et 
al., 2002). Thus, the study aimed to determine whether there is a loss of functional 
connectivity in the brains of patients with low-grade gliomas, and whether any loss 
of connectivity is localised solely within the region in which the tumour is located, or 
whether it extends to different brain regions distant from the tumour itself. Seventeen 
histologically confirmed low-grade glioma patients and 15 healthy control subjects 
had MEG recordings analysed. Bartolomei et al. (2006b) found a loss of functional 
connectivity in the brain tumour group compared with the control group, and this 
extended to multiple brain regions. Therefore, brain regions beyond the margins of 
the tumour itself were disrupted. The disruption was more evident in patients with 
tumours located within the left hemisphere. Thus, functional networks in the brain 
that are required for cognitive test performance were disturbed in various areas of the 
brain, including areas that appear to be ‘normal’ on MRI scanning. This preliminary 
study therefore proposes that disruption of functional networks throughout the brain 
as a result of the presence of a tumour may explain the observed global cognitive 
impairment (e.g. in psychomotor and executive function domains) in low-grade 
glioma patients cannot be explained by focal tumour-related effects. However, given 
that all the patients in the study had already undergone surgery to obtain a diagnosis 
of low-grade glioma, the potential role of surgery in disrupting functional networks 
cannot be distinguished from the effect of the tumour itself. Additionally, no 
cognitive testing was carried out in order to determine the presence and/or the extent 
of cognitive impairment in the patients recruited into the study.
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Thus, Bosma et al. (2008) carried out a further investigation using MEG analysis  to 
relate functional connectivity directly to neurocognitive function in 17 low-grade 
glioma patients and 17 age, sex and education-matched healthy controls. MEG 
recordings were taken for each participant, each of whom then completed a detailed 
cognitive test battery that included measures of psychomotor function (Letter-Digit 
Substitution Test); executive function, attention and visual scanning (Concept 
Shifting Test); attention, mental speed and mental control (Stroop Colour Word 
Test); verbal learning, organisation and memory (Visual Verbal Learning Test); 
selective attention, mental concentration and information processing (Memory 
Comparison Test) and frontal dysfunction and flexibility (Categoric Word Fluency). 
The low-grade glioma patients were found to be impaired on measures of 
psychomotor function, working memory, information processing speed and attention 
by comparison with the matched control group. The findings of the aforementioned 
study (Bartolomei et al., 2006b) was confirmed by this follow-up study. The low-
grade glioma patients were found to have significant differences in resting-state 
functional connectivity compared with the healthy control group. This again suggests 
that the tumour causes disruption to functional networks throughout the brain. 
Moreover, loss of functional connectivity in the delta, theta and lower and upper 
gamma bands and neurocognitive function were significantly correlated in the low-
grade glioma patient group, thus suggesting that cognitive impairment, specifically in 
the domains of attention and information processing, in brain tumour patients may 
arise in part as a result of disturbed functional connectivity in these specific wave 
bands. 
Thus, evidence exists to suggest that the location of the tumour, in particular the 
hemisphere in which it is located, may cause specific cognitive impairment. 
However, recent research has shown that the more global executive function and 
information processing impairments that are particularly evident in patients with 
low-grade gliomas may arise as a result of disruption to the discrete functional 
networks in the brain that are involved with performing cognitive tasks.
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1.5 Treatment effects on cognition
As has been shown, although the causes of cognitive impairment in brain tumour 
patients are not fully understood, it is likely that tumour type and location within the 
brain both contribute to some degree. Studies have also addressed the role of 
treatment-related variables including surgery, radiotherapy and chemotherapy, 
steroid therapy and drugs such as anti-epileptic medications that are commonly 
prescribed to patients who suffer seizures. Examining the treatment-related cognitive 
sequelae is of great importance in neuro-oncology, since the majority of patients 
have a poor prognosis. Therefore a treatment that has little or no effect in terms of 
improving survival may still be beneficial if it improves or even maintains cognitive 
function since impaired cognition can result in poor quality of life. Conversely, the 
utility of a therapy that only modestly prolongs survival may be questionable if it has 
a significantly detrimental effect on cognitive function.
1.5.1 Surgery and cognitive function
The first-line treatment for a brain tumour is most often surgery in the form of
resection or biopsy to obtain a histological diagnosis, and in some cases, to alleviate 
symptoms of increased intracranial pressure. Surgical intervention is not without risk 
and tumour biopsy or resection may cause or exacerbate existing deficits due to 
damage of normal brain tissue that surrounds the tumour (Taphoorn and Klein, 
2004). A number of studies have addressed the potential relationship between 
surgery and cognitive impairment.
Vecht et al. (1990) assessed the effect of the extent of surgery on the neurological 
function more generally, as opposed to cognitive function, of high-grade glioma 
patients. A retrospective analysis of 66 patients with anaplastic astrocytoma and 177 
patients with GBM indicated that more extensive surgery as opposed to limited 
resection did not have any negative effect on post-operative neurological function. 
Although this early study did not formally assess cognitive function, it does suggest 
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that extensive surgery to remove a high-grade glioma does not impact negatively on 
neurological status, at least in the initial post-operative period. 
Whittle et al. (1998) looked specifically at the effects of resective surgery for left-
sided tumours on language functions, since language impairment is a common
symptom of a left hemisphere lesion. Forty consecutive patients were recruited and
completed the Western Aphasia battery (WAB) and the Boston Naming Test (BNT) 
preoperatively and postoperatively, prior to discharge. The WAB is a group of 
subtests assessing aspects of auditory and reading comprehension in addition to oral 
and written expression. The BNT is a test of confrontation-naming that yields a score 
out of 60 with score of 48 or less taken to represent impairment. It was found in the 
study that language function, as measured by the WAB and BNT, actually improved 
in 92% of patients who had some degree of dysphasia prior to surgery. This suggests 
that, in the case of language dysfunction, surgery may actually relieve pre-existing 
impairment. Moreover, of those patients who scored within normal limits on the 
language assessments prior to surgery and therefore were not deemed to be
dysphasic, none showed any significant postoperative change. Thus, resective 
surgery for left-sided brain tumours does not appear to negatively impact language 
function in the initial pre-operative period and may actually offer some benefit in 
improving speech in those patients who were dysphasic pre-operatively. However,
since no control group was recruited into this study, the potential effects of practice
on the tasks administered are unclear and may account for some of the improvement 
observed in such a high proportion of patients. Further studies should be carried out 
in this area, to support the conclusions made by Whittle et al. (1998).
However, in contrast with the idea that surgery tends to alleviate cognitive 
dysfunction, the study by Reijneveld et al. (2001) described previously (see section 
1.3.2), reports that patients with a histologically proven low-grade glioma (i.e. those 
who had undergone surgery to confirm the diagnosis) performed significantly less 
well on measures of psychomotor function and health-related quality of life as 
assessed by the MOS SF-36 Short-Form Health Survey, than did a case-matched 
group of patients with a low-grade glioma diagnosed on the basis of MRI or CT 
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scanning alone. This would therefore suggest that, in this group of low-grade glioma 
patients, surgery caused, or at least exacerbated the severity of existing cognitive 
deficits. However, as the authors highlight, it is not possible to confirm whether the 
decreased cognitive functioning of patients with proven low-grade gliomas should be 
attributed to the surgical procedure, or whether other variables may account for the 
differences. These include potential differences in anxiety levels between the groups, 
given that mood was not measured, in addition to the potential for selection bias
since those patients for whom surgery was deferred were likely to have fewer 
impairments than those who had earlier surgical intervention. No information 
regarding the pre-operative neuropsychological status of these patients was available, 
and this limits any conclusions regarding the contribution of surgery to cognitive 
dysfunction in the study.
Teixidor et al. (2006) provide further evidence to suggest that brain tumour surgery, 
at least in low-grade glioma patients, may cause a worsening of existing deficits, at 
least in the initial pre-operative period. Verbal working memory was examined 
before and after surgery in a group of patients who had awake surgery to resect a 
low-grade tumour. Twenty-three such patients were recruited into the study and 
verbal working memory was assessed before and immediately after surgery. A 
further 8 patients had the assessment for a third time, 3 months post-surgery. Results 
indicated that, pre-operatively, 91% of the patients tested had impairment in verbal 
working memory. This provides further evidence to suggest that cognitive 
impairment may be a result of the tumour itself in these patients. Furthermore, in the 
immediate post-operative period, 96% of the patients had worsening of verbal 
working memory, with the authors reporting that 22 of the 23 patients had lower 
scores on the neurocognitive assessments following resection of the tumour. In five 
of the nine tests administered, the difference between pre- and post-operative scores 
was found to be statistically significant in the group of low-grade glioma patients. 
However, of the 8 patients studied 3 months later, 5 recovered their preoperative 
scores and a further 3 actually improved significantly on the assessment of verbal 
working memory. This again suggests that cognitive impairments, like physical
neurological impairments that also commonly occur after awake surgery (Duffau et 
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al., 2003) are mainly transient and scores may actually exceed preoperative ones 3 
months after surgery.
In the aforementioned study of frontal lobe meningioma patients, 54 patients were 
assessed neuropsychologically both pre and post-operatively (Tucha et al., 2003).
The tests included in the battery are detailed in section 1.3.4 of this chapter. There 
were no significant differences between the meningioma patient’s pre- and post-
operative scores on the tests of memory (with the exception of working memory), 
visuoconstructive abilities or executive functions. Several attentional functions, 
including tonic alertness, divided attention, flexibility and shifting were actually 
found to improve post-operatively in this patient group, suggesting that surgical 
removal of the tumour did not have any negative impact on the cognition. However, 
given that the same standardised cognitive measures were administered to patients
pre and post-operatively, practice effects may explain the improvements observed to 
some degree. The authors suggest that the effect of practice is likely to have had been 
minimal on the attentional measures since the tests used were generally designed to 
be used for repeated assessment. However, to enhance the robustness of their 
findings, the test performance of a group of healthy volunteers who were tested on 
two separate occasions were analysed. There was found to be a significant 
improvement in immediate and delayed recall of verbal information, with no other 
significant changes found on the other tests. Thus, this study supports the proposal 
that surgery for a brain tumour does not tend to negatively impact cognition, at least 
in meningioma patients. 
Therefore, evidence to suggest that surgery may play some role as a cause of 
cognitive deficits in brain tumour patients is somewhat conflicting, with some studies 
proposing that it has little or no negative effect and may actually alleviate existing
deficits to some degree, yet others suggest that surgery results in deterioration in
cognitive function. Any impairments following surgery may however be mainly 
transient, and this emphasises the importance of carrying out extended follow-up 
assessments in order to determine whether any specific long-term effects of surgical 
intervention exist.
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1.5.2 Radiotherapy and cognitive function 
Following surgical intervention, dependent upon the age and functional status of the 
patient, those with malignant gliomas (WHO grade III and IV) are likely to be 
offered immediate radiotherapy. The effects of radiotherapy on the brain, and in 
particular on cognitive function, have been widely studied with varying results. Until 
the mid 1980s, brain tumour patients receiving radiotherapy were given standard 
whole-brain radiotherapy (WBRT). There is little doubt that WBRT had significant 
effects on cognitive function with Gregor et al. (1996) showing that short-term 
memory was particularly affected in those patients who survived for more than 5 
years following treatment. However, radiotherapy treatment protocols have changed 
significantly over the past 20 years with patients now commonly offered partial brain 
irradiation that is targeted specifically towards the brain areas invaded by tumour, 
using smaller fraction sizes. Studies have generally found this treatment protocol to 
have less of an impact on cognition (Taphoorn and Klein, 2004). 
The effects of radiation therapy on the cognitive function of patients with low-grade 
gliomas in particular have received a great deal of attention. This is due to the longer 
survival of these patients and well-documented controversy surrounding the question 
of whether to offer patients with a low-grade glioma immediate radiotherapy, or 
whether to withhold treatment until such a time as the tumour progresses (Whittle, 
2004). A randomised trial reported that although early radiotherapy after surgery 
lengthens the time to tumour progression, it has no effect on overall survival (van 
den Bent et al., 2005) and is now generally accepted that radiotherapy can be 
deferred in low-grade glioma patients who have a good performance status. 
Armstrong et al. (2002) examined the effects of radiotherapy on both the cognitive 
and radiographic outcomes of 26 patients with low-grade brain tumours who were 
without risk factors for vascular damage (e.g. hypertension). The patients were tested 
on a yearly basis from baseline (6 weeks post-surgery, prior to radiotherapy) to 6 
years. A test battery comprising a large number of standardised neuropsychological 
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tests that were designed to assess a number of different aspects of cognition was 
administered and scores on a total of 37 different tests were included in analyses. In 
contrast with previous studies that report between 20% and 80% of patients exhibit 
some degree of cognitive impairment between 2 and 20 years after receiving 
radiotherapy (North et al., 1990, Meyers et al., 2000) Armstrong et al. (2002) found 
no evidence of any general cognitive decline in these low-grade glioma patients 3 
years after treatment. However, a late-delayed effect of radiotherapy was 
demonstrated by a decline in selective areas of cognition, namely in visual memory,
that began 5 years following radiotherapy. In contrast, MRI scan images showed 
white matter atrophy from 6 months to 3 years post-treatment, with no further 
progression evident after this time. The study is limited by the high levels of attrition 
that occurred 2 years post-radiotherapy as it is likely that those patients who did not 
complete the full follow-up were those patients who had the most severe functional 
and/or cognitive deterioration. As such, the study may underestimate the potential 
effects of radiotherapy on cognitive function. 
Torres et al. (2003) investigated the effect of modern (partial) brain radiation therapy 
on the cognitive functioning of low-grade brain tumour patients in a longitudinal 
study. Seventeen patients with low-grade gliomas were tested on a battery of 
neuropsychological assessments pre-radiotherapy (baseline) and at 3, 6, 12 and 24 
months subsequently. The tests were chosen on the basis of their sensitivity to brain 
dysfunction, their emphasis on attention, processing speed and memory and their 
suitability for repeated administration. Twelve of the 17 patients had no tumour 
progression during the course of the study and these patients showed a slight 
improvement in verbal learning between baseline and 3 month follow-up that could 
likely be attributed to practice effects. There was no evidence of decline on any of 
the other measures in these patients. Between 3 and 6 months, 6 months and 1 year, 
and 1 and 2 years, there was no decline on any of the tests administered in this group 
of low-grade glioma patients without tumour progression. Therefore, no ‘early-
delayed’ cognitive effect of radiotherapy was observed as described by previous 
studies (Vigliani et al., 1996). The three patients who were ‘progressors’ during the 
study showed a general decline in test performance between baseline and 1 year by 
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comparison with two patients who had surgery but not radiotherapy, who served as 
controls. Thus, this study found evidence to suggest that there is a favourable 
outcome in terms of cognitive function in the first 2 years following partial 
radiotherapy, at least in adult patients with low-grade tumours. However, there are 
numerous methodological criticisms that can be made of this study. Primarily, the 
sample size was very small, with only two patients serving as control patients. These 
‘controls’ were not matched with the study group with respect to age, sex and 
education and the lack of randomisation of patients to radiotherapy and non-
radiotherapy means that there was likely some selection bias surrounding which 
patients were selected for post-operative radiotherapy. The authors themselves 
suggest that these limitations should be considered when generalising the results to 
other patients, especially those out with the treatment centre in which the study was 
conducted. 
Although the majority of studies that have examined the potential early and delayed 
effects of radiotherapy have focused on low-grade glioma patients, some studies 
have focused solely on radiotherapy-effects in high-grade glioma patient cohorts. 
Taylor et al. (1998) carried out a prospective study in which they administered the 
Folstein Mini Mental State Examination (MMSE) at baseline,  6, 12, 18 and 24 
months to a group of high-grade glioma patients who were treated with combined 
radiotherapy and chemotherapy. Significant cognitive decline (described as a greater 
than 3 point decrease in baseline MMSE score) in patients without tumour 
progression, was observed in 11% (13/119) of the patients at 6 month evaluation, 6% 
(3/54) of the cohort at 12 months, 10% (3/30) at 18 months and 18% (4/22) at 24 
months post-treatment. Those patients who had a significant decrease in MMSE 
score were more likely to be older and to have a poorer performance status. The 
authors conclude that there was no clear trend towards increasing cognitive 
impairment in this group of patients following radiotherapy and chemotherapy 
treatment. However, in addition to a high rate of attrition which may have biased the 
results, the use of the MMSE as an assessment of cognition in this study is a 
significant limitation. The MMSE has been validated for use with dementia patients 
but has not been validated for use in brain tumour patients. Meyers and Wefel (2003)
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state that the MMSE lacks sensitivity when used to assess cognitive function in 
cancer patients in general. In particular, they highlight the fact that it is particularly 
unsuitable for use in radiotherapy trials since it does not assess the cognitive 
functions that are most likely to be affected by radiotherapy, such as learning and 
memory, processing speed, executive function and fine motor control. 
Therefore, a number of studies have assessed the cognitive effects of radiotherapy, 
with the majority showing that focused brain irradiation has fewer and less severe 
cognitive deficits than whole brain radiotherapy. However, despite these treatment 
advances, there is still likely to be some degree of cognitive impairment following 
radiotherapy and this may not be evident until a number of years following 
treatment. 
1.5.3 Prescribed Medication and Cognition
1.5.3.1 Antiepileptic drugs
Epileptic seizures are a common presenting symptom of a low-grade glioma with up 
to 80% of these patients presenting with seizure disorder (Whittle, 2004). The 
potential deleterious effect of antiepileptic drugs on cognitive function has been 
addressed in a small number of studies. In a study of 195 low-grade glioma patients 
that aimed to differentiate between tumour and treatment effects on cognition, it was 
found that patients on antiepileptic medication performed significantly less well on 
several attentional and executive function measures compared with patients who 
were not taking antiepileptic drugs. The patients who had been prescribed
antiepileptic medication also had significantly reduced self-reported cognitive 
function (Klein et al., 2002). Seizures themselves may also contribute to cognitive 
decline. In a study of patients with refractory temporal lobe epilepsy it was found 
that those patients with a longer duration of epilepsy were most severely impaired on 
measures of psychometric intelligence, as measured by the full scale intelligence 
quotient of the Wechsler Adult Intelligence Scales (Jokeit and Ebner, 1999).
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Therefore, Klein et al. (2003a) recruited 156 low-grade glioma patients with an 
epilepsy burden ranging from ‘none’ to ‘severe’ (based on seizure frequency and use 
of antiepileptic drugs) and compared the cognitive ability of the LGG group with that 
of a matched group of healthy controls. The study aimed to determine the impact of 
both epilepsy itself and of antiepileptic drug treatment (AEDs) on cognitive 
functioning and health-related quality of life (HRQOL). The LGG group were 
divided into one of six groups dependent on their epilepsy burden, ranging from 1 -
epilepsy free to 6 - epilepsy, more than 6 seizures in the previous year. Of the LGG 
patient group, 86% had epilepsy and had been prescribed AED therapy. A 
comprehensive test battery that measured the domains of information processing 
speed, psychomotor function, attentional functioning, verbal memory, working 
memory and executive functioning was completed by each patient. The Medical 
Outcomes Study (MOS) Short-Form Health Survey was also administered as a 
measure of health-related quality of life. The tests in the neurocognitive test battery 
included the Line Bisection Test, Facial Recognition Test, Judgement of Line 
Orientation Test, Letter-Digit Substitution Test, Visual Verbal Learning Test, 
Working Memory Task, Stroop Colour-Word Test, Categoric Word Fluency Task 
and Concept Shifting Test. After controlling for differences in age, sex and 
education, it was found that the LGG patient group had significantly lower scores 
than the healthy control groups on measures in all of the aforementioned domains. A 
higher epilepsy burden was associated with slower information processing speed, 
impaired psychomotor function, working memory capacity and executive 
functioning. However, there was no association between higher epilepsy burden and 
impaired attentional functioning or verbal memory capacity. Further analysis 
suggested that patients using antiepileptic drugs performed less well than those not 
using antiepileptic medications on all domains, with the exception of verbal memory. 
This suggests that AEDs have a specific, negative effect on cognitive function, yet 
the seizures themselves have little impact. Although the tumour and treatment 
characteristics varied between patients, there was no significant overall difference in 
terms of sex, educational level, histological diagnosis, tumour lateralisation or 
treatment (surgical intervention and/or radiotherapy) in each of the patient subgroups 
and this minimises the potential confounding effects of these variables. Thus, the 
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potentially deleterious effects of AEDs should be considered in studies addressing 
cognitive function in cohorts of brain tumour patients, and in particular in studies of 
low-grade glioma patients.
1.5.3.2 Steroids
Corticosteroids are prescribed to the majority of brain tumour patients at some point 
during the course of their disease, and are primarily used to alleviate tumour-related 
vasogenic oedema and the associated symptoms (Koehler, 1995). Dexamethasone is 
the most commonly used corticosteroid prescribed to patients with brain tumours 
(Taphoorn and Klein, 2004). A number of studies have reported impairments in 
several different cognitive domains associated with the use of dexamethasone, 
including a decrease in immediate and delayed free recall in healthy participants
(Newcomer et al., 1994) and a positive correlation between severity of dementia and 
cortisol levels associated with use of dexamethasone in groups of patients with
Alzheimer’s disease (Balldin et al., 1983, Davis et al., 1986). Corticosteroids can 
also cause a steroid-induced psychosis, although this is a relatively rare and usually 
reversible complication (Kershner and Wang-Cheng, 1989). Thus, dexamethasone 
may play some role in causing cognitive impairment in brain tumour patients. 
However, it is more likely that steroid therapy in brain tumour patients works to 
alleviate cognitive impairment by reducing tumour-related oedema (Taphoorn and 
Klein, 2004).
1.6 Cognitive function as a prognostic indicator
Measurement of cognitive function in brain tumour patients has a potential utility as
a measure of the efficacy of a particular treatment, with or without an increase in
median survival time. More recently, studies have offered evidence for a further 
practical utility of cognitive testing in neuro-oncological patients: cognitive function, 
as measured by standardised tests, may serve as a prognostic indicator that could
indicate tumour progression, even before any evidence of this can be seen on MRI 
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scanning. This could facilitate the application of earlier therapeutic interventions that
could, in turn, result in improved outcome (Armstrong et al., 2003).
Therefore, a number of studies have examined the potential relationship between
measures that directly reflect brain function (i.e. cognitive function) and the duration 
of survival, specifically in patients with a glioma for whom survival times are 
limited. Meyers et al. (2000) examined the potential for cognitive function to predict 
survival in patients with recurrent malignant brain tumours. Eighty patients with 
recurrent GBM or anaplastic astrocytoma were recruited, each of whom completed 
baseline testing before commencing any post-surgical treatment. Follow-up sessions 
took place on a monthly basis thereafter and 58 patients (73% of the total cohort) had 
at least one follow-up session. The test battery was selected specifically to minimize 
the effects of repeated administration and lasted around 40 minutes in total. Tests 
administered to each patient included Digit Span as a measure of attention, Digit 
Symbol (graphomotor speed), Hopkins Verbal Learning Test (memory), Controlled 
Oral Word Association (verbal fluency), Trail Making Test Part A (visual-motor 
scanning speed), Trail Making Test Part B (executive function), Grooved Pegboard 
(motor speed and dexterity), Functional Assessment of Cancer Therapy (quality of 
life) and Functional Independence Measure (activities of daily living). Univariate 
Cox analyses of the nine cognitive tests revealed that baseline performance on seven 
of the nine variables was significantly related to survival. After adjusting for several 
potential confounding variables including age, Karnofsky Performance Score (KPS), 
histology and diagnosis-to-test interval, performance on a measure of memory 
(Hopkins Verbal Learning test) remained significantly related to survival. 
Multivariate analyses revealed that the clinical variables, histology (i.e. GBM or 
anaplastic astrocytoma) and number of tumour recurrences were significantly related 
to survival. The extent of resection, age, KPS, time since diagnosis and the number 
of previous surgeries were not significantly related to survival. However, better 
performance on three of the cognitive tests – Digit Span, Digit Symbol and Hopkins 
Verbal Learning Test – was significantly related to longer survival. Models 
incorporating scores on these three tests with the clinical variables accounted for 
49% of the variance in survival, compared with 34% when only the clinical variables 
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were included. When the nine cognitive scores were added to the clinical variables, 
53% of the variance in survival was accounted for. Thus, according to this study, a 
combination of tumour prognostic variables and assessments of cognitive function 
appear to more accurately predict survival than clinical variables alone. This again
highlights the potential importance of carrying out cognitive assessments with neuro-
oncological patients. 
Klein et al. (2003b) recruited 68 consecutive, newly-diagnosed patients with 
histologically-confirmed high-grade gliomas (WHO Grade III and IV) who were to 
receive radiotherapy, as part of a longitudinal study into cognitive functioning and 
health-related quality of life in high-grade glioma patients (Klein et al., 2001). The 
methodology of the study is described in section 1.3.1 of this chapter. In brief, 
cognitive, performance and functional status was assessed and the cognitive test 
battery included assessments of perception, memory, attention and executive 
function. At the time of analysis, 61 of the 68 patients included in the study had died 
and 7 patients were ‘censored’ and not included in the analysis due to a lack of 
survival data, although it unclear whether all 7 censored patients were still alive or 
whether some may have been lost to follow-up. The median survival of patients who 
had cognitive impairment was significantly shorter (6.8 months) than that of those 
who had no cognitive deficit (13.6 months). However, when age, tumour grade, 
lateralisation, size, neurosurgical intervention (biopsy or resection), performance 
status and cognitive status were all included in a multivariate Cox proportional 
hazards model, only older age and higher tumour grade were independently related to 
poorer survival. Although cognitive status was not found to be independently 
predictive of survival in this combined model, the presence of cognitive deficit at the 
time of surgery in older patients with WHO Grade IV glioma (i.e. patients older than 
50 years; n = 42), but not in the other patient groups, was associated with 
significantly poorer survival. Therefore, this study suggests that, in older patients 
with GBM, cognitive functioning may have some prognostic value, although larger 
cohorts of patients may be required to confirm this finding. Again, this highlights the 
utility of cognitive testing, not only to provide important clinical information that can 
inform suitable interventions, but as a possible prognostic indicator, at least in older 
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patients with GBM. However, no attempt was made to measure premorbid ability in 
this study and a relatively small number of patients were enrolled which may 
question the validity of this finding. Nevertheless, this study paves the way for future 
research into this area that should include larger cohorts of patients with a greater age 
range. 
Meyers and Hess (2003) have shown that cognitive deterioration may actually be the 
first sign of tumour progression, in the absence of radiological evidence of 
progression on CT or MRI scanning. Fifty-six patients with recurrent glioblastoma or 
anaplastic astrocytomas completed assessments of cognitive function, quality of life 
and ability to carry out activities of daily living prior to treatment and at regular 
intervals forthwith. Specifically, the test battery included measures of attention span 
(Digit Span test); graphomotor speed (Digit Symbol Coding); memory (Hopkins 
Verbal Learning Test); verbal fluency (Controlled Oral Word Association Test); 
visual-motor scanning speed and executive function (Trail Making Test Parts A and 
B) and motor speed and dexterity (Grooved Pegboard). Quality of life was assessed 
by the Functional Assessment of Cancer Therapy and activities of daily living were 
measured by the Functional Independence Measure. It was found that cognitive 
decline, as revealed by a battery of neurocognitive tests, occurred approximately 
50% earlier (6 weeks) than MRI evidence of tumour progression. When only scores 
on the 3 tests most sensitive to cognitive decline were included in analyses, cognitive 
decline as measured by the Reliable Change Index (RCI) was still found to occur 
more than a month prior to MRI evidence of tumour progression. This decline was
observed even although improvement in performance on the tests was expected due 
to practice effects. Thus, it was concluded that direct assessment of brain function by 
means of cognitive testing is more sensitive than MRI scanning evidence of time to 
progression and could predict tumour recurrence more than a month prior to MRI 
confirmation of this tumour progression. This finding again points to the importance 
of carrying out serial cognitive assessment in patients with brain tumours. 
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1.7 Issues associated with measurement of cognitive 
function in brain tumour patients
As has been shown, measurement of cognitive function in brain tumour patients at 
various times throughout the disease journey can convey numerous benefits in terms 
of assessing the patient’s ability to carry out daily activities, offering targeted 
interventions to ameliorate the effects of such impairments and to guide treatment 
decisions. Detailed cognitive assessment can provide a measure of the efficacy of 
new and existing treatments and may provide a means of identifying tumour 
progression before structural evidence of this can be seen on an MRI scan. However, 
cognitive assessment of brain tumour patients can be particularly problematic and a 
number of different variables may threaten the validity of in-depth cognitive 
assessments.
Several demographic factors - namely age, gender and educational level are known 
to have a significant effect on cognitive test scores (Laursen, 1997). When analysing 
and comparing cognitive test scores between two or more groups of participants, it is 
important to not only control for the effect of age and gender during the analysis 
procedure but also to consider the premorbid ability of the patient. The National 
Adult Reading Test (NART) is commonly employed as an estimate of prior 
intelligence in studies of cognition in several different clinical populations. NART 
score is significantly correlated with measures of full-scale intelligence, and 
importantly, has been shown to provide an index of prior, as opposed to current, 
intellectual function in clinical populations (Crawford et al., 2001). However, given 
that the test involves reading aloud a list of words, performance is largely dependent 
upon intact speech function. Many patients with brain tumours will experience 
speech impairment to some degree during the course of their disease, although this is 
largely dependent upon the location of the tumour. No studies have investigated the 
validity of the NART as an index of premorbid ability in patients with brain tumours. 
However, it is possible that, when administered to patients with some degree of 
dysphasia and/or confusion, the task may not have the same validity as it has been 
shown to have in studies of healthy individuals. Certainly, NART performance has 
been shown to be compromised in patients with Alzheimer’s disease, with NART 
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performance becoming progressively worse as disease severity increases (O'Carroll 
et al., 1995). Therefore, since no validation studies have been carried out to date, the 
NART may not be a feasible tool with which to estimate premorbid ability in patients 
with brain tumours.  
Successful performance on cognitive tests often depends upon a large number of 
discrete functions. However, many standardised cognitive tests also rely heavily on 
the intactness of more basic functions such as motor and sensory and abilities, in 
addition to the participant having a normal level of consciousness (Taphoorn and 
Klein, 2004). Since a number of brain tumour patients experience mild focal 
neurological deficits especially of language, motor function and/or vision, successful
performance of even short relatively tests may be impeded if the patient does not 
have suitable vision with which to see the stimulus materials, or has a hemiparesis 
that prevents successful completion of paper and pencil tasks (Zbinden et al., 2006).
Inaccurate test data may be gathered as a result of emotional distress on the part of 
the patient and is a further problem associated with carrying out cognitive 
assessments with neuro-oncological patients. Emotional distress can result in reduced 
attention, vigilance and motivation, and each of these functions play an integral role 
in successful completion of almost all cognitive assessments (Taphoorn and Klein, 
2004). The issue of heightened emotional distress must be given particular 
consideration when assessing cognitive function in patients with brain tumours. 
Kilbride et al. (2007) report heightened levels of anxiety in brain tumour patients 
after surgery and before commencing radiotherapy as measured by the Hospital 
Anxiety and Depression Scale (HADS), with a greater prevalence of anxiety 
specifically reported in younger patients. Furthermore, Grant et al. (1994) found that 
depression has a negative impact on performance on tests assessing memory and 
language domains (Williams Delayed Recall Test and Boston Aphasia Severity 
Rating Scale) and Pringle et al. (1999) report that patients with a meningioma 
experienced higher levels of anxiety and depression as measured by the HADS than 
those with any other type of tumour. The study also suggested that levels of both 
anxiety and depression were found to be significantly lower after surgery compared 
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to measures taken before surgery, as measured by the HAD Scale. Since the presence 
and extent of emotional distress is likely to fluctuate throughout the patient’s 
journey, this could have a significant effect on the results of serial cognitive 
assessments, with poorer performance during periods of heightened anxiety perhaps 
reflecting greater emotional disturbance as opposed to treatment effects.
Klein et al. (2001) suggest that recruiting a comparison group of patients with a non-
CNS cancer diagnosis is a useful means of controlling for the unique stressors 
associated with a diagnosis of cancer and their potential effects on cognitive test 
performance. However, in a detailed study, Andrewes et al. (2003) explored the 
emotional and social function of brain tumour patients in the post-surgical period. 
Following surgery, patients completed the Emotional and Social Dysfunction 
questionnaire (ESDQ). The ‘partner’ version of the questionnaire was completed by 
the patient’s spouse or someone with a similar relationship who knew the patient 
well. The brain tumour patients and their partners were compared with 49 self-rating 
controls with a terminal cancer diagnosis who had undergone surgery to extra-
cerebral areas and 44 partner-related controls. The brain tumour group comprised 
patients with astrocytoma (n=13), meningioma (n= 26), neuroma (n=13) and 
pituitary adenoma (n=17). It was found that in the post-surgical period, brain tumour 
patients suffered more emotional and social dysfunction as measured by the ESDQ 
than the matched control group. Specifically, post-hoc analyses revealed significantly 
increased self-rating of the astrocytoma patient group on the anger, helplessness,
inertia, fatigue, indifference, euphoric and inappropriate scales, compared with 
controls. Moreover, when the brain tumour patients were divided more generally into 
benign and malignant tumour groups, the malignant group rated themselves 
significantly worse on the self-report and partner versions of the ESDQ. This study
questions the utility of recruiting different groups of cancer patients to serve as a 
control group (Klein et al., 2001), since the brain tumour patients in this study 
reported higher levels of emotional dysfunction than controls who had a similar 
prognosis and surgical treatment. Thus, the potential effect of the unique emotional 
distress that brain tumour patients experience may not be eliminated by recruiting 
other cancer patient groups for comparison. However, an adequate control group is 
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extremely important to allow these effects to be controlled for as much as feasibly 
possible.
Comprehensive assessment of cognitive function requires a battery of tests that 
assess a number of different cognitive domains including language, attention, 
memory and executive functions (Taphoorn and Klein, 2004). However, completing 
a detailed battery of cognitive assessments is time-consuming and may therefore 
fatigue or be particularly stressful for patients with brain tumours. In turn, increased 
fatigue or feelings of stress may reduce motivation and, in turn, negatively influence 
test scores. Additionally, patients are less likely to take part in studies that place 
considerable demands upon the participant and as a result, test scores may be 
unrepresentative (Scotland et al., 2009). Therefore, some studies have employed 
short cognitive screening tools, such as the Mini Mental State Examination (MMSE) 
as a measure of cognitive functioning, particularly when assessing the cognitive 
effects of radiotherapy on brain tumour patients (Brown et al., 2003). However, the 
shortcomings of the MMSE as a measure of cognitive dysfunction in brain tumour 
patients have been highlighted (Meyers and Wefel, 2003). The MMSE was initially 
devised as a brief screening tool for dementia and although it is sensitive to severe 
cognitive dysfunction, scores in the “normal” range (a score ≥ 27/30 points) may not 
necessarily reflect intact cognition. Moreover, Meyers and Wefel (2003) suggest that 
stable MMSE scores over time do not necessarily reflect no significant change in 
cognitive function. The MMSE specifically assesses aphasia, apraxia, orientation and 
attention. However, a number of other cognitive functions have been shown to be 
impaired in brain tumour patients, including learning, memory, executive function 
and processing speed. Therefore, brief assessments of cognition such as the MMSE 
are likely to be insensitive to cognitive impairment in a large proportion brain tumour 
patients and there is therefore a need for more sophisticated and discriminating 
neurocognitive assessment tools for use in cohorts of patients with brain tumours
(Klein and Heimans, 2004). 
A number of cognitive tests comprise only one version and as such are unsuitable for 
repeated assessment since practice effects may artificially inflate scores on 
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subsequent testing sessions. Practice effects have been found to be particularly 
evident on tests that have a large speed component, require a unique and unfamiliar 
response mode or have a single solution and practice effects are of particular 
importance in tests of memory since repeated assessment inevitably results in 
learning of test materials (Lezak et al., 2004). Some tests have specifically been 
designed for repeated assessment and have alternate forms that significantly reduce 
practice effects. However, the proportion of cognitive tests that fulfil suitability 
criteria for repeated assessment is small since these alternate forms of the same test 
must have interform reliability (Lezak et al., 2004). Thus, practice effects are an 
important consideration in many studies that conduct serial cognitive assessments in 
brain tumour patients, for example, to assess the effect of a specific treatment 
regime. 
Weitzner and Meyers (1997) suggest that, in order for neurocognitive tests to be 
useful in clinical trials involving brain tumour patients, they must be short, 
repeatable, sensitive to change and a test battery should measure different brain 
functions. However, due to the aforementioned problems inherent in the 
measurement of cognition in this group, many commonly-used methods of 
assessment fall short of this standard. It would therefore be desirable to have an 
assessment method that not only avoids the plethora of problems inherent in 
measuring cognition in brain tumour patients, but also measures an important 
function.
1.8 Brain Tumours and Information-Processing 
In addition to the specific cognitive deficits many brain tumour patients experience 
throughout the course of their illness, many patients also present with a generalised 
psychomotor or information-processing slowing, with or without focal neurological 
deficits. Until recently, no useful assessment tool had been identified as a means of 
measuring the extent of this slowing in information-processing that is common to
patients with brain tumours. However, Zbinden et al. (2006) performed a preliminary 
study to examine whether inspection time, a measure of the efficiency of the brain’s 
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visual information processing, was impaired in patients with intracranial tumours.
Twenty-three newly diagnosed brain tumour patients who were to undergo surgery to 
biopsy or resect the tumour were recruited into the study and were compared with 24 
age and sex-matched control patients who were having elective spinal surgery. Both 
groups of patients completed a battery of neuropsychological tests that assessed a 
number of different aspects of cognition, including the Rey Auditory Verbal 
Learning Test (a measure of learning and memory), National Adult Reading Test
(premorbid function), Digit Symbol Coding (processing speed and attention), Trail
Making Test Part B (mental flexibility) and the Edinburgh Functional Impairment 
Tests (EFIT; which provide a measure of memory, speech and limb function). Visual 
information processing was assessed by the inspection time test. The inspection time 
test is a two-alterative, forced choice, computer-based measure and the test 
methodology and background is fully described in Chapters 2 and 3. Patients 
completed these tests pre-operatively and repeated a number of the measures, 
including inspection time, in the post-operative period. To compare pre-operative test 
scores, general linear modelling was used with age included as a covariate since 
inspection time scores were found to correlate with patient age. Patients with brain 
tumours had significantly lower inspection time scores than the control patients,
indicating a slowing in visual information processing at the time of presentation. 
However, no significant differences were found between the brain tumour and spinal 
surgery groups on any of the other cognitive measures that were administered in the 
pre-operative period. Moreover, the spinal surgery control cohort did not differ 
significantly in terms of pre- and post-operative inspection time score, with all
patients scoring within ± 5% of their pre-operative score when tested at follow-up. 
However, in the brain tumour cohort, although there was no significant overall 
change in post-operative inspection time score, 70% of the cohort either increased or 
decreased their IT score by between 5 and 20%, with 9 patients showing significant 
improvement and 7 deteriorating significantly. This preliminary investigation thus 
suggests that visual inspection time may be a potentially useful measure in clinical 
neuro-oncology. The task itself overcomes many of the problems associated with 
measuring cognition in neuro-oncological patients and the specific advantages the 
task holds as a method of assessment in brain tumour patients and other clinical 
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populations and a review of the inspection time literature are discussed further in 
Chapter 2.
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2 Inspection Time 
2.1 History of Inspection Time
The study of individual differences in cognitive ability, and the underlying causes of 
these differences, is an area of research that has been of interest to both scientists and 
psychologists for many years. Galton (1883) and Spearman (1904), both pioneers of 
research into intelligence, believed that individual differences in mental ability could 
be explained by differences in performance of the most simple of psychological 
functions (Deary and Stough, 1996). More recently, research in this area has returned 
to the theoretical stance of these authors, with reductionist efforts used to examine 
the structure of human cognition and mental ability. This area of research subscribes 
to the idea that studying the most basic cognitive processes will further our 
understanding of individual differences in intelligence, since these basic processes 
correlate with higher mental abilities. Reaction time paradigms, and other tasks that 
involve measuring the speed with which a simple task is performed, have commonly 
been employed by researchers in an attempt to explain human intelligence 
differences and a small but consistent association between reaction time and 
psychometric intelligence has been found (Deary and Stough, 1996). However, there 
exists some controversy over exactly what are the fundamental processes that 
reaction time tasks measure and task results can be confounded by motor problems
and practice effects (Widaman and Carlson, 1989). These reaction time studies have 
therefore been unable to identify a basic process that can account for a significant 
proportion of the variance in human intelligence (Deary and Stough, 1996).
Given the limitations of reaction time paradigms in determining the underpinnings of 
human cognitive abilities, the inspection time task has attracted a great deal of 
interest in this area. Of the tasks that claim to measure the most elementary cognitive 
processes, inspection time has perhaps proven to have the greatest potential to 
account for the differences in human intelligence. The task itself correlates 
significantly with a number of different standardised tests of psychometric 
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intelligence. Moreover, it has a clinical utility and has been used to assess the early 
stages of visual information processing in a number of different clinical and non-
clinical groups. The neuroanatomical correlates of the inspection time task itself have 
been studied in functional MRI (fMRI) studies and the task has also been 
administered to groups of children, and employed as a potential tool to explain the
observed deterioration in general cognitive function with increasing age in older 
adults. This chapter will therefore discuss: the relationship between inspection time 
task performance and higher mental abilities; the neuroanatomical substrates of the 
task; inspection time studies in children and older adults; the potentially heritable 
nature of the task; and the utility of the inspection time task as an assessment 
measure in a number of different clinical groups. 
2.2 Method of Testing
It is useful to first give an overview of what the typical method of inspection time 
testing involves. Measuring an individual’s inspection time is a relatively 
straightforward process and this immediately gives the task an advantage over many 
other, more complex methods of cognitive assessment. There exist several different 
methods of testing, however, the two forms of a typical inspection time stimulus are 
shown in Figure 2.1. Each stimulus shape comprises two parallel, vertical lines 
joined by a shorter horizontal bar at the top. The stimulus is shown in each trial in the 
form of one of the versions shown: it has either a longer leg on the left or a longer leg 
on the right. Discriminating between which line is longer (i.e. left or right) is a 
simple task for most individuals provided they have adequate visual function. 
However, if the stimulus is presented for a very short amount of time and is 
subsequently covered by a backward mask, this can make discriminating between the 
lengths of the lines very difficult indeed. The backward mask used in the inspection 
time task consists of a jumble of vertical lines that create a forest-type mask (see 
Figure 2.2). This mask essentially prevents the stimulus from being processed any 
further. The time between the beginning of the stimulus presentation and the onset of 
the backward mask is known as the stimulus onset asynchrony (SOA; Sadler and 
Deary, 1996).
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Figure 2.1. The two possible stimulus shapes shown 
during each inspection time trial.
Figure 2.2. Two possible sequences of events in each inspection time trial
In early inspection time research efforts the task was presented tachistoscopically
(Vickers et al., 1972, Nettelbeck and Lally, 1976). A tachistoscope is an instrument 
that can be used to project images onto a screen for precise, varied periods of time, 
and is accurate to a few milliseconds. In the present day, a computer with a fast 
vertical refresh rate is used to present the stimuli and to record participants’ 
responses. 
The inspection time task comprises a number of trials, the sequence of events for 
each single trial can be seen in Figure 2.2. In each trial the participant is shown a 
warning cue (cross) in the centre of a computer screen. This cross is then replaced by 











mask to prevent any further processing of the stimulus. In each trial, the participant is 
required to indicate, by means of pressing a button on the computer keyboard, which 
of the lines was longer (left or right). The method of administration of the test varies 
between studies. The commonly-used version of the task includes a large number of 
experimental trials, in which the stimuli shapes are shown randomly at differing 
durations in order to provide an estimate of the participant’s inspection time. In the 
version of the task employed in the present study, the durations for which the shapes 
are shown ranges from 200ms to 6ms, with 10 presentations at each duration. The 
participant undertakes a number of practice trials prior to the test trials. This allows a 
detailed explanation of the task to be given and the participant is given the 
opportunity to become familiar with the task prior to undertaking the test trials. 
Participants are instructed that there are no requirements to respond quickly, and that 
responses should be made at leisure. A participant’s inspection time is often 
expressed as the duration required for a given level of accuracy in responding to be 
achieved, e.g. 85% or 90%. However, a total accuracy score of correct responses 
from a total of 150 is also frequently used to measure inspection time. Usually data 
from those participants who score <17/20 on the longest two stimulus durations 
(150ms and 200ms) are considered invalid as most participants should be able to 
obtain a near perfect score at these durations if the task has been properly 
understood. Thus, any participant who scores <17/20 on the two longest presentation 
durations may not have fully understood the task instructions.
The inspection time task is therefore a relatively quick and simple measurement of 
the early stages of visual information processing that can be applied to a number of 
different groups of participants. 
2.3 Theory of Inspection Time
Although the inspection time task was designed to be essentially theory-neutral, the 
underlying rationale of the inspection time task is based largely upon two main 
theories (Vickers and Smith, 1986). The first of these is a perceptual model of 
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discrimination that assumes visual information is gathered from the environment in 
small ‘quanta’ (Vickers, 1970). The second theory is termed the ‘accumulator model’ 
of decision making. This model postulates that, in order to make a forced choice 
discrimination, an individual will take a series of samples of the available sensory 
information until a critical amount of information has been obtained, such that one of 
the stimulus alternatives is favoured (Nettelbeck and Lally, 1976, Deary and Stough, 
1996). This is referred to as an ‘optional stopping process’. Optional stopping models 
assume that responses will reflect the level of caution with which the decision is 
made. Thus, this type of model will reflect the speed-accuracy trade-off. Vickers et 
al. (1972) proposed that, in some instances, a single observation might provide 
enough information from which to make a forced-choice decision and were 
interested in how quickly this observation could be made. Thus, the inspection time 
task was devised and the term ‘inspection time’ itself was defined as:
“the time required by a subject to make a single observation or inspection of the 
sensory input on which a decision of relative magnitude is based” (Vickers et al., 
1972).
In early inspection time studies, it was initially hypothesised that inspection time 
would be around 100ms and there would be little inter-individual variation. 
However, average inspection time was found to be 105ms but a great deal of 
variation between participants was observed, with estimates ranging from 74 – 144 
ms. Since the design of the paradigm is such that the effects of sensory noise and 
other variables are minimised, it was proposed that inspection time may provide a 
useful measure of the time taken to make a single observation of sensory input that 
may be a basic factor that limits perceptual speed and cognitive performance more 
generally (Vickers and Smith, 1986).
2.4 Inspection Time and Higher Mental Abilities
The idea that individual differences in the speed of mental functioning, as measured 
by the inspection time task, may be somehow related to individual differences in 
intelligence, as measured by cognitive and IQ-type tests, has attracted a great deal of 
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interest. A large number of studies have been carried out to determine whether this 
theory is supported and inspection time does account for some of the variance in 
human mental ability. These studies have been carried out using a variety of different 
clinical and age groups and studies have used a variety of different cognitive and 
intelligence tests as surrogate measures of intelligence. Moreover, different versions 
of the inspection time task have been devised, including an auditory version as well 
as the more frequently employed visual version of the task (Deary et al., 1989, Parker 
et al., 1999). 
Nettelbeck and Lally (1976) were among the first authors to report a significant 
correlation between inspection time scores and performance on the Wechsler Adult 
Intelligence Scales. This was an extremely significant finding which paved the road 
for research in the years to come, and this research continues to the present date. 
However, given that their study recruited only a small number of participants (n = 
10) who had widely ranging IQ scores, the relationship between inspection time and 
IQ (IT-IQ) was likely to have been somewhat exaggerated. As a result, subsequent 
studies questioned whether the finding could be replicated within the general 
population. Nettelbeck and Kirby (1983) found that the IT-IQ correlation was 
considerably lower when data from participants with exceptionally low IQ scores 
were excluded from analyses. However, this was not the case when those with high 
IQs were not included in analysis. Therefore, results of early studies examining the 
relationship between inspection time and general intelligence were somewhat 
contradictory. Lubin and Fernandez (1986) concluded that the variability in results 
across different studies meant that no definitive conclusions could be drawn with 
regards to the potential existence of the IT-IQ relationship.
Kranzler and Jensen (1989) carried out a meta-analysis, accumulating data from all 
studies that had examined the IT-IQ relationship until this date. Their primary aim 
was to determine whether the IT-IQ relationship does in fact exist, and if so, to 
estimate the size of the relationship between inspection time and intelligence. They 
included 31 separate studies, both published and unpublished, with 1,120 participants 
in total. The meta-analysis found that inspection time is (negatively) related to IQ, 
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and this relationship is particularly strong with measures of general IQ and 
performance IQ. For adults with general IQ scores, an uncorrected correlation of -.30 
with inspection time scores was obtained. After correcting for artifactual error 
sources (e.g. sampling error, attenuation and range restriction), the correlation was -
.54. This meta-analysis therefore provided strong evidence to support the existence 
of the IT-IQ relationship.
More recently, the above-described meta-analysis has been updated in a further 
examination of the relationship between inspection time and IQ (Grudnik and 
Kranzler, 2001). More than 90 published and unpublished studies were included, 
with a total of 4,200 participants. Again, this meta-analysis found evidence to 
suggest there is a substantial relationship between inspection time and IQ. These 
authors report that, in the total sample, an uncorrected correlation of -.30 between 
inspection time and IQ was obtained. When artifactual effects of sampling error, 
error of measurement and range variation were corrected for, the correlation between 
inspection time and intelligence was found to be -.51  and this relationship was 
generally the same for adults and children ( -.51 and -.44 for adults and children, 
respectively). Grudnik and Kranzler (2001) also extended the previous meta-analysis 
by addressing two new questions with regard to the IT-IQ relationship. Firstly, they 
examined whether the relationship is the same across different types of inspection 
time task - auditory inspection time and the more commonly employed visual version 
of the task. Auditory versions of the inspection time task have been developed in an 
attempt to determine whether the IT-IQ relationship is unique to measures of visual 
information processing or whether it is a general property of the sensory systems. 
Early versions of the auditory inspection time (AIT) task involved presentation of 
two differently pitched tones at durations of between 200msec and 6msec. The 
participant was required to indicate in which order the tones were presented, i.e. high 
– low or low – high (Deary et al., 1989).  More recently, Parker et al. (1999) devised 
an AIT task that they proposed would overcome the limitations associated with the 
original version – predominantly its reliance on the participant’s ability to 
discriminate between frequencies which was reported to be excessively difficult for a 
number of participants (Irwin, 1984). The revised version of the AIT required the 
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participant to indicate the apparent location (left or right) of a tone that was delivered 
via headphones to produce a ‘dichotic phantom’. The duration of a backward masked 
tone was varied in order to provide an estimate of auditory inspection time. Grudnik 
and Kranzler (2001) found the mean corrected correlations for visual and auditory 
inspection time tasks with IQ measures were -.49 and -.58 respectively and this 
suggests that the relationship is similar for both versions of the inspection time task. 
Thus, the IT-IQ relationship has been well-established and it would appear that the 
relationship exists for both visual and auditory versions of the task.
Attempts to explain the significant correlation between inspection time and 
intelligence have looked upon inspection time as measuring the speed of a single 
mechanism such as “sampling input” (Nettelbeck, 2001). Brand is a strong supporter 
of the theory that inspection time measures inter-individual differences in speed of 
perceptual processing and it is this basic “mental speed” construct that underpins 
individual differences in intelligence (Brand, 1996). However, although some 
authors subscribed to this idea that individual differences in inspection time (i.e.
differences in ‘mental speed’) are in part responsible for individual differences in 
general intelligence, some researchers take an opposing stance and propose that 
better scores on inspection time tasks (i.e. quicker speed of processing) is simply the
result of having higher intelligence scores (Howe, 1988). A number of theories to 
support this proposal have been postulated. It has been suggested that the IT-IQ 
relationship may exist simply because more intelligent individuals are more highly 
motivated to complete the inspection time task (Mackintosh, 1998), or that those 
with a higher IQ tend to be less anxious during such tasks, which may have a 
facilitating effect on inspection time performance (Irwin, 1984). A further proposal is 
that more clever participants tend to form strategies that facilitate performance on 
even simple cognitive tasks such as the inspection time paradigm (Grudnik and 
Kranzler, 2001). These theories would all point to inspection time being simply 
another task in which clever people perform better. However a number of other 
studies have generally refuted this idea that good inspection time performance is a 
result of being more intelligent. The most commonly reported strategy employed by 
participants is the use of apparent motion cues, described by Luciano et al. (2005) as 
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a flicker radiating from the bottom of the shorter line on appearance of the mask. 
Egan (1994) found that although participants who reportedly employed these cues 
had shorter (i.e. faster) inspection times, they did not also have higher IQ scores. 
Furthermore, the aforementioned meta-analysis suggests that strategy utilisation in 
fact impedes inspection time performance, providing evidence against the idea that 
better inspection time performance is the result of having a higher IQ (Grudnik and 
Kranzler, 2001). Moreover, further support for the idea that it is inspection time 
differences that account for some of the variance in IQ scores comes from the use of 
more effective backward masking procedures in the inspection time task, which 
render the task more resistant to strategy use. Evans and Nettelbeck (1993) found 
that the use of backward masking procedures in the IT task has no effect on the 
obtained correlation between inspection time task score and intelligence. Finally, 
Stough et al. (1996) refute the idea that inspection time and IQ are related because of 
personality and/or temperament variables, reporting that personality factors 
indicative of a more motivational temperament did not mediate the IT-IQ 
relationship. It would therefore appear that there exists little or no evidence to 
suggest that strategy use and personality factors play a significant role in the IT-IQ 
relationship. 
Further evidence points to the fact that it is differences in the efficiency of 
information processing, as measured by the inspection time task that can explain a 
significant proportion of human intelligence differences. Deary (1995) carried out a 
study in which children (n = 104) were given an auditory inspection time task and IQ 
tests at age 11 and again at age 13. Three possible models were tested: that AIT at 
age 11 causes later IQ at age 13; that IQ at age 11 causes later AIT at age 13; or that 
there is equal reciprocal causation. It was found that the first model was the best fit 
and inspection time score at age 11 was found to predict IQ score at age 13 but that 
the reverse was not true. This finding therefore supports the theory that inspection 
time accounts for some of the observed individual differences in IQ. There is little 
evidence to suggest that it is IQ that causes inspection time scores, and this study 
suggests that the converse is more likely to be true, and inspection time may account 
for approximately 20% of intelligence test variance (Deary, 1995).
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Therefore, a substantial amount of evidence exists to suggest that inspection time 
accounts for a substantial minority of individual differences in human intelligence
and research has now been directed towards examining whether inspection time is 
differentially related to specific aspects of cognitive function.
2.4.1 Inspection time and factors of intelligence
Carroll (1993) found that there are several group factors within cognitive ability and 
these include crystallized intelligence, fluid intelligence and processing speed, 
among others. These group factors load on a higher-order general intelligence (‘g’) 
factor (Petrill et al., 2001). Johnson et al. (2008) found evidence to support the idea 
that there is a unitary general intelligence construct (‘g’), in a study that found the 
correlations between the ‘g’ factors obtained from five different cognitive test 
batteries were consistently high. Together with the results of a previous, similar 
study (Johnson et al., 2004b), this study not only supports the idea of a general 
intelligence factor but also suggest that most assessments of cognition identify a 
common underlying component of general intelligence. Since it is now generally 
accepted that there is a highly significant association between inspection time and 
measures of psychometric intelligence, research efforts have shifted focus towards 
specific examination of whether inspection time is differentially related to different 
types of cognitive abilities and, in particular, whether inspection time is related to 
intelligence at the general ‘g’ level or whether it contributes to group factors. The 
strength and indeed the very existence of the IT-IQ correlation have been shown by 
numerous studies to be dependent upon the tests used for comparison, with certain 
cognitive ability measures correlating more strongly with inspection time than others 
(Burns et al., 1999). 
The IT-IQ relationship is stronger for measures of performance IQ (‘fluid’
intelligence) as opposed to tests that measure verbal IQ (‘crystallized’ intelligence,
(Kranzler and Jensen, 1989). Deary (1993) recruited 87 participants from a diabetic 
outpatient clinic, each of whom completed the Wechsler Adult Intelligence Scales 
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(WAIS) and the inspection time task. The participants were otherwise healthy and 
had varied educational and social backgrounds. Three stages of analysis including 
correlations, exploratory factor analysis and confirmatory factor analysis revealed 
that although inspection time had a near zero loading on a verbal factor, it loaded 
highly on the WAIS subtests that measure performance IQ. Inspection time therefore 
appears to be significantly related to performance IQ, but is only weakly related to 
verbal IQ. These results support previous studies that have found inspection time to 
be significantly more strongly related to measures of performance IQ (Kranzler and 
Jensen, 1989). Although a clinical population comprised the sample for this study, 
full-scale IQ scores had an approximate near-normal distribution, suggesting that the 
sample were likely representative of the general population although future studies 
should seek to confirm Deary’s (1993) findings in a cohort of healthy participants.
Similarly, Osmon and Jackson (2002) examined the relationship between inspection 
time performance and three specific aspects of intelligence using three factors from 
the Woodcock-Johnson Battery of Cognitive Ability (Revised) – the visual 
processing factor (Gv), the fluid intelligence factor (Gf) and also the crystallized 
intelligence factor (Gc). Forty college students (19 male and 21 female) completed 
inspection time testing, in addition to six tests from the aforementioned battery in 
order to obtain the three factor scores. The six tests included Visual Closure and 
Picture Recognition (visual processing; Gv); Picture Vocabulary and Oral 
Vocabulary (crystallized intelligence; Gc); and Analysis-Synthesis and Concept 
Formation (fluid intelligence; Gf). Correlations, partial correlations and multiple 
regression were used to evaluate any relationships between inspection time and the 
three intelligence factors studied. There was found to be a moderately strong 
correlation between inspection time and the visual processing factor and inspection 
time and the fluid intelligence factor. However, after controlling for its relationship 
with fluid intelligence, the relationship between inspection time and the visual 
processing factor was no longer significant. The partial correlation between 
inspection time and fluid intelligence remained significant after controlling for the 
relationship with visual processing. To predict inspection time using fluid, visual 
processing and, crystallized intelligence factors, forward stepwise multiple 
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regression was carried out. This showed only the fluid intelligence factor to be a 
significant predictor of inspection time. Therefore, this study offers further support to 
suggest that inspection time is specifically related to a measure of fluid intelligence
(i.e. performance IQ). However, the findings of this study must be accepted with a 
certain degree of caution given the relatively small sample size with an age range 
(mean 23.61 years, SD = 7.04) and a likely restricted range of intelligence, with low 
IQ participants under-represented in the study since the participants comprised 
college students. The authors themselves suggest that due to a combination of these 
factors, the large correlation found to exist between fluid intelligence and inspection 
time may be the result of sampling error. Additionally, the authors acknowledge that 
the mask used in the inspection time task may have resulted in inspection time values 
being inaccurately low since it has previously been shown that use of this traditional 
form of the mask results in around 50% of college students employing an “apparent 
motion” strategy which makes it possible to perceive quicker presentation rates. 
Therefore, given the sample of students recruited into the study, the inspection time 
values obtained cannot be taken as an accurate reflect of inspection time in these 
participants. Thus, it is proposed that future work should involve replication of the 
study using an auditory as opposed to visual version of the inspection time paradigm. 
Should a similar relationship between inspection time and fluid intelligence be found 
when an auditory version of the task is used, the hypothesis that inspection time 
reflects some fundamental components of fluid intelligence could be accepted with 
greater confidence (Osmon and Jackson, 2002)
Petrill et al. (2001) examined whether inspection time is related to psychometric 
intelligence through group factors, general factors, or both. Five hundred and sixty-
eight identical and fraternal twins were recruited, ranging in age from 6 to 13 years. 
Each participant was tested on three separate occasions. The 11 subtests from the 
Wechsler Intelligence Scale for Children – Revised (WISC-R) were administered as 
a measure of psychometric intelligence. Elementary cognitive tasks, including 
simple-choice reaction time, Stimulus Discrimination (SD), Probe Recall (PR) and 
Tachistoscopic Threshold (TT), all from the Cognitive Abilities Test battery were 
also administered to each participant. The Tachistoscopic Threshold task is a 
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computer-based task in which two diagrams were presented simultaneously for a 
brief duration and were then masked. Participants were required to determine 
whether the two diagrams were the same or different and the task was used as a 
measure of visual information processing, instead of the inspection time task, in this 
study. After correcting for the effects of age and sex, it was found that inspection 
time (as measured by the Tachistoscopic Threshold task) and other elementary tasks 
(SD, PR and simple-choice reaction time) predict general intelligence. In keeping 
with results of studies described above, it was also found that inspection time 
predicts performance ability independent of other elementary tasks. Elementary task 
scores were found to account for 31% of the variance in general psychometric ability 
(‘g’) with 26% of this variance related to a factor comprised of motor-based tasks 
and inspection time. The other 5% of the variance in ‘g’ accounted for by elementary 
tasks was found to be related specifically to inspection time. In terms of the variance 
in performance (fluid) IQ, 3% of the variance is related to inspection time, but not 
other elementary tasks. Petrill et al. (2001) propose that these findings suggest 
inspection time may tap variance that is unique to performance (fluid) and general IQ 
that is not measured by motor-based tasks such as reaction time. Future studies that 
involve administration of other, more commonly-used versions of the inspection time 
task, as opposed to relying solely on the Tachistoscopic Threshold task, as well 
administering a larger battery of intelligence tests, would help to confirm these 
preliminary results.  
Therefore, it has been proposed that inspection time correlates most strongly with 
measures of fluid intelligence and this has been based upon the premise that 
performance IQ tests from the WAIS provide a measure fluid ability. However, 
Burns and Nettelbeck (2003), in a study that aimed to fit the inspection time within a 
model of cognitive ability, concluded that performance IQ measures from the WAIS 
do not in fact measure fluid ability. Ninety adult participants were administered a 
battery of psychometric and chronometric tasks including inspection time, and 
measures of reaction time. It was found that inspection time loaded on a general 
speed factor and a general ability factor, but not on a fluid ability factor. Moreover, 
the study found that none of the performance IQ measures from the WAIS loaded on 
61
fluid ability and the authors therefore conclude that inspection time does not measure 
fluid ability. The finding that inspection time was related to a general speediness 
factor and also to a general ability factor suggests that information-processing speed 
may be common to all cognitive abilities, and this theory should be investigated 
further in future studies (Burns and Nettelbeck, 2003). 
Therefore, in more recent years, there has been a shift from testing the strengths of 
the IT-IQ relationship with research efforts now focusing on: examination of the 
processes that are involved in performing the inspection time task; the types of 
mental ability that correlate most strongly with inspection time; the reasons for the 
inspection time - ability correlations; the biological bases of inspection time 
performance; and practical applications of inspection time testing. 
2.5 Neuroanatomical Substrates of Inspection Time
Given that inspection time scores have consistently been found to account for a 
substantial minority of the variance in human intelligence, research has shifted focus 
to examine the biological basis of the task, with studies attempting to elucidate the 
specific brain processes that may be involved during visual information processing, 
as measured by the inspection time task. 
2.5.1 Functional MRI Scanning Studies
Further research has since been directed towards obtaining more detailed information 
regarding the brain processes involved in the inspection time task. Deary et al. (2001)
examined whether carrying out the inspection time task is associated with activation 
of particular brain areas. In a preliminary investigation detailing whether individual 
differences in inspection time and IQ test performance are associated with activation 
in the same brain areas, functional MRI scanning (fMRI) was carried out on seven 
participants during concurrent administration of the inspection time task. During 
scanning and observation of inspection time stimuli, participants were directed to 
make their responses mentally, i.e. no physical record of their discriminations was 
made. A block mode design, using three blocks was employed for the inspection time 
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testing. One block was referred to as the ‘null’ condition in which no inspection time 
stimuli were shown, only the cue and the backward mask were presented. The second 
block was the ‘hard’ condition, in which the stimuli were shown for a duration of 
only 40ms. The third block was an ‘easy’ condition where the stimuli were shown for 
200ms on each occasion. The preliminary data obtained in this study showed a 
pattern of brain activation and deactivation during completion of the inspection time 
task in this group of well-educated, healthy participants. ‘Activated’ areas are 
described as those brain regions with a higher amplitude blood oxygen-level 
dependent (BOLD) signal in the ‘hard’ compared with ‘easy’ conditions. 
‘Deactivated’ areas were described as brain regions showing a lower amplitude 
BOLD signal during the ‘easy’ condition, compared with the ‘hard’ condition. It was 
found that, during the “hard” compared to “easy” versions of the IT task, several 
areas were activated, and several deactivated. Activated areas included the anterior 
hemispheric fissure region, the precentral cortex bilaterally near the vertex, small 
amounts in both posteroinferior parietal regions, both anterolateral frontal cortices 
and both posteroinferior frontal regions. Similarly, several areas were found to be 
deactivated when responding to ‘hard’ versus ‘easy’ inspection time stimuli. These 
areas include bilaterally in the anterior frontal cortices, extending into the inferior 
frontal cortex and the left posterior temporal cortex. Deactivation in the medial 
parasagittal cortex extending up from the medial occipital cortex into the parietal 
region was also observed, alongside a small deactivated area located in the right and 
left frontal cortices. These activated and deactivated areas fit the researchers’ 
hypothesis that those brain regions shown to be involved with higher cognitive 
activities by previous studies (Duncan et al., 2000, Esposito et al., 1999) were 
similarly affected when performing the inspection time paradigm. 
Following these preliminary results, Deary et al. (2004) carried out a second fMRI 
study of the functional anatomy of the inspection time task in an attempt to overcome 
some of the significant limitations associated with the pilot study. These limitations 
included: a small sample size; pre-warning participants whether they would receive 
easy, hard or control stimuli; limited practice testing on inspection time; and finally 
the failure to collect participant responses to the inspection time stimuli during 
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imaging. Therefore, this follow-up study recruited 20 participants, each of whom 
undertook three inspection time test sessions. The baseline session took part prior to 
MRI imaging in order to allow familiarisation with the test and the other two 
inspection time tests (160 trials in each) took place while the participant was in the 
MRI scanner. The fMRI design for these tests was event-related. The blood 
oxygenation level-dependent (BOLD) response was computed as a function of the 
eight levels of inspection time stimulus duration (from 6ms – 150ms) and also as a 
function of the behavioural responses made by the participant. The aim of the study 
was ultimately to show that the cerebral processing network underlying inspection 
time task performance alters depending on task difficulty, as determined by the 
duration for which the stimulus is shown. Bilateral activation in the inferior fronto-
opercular cortex, superior/medial frontal gyrus, and anterior cingulate gyrus was 
observed during presentation of the quicker, more difficult inspection time stimuli. 
Additionally, a number of posterior brain areas showed a signal decrease as a 
function of shorter (i.e. more difficult) stimulus duration and these areas specifically 
include the left inferior occipital gyrus, the left posterior mid-temporal gyrus and the 
right posterior inferior temporal gyrus. These patterns of activation and deactivation 
were consistent with those identified in the pilot study (Deary et al., 2001). 
Functional connectivity analysis suggested that there exist two separate networks in 
the brain that are associated with carrying out the inspection time task. The first 
anterior network comprises the fronto-opercular area, intrasylvian area, medial 
frontal gyrus and the anterior cingulate cortex. A second, posterior network was also 
identified and this network includes the precuneus, the posterior cingulate gyrus, the 
occipital gyrus, and the right superior inferior/mid temporal gyrus comprising 
sensory-related regions. This posterior network responded more strongly to 
inspection time stimuli that were shown for longer durations (i.e. ‘easier’ stimuli). 
These more easily processed stimuli can be considered as “informative percepts”. 
Some of the aforementioned regions are known to be involved in visual and 
visuospatial processing. However, others brain areas, including the inferior parietal 
lobe posterior cingulate, are activated during less specific, fundamental information-
processing functions and it would therefore appear that, when performing the 
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inspection time task, these visual areas are fused with the less specific areas in order 
to process more informative percepts (Deary et al., 2004).   
Conversely, the anterior network identified through functional connectivity 
comprises brain areas that are activated as task demands increased (i.e. when 
inspection time stimuli were presented for shorter amounts of time). The authors 
propose that this network may be fused together in order to process degraded 
percepts and/or when associative skills are necessary to complete a task. Thus, 
activation of this anterior network may explain in part the IT-IQ association. This 
study therefore offers insight into the specific neural networks that are essential to 
inspection time task performance, in a cohort of young healthy adults.  
2.5.2 Neurochemical Correlates
However, despite the important contribution of brain imaging data to inspection time 
research, fMRI studies do not allow us to infer what the neuronal processes that 
underpin inspection time performance are. Examining the neurochemical correlates 
of inspection time is essential in attempts to describe a complete biological model of 
inspection time. 
Early research efforts in this area evolved from studies that found a nicotine-related 
improvement in inspection time performance (Stough et al., 1995). Thirty-five 
regular smokers were recruited and asked not to smoke or drink caffeine for 2 hours 
prior to the testing session. Each participant completed 3 separate testing sessions in 
which they completed the inspection time task under sham smoking, no-smoking or 
nicotine smoking conditions. There was found to be a significant effect of smoking 
status, with significantly improved inspection times obtained under smoking 
conditions than those in the sham or no smoking conditions. This finding is 
consistent with the results of other studies in which other measures of processing 
speed were used (Bates et al., 1994). The authors therefore suggest that nicotine may 
enhance visual information processing by enhancing stimulus sampling. 
Subsequently, research was directed towards examination of the potential role of the 
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cholinergic system in mediating the IT-IQ relationship, given that nicotine acts as an 
agonist that stimulates the release of the neurotransmitter acetylcholine (Thomson et 
al., 2000). In their review of work primarily carried out in their own laboratories, 
Stough et al. (2001) therefore examine the relative contribution of a number of key 
human neurotransmitters and their effect on inspection time performance in healthy 
volunteers. In a number of different studies inspection time performance was 
measured before and after modulating different important central nervous system 
neurotransmitters and receptor systems. The review concludes that the studies 
implicate the neurotransmitter acetylcholine and the cholinergic system in successful 
inspection time performance. Other psychometric tests also seem to rely upon the 
cholinergic system, although the serotonergic and dopaminergic systems may also be 
involved in performance of other psychometric measures. These results are further 
supported by studies that have reported cholinergic system disturbance and 
impairment in inspection time performance in patients with Alzheimer’s disease. It is 
proposed that future research should focus on examining both the neurochemistry 
and brain imaging together while the inspection time task is being performed in order 
to further understanding of the biological basis of the inspection time task. 
Studies have also examined the influence of induced hypoglycaemic states on 
inspection time performance and this has offered further insight into the specific 
biological processes involved in the task. Given the evidence from controlled studies 
of experimentally-induced hypoglycaemia that have shown hypoglycaemia to impair 
the function of the central nervous system, Strachan et al. (2001) carried out a 
controlled study of the impact of hypoglycaemia on the functioning of the peripheral 
nervous system. Sixteen healthy individuals were tested on two separate occasions –
one under eugylcaemic (i.e. ‘normal’) conditions and one the other occasion, under 
induced hypoglycaemia. A practice session was also carried out in order to 
familiarise participants with the test procedure. Under both conditions, participants 
completed a cognitive test battery, which included inspection time testing. The motor 
nerve conduction velocities and the amplitude of the motor action potentials were 
also measured during each session. Results indicated that hypoglycaemia caused
impaired cognitive performance and information processing. Inspection time was 
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significantly slower during induced hypoglycaemia, as were components of a 
reaction time test. However, since motor conduction velocity and motor action 
potentials were not affected by hypoglycaemia, the authors conclude that while 
multiple levels of information processing functioning may be altered during 
hypoglycaemic state, peripheral nerve functions are unaltered and it may be the case 
that the peripheral nervous system does not reflect the central nervous system’s need 
for glucose. However, this study provides evidence against previous propositions that 
peripheral nerve conduction velocity differences may explain in part the association 
between psychometric intelligence and information processing ability (Rijsdijk and 
Boomsma, 1997). Since moderate hypoglycaemia was found to have a negative 
effect on cognitive test scores, reaction times and inspection time performance but 
peripheral nerve conduction velocity remained unaffected, this refutes the idea that 
speed of conduction in the peripheral nervous system reflects the speed of nerve 
conduction in the central nervous system and peripheral nervous system speed cannot 
be used as a measure of speed of information processing and intelligence. However, 
further studies are required to confirm this finding. 
Therefore, current research has identified the potential role of different 
neurotransmitters in mediating inspection time performance. However, future 
research is needed to gain further insight into the neurochemical underpinnings of 
inspection time and other cognitive processes in order to develop an accurate 
neurochemical model of inspection time and other, more complex cognitive 
functions (Stough et al., 2001).
2.6 Inspection Time in Children
There is now a general consensus that the efficacy of processing speed explains, at 
least in part, the correlation between inspection time and IQ in adult participants. 
However, as Anderson et al. (2001) observe, there has been some controversy with 
regards to exactly what inspection time measures in children. Nettelbeck and Lally 
(1979) carried out one of the first studies examining inspection time in child 
participants and they observed a reliable decrease in inspection time (i.e. shorter 
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exposure time required to make an accurate judgement) in children with increasing 
age and this finding has since been replicated by Nettelbeck and Wilson (1985) who 
recruited 10 school children from each of seven different school grades (ages 7 – 13 
years). Each child completed inspection time testing and the 7 and 11 year old 
children repeated the task 2 years later. A different sample also completed the task on 
two separate occasions, approximately 2 weeks apart. A practice-related 
improvement was observed in the group of children who were tested twice with a 
two week-interval between sessions. However, this change was not nearly as 
significant as the change seen in the groups who were tested over the two year 
period. It is therefore proposed that the observed longitudinal improvements in 
inspection time were due to maturation changes, perhaps developmental changes in 
speed of processing. 
The theory that improvement in processing speed with increasing age in children 
could account for changes in inspection time performance has not, however, been 
universally accepted. Anderson (1986) and Anderson et al. (2001), in a partial 
replication of a study by Nettelbeck and Wilson (1985), argued that experience of the 
inspection time task had a much larger effect on children’s task performance than did 
maturation. A later study detailed inspection time performance in children compared 
inspection time scores and Peabody Picture Vocabulary Test (PPVT) performance in 
a group of children aged 6-13 years who were tested in 2001 with scores obtained in 
1981 from a group of children aged 6 -13 years who attended the same school
(Nettelbeck and Wilson, 2004). It was found that, although there was a significant 
improvement in general intelligence scores in the cohort tested in 2001 (known as the 
“Flynn effect” (Flynn, 1999), inspection time scores had remained constant over 
time. Inspection time scores were still significantly correlated with intelligence, as 
measured by the PPVT. This study therefore suggests that the Flynn effect (i.e. 
observed IQ gains in children over a duration of 20 years) is not attributable to 
improvements in processing speed, as measured by the inspection time task. The 
study offers strong evidence to support the proposal that inspection time provides a 
measure of a fundamental mental function that is involved in human intelligence. 
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Whatever this function may be, it appears to be unaffected by environmental 
influences that likely cause the observed improvements in intelligence test scores.  
The finding that both cohorts showed the expected age effects that have previously 
been observed in studies examining inspection time performance in children (i.e. 
shorter inspection times with increasing age) provides evidence against Anderson, 
Reid and Nelson’s (2001) proposal that task exposure can account for the observed 
improvement in inspection time with increasing age in children. Further evidence to 
refute Anderson et al’s (2001) theory comes from Nettelbeck and Vita (1992) who 
found evidence to suggest that although practice can reduce the aforementioned 
developmental trends in inspection time, it does not remove them altogether. Thus 
there does seem to be an age-related improvement in inspection time scores that is 
present even after controlling for previous inspection time task exposure. 
Edmonds et al. (2008) carried out the first twin study of inspection time in pre- and 
post-adolescent children providing further cross-sectional data regarding the way in 
which inspection time scores change with age. Pairs of twins and single children 
aged between 7 and 17 years were tested on inspection time in addition to cognitive 
and neuropsychological assessments. The Wechsler Intelligence Scales for Children 
(WISC-III) provided the cognitive measures and the NEPSY, a standardised 
neuropsychological assessment that measures attention/executive, language, 
sensorimotor, visuospatial and memory domains. A definite improvement in 
inspection time with increasing age was reported in this cross-sectional participant 
sample. To facilitate data analysis, the children were grouped into quintiles based 
upon their age at the time of participation in the study so as the youngest 20% of the 
sample comprised the first quintile and the oldest 20% comprised the fifth quintile. 
One-way ANOVA showed a significant effect of age quintile on IT score. 
Furthermore, in the whole sample, a positive relationship between inspection time 
score and participant age was found. These age-related changes could not be 
explained by potential confounders such as birth characteristics or social background. 
In keeping with results examining the IT-IQ relationship in adults, this study found 
inspection time to be significantly correlated with IQ score in this cohort of children 
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aged between 7 and 17 years and the association remained significant after 
controlling for age. A raw correlation of 0.58 was found between inspection time 
score and Full-Scale IQ (FSIQ) in the whole sample and this was significant (p < 
0.01). After correcting for age, the correlation was 0.26 (p < 0.01). Inspection time 
was reported to correlate specifically with tasks assessing attention/executive 
function, language, sensorimotor skills, and memory subtest scores. Given that an 
age-related improvement in inspection time and an inspection time-IQ relationship 
have now been established, Edmonds et al. (2008) propose that research in this area 
should now focus on determining exactly what the mechanisms that form the basis of 
these relationships are. These authors propose that this may be done in three ways: 
by further examination of the neural correlates of inspection time; by searching for 
specific genes that may contribute to the shared variance between inspection time 
and intelligence; or through investigation of any environmental factors that may 
improve the relationship between IQ and inspection time.
2.7 Inspection Time in Older Adults
Age-related decline in cognitive function has attracted a great deal of interest. 
Attempting to understand the psychological and biological foundations of cognitive 
ageing is important in order to facilitate the design of useful interventions and 
treatments to counteract the detrimental effects of a decrease in mental capacity with 
age (Waiter et al., 2008).
There is a great deal of variance in terms of the rate at which individuals age 
cognitively and even in a single individual, different cognitive functions show 
different rates of change. Spatial abilities, reasoning and problem solving, memory 
and decision-making (i.e. measures of ‘fluid’ abilities) have been found to show the 
greatest decline after the age of 50 compared with ‘crystallized’ abilities (Nettelbeck 
and Rabbitt, 1992). A number of theories have been postulated in an attempt to 
explain the basis of this age-related cognitive decline. Salthouse (1996) supports the 
theory that speed of information processing may play an important role in 
understanding the processes involved in cognitive ageing. This theory suggests that 
70
with increasing age there is a decrease in the speed with which the most simple of 
mental operations can be carried out. This decline in mental speed may, in turn, 
result in a decline in the ability to perform higher-order cognitive functions, since 
many are underpinned by speed of processing. Zimprich and Martin (2002) found 
mental speed changes as assessed by a Number Connection test, and changes in fluid 
intelligence to be significantly correlated (.53 in a sample of 417 older adults 
assessed over a period of 4 years). Thus, measuring speed of visual information 
processing in older adults may be clinically useful by providing an assessment of the 
extent of cognitive decline. A number of different standardised psychometric tests 
are designed to assess speed of processing in humans. However, the majority are 
confounded in elderly people by their reliance on additional high-level, more 
complex functions (i.e. Digit-symbol coding from the Wechsler Adult Intelligence 
Scales), or involve speeded reactions which are likely to be slower in more elderly 
people irrespective of the extent of cognitive decline (e.g. reaction-time tasks). 
Therefore the inspection time task may have a specific utility in this area given its 
advantages over more traditional tasks that measure processing speed. As such, it has 
been used as a method of assessment in older adults in order to examine whether 
slowed visual information processing is related to more general cognitive decline as 
measured by standardised measures of cognition. 
Nettelbeck & Rabbitt (1992) found that, in a cohort of 104 participants aged between
54 to 85 years, performance on a reaction-time measure, the inspection time task and 
on the speeded coding task (digit symbol coding) from the Wechsler Adult 
Intelligence Scales (WAIS) accounted for almost all age-related changes in cognitive 
performance, as measured by a number of different tasks, including measures of 
general fluid abilities. These findings support the proposal that an age-related decline 
in information-processing speed may play an important part in explaining age-related 
cognitive decline (Salthouse, 1996). However, given that chronological age made a 
significant contribution to scores on two tests of learning and retention, over and 
above that attributable to processing speed differences, this suggests that poorer 
information processing speed with age cannot explain all age-related cognitive 
changes. The authors suggest that further research should seek to determine whether 
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changes in memory and learning abilities with increasing age occur independently of 
the age-related decline in information-processing speed.
The aforementioned study by Nettelbeck and Wilson (2004) has also highlighted the 
potential for the inspection time task to act as a biological marker for cognitive 
ageing. Different cognitive abilities decline at different rates and speed of 
information processing is thought to have a significant influence on the rate at which 
decline occurs. Although a gradual slowing in information processing speed and 
therefore a decline in cognitive abilities may occur during early adulthood, these 
abilities are thought to remain generally stable until the sixth decade of life. 
However, Der and Deary (2006) report that while simple reaction time shows little 
slowing until around age 50, choice reaction time slows from early adulthood. The 
rate of decline differs between individuals and reliable biomarkers are being sought 
in order to predict changes in function as a result of ageing, with efforts particularly 
focused upon identifying a marker of accelerated cognitive decline (Stern and 
Carstensen, 2000). Nettelbeck and Wilson (2004) suggest that, given the inspection 
time task is a proven measure of the speed of visual information processing, is 
significantly related to general mental ability and has apparent stability across 
generations (in contrast to many other standardised tests), this may render the task a 
potential candidate as a biomarker with which to assess cognitive changes with 
increasing age. 
Bonney et al. (2006) examined inspection time performance in older adults who were 
diagnosed with mild cognitive impairment (MCI) and were therefore deemed to be at 
greater risk of developing further cognitive decline or dementia. They found that 
inspection time is significantly increased (i.e. slower) in participants with MCI by 
comparison with age, sex and education-matched controls, thus suggesting that 
slowed information processing is common to patients with MCI. Due to the cross-
sectional nature of the study, it was not possible to determine whether inspection 
time performance can predict those at risk of significant cognitive decline, but the 
study paved the way for future studies that may examine longitudinally whether 
changes in inspection time over time have any prognostic value.
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Waiter et al. (2008) investigated the potential utility of inspection time as a 
biomarker in a study that examined whether successful cognitive ageing is associated 
with retaining those functional brain networks that have previously been shown to be 
involved with successful information processing (and therefore successful inspection 
time performance) in healthy young people (Deary et al., 2001, Deary et al., 2004). 
Members of the Aberdeen Birth Cohort 1936 were recruited at age 70 years and were 
divided into two groups for the purposes of this study. The Aberdeen Birth Cohort is 
a group of individuals who had completed the Moray House Test No.12 which 
assesses verbal, numerical and spatial reasoning as well as other mental abilities at 
age 11. These individuals were followed up many years later at which time they were 
administered a battery of cognitive tests at age 64, 66 and 68 years. The members of 
the cohort were separated into two groups, both of which had similar cognitive 
ability at age 11, as evidenced by similar scores on the Moray House Test. However, 
the first group comprised members of the birth cohort who had shown ‘successful’ 
cognitive ageing (referred to as the cognitive sustainers) and the second group 
consisted of members who had ‘unsuccessful’ cognitive ageing (cognitive decliners). 
Successful and unsuccessful cognitive ageing was determined by scores on Raven’s 
Standard Progressive Matrices. Both the cognitive sustainers and decliners had their 
BOLD (blood-oxygen level dependent) activation-deactivation pattern assessed 
during fMRI scanning while performing the inspection time task. Both groups 
showed a clear pattern of BOLD activation and deactivation when processing the 
most difficult inspection time stimuli (i.e. those that were shown for very short 
durations). When participants made a correct response to the hardest stimuli, 
activation was seen in the medial, precentral and inferior frontal gyri and 
deactivation in many more posterior regions was observed. When analysed as two 
subgroups, the cognitive decliners had far fewer significantly activated regions than 
did the cognitive sustainers. The anterior cingulate region was significantly more 
activated in the cognitive sustainers as compared to the decliners. 
Functional connectivity maps found there to be more extensively association 
between brain regions in the cognitive sustainers than in the cognitive decliners. The 
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authors conclude that when performing the inspection time task, a measure on which 
performance declines with increasing age, older participants whose cognitive ability 
(in particular non-verbal reasoning ability) has remained relatively intact with age 
have a BOLD activation-deactivation pattern than is very similar to that observed in 
younger humans. Conversely, participants whose non-verbal reasoning ability has 
significantly declined with age have a far less extensive pattern of associations. 
Specifically, the activation in the anterior cingulate gyrus is significantly different 
between the cognitive sustainer and decliner groups and this area was previously 
identified as being significantly activated when more difficult inspection time stimuli 
were shown to younger people (Deary et al., 2004). This study therefore concludes 
that, in older adults who have more intact cognitive functions, similar neural 
networks underlie information processing speed to those identified in younger 
individuals, and therefore the task warrants further research as a marker of imminent 
worsening of cognitive function in old age.
Therefore, the inspection time task is a valuable tool with which to assess cognitive 
decline with increasing age. Current research efforts are attempting to validate the 
task as a biomarker that may indicate, and even predict, those individuals who will 
be cognitive sustainers or decliners in older age. 
2.8 Inspection Time and Heritability
The genetics of cognition in general has attracted interest over recent years. Research 
has attempted to determine whether genetic variants influence individual differences 
in processing speed and also in working memory since both of these functions have 
been shown to underpin the ability to perform higher level functions.
The heritability of the inspection time measure has been investigated in twin studies 
to determine whether the association between inspection time and IQ can be 
explained by a common genetic factor. Luciano et al. (2001) recruited one hundred 
and eighty-four pairs of monozygotic twins (i.e. twins who share 100% of their 
genes) and 206 pairs of dizygotic twins (i.e. twins who share approximately 50% of 
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their genes). Each participant was tested on inspection time and full-scale IQ was 
assessed by the Multidimensional Aptitude Battery as part of an ongoing study of the 
genetics of cognition. This study estimates the heritability of the inspection time 
measure using the ‘twin design’ and methods of analysis that reduce the large 
phenotypic variance in inspection time into genetic and environmental components. 
The twin design method, in which monozygotic (MZ) and dizygotic (DZ) pairs of 
twins are compared suggests that if the causes of familial similarity are the additive 
genes that are transferred from parent to child, the correlation in performance of MZ 
twins is expected to be twice that of DZ twins. This is because DZ twins share twice 
as many genes as DZ twins and the theory assumes that the environmental influences
are the same in MZ and DZ twins. Results of twin correlations for inspection time 
showed MZ twins to have greater similarity (r = .34) than DZ twins (r = .21). 
However, since the MZ twin correlation failed to reach that of the test-retest 
correlation, this suggests that non-shared environmental influences likely play some 
role in individual inspection time performance variation. Bivariate analyses of the 
association between inspection time and IQ suggested that a common genetic factor 
could account for 36% of the variance in inspection time and 32% of the variance in 
IQ. No significant common environmental factor was revealed. The genetic 
correlations between inspection time and the IQ measures were higher than the 
phenotypic correlation. This therefore suggests that the variation in genes that result 
in faster inspection time have a strong relationship with the variation in genes that 
are linked to higher IQs. Thus, evidence from this study suggests that inspection time 
shares a strong genetic relationship with IQ (Luciano et al., 2001). This finding 
supports the results of other studies that have investigated other elementary measures 
of processing speed and their relationship to intelligence.
The twin design has also been used to investigate whether genetic or environmental 
factors make the greatest contribution to variation in inspection time scores and also 
to determine whether genetic or environmental factors mediate the IT-IQ relationship
(Posthuma et al., 2001). Inspection time and IQ data (assessed by the Dutch version 
of the WAIS 3R) were collected from 688 family members from 271 extended twin 
families. Variance components analysis revealed that 46% of the variance in 
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inspection time could be attributed to genetic influences and the remaining 54% was 
explained by non-shared environmental influences. A significant phenotypic 
correlation was found to exist between inspection time and Verbal IQ (0.19) and 
inspection time and Performance IQ (0.27) and a common genetic factor accounting 
for 10% of the genetic variance in Verbal IQ and 22% of the genetic variance in 
Performance IQ was entirely responsible for the correlations. 
Thus inspection time appears to be genetically correlated with intelligence (Luciano 
et al., 2001, Posthuma et al., 2001). Luciano et al. (2004) therefore addressed the 
question of whether the observed genetic variation in inspection time is associated 
with intelligence through a unitary factor that influences diverse measures of 
processing speed and IQ. Monozygotic and dizygotic pairs of twins completed 
measures of inspection time, choice reaction time and IQ (measured by the verbal 
and performance subtests of the Multidimensional Aptitude Battery and Digit 
Symbol Substitution from the Wechsler Adult Intelligence Scale – Revised). It was 
found that the covariation among processing measures (inspection time and choice 
reaction time) and IQ test scores could best be explained by a model that comprises a 
general and specific genetic factor structure, a shared environmental factor that 
influenced all tests except inspection time, and unique environmental effects that 
were specific to individual measures. They therefore concluded that a unitary factor 
is unable to sufficiently account for the relationship between measures of cognitive 
speed, including inspection time, and standardised measures of cognitive function. 
Edmonds et al. (2008) also used the twin design to investigate the genetic 
contribution to inspection time, on this occasion in children under the age of 16 
years. The methodology used in the study is described in section 2.6.  Briefly, 
Edmonds et al., (2008) tested pairs of twins and single children aged between 7 and 
17 years old on measures of inspection time, standardised IQ tests (WISC-III) and 
measures of neuropsychological functioning (NEPSY). In addition to reporting the 
age-related inspection time changes, genetic analyses of inspection time and IQ were 
carried out. The heritability of inspection time was estimated to be 45% in childhood 
and early adolescence suggesting that a high proportion of the variation in inspection 
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time in this age group is genetic. The best-fit model for the sources of the covariance 
in inspection time and IQ was one containing both genetic and unique environmental 
factors and this supports previous findings of the few studies that have examined the 
heritability of inspection time using the twin-design (Luciano et al., 2001, Posthuma 
et al., 2001).
Despite the potential limitations of the twin design, namely that mono- and dizygotic 
twins may not be representative of the general population and thus results may not be 
applicable to the non-twin population, it would appear that a high proportion of the 
variance in inspection time is heritable. Research in this area is still in the early 
stages, and Edmonds et al. (2008) suggest that future work should be directed 
towards identifying the specific genes that contribute to the IT-IQ relationship. 
2.9 Inspection Time in Clinical Populations
The inspection time task has proven utility as a measure of visual information 
processing that has provided an insight into the processes that underpin variance in 
intelligence. However, the task is also potentially useful as a clinical tool that can be 
applied to a number of different populations. 
The fundamental process measured by inspection time has been shown to be 
disrupted in a number of clinical conditions, including Alzheimer’s disease, 
Parkinson’s disease, and hypoglycaemia, among others. The inspection time task has 
a number of advantages over other commonly used measures of processing speed 
and cognitive ability in clinical populations. The apparent simplicity of the task and 
the lack of requirement for intact motor or speech function, render the task easier and 
potentially less stressful for cognitively impaired patient groups to perform than are 
many other similar standardised tests, at the same time as providing an informative 
measure that is significantly correlated with cognition.
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2.9.1 Inspection time and Dementia
The inspection time task has been used to provide an insight into the extent of slowed 
information processing and its relationship to cognitive function in a group of 
participants with mild cognitive impairment in the aforementioned study from 
Bonney et al.,(2006) The task has also been applied to a group of Alzheimer’s 
disease (AD) patients and a group of patients with Korsakoff’s psychosis by Deary et 
al. (1991) and has been proven to be a useful tool with which to gain insight into the 
processes underlying AD. The study involved inspection time and other cognitive 
and psychometric testing of IQ in groups of patients with Alzheimer’s disease and 
Korsakoff’s syndrome. The rationale behind the study was that the early stages of 
visual processing had yet to be thoroughly studied in these groups and inspection 
time yields a continuous variable that could be useful in identifying disease 
progression in these groups. The results showed that the group of patients with pre-
senile Alzheimer’s disease had significant impairment in the early stages of visual 
information processing (i.e. had poorer inspection time scores) compared to the 
Korsakoff’s syndrome patients and also by comparison with a group of intelligence-
matched control participants. This finding is particularly important as impairment in 
the early stages of information processing had not previously been identified in AD 
patients. Furthermore, as the authors highlight, it has generally been accepted that the 
correlation between inspection time and IQ tends to be stronger in groups with 
poorer cognition. However, although the Korsakoff’s patients showed clear 
impairment on a number of the cognitive tasks, they had very similar inspection time 
scores when compared to control participants. The authors suggest that this may be 
because the cognitive deficit in patients with Korsakoff’s syndrome arises as a result 
of impaired processing capacities that are ‘downstream’ of the information 
processing function that is measured by the inspection time task.
2.9.2 Inspection time and Parkinson’s disease
Patients with Parkinson’s disease (PD) have also been the focus of inspection time 
research. One of the first studies in this area was carried out to investigate the 
hypothesis that bradyphrenia (slowing of mental abilities) contributes to the 
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cognitive deficits seen in PD patients (Shipley et al., 2002). The study used the 
inspection time loop task as a measure of information processing. The inspection 
time loop task differs from the traditional inspection time task in that it overcomes 
the potential issue of lack of attention by presenting stimuli in a ‘loop’, with each 
repetition of the loop comprising the same stimuli in the same order. The task 
requires the participant to judge the temporal order of four single letter stimuli. The 
duration for which the stimuli were presented ranged between 100 and 700ms. 
Thirty-two patients with PD and 31 age-matched controls were administered the 
National Adult Reading Test (NART), as a measure of premorbid ability, and 
completed the inspection time loop task. It was found that the group of Parkinson’s 
disease patients had a significantly lower mean score on the inspection time loop task 
than did the control group (p = 0.02). This poorer ability to discriminate the temporal 
order of stimuli was apparent even after controlling for pre-morbid IQ, as measured 
by the NART. These results suggest that there may be a slowing of information 
processing abilities in PD that is associated with slowed intake of sensory 
information (Shipley et al., 2002). 
Johnson et al. (2004a) utilised the more traditional version of the inspection time task 
as a measure of elementary cognitive function in patients with Parkinson’s disease. 
Intact motor functioning plays a vital role in successful completion of traditional 
reaction time paradigms that are often as administered as a measure of “basic” 
cognition. Since motor function is often disrupted in PD patients, inspection time 
may provide a suitable alternative measure of elementary cognitive function in this 
group of patients. A group of “optimally medicated” PD patients were compared 
with a group of healthy age-matched controls on the inspection time task. In the first 
part of their study, results indicated that PD patients required significantly longer 
stimulus presentation time in order to make a correct judgment than did the healthy 
control group, suggesting that visual information processing is significantly slowed 
in this patient group. In a second experiment, a group of PD patients were tested on 
inspection time both when they had and had not taken their usual dopaminergic 
medication and were compared with age-matched controls. A significant impairment 
on inspection time was observed in the PD group, irrespective of whether they had 
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taken their medication or not, by comparison with the healthy control group. This 
study therefore confirms previous findings that suggest there is a significant deficit in 
perceptual processing in PD patients. Given that the medicated and non-medicated 
groups had similar inspection time scores, the authors suggest that cognitive slowing 
in PD patients may not be improved by dopaminergic drugs. 
2.9.3 Inspection time and Depression
The inspection time task has also been employed as a measure of processing speed in 
patients with clinical depression. Tsourtos et al. (2002) used the inspection time task 
to determine whether speed of visual information processing is slowed in young 
patients with unipolar depression. Following an earlier study which concluded that 
younger depressed patients do not show the cognitive slowing that has been observed 
in middle-aged and older depressed patients (Purcell et al., 1997), Tsourtos et al. 
(2002) wished to determine whether this finding was an artefact of the cognitive 
speed measures employed since they relied upon on a number of other cognitive 
functions, in addition to processing speed. The inspection time task therefore offered 
a suitable measure of the early stages of visual information processing that is 
unaffected by motor speed or other cognitive strategies, and may therefore provide a 
more reliable measure of cognitive slowing in depressed patients. Tsourtos et al. 
(2002) recruited 20 unmedicated inpatients with a diagnosis of unipolar depression, 
19 medicated depressed inpatients and 20 age, sex and verbal-IQ matched healthy 
controls. Each group completed inspection time testing and inspection time scores 
were found to be significantly different between the three experimental groups. 
There was a significant difference between the control group and the unmedicated 
depressed group but no significant differences between the control group and the 
medicated depressed group were found in post-hoc analyses. The unmedicated group 
had significantly slower inspection times than the medicated group. Therefore, in 
contrast to previous findings this study showed that speed of information processing, 
as measured by the inspection time task, is impaired in young, unmedicated, unipolar 
depressed patients. That the medicated, depressed patients had significantly faster 
inspection times than the group of unmedicated depressed patients suggests that the 
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cognitive slowing that is associated with a diagnosis of depression may be somewhat 
ameliorated by medication. The authors therefore propose that assessment of 
cognitive slowing should be included in the neuropsychological profile of depression 
in patients of all ages in future studies of depression. The study also emphasises that 
the potential effects of medication should be considered in studies that detail 
cognitive function in depressed patients. 
2.9.4 Inspection time and Schizophrenia
Visual backward masking (VBM) tasks that employ a methodology similar to that of 
the inspection time task have frequently been employed as a measure of early 
information-processing deficits that have consistently been observed  in individuals 
with schizophrenia (Braff et al., 1991). Butler et al. (1996) tested both medicated and 
unmedicated schizophrenic patients on a VBM task and found that no significant 
differences in between the performance of the two groups, despite the fact that 
symptoms were reported to change on and off medication. 
In addition to providing an assessment of the effects of prescribed medications on 
visual information processing, VBM tasks have also been used to examine the 
relationship between visual pathway function and symptomatology in patients with 
schizophrenia. Butler et al. (2002) tested the hypothesis that the VBM deficit in 
schizophrenic participants is the result of an overactive transient visual pathway 
response to the mask. Thirty-five patients with a diagnosis of either schizophrenia or 
schizoaffective disorder and thirty-five control participants completed a traditional 
backward-masking task in addition to tasks in which the mask had been altered to 
bias stimulation to transient (low spatial frequency) or sustained (high spatial 
frequency) channels. Results confirmed a significant deficit on the traditional 
backward-masking task in schizophrenic patients compared with controls, supporting 
the findings of the aforementioned studies. The group of schizophrenic patients were 
also significantly impaired on both the low and high spatial frequency versions of the 
task by comparison with the healthy control group. There was no difference between 
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the performance in the medicated and unmedicated conditions, lending further 
support to Butler et al.’s (1996) findings. 
Thus, although no studies to date have used the inspection time task itself as a 
measure of information processing in schizophrenic patients, similar visual 
backward-masking tasks have a proven utility as a measure of slowed information-
processing in this group. Further research should perhaps consider the use of 
inspection time in order to gain further insight into the processes that underlie the 
disruption of visual information processing in people with schizophrenia. 
2.9.5 Inspection time and Anaesthesia
The inspection time task has been used as a measure of the effect of nitrous oxide 
that is used for anaesthesia on psychomotor function in a single study (Cheam et al., 
1995). A battery of psychomotor and information processing test measures were 
completed (inspection time, tapping frequency, critical flicker fusion, picture 
memory and time sense) by seven healthy volunteers who had been administered 
various concentrations of nitrous oxide. It was found that, in addition to dose-related 
memory impairment and reduction in tapping frequency, an increase in inspection 
time was also observed. That is, visual information processing was slowed as a result 
of nitrous oxide. No other studies have been carried out to date using inspection time 
as a measure of processing slowing following a general anaesthetic to confirm the 
findings of this small study. 
2.9.6 Inspection time and Dyslexia
Only a single study has been carried out specifically investigating inspection time 
performance in dyslexic individuals, although a lot of work has focused on assessing 
information processing speed in dyslexic individuals, using other measures. Whyte et 
al. (1985) recruited a group of children who were either dyslexic or normal readers. 
Each child completed the inspection time task. The dyslexic children were found to 
have significantly longer inspection times (i.e. slower information processing) than 
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the group of normal readers. Additionally, there was greater inter-individual 
variation in the dyslexic group and this group also benefited from more practice trails 
than did the control group. It is therefore proposed that the inspection time task may 
measure a process that plays a role in the development of reading skills and that 
speed of information intake, as opposed to more general perceptual impairment may 
be involved in dyslexia. Furthermore, it would appear that dyslexic children suffer 
more task anxiety, given the observed improvement in inspection time performance 
with practice. It is therefore proposed that the difficulties experienced by dyslexic 
individuals may result from difficulties at a simple level and more practice 
opportunities may improve performance on inspection time and other information 
processing tasks. Given the small sample size and the interesting results of this study, 
it is surprising to note that no further studies assessing the utility of the inspection 
time as a measure of visual information processing in dyslexic individuals have been 
carried out to date. 
2.10 Inspection Time – Conclusions
Since its conception in 1972, a great deal of research has been directed towards the 
inspection time task. The IT-IQ relationship has been established and studies have 
consistently found that inspection time is strongly related to measures of 
performance IQ. Studies examining the potentially heritable nature of this 
relationship are on-going and the neurological correlates of the task are similarly 
being studied in an attempt to underpin the reasons for which differences in human 
intelligence exist. Event-related MRI studies are currently being used in older adults, 
in an attempt to identify the key to successful cognitive ageing. This in turn, may 
help to identify potential interventions to ameliorate the symptoms of age-related 
cognitive decline. Moreover, the inspection time task has proven utility as a measure 
of processing ability in various clinical populations, including patients with 
Parkinson’s disease, Alzheimer’s disease and schizophrenia and is increasingly being 
employed as a clinical tool.  This is because the inspection time task itself holds a 
number of advantages over other standardised tests of cognition: it can be applied 
across a wide age range, from young children, to older adults; it provides a measure 
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of a fundamental process and is therefore unaffected by many potential confounding 
variables, such as motor and/or speech problems. Furthermore, unlike many 
neurobehavioural tests, it has very limited practice effects since there is no ‘content’
to the stimuli presented and is therefore useful for repeated administration .The task 
also offers a relatively quick and easy measure of general cognition which is less 
stressful and tiring than comprehensive cognitive test batteries that are generally very 
time-consuming. Thus, the inspection time task continues to attract a great deal of 
research attention and is becoming an increasingly important measure of information 
processing ability in a number of clinical populations. 
2.11 Aims of Thesis
Given the advantages the inspection time test holds over many other standardised 
measures of cognition, its potential utility in neuro-oncology is of interest. Most 
patients with brain tumours are initially treated with surgery (biopsy or resection). 
Given the limited survival time associated with many primary and metastatic brain 
tumours it is important that quality of life is not negatively affected by surgical 
intervention. Most studies of neurosurgical complications associated with brain 
tumour surgery report physical as opposed to cognitive impairments, despite the fact 
that cognitive dysfunction can have the greatest impact on quality of life. 
Furthermore, few studies have assessed cognitive function in brain tumour patients at 
the time of presentation which makes elucidation of the role of the tumour itself and 
the effects of different treatments on cognition problematic. Therefore, a measure of 
visual information processing before and after surgical intervention in neuro-
oncological patients would be informative. Following the successful pilot study that 
demonstrated slowed inspection times in brain tumour patients (Zbinden et al., 2006)
this thesis now aims to carry out a larger, prospective study to further evaluate the 
role of inspection time as a measure of visual information processing ability in 
patients with brain tumours. 
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Specifically, the following research questions will be addressed:
(i) Is visual information processing slower in a larger cohort of brain tumour 
patients prior to surgical intervention, by comparison with age and sex-
matched surgical and healthy control groups? 
(ii) What are the effects of tumour type, location and laterality on inspection 
time and other functions?
(iii) Prospectively, what are the effects of surgery on brain tumour patients’
inspection time functions alone, and in relation to other 
neuropsychological measures? 




Three groups of participants were recruited into the study. The study group (brain 
tumour group, n = 118) comprised newly-presenting patients who were admitted to 
the Department of Clinical Neurosciences (DCN), Western General Hospital, 
Edinburgh. This group of patients were to undergo a first surgery to biopsy or resect 
a supratentorial intracranial tumour (either primary or secondary) that had been 
diagnosed on CT or MRI scanning. The second group (spinal surgery controls, n = 
85) were a group of patients who were admitted to DCN for elective surgery to treat 
degenerative lumbar or cervical spine disease. The third group (healthy controls, n = 
80) consisted of healthy volunteer participants who were not receiving any treatment 
as a hospital inpatient. All three groups were matched as far as possible in terms of 
age, sex and National Adult Reading Test score (NART, as a measure of premorbid 
intelligence). 
3.2 Patient recruitment
Detailed recruitment procedures were implemented in order to maximise the number 
of patients recruited into the study. Regular contact was made with relevant medical 
staff on the DCN wards, including pre-admissions nurses, nurse practitioners and 
doctors who were responsible for brain tumour and spinal surgery patient care. 
Recruitment posters detailing the study and relevant contact details for the researcher 
were placed visibly on the wards to remind staff that recruitment was on-going (see 
appendix A). The admissions diary for the aforementioned wards was consulted on a 
daily basis in order to obtain names of potentially eligible elective spinal surgery and 
brain tumour cases. 
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The researcher approached any suitable patients at an appropriate time, gave verbal 
information about the study and offered the patient an information sheet (appendix 
B). Those patients from the brain tumour and spinal surgery groups who agreed to 
participate completed the first testing session the day before their operation wherever 
possible, although in some cases it was only possible to test the patient on the 
morning of their operation. In a number of other cases, spinal surgery and brain 
tumour patients were recruited and tested during their visit to the Pre-Admission 
Clinic (PAC), or Planned Investigation Unit (PIU), up to a week before the date of 
their operation. This alternative recruitment protocol arose following a change in 
admission procedures that resulted in the majority of elective surgery patients being 
admitted on the day of their planned surgery. Thus, approaching and testing patients 
during their pre-operative outpatient assessment overcame the difficulties associated 
with recruiting patients pre-operatively. 
Brain tumour patients were excluded if:
 They had previously undergone surgery to remove a brain tumour (i.e. not 
undergoing first craniotomy),
 They had a past medical history that included any psychiatric illness or brain-
related disease,
 They did not speak English as a first language,
 They had a severe visual defect (although a number of participants in the 
brain tumour group had some form of visual field defect),
 They had undergone previous radiotherapy to the brain,
 They were unable to give informed consent (e.g. due to confusion and/or 
dysphasia).
3.3 Healthy control group recruitment
Members of the healthy control group were recruited from a number of sources, 
namely the University of Edinburgh’s Psychology Department Recruitment Panel. 
The recruitment panel comprises volunteer members of the public who are willing to 
be contacted as potential control participants in research studies taking place within 
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the University of Edinburgh. Permission to use the recruitment panel was sought and 
granted. Where possible, potential participants were contacted and given information 
about the study, including the relevant participant information sheet (see appendix C)
via electronic mail. Those members of the panel for whom no e-mail address was 
available were contacted by letter (see appendix D), and were asked to contact the 
researcher should they be willing to participate in the study. The healthy control 
group also comprised volunteers recruited from a number of other sources, including 
volunteer colleagues, friends and family of the research team. Potential participants
who had any prior knowledge of any of the tests used were excluded. Healthy control 
group participants were tested at a mutually convenient time and their travel to and 
from the hospital was reimbursed, where applicable.
Demographic data including age, occupation, educational background and 
handedness were recorded for all participants. Data concerning tumour type (WHO 
classification), location, clinical features, surgery type (biopsy or resection) and 
medications were also recorded for the brain tumour cohort. 
3.4 Procedure
The brain tumour and spinal surgery groups completed a detailed battery of 
neuropsychological, mood and functional tests prior to surgery (baseline/session 1). 
Informed consent was given prior to commencing the testing session (see appendix E
and appendix F). Completion of the battery in its entirety required approximately 1 
hour. Both surgical patient groups were tested on a second occasion, post-surgery 
and prior to discharge from hospital (approximately 4 or 5 days later). This second 
testing session lasted about 20-30 minutes. At session two, patients repeated a 
number of the tests carried out during session 1 (see Table 3.1 for schedule of tests). 
Members of the brain tumour cohort were tested on a third occasion, where possible. 
This third testing session usually took place when the patient attended hospital for a 
follow-up neuro-oncology out-patient appointment, between 10 and 14 days post-
surgery. The third session lasted 20 - 30 minutes. The majority of patients who 
completed the third follow-up session were glioma patients since patients with other 
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tumour types did not routinely return for follow-up in this initial post-operative 
period. Additionally, most patients who completed session 3 testing completed only 
inspection time testing since there was often limited time available for testing prior to 
the patient’s scheduled appointment. Given that patients were given their histological 
diagnosis at this appointment, it was not feasible to test after their appointment. The 
healthy control group completed the baseline session at a time of their choosing, and 
session two was completed between 2 and 10 days later to mirror the pre and post-
operative testing of the surgical patient groups. All participants were given the tasks 
in the same order (see appendix G), with the exception of cases where some tasks 
were omitted due to patient fatigue, time constraints or patient refusal to complete 
one or more of the tasks.  
Testing sessions were carried out at a variety of different times throughout the day in 
order to fit in with the demands of the hospital ward and to minimise disruption to 
the patient. All testing sessions were carried out in the same private, quiet room 
within the hospital, under consistently artificially lit conditions. 
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IT + DS + EFIT X X
Other Cognitive X
QOL
Table 3.1. Schedule of tests.  IT = Inspection Time; DS = Digit Symbol-Coding; 
QOL = Quality of Life Assessment; EFIT = Edinburgh Functional Impairment Tests; 
Other Cognitive = National Adult Reading Test, Rey Auditory Verbal Learning Test, Trail 
Making Test Part B, Verbal Fluency, Letter-Number Sequencing, Hospital Anxiety and 
Depression Scale, Barthel Disability Index, Karnofsky Performance Scale.
3.5 Measures
The following measures comprised the baseline test battery and a number of the tasks 




The test was run and responses analysed using E-Prime software. All stimuli were 
presented on an iiyama computer monitor, running at a vertical refresh rate of 
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approximately 120 Hz. Participants were seated comfortably directly in front of the 
monitor, with their eyes approximately 75cm from the computer screen. 
The inspection time task comprises a two-alternative forced choice procedure in 
which participants are asked to make a simple visual discrimination. They must 
decide which of two parallel vertical lines of visibly different length is longer. In 
each trial, a small cross is presented in the centre of the computer screen for a 
duration of 500 ms, serving as a cue. The cue is then replaced by one of the two 
potential stimulus shapes, which is then immediately covered by a mask (see 
Figure.3.1). The method of constant stimuli was used, meaning that a fixed number 
of trials were presented randomly at a number of pre-determined stimulus exposure 
durations. Therefore, participants completed ten trials at each of 15 stimulus 
presentation durations, presented randomly, and the task comprised a total of 150 
trials. The durations for which the stimulus shape was shown were (in milliseconds): 
6, 12, 19, 25, 31, 37, 44, 50, 62, 75, 87, 100, 150 and 200. The 150 trials were 
divided into 5 blocks of 30 trials, with a break in between each block. This break 
allowed participants to rest their eyes for a short time, should they so wish. After 
each trial was complete (i.e. after the mask had been shown), participants were 
prompted to indicate which line (left or right) they thought was longer (i.e. to 
indicate which stimulus shape was shown) by pressing one of two keys on the 
computer keyboard. Each participant was instructed to respond at leisure since 
response times were not recorded. A number of practice trials alongside standardised, 
detailed instructions from the researcher were given to each participant prior to 
presentation of the150 test trials to ensure comprehension of the task and 
familiarisation with the relevant response keys. A small number of patients in the 
brain tumour group who had some form of motor weakness or who were anxious at 
the prospect of using a computer preferred to voice their responses. For this small 
proportion of patients, the researcher pressed the appropriate button for each 
response and did so in a location from which it was not possible to see the computer 
screen, in order to avoid any potential bias. 
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Figure 3.1. Sequence of events in each inspection time trial
3.5.1.2 Rey Auditory-Verbal Learning Test (RAVLT; Rey, 1964)
The RAVLT is a memory test that consists of two lists of 15 unrelated words (List A 
and List B; see appendix H). List A is read aloud at a rate of one word per second 
and the participant is instructed to recall as many words as they can, in any order. 
This procedure is then repeated four times. Thus, there are 5 presentations of List A, 
with recall of words from the list after each presentation. The 5 List A trials are then 
followed by a single presentation of the second list of words (List B), with recall of 
as many words from List B as possible. The participant is then instructed to recall as 
many words as possible from List A, on this occasion without the list being read 
aloud. A delayed recall trial of List A is given 20-30 minutes later (following 
completion of the inspection time task). At this time, the participant is again 
instructed to recall as many words as possible from List A, again without the list 
being read aloud. On each occasion, the examiner records each word recalled, in the 
order the participant recalls them.
The RAVLT provides a measure of learning and retention and is an assessment of 
many aspects of memory including word-span, acquisition, interference and delayed 
recall. Word list learning has also been found to be the most sensitive measure of 
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verbal memory, because there is no context in which to associate the different items 
to be remembered which increases task difficulty (Lezak et al., 2004).
3.5.1.3 National Adult Reading Test (NART; Nelson, 1982)
The NART is a list of 50 phonetically irregular words, i.e. words that do not follow 
the usual grapheme-phoneme pronunciation rules, listed in order of increasing 
difficulty (see appendix I). Participants are required to read the list aloud and are 
instructed to simply guess how to pronounce any words they do not recognise. 
Correct pronunciation of the words suggests that the patient has prior knowledge of 
them and the test was scored as the number of words incorrectly pronounced from a 
total of 50 on this occasion. 
There is strong evidence to support the hypothesis that performance on the National 
Adult Reading Test (NART) significantly reflects scores on standardised measures of 
intelligence. Specifically, NART performance at age 77 has been found to correlate 
significantly with IQ scores obtained from the same participants at age 11. This 
suggests that the NART may provide a reliable index of prior intellectual functioning 
(Crawford et al., 2001). Moreover, test scores are relatively unaffected by 
neurological or psychiatric disorder and as such can provide an estimate of prior, as 
opposed to current, level of intellectual functioning (McGurn et al., 2004). Therefore, 
the NART was administered as a measure of premorbid intelligence. 
3.5.1.4 Trail Making Test Part B (Reitan, 1958)
This is the second of a two-part pen and paper test devised by Reitan (1958). The test 
is presented on a single piece of A4 paper comprising a number of randomly placed 
encircled numbers and letters and the participant is instructed to connect the 
encircled numbers and letters consecutively with straight lines, alternating between 
the two sequences (e.g.1-A-2-B-3-C etc, see appendix J). A shorter practice page is 
completed prior to completion of the actual test page to ensure the participant has 
fully understood the task instructions. Participants are encouraged to connect the 
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circles as quickly but as accurately as possible and the score is the time taken, in 
seconds, to connect all the circles correctly. 
The trail making test part B provides a measure of scanning and visuomotor tracking, 
divided attention and cognitive flexibility although motor speed has a strong 
contribution to successful, quick completion of this task (Lezak et al., 2004). Poor 
performance on the test has been found to reflect cognitive inflexibility to a modest 
degree with test scores correlating more highly with a test of perseveration 
(Wisconsin Card Sorting Test) than with digit span, letter fluency, or memory scores 
(Korte et al., 2002). Moreover, both parts A and B of the trail making test have been 
found to be a sensitive measure of cognitive impairment in people with dementia, 
even in the early stages of the disease (Botwinick et al., 1988). Performance on both 
version of the test has also been found to be slower than control participants in 
patients with mild traumatic brain injuries (Leininger et al., 1990).
3.5.1.5 Verbal Fluency (Controlled Oral Word Association Test; 
(Benton and Hamsher, 1989)
The Controlled Oral Word Association Test (COWAT) is a measure of verbal 
fluency that requires the patient to spontaneously produce as many words as possible 
beginning with a specific letter of the alphabet within a specified time frame (60 
seconds). The letters C, F and L were used in the present study. Participants were 
instructed to verbalise as many words as they could think of beginning with each 
letter, excluding proper nouns, numbers and repetitions of the same word with a 
different suffix. A practice trial using the letter ‘S’ was undertaken prior to the main 
test and the researcher recorded each word produced during each trial (see appendix 
K). The score on the COWAT is the total number of words generated for each of the 
three letters. 
The COWAT has been validated with a number of different letter combinations, 
including ‘C, F, and L’ and ‘F, A, and S’ and performance across these different 
forms of the tasks does not differ significantly in healthy groups, psychiatric patients 
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and patients with suspected CNS impairment (Troyer, 2000, Lacy et al., 1996). 
Moreover, written word fluency and phonemic fluency also correlate significantly 
(Cohen and Stanczak, 2000). Effective performance on this task is thought to involve 
executive functions that include cognitive flexibility, strategy utilisation, suppression 
of interference and response inhibition (Abwender et al., 2001). The verbal fluency 
task is sensitive to brain dysfunction and patients with frontal lesions have been 
found to generate fewer words on the test, with left frontal lesions resulting in greater 
impairment than right frontal lesions (Miceli et al., 1981).
3.5.1.6 Digit Symbol-Coding (Wechsler, 1997)
This is a subtest from the Wechsler Adult Intelligent Scales (WAIS-III) and is an 
assessment of psychomotor performance that is largely unaffected by memory, 
learning and intellectual ability (Erber et al., 1981). The numbers 1-9 are each paired 
with a different symbol, shown in a key displayed at the top of the page. Rows of 
randomly presented numbers with empty boxes below in which the corresponding 
symbol should be drawn are shown on the same page, below the key (see appendix 
L). The participant is instructed to draw the relevant symbol under the corresponding 
number and to complete as many as possible in a 120 second time-frame. The score 
is the number of boxes filled in correctly within the time limit. 
Test-retest reliability is high for this WAIS-III subtest, with correlation coefficients 
between .82 and .88 obtained in cohorts of healthy participants (Matarazzo and 
Herman, 1984, Wechsler, 1981). However, test-retest reliability tends to vary when 
clinical populations are studied, with poor reliability for schizophrenic patients, but 
coefficients near normal levels for patients with mild traumatic brain injury (Lezak et 
al., 2004).
3.5.1.7 Letter-Number Sequencing (Wechsler, 1981)
Letter-number sequencing is a subtest of the Wechsler Adult Intelligence Scales 
(WAIS-III). The patient is read a mixed random combination of numbers and letters 
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and is required to repeat the numbers first, in ascending order, followed by the letters 
in alphabetical order. The task increases in difficulty from two items to eight items,
with three trials at each level of difficulty (see appendix M). The span is increased 
until the participant fails all three trials of one length (up to eight characters). Crowe 
(2000) has shown that performance on this task is related not only to digit span and 
attentional measures, but is also a measure of processing speed and visual-spatial 
working memory. 
3.5.2 Mood Assessment
3.5.2.1 Hospital Anxiety and Depression Scale (HADS, Zigmond & 
Snaith, 1983)
This is a short questionnaire which was completed independently by the majority of 
participants. The questionnaire is a self-screening one for anxiety and depression and 
was designed specifically to detect emotional disorder in hospitalised patients 
(Zigmond and Snaith, 1983). Participants are instructed to answer each item based on 
their feelings over the past week and are also encouraged to give an immediate 
response and not to spend too long thinking about their answers (see appendix N). 
The HADS has been found to be a sensitive measure of post-stroke depression 
although it is reported to be a better measure in men than in women (Aben et al., 
2002).
3.5.3 Functional Assessments: Edinburgh Functional 
Impairment Tests (EFIT)
The EFITs consist of four separate assessments of patient function designed to 
provide a brief, easily administered assessment of upper and lower limb function, 
language and short-term memory (Grant et al., 1994).
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3.5.3.1 Nine Hole Peg Test
The Nine Hole Peg Test (NHPT) assesses manual dexterity and upper limb function. 
The participant is required to place nine wooden dowels (9mm diameter, 32mm long) 
into a wooden base with nine holes spaced 50mm apart as quickly as possible, using 
one hand at a time and picking up only one peg at a time. A stop-watch was used to 
record the time taken for each hand separately, measuring the time taken from the 
first touch of the first peg until the last peg was placed. In cases where the tests could 
not be completed for one or both hands due to severe weakness or numbness, the test 
was terminated and a score of 180 seconds recorded. A NHPT score of >18 seconds 
is considered abnormal. 
3.5.3.2 Timed Ten Metre Walk
The Timed Ten Metre Walk (TMW) is a quick and objective test of lower limb 
function.  Participants are instructed to walk as fast as they can, without running, 
along a straight line ten metre course. The time taken was recorded using a stop-
watch and a TMW time of ≥ 8 seconds is considered abnormal. 
3.5.3.3 Williams Delayed Recall Test
The Williams Delayed Recall Test (WDRT) is a short assessment of delayed recall 
(memory) where the participant is shown a piece of A4 paper with nine black and 
white pictures of unrelated, everyday objects on it. The participant is instructed to 
have a good look at the pictures and to try their best to remember them. He/she 
verbally identifies the pictures to the researcher and is then given a few seconds 
longer to examine the pictures. About 6 minutes later (following completion of the 
NHPT and Boston Aphasia Severity Rating Scale subtests), the participant is 
instructed to recall as many of the pictures as they can, in any order. If the patient is 
unable to recall all nine objects, he or she is given a pre-determined prompt for the 
missing objects. If any objects are not correctly recalled following the prompt, the 
participant is then shown 15 pictures, 9 of which are the original ones and is asked to 
identify the original objects. Scoring is as follows: 2 points for every item not 
97
recalled spontaneously, 3 points for each item not recalled with a prompt and 4 
points for each item not recognised from the visual prompt. A WDRT score of >16 is 
considered abnormal (Clyde et al., 1998). The WDRT has three versions (A, B and 
C, see appendix O), allowing for repeated administration and a Latin-square method 
was used to randomise the versions given to each participant at the different testing 
sessions. 
3.5.3.4 Boston Aphasia Severity Rating Scale
The Boston Aphasia Severity Rating scale (BASRS) assesses language and allows 
the researcher to rate presence and severity of dysphasia on an ordinal scale. Scores 
on the BASRS range from 6 (normal speech) to 0 (no useful speech or auditory 
comprehension). Language function was scored on this scale for each patient after 
listening to conversational speech during the testing session and through formally 
asking the patient to describe what was going on in a the ‘cookie theft’ from the 
Boston Diagnostic Aphasia Examination, see appendix P). A BASRS score of < 6 
indicates the presence of some degree of speech impairment and, as such, is 
considered abnormal. 
3.5.4 Quality of Life Assessment
3.5.4.1 European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-C30) + Brain Cancer 
Module (QLQ-BN20)
The EORTC QLQ-C30 is commonly used to measure health-related quality of life in 
cancer patients. It comprises five functional scales (physical, role cognitive, 
emotional and social); three symptom scales (fatigue, pain and nausea and vomiting), 
a global health status/QOL scale and a number of single items assessing additional 
symptoms that are frequently reported by cancer patients (dyspnoea, loss of appetite, 
insomnia, constipation and diarrhoea and perceived financial impact of the disease). 
The brain cancer module has been developed primarily for brain tumour patients who 
are undergoing radiotherapy and/or chemotherapy and includes 20 questions that 
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assess the following: future uncertainty, visual disorder, motor dysfunction, 
communication deficit, other disease symptoms such as headaches and seizures and 
treatment toxicities including hair loss (see appendix Q). The majority of participants 
completed the questionnaire independently, although some brain tumour patients did 
require assistance to indicate their responses due to either motor problems or mild 
confusion. 
3.5.5 Clinical Assessments
3.5.5.1 Barthel Disability Index (BDI, (Mahoney and Barthel, 1965)
This assessment was completed by the researcher as a measure of physical disability 
by rating the patients’ ability to perform a number of activities of daily living (see 
appendix R). Ratings were made based on the researchers’ own observations,
through conversation with the patients themselves and consultation of the patient’s 
notes, in addition to consultation with medical staff involved with the patient’s care, 
where necessary. The Barthel Disability Index yields a score /20, with a score of less 
than 20 considered abnormal. 
3.5.5.2 Karnofsky Performance Scale (KPS, (Karnofsky and 
Burchenal, 1943)
The KPS is a scale that is often used to assess terminally ill patients and allows 
classification in terms of functional impairment and medical care requirements. 
Ratings were made for each patient on the basis of the researchers’ judgements and 
scored on a scale from 100 (no impairment) to 0 (dead, see appendix S). KPS score is 




Before reporting the results of the study, it is important to consider the sample of 
brain tumour patients who were successfully recruited into the study in the context of 
the entire newly-presenting cohort of patients that were admitted to the department 
during the recruitment period. Therefore, a recruitment log was kept from the outset 
of the study to record all newly presenting brain tumour patients who were not 
entered into the study, and the reason for which they did not participate. This was 
done to determine whether the sample of brain tumour patients recruited into the 
study was representative of the total number of new patients admitted to the 
neurosurgical ward during the course of the study recruitment phase. 
4.2 Results
According to the recruitment log, a total of 294 newly diagnosed patients, who 
potentially fulfilled eligibility criteria for the study, were admitted to the department 
for a surgical biopsy or resection of a supratentorial brain tumour between April 
2006 and January 2009. Of these, 220 (74.8%) were eligible to take part in the study 
(see Figure 4.1). The remaining 74 patients (25.2%) were excluded from the study 
for either medical reasons such as severe visual acuity or visual field defects, severe 
dysphasia or impaired mental status that precluded obtaining informed consent from
the patient; or sensorimotor impairment that prevented the patient from being 
transported to the testing office; or as a result of co-morbidities including Down 
Syndrome, mental health problems or chronic alcoholism (‘ineligible’).
Of the cohort eligible to take part in the study (n = 220), only 53.6 % (n = 118) were 
recruited, since 24.6% of the eligible patients (n = 54) declined to take part. The 
remaining 21.8% (n = 48) were not entered into the study because they were ‘missed’ 
by the researcher. This was due to either annual leave, failure of ward staff to inform 
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that a new patient had been admitted, or because the patient was admitted or 
transferred to the ward very late on the day before their operation. 
In the total cohort of newly presenting patients who were admitted between April 
2006 and January 2009 (n = 294), two patients were recruited into the study and did 
not subsequently undergo any surgical intervention. These two cases are therefore 
excluded from the following analysis. In the revised total cohort (n = 292), the 
majority of patients were subsequently found to have a high-grade glioma (54.8%), 
low-grade glioma (10.6%), meningioma (16.1%) or metastasis (10.6%) (see Table 
4.1). However, in the study cohort (i.e. the group of patients who participated in the 
study, excluding the two cases who did not have surgery), only 44% had a high-
grade glioma and 19.8% had a low-grade glioma. This difference arose because the 
majority of patients in the medically ineligible group had a high-grade glioma 
(64.9%), whereas only 4.1% of ineligible patients had a low-grade glioma. 
The group of patients who declined, were deemed medically ineligible, or were 
missed, were combined to form a single ‘non-participation’ group. The group of 
patients who did participate were compared with the ‘non-participation’ group in 
terms of tumour type using a chi-square test. The analysis revealed a significant 
association between group and tumour type, χ²(4) = 20.76, p < 0.001. This confirms 
that fewer high-grade glioma patients than expected were entered into the study, 
whereas a higher number of low-grade glioma patients than expected did take part 
(see Table 4.1). 
The ‘declined’ and ‘medically ineligible’ groups were then combined to create a 
second ‘non-participation’ group. By not including the group of ‘missed’ patients, 
this makes the comparison more relevant to other, similar studies of cognition in 
newly-presenting brain tumour patients. Comparison of the participation group 
against the combined declined and ineligible groups again revealed a significant 
association between the group and tumour type, χ²(4) = 16.67, p = 0.002. This again 
demonstrates that a higher than expected number of high-grade glioma patients did 
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not participate in the study. Conversely, fewer low-grade glioma patients than 
expected did not take part.
Finally, the participation group were compared with the group of patients who were 
approached but declined to take part in the study. In this instance, the association 
between group and tumour type failed to reach statistical significance, χ²(4) = 8.49, p 
= 0.075. 
A paper detailing the potential for bias in neuro-oncological studies, including 
recruitment data from April 2006 – December 2007 has been accepted for 
publication (Scotland et al., 2009; see appendix T). 
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Figure 4.1. Flowchart detailing brain tumour cohort eligibility for the study and recruitment. 
Total number of
brain tumour patients 
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Table 4.1. The number of patients with each tumour type in the total cohort (excluding 2 patients who were recruited but did not undergo surgery to 
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Detailed examination of the recruitment log kept throughout the duration of the study 
revealed that a large number of patients were ineligible for medical reasons (74/294) 
and a large number of patients who were approached subsequently declined to take 
part in the study (54/220). Furthermore, a significant number of potentially eligible 
patients were not approached at all (48/220). There were significant differences 
between the histological characteristics of the brain tumour patients who were 
successfully recruited into the study and those who did not participate for any of the 
aforementioned reasons. By comparison with the combined cohort of ‘non-
participating’ patients who were either ineligible, declined to participate or were not 
approached (‘missed’), the recruited cohort comprised significantly fewer patients 
with high-grade gliomas than expected and, conversely, significantly more patients 
with low-grade gliomas than expected did participate in the study. This finding was 
replicated when only those patients who declined and those who were ineligible were 
included in the ‘non-participation’ group. Comparison of the patients who were 
approached but declined participation with those who did take part in the study did 
not reach the conventional level of statistical significance. 
Recording and examining the characteristics of not only those patients who were 
successfully entered into the study, but of all potentially eligible patients and 
detailing the reasons for non-participation is of particular importance in studies such 
as the present one. Flick (1988) highlights the issue of ‘preinclusion attrition’ which 
occurs when potential participants do not participate in the study as a result of some 
selection bias. Thus, considering preinclusion attrition allows us determine whether 
specific groups of patients are more likely to participate than others and is an 
important consideration when considering the representative nature of a patient 
sample and subsequent results. 
The unexpectedly high refusal (decline) rate in the brain tumour group in the present 
study was in contrast with several other studies that have been conducted in the same 
unit, including two non-interventional, non-testing but nevertheless demanding 
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studies (Bastin et al., 2006, Schwindack et al., 2005) and an ongoing non-
interventional clinicopathological study (Whittle et al., 2007). However, the 
cognitive testing demands of the present study may have specifically contributed to 
the high refusal rate. Certainly, the specific problems associated with 
neuropsychological testing in brain tumour patients have been documented 
qualitatively, although few studies report recruitment rates quantitatively (Taphoorn 
and Klein, 2004). In the present study, it was clear that the anxiety associated with a 
sudden diagnosis of a brain tumour and trepidation at the prospect of completing 
neuropsychological tests appeared to be the primary reason for patient refusal, 
although this was not documented quantitatively. The specific need to recruit patients 
in the pre-operative period was also particularly problematic and this may explain 
why relatively few studies have documented cognitive function in brain tumour 
patients at the time of presentation and prior to any surgical treatment, yet several 
similar studies have successfully examined cognition following surgery and/or 
radiotherapy in this patient group.(Bosma et al., 2007, Ek et al., 2005, Klein et al., 
2001). However, although the decline rate in the present study was considerably 
higher than that observed by other neuro-oncological studies that were carried out in 
the same unit, the successful recruitment rate of 54% of eligible patients (40% of the 
total cohort) is comparable with studies in other areas, including a community-based 
clinical research study in which 47% of all eligible participants were successfully 
recruited (Wiemann et al., 2005). The recruitment rate in the present study was also 
higher than the mean enrolment proportion (32.7%) across 112 recruitment sites into 
a Cardiac Arrhythmia Suppression Trial (CAST; (Shea et al., 1992) and higher than 
the 22.4% of cases successfully recruited into a randomised interventional ISAT 
study (ISAT, 2002).
A large proportion of newly presenting patients were subsequently found to be 
ineligible (25%) and were therefore excluded and not approached. This ineligibility 
was usually a result of acute confusion and/or dysphasia that precluded informed 
consent. Memory problems, confusion and speech impairment are commonly 
reported symptoms in neuro-oncological patients and in an audit of Scottish brain 
tumour patients, Grant (2004) reports that memory problems/confusion were present 
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in 31% of patients at the time of hospital presentation and dysphasia was noted in 
21% of patients. These data are in keeping with the proportion of patients deemed to 
be ineligible for these reasons in the present study.
Of the total cohort of newly presenting patients with supratentorial brain tumours for 
whom surgical intervention was planned, 55% had a high-grade glioma, 11% had a 
low-grade glioma, 16% had a meningioma, 11% a metastasis and the remaining 8% 
had other tumour types. These figures are broadly in keeping with those reported in 
the literature (McKinney, 2004). However, the majority of studies reporting the 
incidence of tumours examine primary brain tumours or gliomas specifically and this 
makes it difficult to determine the representative nature of the total brain tumour 
cohort who represented to the neurosurgical wards. However, given the large 
geographical area covered by the unit, it can reasonably be assumed that the total 
recorded cohort were representative of the brain tumour population in the UK. 
The finding that the group of brain tumour patients who participated have
significantly different histological characteristics than those who declined, were 
ineligible and missed combined, and also by comparison with the combined group of 
patients who declined or were ineligible patients is an important consideration when 
extrapolating the results of the present study. Low-grade glioma patients were over-
represented and high-grade glioma patients were under-represented in the recruited 
cohort and this finding is perhaps unsurprising for a number of reasons. Patients with 
more aggressive tumours (i.e. high-grade gliomas) tend to present with more severe 
focal and global symptoms that may impair their ability to give informed consent to 
participate in cognitive assessments. Moreover, patients with suspected high-grade 
gliomas more often present on an emergency basis and are often admitted to the 
hospital ward for only a short time before surgery, in contrast with their low-grade 
counterparts. This procedure can be problematic when the study protocol necessitates 
patient recruitment and testing prior to surgical intervention. Patients with a 
suspected low-grade glioma are more likely to be offered surgery on an elective 
basis, often after a period of ‘watch and wait’ observation (Whittle, 2004). Therefore, 
given that patients with a low-grade glioma are more likely to have had time to adjust 
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to the diagnosis of brain tumour, that ample time is generally available to recruit 
these patients prior to surgery, and these patients tend to have less severe deficits, the 
number of patients who refuse, are missed or deemed ineligible is likely to be fewer 
and this may explain the above findings. 
The disparity between the proportion of high and low-grade glioma patients in the 
recruited and non-recruited groups may well bias the final outcome of the present 
study. Since patients with high-grade gliomas would likely have performed less well 
than their low-grade counterparts (Bosma et al., 2007), the recruited brain tumour 
cohort may have performed better than a truly representative cohort and this must be 
considered when interpreting the results detailed in the following chapters. The 
potential for consent or participation bias should also be considered in other similar 
neuropsychological studies in neuro-oncology and these findings have been 





Between April 2006 and January 2009, 118 brain tumour patients (60 male, 58 
female) were recruited into the study. A further 85 spinal surgery controls (39 male, 
46 female) and 80 healthy volunteer controls (31 male, 49 female) were also 
evaluated during this period. The demographic characteristics of each group are 
shown in Table 5.1. 
Chi-square tests showed that there were no significant differences between the three 
groups with respect to sex (χ² (2) = 2.810, p = 0.245). The mean age of participants 
in the brain tumour group was 50.0 years (SD 13.0), was 47.8 years (SD 11.2) in the 
spinal control group, and was 49.1 years (SD 16.4) in the healthy control group. One 
way ANOVA revealed no significant differences between participant age in the three 
groups (F(2,282) = 0.681 p = 0.507). Similarly, chi-square analysis showed there to 
be no significant differences in handedness between the three groups (χ² (4) = 4.715, 
p = 0.318). 
Crosstabulation revealed that many more participants in the healthy control group 
had university degree level qualifications than expected (see Table 5.2), suggesting
that the healthy control group had achieved higher levels of education that the brain 
tumour and spinal surgery groups. Formal testing, using Pearson chi square analysis 
of the highest levels of qualification achieved by participants in each of the three 
groups, revealed significant differences between the groups (χ² (12) = 103.260, p < 
0.001). 
The mean National Adult Reading Test (NART) score, included as a measure of 
premorbid ability, was 20.6 (SD 9.4) for the brain tumour group. The corresponding 
mean score for the spinal surgery control group was 19.9 (SD 9.3) and for the healthy 
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control group was 11.7 (SD 5.0). Higher scores on the NART reflect poorer 
premorbid ability. 
As can be seen from Table 5.3, the group of brain tumour patients had a variety of 
histological diagnoses, with tumours located in a variety of different brain regions. 
Thirty patients had a biopsy of the tumour, and 86 had a resection. The remaining 
two patients who were tested at baseline did not subsequently go on to have surgery. 
All brain tumour patients were taking pre-operative dexamethasone. 
5.1.2 Attrition and Follow-Up
Figure 5.1. shows attrition and follow-up rates in the brain tumour, spinal surgery 
and healthy control groups. The majority of healthy control participants completed 
both testing sessions (76/80, 95.0%). A smaller number of spinal surgery control 
patients completed both baseline and post-surgical session 2 testing sessions (67/85, 
78.8%). Of the eighteen patients who did not complete the post-operative testing, 10 
were approached but refused to participate post-operatively. This was usually the 
result of increased pain following surgery. The remaining 8 were classified as 
‘missed’ since they were not approached post-operatively, prior to discharge. This 
was due to the patient having been discharged earlier than expected, without the 
researcher’s knowledge.
In the brain tumour cohort, 64 of 118 (54.2%) participants completed the first post-
operative follow-up testing session, prior to discharge from the hospital ward. Those 
patients who did not complete session 2 either declined to take part at this stage, had 
acute physical and/or cognitive impairment post-operatively that prevented 
completion of follow-up testing or were discharged unexpectedly without the 
researcher being made aware. Of the 118 patients who completed baseline testing, 52 
(44.1%) completed the third testing session, which took place when the patient 
returned for out-patient follow-up. Those patients who did not complete this third 
session, as with those who were not tested at session 2, most frequently declined to 
take part. Furthermore, patients with a diagnosis of a meningioma or metastasis were 
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not routinely offered an out-patient appointment in the department and therefore 
could not be asked to take part in the third testing session. Therefore, the majority of 
patients who completed the third testing session had a diagnosis of either high or 
low-grade glioma. Overall, 80/118 (67.8%) participants in the brain tumour cohort 
completed at least one post-operative follow-up session. Of the 38 patients (32.2%) 
who completed only baseline testing, the majority declined to take part in any post-
operative follow-up (n = 17, 44.7%), or were unable due to post-operative 
complications including increased confusion, dysphasia or hemiplegia (n = 12, 
31.6%). The remaining patients who took part in only baseline testing were either 
missed by the researcher due to annual leave (n = 5, 13.2%) or did not have any 
surgical intervention (n = 2, 5.3%). Comparisons of the baseline performance of 
those participants who completed session 2 follow-up testing and those who did not 
are detailed in appendix Chapter U. 
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5.2 Baseline Analyses: Cognitive Measures 
5.2.1 Overview of Analysis Procedure
Baseline (i.e. pre-operative/session 1) scores on each of the cognitive tests were 
compared between the brain tumour, spinal surgery and healthy volunteer groups 
using general linear modelling (analysis of covariance). Group and sex were entered 
as fixed factors in the models. 
In the whole sample (i.e. all three participant groups combined) who met validity 
criterion in inspection time testing (i.e. at least 17/20 correct on the two longest 
durations, as explained in chapter 2.2), age was correlated with inspection time (r (n 
= 255) = -0.444; p < 0.001). There was also a significant correlation between 
National Adult Reading Test (NART; as a measure of premorbid ability) score and 
total inspection time score in the whole sample combined (r (n = 252) = -0.124, p = 
0.048). Therefore, age at the time of testing and NART score were included as 
covariates in all group comparisons. 
In each of the sections that follow, mean scores for each group (brain tumour, spinal 
surgery control and healthy control) are presented with standard deviations (SD) in 
brackets. The results of the general linear modelling analysis are then reported. 
Estimated marginal means (adjusted for age and NART score) and pairwise 
comparisons are then described for each of the tests administered to highlight the 
differences between the groups where applicable. Least Significant Difference (LSD) 
adjustments were used to compare main effects. There was no significant group by 
sex interaction in any of the models, therefore these data are not reported below.
Table 5.4 shows the results of the general linear modelling analyses for each test and 
Table 5.5 gives the estimated marginal mean (standard error) scores, adjusted for age 
and NART score for the three groups, alongside the p-values for significance for 
pairwise comparisons of the brain tumour group against each of the two control
groups, for each test. 
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5.2.2 Inspection Time Scores: All Inspection Time Data
A total of 114 brain tumour patients, 82 spinal control patients and 80 healthy 
volunteer controls completed the inspection time task in its entirety at baseline and 
all inspection time data, including scores from those participants who were deemed 
to have ‘invalid’ data (i.e. those who scored < 17/20 correct on the longest two task 
durations) were included in the analysis in the first instance. Mean total inspection 
time total scores, with standard deviations shown in brackets, were 114.3 (SD 19.9) 
for the brain tumour group, 121.4 (SD 13.7) for spinal controls and 126.4 (SD 11.5) 
for the healthy control group.
General linear modelling, with total inspection time score (i.e. score /150) as the 
dependent variable revealed a significant main effect of the covariates age, F(1,266) 
= 76.95, p < 0.001, partial η² = 0.224; and National Adult Reading Test (NART) 
score, F(1,266) =18.584, p < 0.001, partial η² = 0.065. Older participants and 
participants with higher (poorer) NART scores were significantly more likely to have 
lower inspection time total scores. There was no significant main effect of sex in the 
model, F(1,266) = 2.604, p = 0.108, partial η² = 0.010. There was a significant main 
effect of group (i.e. brain tumour, spinal or healthy control) in the model that 
included the effects of age and NART score, F(2,266) = 7.994, p < 0.001, partial η² = 
0.057.  
Pairwise comparisons using LSD tests revealed a significant difference between the 
brain tumour group and the spinal group (p = 0.005) and a significant difference 
between the brain tumour group and the healthy volunteer group (p < 0.001). 
Estimated marginal mean scores, adjusted for age and NART score, were 115.9 (SE 
1.3) for the brain tumour group and 121.6 (SE 1.6) for the spinal surgery group, 
showing that the brain tumour group had significantly poorer scores than the surgical 
control group. The corresponding mean score for the healthy control group was 
124.2 (SE 1.7). Therefore, the brain tumour group were also significantly impaired 
on inspection time at baseline by comparison with the healthy control group. There 
was no significant difference between the performance of the spinal surgery control 
group and the healthy control group (p = 0.280).
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Inspection Time Performance at Baseline in the Three Groups: 



































































   
Figure 5.2.  Psychometric curves describing inspection time performance (all data) in the 
brain tumour, spinal surgery and healthy control groups. Points are estimated marginal 
means adjusted for age and NART score. Error bars: Standard Error Means.
The differences between the brain tumour group and each of the control groups on 
the inspection time task are demonstrated in Figure 5.2. which shows estimated 
marginal mean scores, adjusted for age, sex and NART score, out of a possible total 
of 10 across each duration on the task (i.e. from 6ms – 150ms). The three groups 
score similarly when the stimuli are shown for very brief time periods. However, at 
intermediate and the longer durations, the line for the brain tumour patients is shifted 
to the right, compared with the spinal and healthy control groups. This suggests 
slower visual information processing in the brain tumour cohort by comparison with 
both control groups.
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5.2.3 Inspection Time Scores: Valid Inspection Time Data
Sixteen brain tumour patients, five spinal surgery controls and two healthy volunteer 
controls did not perform to criterion on inspection time at baseline and failed to score 
at least 17/20 on the two longest stimulus durations. These scores were recorded as 
‘invalid’ as the participant might not have fully understood the task instructions (as 
described in Chapter 2.2). Therefore, the above described-analyses were repeated 
using only data from those participants with ‘valid’ inspection time scores. 
When the invalid scores were not included in the analysis, the mean baseline 
inspection time scores were 120.1 (SD 13.7) for the brain tumour group, 123.3 (SD 
11.0) for the spinal control group and 127.2 (SD 10.3) for the healthy control group.
The covariates age, F(1,244) = 73.362, p < 0.001, partial η² = 0.23; and NART score, 
F(1,244) = 7.018, p = 0.009, partial η² = 0.03, had a significant main effect in the 
model that included only valid inspection time scores. Older age and poorer NART 
scores were significantly associated with lower inspection time scores. The effect of 
sex was not significant in the model, F(1,244) = 3.141, p = 0.078, partial η² = 0.013. 
Participant group had a significant main effect on valid total inspection time scores in 
the model that included the effect of the covariates age and NART score, F(2,244) = 
6.400, p = 0.002, partial η² = 0.05.
Pairwise comparisons showed a trend towards a difference between the brain tumour 
and spinal surgery control groups; however, this did not reach the conventional level 
of statistical significance, (p = 0.066). Estimated marginal means, adjusted for age 
and NART score showed that the brain tumour group scored lower overall than the 
spinal group on the inspection time task at baseline (120.5 (SE 1.1) vs. 123.4 (SE 
1.2), respectively). The difference between the brain tumour group and healthy 
control group was significant (p < 0.001). Estimated marginal means, adjusted for 
age and NART score, suggest that the brain tumour patients had significantly poorer 
inspection time scores than the healthy controls (120.5 (SE 1.1) vs. 126.7 (SE 1.3), 
respectively). The difference between the healthy control group and spinal control 
group did not reach significance (p = 0.076).
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Inspection Time Performance at Baseline in the Three Groups: 
























































Figure 5.3. Psychometric curves describing inspection time performance (valid data only) in 
the brain tumour, spinal surgery and healthy control groups. Points are estimated marginal 
means adjusted for age and NART score. Error bars: Standard Error Means.
Figure 5.3 shows estimated marginal mean scores, adjusted for age and NART score, 
out of a possible total of 10 for valid inspection time scores, at each of the 15 
durations on the inspection time task. Again, the three groups score similarly (i.e. 
respond at chance) when the stimuli are shown for very brief time periods and also at 
longer time periods, where the three groups respond almost perfectly. However, at 
intermediate durations, the line for the brain tumour patients is shifted to the right,
when compared with the healthy control group and to a lesser (non-significant) 
degree when compared with the spinal surgery control group. This again suggests 
slowed visual information processing in the brain tumour cohort, particularly when 
compared with the healthy volunteer control group. 
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5.2.4 Rey Auditory Verbal Learning Test
Eighty-seven brain tumour patients completed the Rey Auditory Verbal Learning 
Test (RAVLT) at baseline. Seventy-four spinal surgery patients and 80 members of 
the healthy control group also completed the test.
The mean total number of words recalled across all 8 trials of the RAVLT was 61.7 
(SD 17.5) for the brain tumour group; 71.0 words (SD 15.7) for the spinal surgery 
group and the healthy control group had a mean score of 82.0 words (SD 13.8) 
words. The number of words correctly recalled was the dependent variable in the 
general linear model.
There was a significant main effect of the covariates age, F(1,233) = 84.008, p <
0.001, partial η² = 0.27; and NART score, F(1,233) = 41.310, p < 0.001, partial η² =
0.15, in the model. Older participants and participants with poorer NART scores 
were significantly more likely to recall fewer words on the test. Sex also had a 
significant main effect in the model, F(1,233) = 6.905, p = 0.009, partial η² = 0.03. 
Female participants were more likely to have higher scores than male participants. 
Participant group had a significant main effect in the model that included the effects 
of age and NART score, F(2,233) = 18.924, p < 0.001, partial η² = 0.14.
Pairwise comparisons revealed a significant difference between the brain tumour and 
spinal surgery groups (p < 0.001), and a significant difference between the brain 
tumour and healthy control groups (p < 0.001). The estimated marginal mean scores 
on this test, adjusted for age and NART score, were 64.3 (SE 1.4), 72.2 (SE 1.5) and 
77.8 (SE 1.6) for the brain tumour, spinal and healthy control groups, respectively. 
Therefore, the brain tumour group had significantly lower scores on this memory test 
than both of the control groups. Additionally, there was a significant difference 
between the healthy control group and spinal surgery group (p = 0.014), showing that 
the healthy control group significantly outperformed the spinal control group on the 
RAVLT.
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5.2.5 Trail Making Test Part B
The Trail Making Test Part B was completed by 96 members of the brain tumour 
group, 82 members of the spinal control group and 80 members of the healthy 
control group.
The mean time taken for the brain tumour group to complete this test was 94.9 (SD 
31.7) seconds. Mean scores for the spinal surgery controls and healthy controls were 
81.2 (SD 24.1) and 69.0 (SD 20.9) seconds, respectively. 
There was a significant main effect of age in the general linear model, F(1,250) = 
56.88, p < 0.001, partial η² = 0.19. The covariate NART score also had a significant 
main effect in the model, F(1,250) = 47.72, p < 0.001, partial η² = 0.16. Younger 
participants and those with lower (better) NART scores were significantly more 
likely to complete the test in a shorter time. Sex had no significant main effect in the 
model, F(1,250) = 0.256, p = 0.613, partial η² = 0.001. There was a significant main 
effect of group on the test scores in the model that included the effects of age and 
NART score, F(2,250) = 10.70, p < 0.001, partial η² = 0.08.
Pairwise comparisons revealed a significant difference between the brain tumour and 
spinal surgery groups (p < 0.001). The estimated marginal mean scores, adjusted for 
age and NART score, show that the brain tumour group were significantly slower to 
complete the test than the spinal control group (91.3 secs (SE 2.4) and 79.0 secs (SE 
2.6), respectively). The estimated marginal mean score for the healthy control group 
was 75.2 secs (SE 2.8). The healthy control group were significantly faster than the 
brain tumour group (p < 0.001). The difference between the spinal and healthy 
control groups was not significant (p = 0.331). 
5.2.6 Verbal Fluency
Ninety-one participants in the brain tumour group completed the verbal fluency test. 
Seventy-eight members of the spinal control group and 80 healthy controls also 
completed the task.
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The mean number of words produced on this test was 28.6 (SD 12.0) for the brain 
tumour group. The spinal control patients produced a mean of 35.0 words (SD 13.1) 
and healthy controls produced a mean of 45.0 words (SD 12.7) on the task. 
There was no significant main effect of age in the model, F(1,241) = 2.470, p = 
0.117, partial η² = 0.010. The covariate NART score did have a significant main 
effect in the model, F(1,241) = 70.56, p <0 .001, partial η² = 0.23. Sex also had a 
significant main effect, F(1,241) = 5.94, p = 0.016, partial η² = 0.02. Female 
participants and participants with lower (better) NART scores were significantly 
more likely the have better scores on the verbal fluency test. There was a significant 
main effect of group on verbal fluency scores in the model that included the effects 
of the covariates, F(2,241) = 13.77, p < 0.001, partial η² = 0.10. 
Pairwise comparisons using LSD tests revealed a significant difference between the 
brain tumour group and the spinal surgery control group (p = 0.002). The estimated 
marginal mean score, adjusted for age and NART score, for the brain tumour group 
was 31.0 (SE 1.2) on this test, and for the spinal control group was 36.4 (SE 1.3). 
Thus, the brain tumour group produced significantly fewer words than their spinal 
surgery counterparts. LSD tests also revealed a significant difference between the 
brain tumour and healthy control groups (p < 0.001). The estimated marginal mean 
score for the healthy control group was 40.8 (SE 1.4) showing that the brain tumour 
group also had significantly lower scores than the healthy control group. The 
difference between the spinal and healthy control groups was significant (p = 0.023). 
The healthy control group performed better than the spinal surgery control group on 
the verbal fluency task at baseline.
        
5.2.7 Digit Symbol Coding
One hundred and eleven brain tumour patients, 83 spinal controls and 79 healthy 
controls completed the digit symbol-coding task at baseline. 
Mean scores on this test were 56.4 (SD 22.2), 67.4 (SD 16.9) and 76.2 (SD 15.7) for 
the brain tumour, spinal control and healthy control groups, respectively. 
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There was a significant main effect of the covariates age, F(1,265) = 113.59, p <
0.001, partial η² = 0.30; and NART score, F(1,265) = 57.72, p < 0.001, partial η² = 
0.18, in the model. Older participants and participants who performed less well on 
the NART were significantly more likely to have lower digit symbol-coding scores. 
There was no significant main effect of sex on digit symbol coding scores, F(1,265) 
= 2.929, p = 0.088, partial η² = 0.011. In the model that included the effects of the 
covariates NART and age, there was a significant main effect of group, F(2,265) = 
13.24, p < 0.001, partial η² = 0.09. 
The estimated marginal mean scores, adjusted for age and NART score, were 59.3 
(SE 1.5) for the brain tumour group, 68.0 (SE 1.7) for the spinal control group and 
70.9 (SE 1.9) for the healthy control group. Pairwise comparisons using LSD tests
revealed that the brain tumour group performed significantly less well than the spinal 
surgery group (p < 0.001). The brain tumour group also performed significant less 
well than the healthy control group (p < 0.001). The difference between the spinal 
and healthy control groups was not significant (p = 0.266). 
5.2.8 Letter-Number Sequencing
The Letter-Number Sequencing test was administered to 89 brain tumour patients, 78 
spinal control patients and 79 healthy control participants. 
The brain tumour group scored a mean of 9.4 (SD 3.4) on the test, the spinal control 
group scored a mean of 11.2 (SD 2.7) and the healthy controls had a mean score of 
11.2 (SD 2.6). 
There was a significant main effect of age on task performance, F(1,238) = 69.05, p
< 0.001, partial η² = 0.23. The covariate NART score also had a significant main 
effect in the model, F(1,238) = 59.34, p < 0.001, partial η² = 0.20. Older participants 
and those participants with higher (poorer) NART scores were significantly more 
likely to have lower scores on this test. Sex had no significant main effect in the 
model, F(1,238) = 0.379, p = 0.539, partial η² = 0.002. Participant group had a 
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significant main effect in the model that included the effects of the covariates age 
and NART score, F(2, 238) = 9.67, p < 0.001, partial η² = 0.08.
The estimated marginal mean scores, adjusted for age and NART score, were 9.9 (SE 
0.3) for the brain tumour group, 11.5 (SE 0.3) for the spinal surgery control group 
and 10.3 (SE 0.3) for the healthy control group. Pairwise comparisons revealed that 
the brain tumour group performed significantly less well than the spinal surgery 
patients (p < 0.001). However, there was no significant difference between the brain 
tumour patients and the healthy control group (p = 0.335). Although the estimated 
marginal mean score for the healthy control group was higher than that of the brain 
tumour group, the difference was not statistically significant. The performance of the 
spinal and healthy control groups were also significant different (p = 0.004). The 
spinal surgery control group performed significantly better than the healthy control 
group on this occasion.
5.3 Baseline Analyses: Functional Measures
5.3.1 Overview of Analysis Procedure
The Williams Delayed Recall Test (WDRT), Nine Hole Peg Test (NPHT) and Timed  
Ten Metre Walk (TTMW) subtests of the Edinburgh Functional Impairment Tests 
(EFITs) were analysed in the same way as the cognitive test scores described in 
section 5.2.1, using general linear modelling (analysis of covariance). Age and 
NART were covariates and group (brain tumour, spinal or healthy) and sex were 
fixed factors in each model. 
5.3.2 Williams Delayed Recall Test (EFIT)
One hundred and fifteen brain tumour patients completed this EFIT subtest. Eighty-
three spinal surgery patients and 80 healthy control participants also completed the 
WDRT.
122
The brain tumour group had a mean score of 8.2 (SD 5.1) on the WDRT. The mean 
score for the spinal control group was 5.3 (SD 3.8) and was 4.5 (SD 3.6) for the 
healthy control group. 
There was a significant main effect of both of the covariates age, F(1,270) = 38.24, p 
< 0.001, partial η² = 0.12; and NART score, F(1,270) = 11.01, p = 0.001, partial η² = 
0.04 in the model. Younger participants and participants with lower (better) NART 
scores were significantly more likely to have lower (better) WDRT scores. Sex had 
no significant main effect in the model, F(1,270) = 2.527, p = 0.113, partial η² = 
0.009. The effect of group was significant in the model that included the effects of 
age and NART score, F(2,270) = 12.34, p < 0.001, partial η² = 0.08. 
Estimated marginal mean scores and pairwise comparisons using LSD tests indicated 
that the brain tumour group had significantly higher scores than the spinal control 
group (7.8 (SE 0.4) vs. 5.3 (SE 0.4), with higher scores on this test indicating poorer 
performance, p < 0.001). The difference between the brain tumour and the healthy 
control group was also significantly different (7.8 (SE 0.4) vs. 5.2 (SE 0.5), p < 
0.001). This suggests that the brain tumour patients had significantly higher scores 
(i.e. poorer performance) on this test at baseline than either of the control groups. 
The difference between the healthy control group and the spinal control group was 
not significant (p = 0.855).
5.3.3 Nine Hole Peg Test (Right Hand, EFIT)
In the brain tumour group, 115 patients completed this test using their right hand. 
Eighty-three spinal controls and 80 healthy controls also completed the test.
For this test, the dependent variable was the time taken to complete the test using the 
right hand, in seconds. The mean time taken to complete the test was 14.7 seconds 
(SD 4.5) for the brain tumour group, 12.9 seconds (SD 2.7) for the spinal control 
group and 12.3 seconds (SD 1.5) for the healthy control group. 
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There was a significant main effect of the covariates age, F(1,270) = 33.44, p <
0.001, partial η² = 0.11; and NART score, F(1,270) = 19.47, p < 0.001, partial η² = 
0.06 in the model. This suggests that older age and higher (poorer) NART scores 
were significantly associated with taking longer to complete the test. There was no 
significant main effect of sex in the model, F(1,270) = 1.829, p = 0.117, partial η² = 
0.007. Group had a significant main effect in the model that included the effects of 
age and premorbid ability (NART score), F(2,270) = 6.55, p = 0.002, partial η² = 
0.05. 
The estimated marginal mean scores, adjusted for age and NART score, were 14.4 
(SE 0.3) for the brain tumour group, 12.9 (SE 0.4) for the spinal group and 13.0 (SE 
0.4) for the healthy control group. Pairwise comparisons using LSD tests revealed a 
significant difference between the performance of the brain tumour and spinal 
surgery groups (p = 0.001) and between the brain tumour and healthy control groups 
(p = 0.008). Therefore, the brain tumour group were significantly slower than each of 
the control groups on the NHPT with the right hand. The difference between the two 
control groups (spinal surgery and healthy volunteer) was not significant (p = 0.789). 
5.3.4 Nine Hole Peg Test (Left Hand, EFIT)
This test was completed using the left hand by 113 brain tumour patients, 83 spinal 
surgery controls and 80 healthy controls. 
Mean scores (i.e. time taken to complete the test using the left hand) for this test 
were 16.6 seconds (SD 13.5) for the brain tumour group, 14.3 seconds (SD 1.6) for 
the spinal control group and 12.8 (SD 1.9) for the healthy control group. 
In contrast with the model for the right-hand NHPT, there was only a significant 
main effect of the covariate age on the time taken to complete the test, F(1,268) = 
12.00, p = 0.001, partial η² = 0.04. Older participants took significantly longer to 
complete the test. NART score had no significant main effect in the model, F(1,268) 
= 0.016, p = 0.898, partial η² = 0.000; nor did sex, F(1,268) = 0.380, p = 0.538, 
partial η² = 0.001. Participant group had a significant main effect in the model that 
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included the effects of age and NART score, F(2,268) = 3.74, p = 0.025, partial η² = 
0.03. 
The estimated marginal mean scores on this test, adjusted for age and NART score,
were 16.5 (SE 0.9) for the brain tumour group, 14.5 (SE1.0) for the spinal control 
group, and 12.7 (SE 1.1) for the healthy control group. The difference between the 
brain tumour and healthy control groups was significant (p = 0.008), showing that 
the brain tumour patients too significantly longer to complete the task than the 
healthy control group. There were no significant differences between the brain 
tumour and spinal surgery groups (p = 0.111); or between the healthy and spinal 
surgery control groups (p = 0.237).
5.3.5 Timed Ten Metre Walk (EFIT)
One hundred and two brain tumour patients, 77 spinal controls and 77 healthy 
controls completed this test.
The dependent variable for this measure was the time take to complete the test, in 
seconds. The brain tumour group took a mean of 7.0 seconds (SD 1.8) to complete 
this task. Mean scores for the spinal and healthy control groups were 8.0 seconds 
(SD 2.3) and 6.1 seconds (SD 1.2), respectively. 
There was a significant main effect of the covariate age in this model, F(1,248) = 
33.85, p < 0.001, partial η² = 0.12. Older participants were slower to complete the 
TMW.  Neither NART score nor sex had a significant main effect in the model, 
F(1,248) = 3.647, p = 0.057, partial η² = 0.014; and F(1,248) = 3.113, p = 0.079, 
partial η² = 0.012, respectively. Participant group had a significant main effect in the 
model that included the effects of the covariates, F(2,248) = 19.38, p < 0.001, partial 
η² = 0.14. 
The estimated marginal mean scores, adjusted for age and NART score, were 6.9 (SE 
0.2) for the brain tumour group, 8.0 (SE 0.2) for the spinal group and 6.2 (SE 0.2) for 
the healthy control group. Pairwise comparisons using LSD tests revealed that the 
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brain tumour group were significantly faster than the spinal surgery group (p < 
0.001). The brain tumour group were, however, significantly slower than the healthy 
controls (p = 0.012). The spinal control group were also significantly slower than the 
healthy control group (p < 0.001).
5.4 Baseline Analyses: Mood
The Hospital Anxiety and Depression Scale (HADS) was administered as a measure 
of mood and was completed by 115 brain tumour patients, 82 spinal controls and 80 
healthy control participants at baseline.  In the total sample of the three participant 
groups combined, NART score was significantly correlated with total HADS score
(r(n=277) = 0.226; p < 0.001). Therefore, NART score was also included as a 
covariate in the following analyses. 
5.4.1 Anxiety Scores
The mean anxiety scores for each group on this questionnaire were 8.0 (SD 4.4) for 
the brain tumour group, 7.9 (SD 3.8) for the spinal control group and 6.0 (SD 3.6) for 
the healthy control group.
General linear modelling revealed no significant main effect of the covariate age, 
F(1,269) = 0.011, p = 0.918, partial η² = 0.000; the covariate NART score, F(1,269) 
= 1.164, p=0.282, partial η² = 0.004; or of sex, F(1,269) = 3.175, p = 0.076, partial η² 
= 0.012, in the model. There was however a significant main effect of participant 
group in the model that included the effects of the covariates, F(2,269) = 4.76, p = 
0.009, partial η² = 0.03. 
Pairwise comparisons showed that the brain tumour group and healthy control group 
scores were significantly different (p = 0.004). The estimated marginal mean score 
for the brain tumour group was 7.9 (SE 0.4), compared with 6.0 (SE 0.5) for the 
healthy control group, showing that the brain tumour group had significantly higher 
anxiety scores than the healthy control group. There was no significant difference 
between the brain tumour and spinal control group (p = 0.835). The estimated 
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marginal mean score for the spinal cohort was 7.8 (SE 0.4). The spinal group had 
significantly higher anxiety scores than the healthy controls (p = 0.010).
5.4.2 Depression Scores
The mean scores on the depression scale of the HADS were 4.7 (SD 4.1) for the 
brain tumour group; 5.3 (SD 3.6) for the spinal control group and 2.5 (SD 2.1) for the 
healthy control group. 
The covariate age had no significant main effect in the model, F(1,269) = 2.934, p = 
0.088, partial η² = 0.011; nor did sex, F(1,269) = 1.962, p = 0.162, partial η² = 0.007.
The covariate NART score did have a significant main effect in the model, F(1,269) 
= 6.69, p = 0.010, partial η² = 0.02. Participant group had a significant main effect in 
the model that included the effects of the covariates, F(2,269) = 8.03, p < 0.001, 
partial η² = 0.06. 
Estimated marginal mean depression scores, adjusted for age and NART score, were 
4.5 (SE 0.3) for the brain tumour group, 5.2 (SE 0.4) for the spinal control group and 
2.9 (SE 0.4) for the healthy control groups. Pairwise comparisons showed that the 
brain tumour group had significantly higher depression scores than the healthy 
control group (p = 0.004). However, there was no significant difference between the 
depression scores in the brain tumour and spinal surgery groups (p = 0.174). The 
spinal control group had significantly higher levels of depression as measured by the 
HADS than the healthy controls (p < 0.001).
5.4.3 Total Hospital Anxiety and Depression Scale Scores
Mean total score (i.e. anxiety and depression scores added together) on the Hospital 
Anxiety and Depression Scale for the brain tumour group was 12.7 (SD 7.5). The 
spinal group had a total score mean of 13.2 (SD 6.5) and the healthy control group 
had a mean of 8.5 (SD 5.0). 
The covariate NART score had a significant main effect in the model, F(1,269) = 
4.05, p = 0.045, partial η² = 0.02. There was no significant main effect of the 
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covariate age, F (1,269) = 0.919, p = 0.339, partial η² = 0.003; or sex, F(1,269) = 
3.316, p = 0.070, partial η² = 0.012, in the model. There was a significant main effect 
of group on total HADS scores in the model that included the effects of the 
covariates, F(2,269) = 7.59, p = 0.001, partial η² = 0.05. 
The estimated marginal mean total scores on this questionnaire, adjusted for age and 
NART score, were 12.4 (SE 0.6) for the brain tumour group, 13.0 (SE 0.7) for the 
spinal control group and 8.9 (SE 0.8) for the healthy control group. Pairwise 
comparisons revealed a significant difference between the brain tumour and healthy 
control groups (p = 0.001), suggesting that the brain tumour group had higher scores 
on the HADS than the healthy control participants. There was no significant 
difference between the brain tumour and spinal surgery group scores (p 0.559). The 
spinal surgery control group had significantly higher scores than the healthy control 
group (p < 0.001).
5.5 Baseline Analyses: Functional Measures 
5.5.1 Overview of Analysis Procedure
Since the Barthel Disability Index, Karnofsky Performance Scale and Boston 
Aphasia Severity Rating Scale were only assessed for the brain tumour and spinal 
groups, the same analyses as detailed above were carried out but with brain tumour 
and spinal surgery patients comprising the two groups in the model. However, since 
sex had no significant effect in any of the models for these functional scales it was 
therefore excluded as a fixed factor in the analyses reported below.
5.5.2 Barthel Disability Index
The brain tumour patients had a mean score of 19.6 (SD 1.3) out of a possible score 
of 20, on the Barthel Disability Index, suggesting that the majority of patients had
128
little or no disability. The spinal surgery patients scored a mean of 19.4 (SD 1.2) on 
the measure. 
There was a significant main effect of the covariate age in the model, F(1,195) = 
10.514, p = 0.001, partial η² =0.051. There was also a significant main effect of 
NART score on Barthel Disability Index scores, F(1,195) = 3.975, p = 0.048, partial 
η² = 0.020. However, there was no significant main effect of participant group in the 
model that included the effects of the covariates, F(1,195) = 1.289, p = 0.258, partial 
η² = 0.007. This suggests that the brain tumour and spinal surgery groups did not 
differ significantly in terms of disability as measured by the Barthel Disability Index. 
5.5.3 Karnofsky Performance Scale
The brain tumour group had a mean score of 87.9 out of a possible 100 (SD 10.2) on 
this performance scale, compared with a mean score of 80.4 (SD 8.2) for the spinal 
surgery group. 
There was a significant main effect of the covariates age, F(1,195) = 23.775, p < 
0.001, partial η² = 0.109; and NART score, F(1,195) = 18.246, p < 0.001, partial η² = 
0.086 in the model. Participant group had a significant main effect in the model that 
included the effects of age and NART score, F(1,195) = 43.972, p < 0.001, partial η² 
= 0.184. Estimated marginal mean scores, adjusted for age and NART score, were 
88.2 (SE 0.8) for the brain tumour group and 80.0 (SE 0.1) for the spinal control 
group, suggesting spinal patients had lower scores (indicating a poorer performance 
status) on the Karnofsky Performance Scale. 
5.5.4 Boston Aphasia Severity Rating Scale (EFIT)
A mean rating of 5.9 (SD 0.4) of a possible 6 was given to the brain tumour patients. 
The spinal patients all had ‘normal’ speech ratings, with a mean score of 6 (SD 0.0).
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There was no significant main effect of either of the covariates age, F(1,194) = 
3.458, p = 0.064, partial η² = 0.018; or NART score, F(1,194) = 0.158, p = 0.692, 
partial η² = 0.001, in the model. There was, however, a significant main effect of 
participant group in the model, F(1,194) = 4.100, p = 0.044, partial η² = 0.021. 
Estimated marginal means, adjusted for age and sex, suggest that the brain tumour 
patients had significantly lower ratings on the scale than the spinal surgery patients 
(5.9 (SE 0.0) vs. 6.0 (SE 0.0)). 
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p value for difference*











- No formal education
- O’Grades (or equivalent)



























Handedness 103 right, 15 left 78 right, 6 left, 
1 ambidextrous
74 right, 6 left 0.318
* Based on Pearson Chi-square tests, except for age (One-way ANOVA)
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Actual Count 17 47 18 14 20 1 1
Expected Count 10.8 29.6 15.4 18.8 41.7 1.3 0.4
Spinal
Actual Count 9 19 12 24 19 2 0
Expected Count 7.8 21.3 11.1 13.5 30 0.9 0.3
Healthy
Actual Count 0 5 7 7 61 0 0
Expected Count 7.3 20.1 10.5 12.7 28.3 0.8 0.3
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High – Grade Glioma (WHO III – IV) 51 43.2

















> 1 Lobe 23 19.5
Other 13 11.0
133
Table 5.4. Overview of results of general linear modelling analyses comparing the brain tumour, spinal surgery and healthy control groups on cognitive 
and mood scales.  
Group Sex N Mean³ Standard 
Deviation
Effect of Group Effect of Age
F Sig. (p) n²* F Sig. (p) n²*
Inspection 
Time (Total, 
all data) ¹ 
Brain 
Tumour 
Male 56 118.7 19.2 7.994 < 0.001 0.057 76.946 <0.001 0.224
Female 56 109.9 19.7
Total 112 114.3 19.9
Spinal Male 38 121.6 13.5
Female 44 121.2 14.0
Total 82 121.4 13.7
Healthy Male 31 126.1 13.1
Female 49 126.5 10.6







Male 50 123.4 11.9 6.400 0.002 0.050 73.362 <0.001 0.231
Female 46 116.5 14.6
Total 96 120.1 13.7
Spinal Male 36 123.5 11.0
Female 42 123.1 11.1
Total 78 123.3 11.0
Healthy Male 30 127.3 11.5
Female 48 125.2 9.7








Male 46 59.5 17.1 18.924 <0.001 0.140 84.008 <0.001 0.265
Female 41 64.1 17.2
Total 87 61.7 17.5
Spinal Male 34 71.0 14.5
Female 40 71.1 16.9
Total 74 71.0 15.7
Healthy Male 31 77.6 14.6
Female 49 84.8 12.5
Total 80 82.0 13.8
Trail Making 




Male 51 93.2 29.3 10.703 <0.001 0.079 56.881 <0.001 0.185
Female 45 96.7 34.5
Total 96 94.9 31.7
Spinal
Male 37 81.0 27.8
Female 45 81.4 20.8
Total 82 81.2 24.1
Healthy 
Male 31 68.3 21.0
Female 49 69.5 20.9







Male 45 26.7 9.4 13.772 <0.001 0.103 2.470 0.117 0.010
Female 46 30.6 14.0
Total 91 28.7 12.0
Spinal Male 38 32.2 13.5
Female 40 37.6 12.3
Total 78 35.0 13.1
Healthy Male 31 44.7 13.8
Female 49 45.2 12.0






Male 55 57.9 19.7 13.236 <0.001 0.091 113.58 <0.001 0.300
Female 56 54.9 24.5
Total 111 56.4 22.2
Spinal Male 38 65.1 16.8
Female 45 69.3 17.0
Total 83 67.4 16.9
Healthy Male 31 72.7 14.6
Female 48 78.5 16.1







Male 45 9.4 3.1 9.674 <0.001 0.075 69.054 <0.001 0.225
Female 44 9.4 3.6
Total 89 9.4 3.4
Spinal Male 36 11.5 2.5
Female 42 10.9 2.8
Total 78 11.2 2.7
Healthy Male 30 10.5 2.4
Female 49 11.6 2.7






Male 58 8.4 5.2 12.342 <0.001 0.084 38.241 <0.001 0.124
Female 57 8.0 5.0
Total 115 8.2 5.1
Spinal Male 38 5.7 4.1
Female 45 5.0 3.5
Total 83 5.3 3.8
Healthy Male 31 5.2 4.1
Female 49 4.1 3.2
Total 80 4.5 3.6
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EFIT Nine 





Male 58 14.8 4.1 6.547 0.002 0.046 33.441 <0.001 0.110
Female 57 14.7 5.0
Total 115 14.7 4.5
Spinal Male 38 13.2 2.0
Female 45 12.7 3.1
Total 83 12.9 2.7
Healthy Male 31 12.8 1.5
Female 49 12.0 1.5
Total 80 12.3 1.5
EFIT Nine 





Male 56 15.6 3.5 3.742 0.025 0.027 11.997 0.001 0.043
Female 57 17.6 18.8
Total 113 16.6 13.5
Spinal Male 38 14.1 2.4
Female 45 14.5 4.4
Total 83 14.3 3.6
Healthy Male 31 13.1 1.9
Female 49 12.7 1.9







Male 55 6.7 1.6 19.377 <0.001 0.135 33.845 <0.001 0.120
Female 47 7.3 1.9
Total 102 7.0 1.8
Spinal Male 34 7.6 2.1
Female 43 8.3 2.5
Total 77 8.0 2.3
Healthy Male 31 6.1 1.2
Female 46 6.0 1.3








Male 58 7.6 4.3 4.764 0.009 0.034 0.011 0.918 <0.001
Female 57 8.4 4.4
Total 115 8.0 4.4
Spinal Male 38 7.7 4.2
Female 44 8.1 3.5
Total 82 7.9 3.8
Healthy Male 31 5.1 3.2
Female 49 6.6 3.7










Male 58 4.1 3.6 8.028 <0.001 0.056 2.934 0.088 0.011
Female 57 5.4 4.4
Total 115 4.7 4.1
Spinal Male 38 4.8 3.3
Female 44 5.8 3.8
Total 82 5.3 3.6
Healthy Male 31 2.7 2.1
Female 49 2.3 2.2








Male 58 11.7 7.1 7.589 0.001 0.053 0.919 0.339 0.003
Female 57 13.8 7.9
Total 115 12.7 7.5
Spinal Male 38 12.4 6.6
Female 44 13.8 6.3
Total 82 13.2 6.5
Healthy Male 31 7.8 4.6
Female 49 8.9 5.2
Total 80 8.5 5.0
¹ Higher scores represent better function 
² Higher scores represent worse function
       ³ Raw mean score
      * n² = the proportion of variance accounted for by the covariate (group or age)
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Table 5.5. Estimated marginal mean scores, adjusted for age and NART score, for each participant group on each baseline test and post-hoc pairwise 
comparisons.
Estimated Marginal Mean (Standard Error) Pairwise Comparisons – p-value for 
significance






(Total, all data) ¹  
115.9 (1.3) 121.6 (1.6) 124.2 (1.7) 0.005 < 0.001
Inspection Time
(Total, valid data)¹
120.5 (1.1) 123.4 (1.2) 126.7 (1.3) 0.066 < 0.001
Rey Auditory Verbal 
Learning Test  (Total) ¹
64.3 (1.4) 72.2 (1.5) 77.8 (1.6) < 0.001 < 0.001
Trail Making Test Part 
B (secs) ²
91.3 (2.4) 79.0 (2.6) 75.2 (2.8) < 0.001 < 0.001
Verbal Fluency (Total)¹ 31.0 (1.2) 36.4 (1.3) 40.8 (1.4) 0.002 < 0.001
Digit Symbol Coding 
(Total) ¹




9.9 (0.3) 11.5 (0.3) 10.3 (0.3) < 0.001 0.335
EFIT Williams Delayed 
Recall Test (total)² 
7.8 (0.4) 5.3 (0.4) 5.2 (0.5) < 0.001 < 0.001
EFIT Nine Hole Peg 
Test (Right Hand, secs)²
14.4 (0.3) 12.9 (0.4) 13.0 (0.4) 0.001 0.008
EFIT Nine Hole Peg 
Test (Left Hand, secs)²
16.5 (0.9) 14.5 (1.0) 12.7 (1.1) 0.111 0.008
EFIT Timed Ten Metre 
Walk (secs)²
6.9 (0.2) 8.0 (0.2) 6.2 (0.2) < 0.001 0.012
Hospital Anxiety and 
Depression Scale –
Anxiety Score²
7.9 (0.4) 7.8 (0.4) 6.0 (0.5) 0.835 0.004
Hospital Anxiety and 
Depression Scale –
Depression Score²
4.5 (0.3) 5.2 (0.4) 2.9 (0.4) 0.174 0.004
Hospital Anxiety and 
Depression Scale –Total 
Score²
12.4 (0.6) 13.0 (0.7) 8.9 (0.8) 0.559 0.001
¹ Higher scores represent better function 
² Higher scores represent worse function
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5.6 Discussion 
There was a significant overall effect of participant group (brain tumour, spinal 
surgery control or healthy control) on each of the measures administered at baseline. 
The brain tumour group were found to perform significantly worse than both the 
spinal surgery and healthy control groups on the majority of tests administered. 
Visual information processing, as measured by the inspection time task, was 
significantly disrupted in brain tumour patients by comparison with both control 
groups and the effect size was moderate. When ‘invalid’ inspection time scores were 
excluded a significant impairment, again of moderate effect size, was found in the 
brain tumour group by comparison with the healthy control group. The difference 
between the brain tumour group and the spinal surgery group did not reach the 
conventional level of statistical significance when only valid inspection time data 
was included, although there was a clear trend towards poorer performance in the 
brain tumour group. The brain tumour group performed significantly less well than 
both the spinal surgery and healthy control groups on most of the other cognitive 
measures at baseline. The effect size of participant group was large in the model for 
the Rey Auditory Verbal Learning Test and was moderate for the majority of the 
other cognitive tests. The spinal surgery group performed significantly worse than 
both the brain tumour group and healthy control group on the Timed Ten Metre 
Walk and the brain tumour group, in turn, were significantly slower than the healthy 
control group on this measure. Both the brain tumour and the spinal surgery groups 
had significantly higher levels of anxiety and depression than the healthy control 
group, as measured by the HADS. However, HADS scores did not differ 
significantly between the brain tumour and spinal surgery groups. Disability, as 
measured by the Barthel Index did not differ between the two surgical groups, 
although the spinal surgery group had significantly poorer performance status than 
the brain tumour group, as measured by the Karnofsky Performance Scale. Thus, 
these findings suggest that patients with primary and secondary brain tumours 
located throughout the brain have significantly impaired cognition, at the time of 
presentation, prior to surgery by comparison with matched surgical and healthy
volunteer controls. 
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One of the main aims of this thesis was to evaluate the utility of the inspection time 
task for use in a neuro-oncological setting. The inspection time task proved to be a 
feasible and useful measure of visual information processing that was sensitive to 
impaired function in the brain tumour cohort at the time of presentation to a 
neurosurgical department, prior to surgery. There was a moderate effect size of group 
in the inspection time model. However, the effect sizes for the Rey Auditory Verbal 
Learning Test, Verbal Fluency and Digit Symbol Coding in particular, were large 
and this suggests that inspection time, although evidently able to detect a difference 
between the groups, was perhaps not as sensitive a measure as the aforementioned 
tests. However, inspection time was equally as sensitive as a number of other 
commonly-used standardised tests, suggesting it may have a potential role for 
inclusion in cognitive test batteries in this patient group. The results of the present 
study do however differ from those of a pilot study that tested 23 brain tumour 
patients and 24 spinal surgery controls in the pre and post-operative period on 
inspection time and other cognitive measures (Zbinden et al., 2006). The preliminary 
investigation found that patients in the brain tumour cohort had significantly lower 
inspection time scores than the spinal surgery control group in the pre-operative 
period, a finding that is confirmed by the present study. However, in the pilot study, 
the brain tumour group performed equally as well as the spinal surgery control group 
on a number of other standardised cognitive tests administered pre-operatively, 
including the Rey Auditory Verbal Learning Test, Digit Symbol Coding, the Trail 
Making Test Part B and the Edinburgh Functional Impairment Tests. Conversely, in 
the present study, the brain tumour group were also significantly impaired on these 
tests prior to surgery. Since only 12 of 23 brain tumour patients recruited into the 
pilot study completed these other cognitive measures and it may be that those 
patients who failed to complete the test battery in its entirety were those patients who 
were most severely affected by their disease. Performing a large battery of 
psychometric and cognitive tests can be difficult for brain tumour patients, 
particularly those who experience neurological symptoms. Indeed, as highlighted 
previously, a number of patients in the brain tumour cohort in the present study also 
failed to complete a number of the cognitive tests for a variety of reasons including 
144
poor comprehension of the task, fatigue or motor impairment that prevented task 
completion (e.g. on the trail making test part B). However, the larger cohort recruited 
into the present study may have had more power to detect impairment across a 
number of cognitive domains. 
Thus, inspection time has proven to be a useful measure that has many practical 
advantages as a tool in clinical neuro-oncology. Namely the task does not require 
intact motor function as patients can voice their responses and conversely, it does not 
require intact speech if the patient is able to respond independently. The large 
number of practice trials also give patients who may be mildly confused the 
opportunity to familiarise themselves with the task demands prior to the test trials. 
The inspection time task was well tolerated by the majority of patients enrolled into 
the study, with only 4 of the 118 brain tumour patients (3%) failing to complete the 
task in its entirety at baseline testing. However, 14% of those brain tumour patients 
who did complete the task did not achieve ‘valid’ inspection time scores at baseline 
(i.e. a score of ≥ 17/20 on the longest two durations). Only 6% of the spinal surgery 
group and 3% of the healthy control group had ‘invalid’ scores at baseline. This 
validity criterion has been applied in previous inspection time studies because the 
longest two stimulus presentation durations (150ms and 200ms) are easily visible to 
the majority of participants and therefore, a near perfect score should be obtained on 
these longest trials. Thus, any participant who scores less than 17/20 at these longer 
durations may not have fully understood the task. However, the question of whether 
such validity criterion can be applied to a cohort of patients with brain tumours has 
been raised following the present study. The majority of patients who did not meet 
validity criterion were noted to have appeared to understand the task during the 
practice trials. ‘Valid’ scores may have been obtained by some of these patients had 
the stimuli been shown for longer durations. It is possible that, in some brain tumour 
patients, visual information processing is slowed to such an extent that invalid 
inspection time scores reflect severe impairment, as opposed to lack of 
comprehension of the task. If this is the case, a revised version of the inspection time 
task that involves presenting the stimulus for durations longer than 200ms would 
provide further insight into the extent of visual information processing impairment in 
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neuro-oncological patients. Moreover, given that the inspection time task can take up 
to 30 minutes to complete, it therefore has relatively high attentional demands, 
particularly by comparison with other, shorter cognitive tests. Thus, impaired 
concentration could also explain, in part, the high proportion of ‘invalid’ scores in 
the brain tumour group. A potential alternative to overcome this issue would be to 
use an adaptive staircase procedure for stimulus presentation in the inspection time 
task, instead of the more commonly employed method of constant stimuli that was 
used in the present study. The adaptive staircase procedure is an alternative method 
of presenting the stimuli during the task by which stimulus onset asynchrony (SOA, 
the amount of time for which the stimulus is presented prior to masking) begins at 
320ms when the task commences. A single response error increases SOA by 17ms 
and three consecutive correct answers are required to decrease SOA by 17ms. The 
average SOA over eight reversals (i.e. increases or decreases in SOA) of the staircase 
procedure is taken as the participant’s inspection time score (Gregory et al., 2009). 
This procedure renders the task considerably shorter, with an approximate duration 
of 10 minutes. As such, this could be a more appropriate version of the inspection 
time task for use in neuro-oncological patient populations since it could perhaps 
provide a more accurate assessment method in those patients with reduced 
concentration and/or extensive visual information processing slowing. Therefore, 
further research could involve inspection time testing using this adaptive staircase 
procedure to determine whether visual information processing is slowed in some 
brain tumour patients to such an extent that the aforementioned validity criterion do 
not apply. 
The present study has a number of strengths compared with similar studies that have 
previously assessed the presence and extent of cognitive impairment in brain tumour 
patients. In contrast with many studies that did not recruit a control group for 
comparison and instead simply compared the brain tumour patient’s test scores with 
normative data in order to classify ‘impairment’, a particular strength of the present 
study is that age and sex-matched surgical and healthy control participants were 
tested on the same battery of tests as the brain tumour patient cohort. This allows us 
to make a direct comparison of the performance of the three groups who were 
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administered the same tests, by the same researcher, in precisely the same testing 
environment, thus eliminating the effects of these potential confounding variables.
This methodology also allowed us to both measure and control for each participant’s 
premorbid ability during analysis. Thus, the conclusions made by this and other
studies that recruit a matched control group are likely to be more reliable than those 
made by studies with no control participant group. Moreover, the present study is one 
of few that detail cognition in brain tumour patients prior to any surgical intervention
and as such provides a unique insight into the role of the tumour itself as a cause of 
cognitive deficits. The majority of studies that have attempted to elucidate the effect 
of the tumour on cognition in this patient group have recruited patients in the post-
operative period. It is therefore difficult to determine the role of the tumour and the 
role of surgery as a cause of cognitive impairment in these studies (Kayl and Meyers, 
2003). Thus this study provides a unique insight into the cognitive function of brain 
tumour patients at the time of presentation in a large cohort of patients with diverse 
brain tumours located throughout the brain and suggests that the tumour itself causes 
cognitive dysfunction in a number of different domains.
A detailed battery of tests assessing several different aspects of cognition, in addition 
to inspection time as a measure of visual information processing, was administered at 
baseline testing and this is a further advantage of the study by comparison with a 
number of similar studies in this area. Some previous studies have relied upon Mini 
Mental State Examination (MMSE) scores as an indicator of cognitive status
(Salander et al., 1995). The MMSE was originally devised as a brief assessment for 
use with patients with dementia and is not a sensitive measure of cognition in brain 
tumour patients, many of whom have more subtle deficits in aspects of cognition that 
are not assessed by the MMSE. As such, many patients with ‘normal’ MMSE scores 
may still have cognitive deficits in one or more domains (Meyers and Wefel, 2003). 
Therefore, the use of a detailed cognitive test battery in the present study provides a 
more accurate and meaningful assessment of cognitive function than use of a simple, 
short test like the MMSE that is sensitive to impairments in only the most acutely 
confused patients.
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There also exist some potential weaknesses that are associated with the present study. 
A considerable proportion of brain tumour patients failed to complete the test battery 
in its entirety for a number of reasons, particularly by comparison with the healthy 
control group, the vast majority of whom completed all of the baseline test measures. 
The reasons for incomplete administration of the test battery primarily included 
patient fatigue, poor comprehension of task instructions as a result of confusion that 
prevented task completion, or limited time available for testing due to the competing 
priorities associated with recruiting patients from the hospital ward. A number of 
spinal surgery patients also failed to complete the entire battery, and this was usually 
a result of time constraints since many patients were tested during their pre-
admission appointment or on the same day as their operation. 
The spinal surgery patients were recruited as a comparison group primarily to control 
for the effects of surgery and the anxiety associated with an impending operation. 
Patients admitted for elective spinal surgery were treated within the same department 
as the brain tumour patients and were therefore easy to recruit and minimised the 
possible effects of being an inpatient. These are all particular strengths associated 
with the present study. However, a potential weakness is the failure to recruit a
control group of patients with a diagnosis of cancer that does not involve the central 
nervous system. Klein et al. (2001) propose that all studies of cognition in brain 
tumour patients should be based upon comparisons with a matched group of other 
cancer patients to control for the unique stressors and emotions encountered by 
people with a cancer diagnosis. This methodology would likely have introduced 
several other confounding variables into the study including variation in the duration 
of disease and potential treatment effects that may have affected results. Therefore, 
elective spinal surgery patients were deemed the preferred comparison group in this 
instance. 
The three participant groups, brain tumour, spinal surgery and healthy control, were 
well matched on the demographic characteristics age, sex and handedness. There 
were no significant differences in terms of the highest level of education achieved by 
the members of the brain tumour and spinal surgery groups. However, the healthy 
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control group had achieved significantly higher levels of education than both of the 
surgical groups. This could, in part, explain the better performance of the healthy 
control group on the majority of the baseline measures. However, analysing the data 
using general linear modelling (analysis of covariance) allowed for inclusion of a 
measure of premorbid ability to be included as a covariate, thus, the variance in test 
scores that could be explained by the differing levels of intelligence in the three 
participant groups was included in each model. Ideally, full-scale IQ scores from the 
period prior to development of disease would be available for each patient to provide 
an accurate estimate of premorbid ability from which to gauge the extent of 
deterioration. However, in the absence of a measure of previous mental ability, the 
National Adult Reading Test (NART) was used as a measure of premorbid IQ. The 
NART had been studied extensively and is a proven valid estimate of full-scale IQ
(Crawford et al., 1989). Of particular importance for its use in the present study, it 
has also been successfully validated as a measure of prior as opposed to current 
intellectual ability (Crawford et al., 2001). Thus, this relatively brief, undemanding 
measure has been shown to provide a valid estimate of premorbid intelligence in a 
number of patient groups, including patients with Korsakoff’s syndrome, 
Alzheimer’s dementia and multi-infarct dementia (Crawford et al., 1988, Bright et 
al., 2002). McGurn et al. (2004) also validated the use of the NART as an estimate of
premorbid IQ in patients with dementia, showing that, after controlling for IQ test 
score obtained at age 11, mean NART scores in a cohort of the same participants 
tested at age 80 did not differ significantly, despite the fact that a number of 
participants had a diagnosis of dementia. Thus, the NART appears to be a reliable 
estimate of prior ability in patients with mild to moderate dementia. It is therefore 
reasonable to propose that the NART scores for each participant group in this study 
are likely to provide an accurate estimate of intelligence, even in the presence of 
potential mild confusion in some members of the brain tumour cohort. Thus, 
including NART scores as a covariate in the analyses would likely have effectively 
controlled for the disparity in levels of intelligence between the healthy and surgical 
participant groups. Although, as highlighted in Chapter 1.7, no studies have validated 
the use of the NART in patients with mild dysphasia, few patients in the brain 
tumour group were judged to have significant speech impairment. We can therefore 
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assume that mild difficulties with speech production in a very small proportion of the 
brain tumour patients who participated in the study were unlikely to have 
significantly affected the overall accuracy of NART scores as a surrogate measure of 
premorbid function. 
There was no significant difference between the two surgical patient groups (brain 
tumour and spinal surgery) with respect to disability, as measured by the Barthel 
Disability Index. However, Karnofsky Performance Status scores were paradoxically 
better for the brain tumour group, despite the superior performance of the spinal
surgery control group on the majority of the cognitive tests at baseline. This is likely 
to be the result of physical impairment and pain due to degenerative spinal disease 
and replicates the findings of the pilot study in this respect (Zbinden et al., 2006). 
The majority of the patients in the brain tumour cohort had minimal physical 
impairment since any focal deficits were likely to have resolved to some extent 
following dexamethasone (steroid) therapy. 
Many medications commonly taken by brain tumour patients, namely 
dexamethasone and anti-epileptic medications, have been proven to have deleterious 
effects on cognition, despite their ameliorating effects on focal neurological deficits
and seizure frequency/presence, respectively. All of the patients in the brain tumour 
cohort were taking pre-operative corticosteroids (dexamethasone) and a number of 
patients were also prescribed anti-epileptic medications as a result of tumour-related 
seizures. The cognitive and behavioural effects of corticosteroids have been widely 
studied in a variety of different patient and healthy groups. Corticosteroids have been 
found to significantly related to behavioural decline in patients with Alzheimer’s 
disease (Aisen et al., 2000) and to be significantly associated with a deterioration in 
memory and executive functions in groups of healthy male participants (Lupien et 
al., 1999, Young et al., 1999). Healthy elderly participants with elevated cortisol 
levels as a result of dexamethasone administration have also been found to exhibit 
significant cognitive impairments as measured by the Mini Mental State Examination
(Kalmijn et al., 1998). It is therefore possible that dexamethasone played some role 
in contributing to the observed impairment in cognition on the tests administered at 
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baseline. However, as highlighted by Taphoorn and Klein (2004) in their review, 
severe cognitive impairment as a result of corticosteroids is rare and it is more likely 
that dexamethasone works to alleviate cognitive deficits in the majority of brain 
tumour patients in the same manner by which it improves physical impairment, by 
reducing intracranial pressure and therefore reducing brain oedema. Thus, the extent 
of impairment in the brain tumour cohort at baseline may actually have been 
underestimated, as opposed to exaggerated, due to the potential ameliorating effects 
of steroid therapy. 
Epileptic seizures are a common symptom of brain tumours, particularly in patients 
with low-grade gliomas (Wessels et al., 2003, Whittle, 2004). Forty-five per cent of
the patients in the brain tumour cohort recruited into the present study were thought 
to have had at last a single seizure at some point prior to surgical intervention and 
were prescribed anti-epileptic drugs for this reason. Antiepileptic medication has 
been found to be a risk factor for cognitive impairment, particularly in the domains 
of information processing speed, psychomotor function, executive function and 
working memory in a group of long-term low-grade glioma survivors with well 
controlled seizures (Klein et al., 2003a). The antiepileptic medication prescribed to a 
high proportion of the brain tumour patients in the present study may therefore have 
played a role in the observed cognitive impairment at the time of baseline testing. 
However, given that more than half of the patients in the brain tumour cohort were 
not taking any form of antiepileptic drug, medication effects alone cannot explain the 
poorer overall performance in the brain tumour group at the time of baseline testing. 
Moreover, Tucha et al.(2000) found no difference in the extent of cognitive 
impairment observed in a group of brain tumour patients who were taking 
anticonvulsant medication compared with a group of brain tumour patients who were 
not receiving these drugs. The potential utility of recruiting a control group of 
patients with epilepsy into the present study in order to allow differentiation of the 
effects of the tumour from the potential effects of antiepileptic medication was 
considered. However, recruiting epileptic control patients would have introduced 
additional confounding variables such as differences in the specific anti-convulsants 
prescribed, differing dosages between patients and differing lengths of time for 
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which the medication had been taken and therefore it was decided that recruiting a 
matched control group of epileptic patients was not feasible.
Mood disorder, such as heightened feelings of anxiety and depression are commonly 
reported by brain tumour patients and can result in impaired attention and 
motivation, which in turn may have a deleterious effect on cognitive test 
performance (Taphoorn and Klein, 2004). The Hospital Anxiety and Depression 
Scale (HADS) was included as part of the baseline test battery to facilitate 
comparison of the relative levels of anxiety and depression in each participant group. 
There were no significant differences between the brain tumour and spinal surgery 
groups in terms of scores on the anxiety and depression scales of the HADS. This 
finding is similar to that of Pringle et al. (1999) who found no significant differences
in the HADS scores of brain tumour patients and lumbar spinal surgery control 
patients in the pre-operative period. This would therefore suggest that it is unlikely 
that the poorer performance of the brain tumour patient group prior to surgery can be 
attributed to the negative effects of emotional distress on concentration and/or 
motivation. However, Kilbride et al. (2007) have questioned the sensitivity of the 
HADS to detect anxiety and depression in neuro-oncological patients. They found 
that the HADS scores underestimated the presence of anxiety and depression in a 
group of brain tumour patients compared with the levels of anxiety and depression 
revealed by content analysis of interviews with the same patients. Thus, the brain 
tumour group in the present study may actually have experienced more severe 
emotional distress than their spinal surgery counterparts that was not evident due to 
the poor sensitivity of the HADS to detect heightened anxiety and depression in 
neuro-oncological patients. It is for this reason that recruiting a group of patients 
with a diagnosis of cancer as a control group may have been useful in the present 
study, in order to provide an adequate control for the emotional effects of such a 
diagnosis.
The majority of studies that assess cognitive function in brain tumour patients have 
been unable to elucidate the role of the tumour itself as a cause of cognitive deficits 
as they involve testing after treatment which may itself be the cause of impairment 
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(Taphoorn and Klein, 2004). The present study provides a uniquely large data set that 
provides an insight into the role of the tumour itself in causing cognitive deficits. 
That the brain tumour group performed significantly worse on tests assessing a 
variety of different cognitive domains by comparison with surgical and healthy 
controls supports the findings of one of the few studies that report the prevalence of 
cognitive impairment prior to any intervention, including surgery, in brain tumour 
patients. Tucha et al. (2000) assessed a large cohort of patients with tumours located 
in either the frontal or temporal lobe on a detailed cognitive test battery, prior to any 
treatment. The authors found that 91% of patients were impaired in at least one area 
of cognition, with 78% of the cohort exhibiting executive function impairment and 
60% showing impairment of memory and attention functions. These authors 
conclude that most patients with primary or secondary brain tumours present with 
impairment in some aspect of cognition at the time of admission for, but prior to, 
neurosurgical intervention. The findings of the present study support the conclusions 
made by Tucha et al. (2000) and overcome a number of the limitations of the study, 
namely the failure to recruit an adequate control group for comparison. 
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6 Post-Operative Function
6.1 Overview of Analysis Procedure
Post-operative (session 2) test performance was compared between the brain tumour, 
spinal surgery and healthy control groups using general linear modelling (analysis of 
covariance). Group and sex were entered as fixed effects (between-subjects factors) 
in the models. Age at the time of testing and NART score were included as 
covariates for the reasons detailed in Chapter 5.2.1. Baseline inspection time score 
for each participant was also included as an additional covariate in the models. This 
effectively allows us to compare any differences between baseline and session 2 
performance on each test between the three groups, by controlling for the effects of 
baseline test performance as well as age, and NART score. There was no significant 
effect of sex in any of the models for each of the test scores detailed below. 
Therefore, sex was omitted as a fixed effect in the analyses reported in this chapter. 
The models were run again with group (brain tumour, spinal surgery and healthy 
volunteer) specified as the only fixed effect.
In each of the sections that follow, for each test, raw mean baseline and session 2 
scores for each group (brain tumour, spinal control, or healthy control) are presented 
with standard deviations (SD) in brackets. The results of the general linear modelling 
analysis are then reported. Estimated marginal means (adjusted for age and NART 
score) and pairwise comparisons are described to highlight the differences between 
the groups, adjusted for other variables in the models. Least Significant Difference 
(LSD) tests were used to conduct pairwise post-hoc comparisons. 
The mean number of days between baseline testing and session 2 follow-up testing 
was 6.42 (SD 5.9) for the brain tumour group, compared with 4.39 days (SD 2.3) for 
the spinal control group and 9.16 days (SD 7.3) for the healthy control group.
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Levene’s test showed that the group variances were significantly different, F(2,204) 
= 11.365, p < 0.001. Therefore, the Kruskal-Wallis test was used to compare 
differences in the mean number of days between baseline and follow-up in each 
participant group and this test revealed significant differences between the groups, 
H(2) = 33.454, p < 0.001. The difference between the brain tumour and spinal 
control groups was significant, U = 1452.0, p = 0.001, suggesting the time to follow-
up was significantly longer for the brain tumour group. The difference between the 
brain tumour and healthy control group was also significant, U = 1675.0, p = 0.001, 
suggesting that there was a significantly longer period of time between baseline and 
session 2 testing in the healthy control group by comparison with the brain tumour 
group. Comparison of the spinal and healthy control groups was also significant U = 
1218.0, p < 0.001, suggesting that the time to follow-up was significantly longer for 
the healthy control group than for the spinal control group. 
6.2 Results
6.2.1 Inspection Time Scores: All Inspection Time Data
Of the 118 brain tumour patients who participated in the study, there were 60 
(50.8%) patients with inspection time scores at both baseline and session 2. Sixty-six 
(77.6%) of the 85 members of the spinal control group and 76 (95%) of the 80 
healthy control group also completed both sessions. All inspection time data, 
including ‘invalid’ scores, from participants with scores at both baseline and session 
2 follow-up was included in the analysis in the first instance.
The mean total inspection time score at baseline (i.e. total correct /150) for the brain 
tumour group was 117.6 (SD 20.7) and at session 2 was 113.9 (SD 22.5). The spinal 
control group scored a mean of 122.2 (SD 13.8) at baseline and a mean of 122.4 (SD 
13.4) at session 2. The baseline mean score for the healthy control group was 126.6 
(SD 11.3) and at session 2 was 128.5 (SD 12.8). The mean (standard error) scores at 
baseline and session 2 for each of the three groups are shown in Figure 6.1.
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Figure 6.1. Baseline and session 2 inspection time scores for the three participant 
groups. Points are raw mean scores. Error bars: Standard error means. 
General linear modelling, with inspection time total score entered as the dependent 
variable, revealed a significant main effect of the inspection time score at baseline, 
F(1,196) = 181.988, p < 0.001, partial η² = 0.481. In the whole sample (i.e. all three 
participant groups combined), baseline inspection time score was positively 
correlated with session 2 inspection time score, r(n = 203) = 0.778, p < 0.001. In the 
brain tumour group alone, baseline and session 2 inspection time scores were also 
significantly correlated, r(n = 60) = 0.709, p < 0.001. Similar correlations were 
obtained for the spinal control group, r(n = 67) = 0.813, p < 0.001 and for the healthy 
control group, r(n = 76) = 0.855, p < 0.001. This therefore shows that those 
participants with better baseline inspection time scores also performed significantly 
better at session 2 follow-up.  There was a significant main effect of the covariate 
age on session 2 inspection time scores, F(1,196) = 9.045, p = 0.003, partial η² = 
0.044. Older participants tended to have lower inspection time scores than younger 
participants. There was a significant main effect of the covariate NART score in the 
model, F(1,196) = 4.629, p = 0.033, partial η² = 0.023. Participants with higher (i.e. 
poorer) NART scores had lower session 2 inspection time scores. Participant group 
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had a significant main effect in the model that included the effects of the covariates 
age, NART and baseline inspection time score, F(2,196) = 6.241, p = 0.002, partial 
η² = 0.060. That is, in the presence of the effects of age, NART score and baseline 
inspection time score, there was a significant difference between the performance of 
the three participant groups on inspection time at post-operative (session 2) testing. 
These group differences, as planned, were explored further.
The estimated marginal mean session 2 inspection time score, adjusted for age, 
NART and baseline inspection time score—derived from the above-described 
general linear model—was 118.1 (SE 1.4) for the brain tumour group, 123.1 (SD 1.3) 
for the spinal control group and 124.6 (SE 1.3) for the healthy control group. 
Pairwise comparisons using Least Significant Difference tests show that the brain 
tumour group performed significantly worse than the spinal control group (p = 
0.008) at session 2. The brain tumour group were also significantly worse the healthy 
control group (p = 0.001). There was no significant difference between the spinal and 
healthy control group performance on session 2 inspection time scores (p = 0.424). 
Therefore, there was a significantly greater relative deterioration in inspection time 
performance in the brain tumour group between baseline and session 2 testing by 
comparison with both the spinal surgery and healthy control groups. 
6.2.2 Inspection Time Scores: Valid Inspection Time Data
There were 52 (44.1%) members of the total cohort of 118 brain tumour patients with 
‘valid’ baseline inspection time scores, who also had follow-up inspection time 
(valid or invalid) scores at session 2. ‘Valid’ inspection time scores are data from 
those participants who scored at least 17/20 on the longest two durations, as detailed 
in chapter 2.2. Data from patients who had valid scores at baseline but invalid scores 
at session 2 were also included here as these participants were deemed to have 
proven their comprehension of the task on the first occasion. Sixty-two (72.9%) of 
157
the 85 spinal controls and 74 (92.5%) of the total cohort of 80 healthy controls also 
met these validity criteria. 
The mean baseline inspection time score for the brain tumour group, when only valid 
scores were included, was 123.8 (SD 12.7), and following surgery at session 2 was 
117.5 (SD 19.8). For the spinal group, the mean baseline score was 124.7 (SD 10.1) 
and at session 2 was 124.5 (SD 10.6). The healthy control group scored a mean of 
127.5 (SD 10.0) at baseline and a mean of 129.6 (SD 10.8) at session 2. The mean 
(standard error) scores at baseline and session 2 for each of the groups are shown in 
Figure 6.2.
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Figure 6.2. Baseline and session 2 inspection time scores for the three participant 
groups including only data from participants with valid scores at baseline. Points 
are raw mean scores. Error bars: Standard error means. 
General linear modelling, with total inspection time score at session 2 entered as the 
dependent variable, revealed a significant main effect of the baseline inspection time 
score, F(1,182) = 90.587, p < 0.001, partial η² = 0.332. In the whole sample 
combined, valid baseline inspection time scores were correlated with session 2 
inspection time scores, r(n = 188) = 0.675, p < 0.001. In the brain tumour group 
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alone, valid baseline score was correlated with session 2 score, r(n = 52) = 0.611, p < 
0.001. This was also the case for the spinal control group, r(n=62) = 0.694, p < 
0.001, and for the healthy control group, r(n = 74) = 0.805, p < 0.001. Those 
participants who scored better at baseline performed significantly better at session 2 
follow-up. There was a significant main effect of the covariate age on session 2 
inspection time scores, F(1,182) = 9.203, p = 0.003, partial η² = 0.048. Older 
participants tended to have poorer scores than younger participants. The covariate 
NART score also had a significant main effect in the model, F(1,182) = 6.606, p = 
0.011, partial η² = 0.035. Poorer performance on the NART was significantly related 
to lower inspection time scores at session 2. Participant group had a significant main 
effect in the model that included the effects of age, NART score and baseline 
inspection time scores, F(2,182) = 9.521, p < 0.001, partial η² = 0.095. That is, in the 
presence of the effects of age, NART score and baseline inspection time score for 
those participants with ‘valid’ test scores; there was a significant difference between 
the performance of the three participant groups on inspection time testing at session 
2. These between-groups differences were explored further. 
The estimated marginal mean session 2 inspection time scores for participants with 
valid scores at baseline, adjusted for age, NART and baseline score and derived from 
the general linear model described above were 119.3 (SD 1.4) for the brain tumour 
group, 125.7 (SD 1.3) for the spinal control group, and 127.3 (SD 1.2) for the healthy 
control group. Pairwise comparisons, using Least Significant Difference tests, 
revealed that the brain tumour group performed significantly worse than the spinal 
control group (p = 0.001) and significantly worse than the healthy control group (p < 
0.001). There was no significant difference between the performance of the spinal 
and healthy control groups (p = 0.406). 
Therefore, in the cohort of patients with valid inspection time scores at baseline, 
there was a significantly greater relative deterioration in the brain tumour group 
between baseline and session 2 testing by comparison with both control groups 
(spinal surgery and healthy volunteer).
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6.2.3 Digit Symbol Coding
Of the 118 brain tumour patients who participated in the study, 60 (50.8%) 
completed the digit symbol-coding task at both baseline and post-operatively at 
session 2. Sixty-five of the 85 spinal control patients (76.5%) and 75 of the 80 
healthy volunteer controls (93.8%) completed the task at both baseline and session 2. 
Only data from participants with test scores at both sessions were included in the 
analyses. 
At baseline, the brain tumour patients scored a mean of 62.2 (SD 21.3), compared 
with a mean of 58.2 (SD 21.5) at session 2, post-operatively. The spinal group scored 
a mean of 69.2 (SD 17.3) at baseline compared with a mean of 66.9 (SD 20.0) at 
post-operative follow-up (session 2). The healthy control group had a mean baseline 
score of 76.6 (SD 16.0) and a mean session 2 score of 81.9 (SD 18.2). The mean 
(standard error) scores at baseline and session 2 for each of the groups are shown in 
Figure 6.3.
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Figure 6.3. Baseline and session 2 digit symbol coding scores for the three 
participant groups. Points are raw mean scores. Error bars: Standard error means.
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General linear modelling, with digit symbol coding score at session 2 as the 
dependent variable, revealed a significant main effect of baseline digit symbol 
coding score, F(1,194) = 330.211, p < 0.001, partial η² = 0.630. In the whole sample 
combined, digit symbol coding score at baseline was correlated with digit symbol 
coding score at session 2, r(n = 201) = 0.862, p < 0.001. The correlation between 
baseline and session 2 digit symbol coding scores for the brain tumour group alone 
was also significant, r(n = 60) = 0.892, p < 0.001. Similar significant correlations 
were obtained for the spinal control group, r(n = 66) = 0.726, p < 0.001, and also for 
the healthy control group, r(n = 75) = 0.942, p < 0.001. Those participants with 
higher scores at baseline on digit symbol coding performed significantly better on the 
same test at session 2 follow-up than those participants with lower baseline scores. 
There was no significant main effect of the covariate age on digit symbol scores at 
session 2, F(1,194) = 1.653, p = 0.200, partial η² = 0.008. Similarly, NART score had 
no significant main effect on session 2 scores on the digit symbol coding measure, 
F(1,194) = 0.990, p = 0.321, partial η² = 0.005. Participant group had a significant 
main effect on digit symbol coding scores at session 2, in the model that included the 
effects of baseline test scores, age and NART score, F(2,194) = 13.662, p < 0.001, 
partial η² = 0.123. This suggests that, in the presence of the effects of baseline test 
scores, age and NART score, there was a significant difference between the 
performance of the three participant groups on digit symbol coding at session 2 
follow-up. These differences were explored further, using pairwise comparisons as 
planned.
The estimated marginal mean session 2 digit symbol coding scores, adjusted for the 
effects of age, NART score and baseline digit symbol coding score – derived from 
the above-described general linear model - were 65.4 (SE 1.4) for the brain tumour 
group, 67.7 (SE 1.3) for the spinal surgery control group and 75.5 (SE 1.3) for the 
healthy control group. Pairwise comparisons using Least Significant Difference tests 
demonstrate that the brain tumour group performed significantly worse than the 
healthy control group at session 2 (p < 0.001). However, there was no significant 
difference between the brain tumour group and the spinal control group (p = 0.231). 
The spinal control group performed significantly worse than the healthy control 
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group at session 2 (p < 0.001). This shows that the brain tumour and spinal groups 
both deteriorated significantly more on digit symbol coding at session 2 compared 
than the healthy control group, who had a higher session 2 score compared with 
baseline performance.  
6.2.4 Nine Hole Peg Test (Right Hand, EFIT)
In the brain tumour group, 62 of 118 patients (52.5%) completed the Nine Hole Peg 
Test (NHPT) at both baseline and at session 2 post-operatively. Sixty-four of the 
total cohort of 85 spinal control patients (75.3%) and 76 of the total cohort of 80 
healthy volunteer controls (95.0%) completed the test on both occasions.
The brain tumour group scored a mean of 13.8 seconds (SD 2.9) at baseline on this 
test, and a mean of 14.5 seconds (SD 2.8) at post-operative follow-up (session 2). 
The corresponding mean score for the spinal group at baseline was 12.9 seconds (SD 
2.9) and was 13.5 seconds (SD 2.7) at session 2. The healthy control group scored a 
mean of 12.3 seconds (SD 1.5) at baseline and 12.0 seconds (SD 1.7) at session 2. 
The mean (standard error) scores at baseline and session 2 for each of the three 
groups are shown in Figure 6.4.
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Mean Nine Hole Peg Test (Right Hand) Scores at Baseline and 



























Figure 6.4. Baseline and session 2 nine hole peg test (right hand) scores for the 
three participant groups. Points are raw mean scores. Error bars: Standard error means.
General linear modelling, with right-hand NHPT score at session 2 entered as the 
dependent variable, revealed a significant main effect of baseline score on the right-
hand NHPT, F(1,196) = 161.119, p < 0.001, partial η² = 0.451. In the whole sample 
of participants recruited into the study, baseline nine hole peg test score (right hand) 
was correlated with session 2 NHPT score (right hand), r(n = 203) = 0.750, p < 
0.001. In the brain tumour sample alone, there was a significant correlation between 
the baseline and session 2 scores, r(n = 62) = 0.741, p < 0.001. The correlations were 
also significant for the spinal control group, r(n = 65) = 0.802, p < 0.001 and the 
healthy control group, r(n = 76) = 0.578, p < 0.001. Therefore those participants who 
took longer to complete the task at baseline were significantly more likely to take 
longer to complete the task at session 2. There was a significant main effect of the 
covariate age on session 2 NHPT (right hand) scores, F(1,196) = 7.110, p = 0.008, 
partial η² = 0.035. Older participants tended to take longer to complete the task than 
younger participants. There was no significant main effect of the covariate NART 
score on session 2 NHPT (right hand) scores, F(1,196) = 0.191, p = 0.662, partial η² 
= 0.001. Participant group had a significant main effect in the model that included 
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the effects of the covariates age, NART and baseline score on the NHPT, F(2,196) = 
13.156, p < 0.001, partial η² = 0.118. Therefore, in the presence of the effects of age, 
NART and baseline right-hand NHPT score, there was a significant difference 
between the performance of the three participant groups on right-hand NHPT at 
session 2 follow-up. These differences were explored further, using post-hoc tests as 
planned.
The estimated marginal mean session 2 right-hand NHPT scores, adjusted for age, 
NART and baseline score on the same test – derived form the above-described 
general linear model – were 13.9 (SE 0.2) for the brain tumour group, for the spinal 
control group 13.5 (SE 0.2) and 12.4 (SE 0.2) for the healthy control group. Pairwise 
comparisons using Least Significant Difference tests show that the brain tumour did 
not perform significantly differently from the spinal control group at session 2 (p = 
0.199). The brain tumour group did however perform significantly worse than the 
healthy control group (p < 0.001). The spinal control group also performed 
significantly worse at session 2 than the healthy control group (p < 0.001).
Therefore, the brain tumour group and spinal control group showed a greater relative 
deterioration in nine hole peg test (right hand) performance between baseline and 
session 2 than the healthy control group. There was no significant difference in the 
extent of deterioration between the brain tumour and spinal surgery groups. 
6.2.5 Nine Hole Peg Test (Left Hand, EFIT)
Sixty-one patients in the brain tumour group completed this test at both baseline and 
session 2 follow-up. A further 65 spinal controls and 76 healthy controls also 
completed the NHPT with the left hand on both occasions. 
The mean time taken to complete this test at baseline was 15.3 seconds (SD 3.6) for 
the brain tumour group and at post-operative follow-up (session 2) the mean time 
taken was 18.5 seconds (SD 21.1). The spinal control group had a mean of 14.2 
seconds (SD 3.3) at baseline and a mean score of 15.3 seconds (SD 5.5) at session 2. 
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At baseline, the healthy control group scored a mean of 12.9 seconds (SD 2.0), with a 
mean of 12.6 seconds (SD 1.9) at session 2. The mean (standard error) scores at 
baseline and session 2 for each of the three groups are shown in Figure 6.5.
Mean Nine Hole Peg Test (Left Hand) Scores at Baseline and 




























Figure 6.5. Baseline and session 2 nine hole peg test (left hand) scores for the three 
participant groups. Points are raw mean scores. Error bars: Standard error means.
General linear modelling, with left hand NHPT score entered as the dependent 
variable, revealed a significant main effect of the same test score at baseline, 
F(1,196) = 103.515, p < 0.001, partial η² = 0.346. In the whole sample (i.e. all three 
participant groups combined), baseline left hand NHPT score was positively 
correlated with session 2 score on the same measure, r(n = 203) = 0.673, p < 0.001. 
In the brain tumour group alone, baseline and session 2 score on the left hand nine 
hole peg test were also positively correlated, r(n =61) = 0.859, p < 0.001. Similar 
significant correlations were obtained for the spinal control group, r(n = 66) = 0.529, 
p < 0.001, and for the healthy control group, r(n = 76) = 0.683, p < 0.001. This 
therefore shows that those participants with faster baseline scores on this test were 
more likely to also complete the test faster at session 2. There was no significant 
main effect of age on session 2 left hand NHPT scores, F(1,196) = 1.114. p = 0.293, 
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partial η² = 0.006. There was also no significant main effect of NART score on 
session 2 scores on this test, F(1,196) = 2.027, p = 0.156, partial η² = 0.010. 
Participant group had a significant main effect in the model that included the effects 
of the covariates age, NART and baseline test score on the measure, F(2,196) = 
6.977, p = 0.001, partial η² = 0.066. In the presence of the effects of age, NART 
score and baseline left hand nine hole peg test score, there was a significant 
difference between the performance of the three participant groups on this measure at 
session 2. The between-groups differences were examined further, using pairwise 
comparisons, as planned.
The estimated marginal mean left-hand NHPT scores at session 2, adjusted for age, 
NART and baseline score on the same test and derived from the above-described 
general linear model were 14.9 (SE 0.4) for the brain tumour group, 15.3 (SE 0.4) for 
the spinal control group and 13.3 (SE 0.4) for the healthy control group. Pairwise 
comparisons using Least Significant Difference tests showed there to be no 
significant difference between the performance of the brain tumour and spinal 
control groups on this test at session 2 (p = 0.402). The brain tumour group were 
significantly worse than the healthy control group (p = 0.007) and the spinal control 
group were also significantly worse than the healthy control group (p < 0.001). 
Therefore, there was a significantly greater relative deterioration on the left hand 
NHPT in the brain tumour and spinal control group between baseline and session 2 
testing by comparison with the healthy control group but no significant difference 
between the brain tumour and spinal surgery groups.
6.2.6 Williams Delayed Recall Test (EFIT)
This test was completed at both baseline and session 2 by 62 of the 118 members of 
the brain tumour group (52.5%), 65 of the 85 spinal controls (76.5%) and 76 of the 
80 healthy controls (95.0%). 
The mean scores for the brain tumour group who completed both testing sessions 
were 8.7 (SD 5.2) at baseline and 11.4 (SD 6.1) at session 2. The spinal group scored 
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a mean of 5.1 (SD 3.7) at baseline, and 7.3 (SD 4.0) at session 2. The mean baseline 
score for the healthy control group was 4.5 (SD 3.6), compared with 4.1 (SD 3.1) at 
session 2 follow-up. The mean (standard error) scores at baseline and session 2 for 
each of the three groups are shown in Figure 6.6.
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Figure 6.6. Baseline and session 2 Williams Delayed Recall Test scores for the 
three participant groups. Points are raw mean scores. Error bars: Standard error means.
General linear modelling, with Williams Delayed Recall Test (WDRT) score entered 
as the dependent variable, revealed a significant main effect of the baseline WDRT, 
F(1,197) = 50.304, p < 0.001, partial η² = 0.203. In the whole sample of all three 
participant groups combined, baseline WDRT score was positively correlated with 
the same test score at session 2, r(n = 204) = 0.612, p < 0.001. In the brain tumour 
group alone, baseline and session two scores on this measure were also positively 
correlated, r(n = 62) = 0.495, p < 0.001. The correlation between the two scores for 
the spinal group was r(n = 66) = 0.544, p < 0.001; and for the healthy control group 
was r(n = 76) = 0.601, p < 0.001. Those participants who had lower scores at 
baseline on the WDRT also tended to have lower scores on the same measure at 
session 2. There was a significant main effect of the covariate age on session 2 scores 
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on the test, F(1,197) = 4.521, p = 0.035, partial η² = 0.022. Older participants tended 
to perform less well than younger participants. There was also a significant main 
effect of NART score in the model, F(1,197) = 8.565, p = 0.004, partial η² = 0.042. 
Participants with higher (poorer) NART scores tended to have higher (poorer) scores 
on the WDRT. Participant group had a significant main effect in the model that 
included the effects of the covariates age, NART score and baseline WDRT score, 
F(2,197) = 19.102, p < 0.001, partial η² = 0.162. This suggests that, in the presence 
of the effects of age, NART score and baseline score on the WDRT, there was a 
significant difference between the performances of the three groups at session 2. As 
planned, these group differences were explored using post-hoc pairwise comparisons 
(Least Significant Difference tests). 
The estimated marginal mean session 2 scores on the WDRT, adjusted for age, 
NART and baseline score on the same test and derived from the above-described 
general linear model, were 9.7 (SE 0.5) for the brain tumour group, 7.5 (SE 0.5) for 
the spinal control group and 5.2 (SE 0.5) for the healthy control group. Pairwise 
comparisons using Least Significant Difference tests show that the brain tumour 
group performed significantly worse than the spinal control group at session 2 (p = 
0.002). The brain tumour group were also significantly worse than the healthy 
control group (p < 0.001). The spinal group were significantly worse than the healthy 
control group (p = 0.001). This suggests there was a significantly greater relative 
deterioration in WDRT performance in the brain tumour group between baseline and 
session 2 by comparison with both the spinal surgery and healthy control groups. The 
spinal group also deteriorated significantly more by comparison with the healthy 
control group. 
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6.2.7 Timed Ten Metre Walk (EFIT)
This test was completed at both baseline and session 2 by 56 of the 118 members of 
the brain tumour cohort (n = 118, 47.5%), 57 of the 85 spinal control patients 
(67.1%) and 72 of the 80 healthy volunteer controls (90%). 
The brain tumour patients who completed this test on both occasions (baseline and 
session 2) scored a mean of 6.7 seconds (SD 1.4) at baseline and a mean of 7.1 
seconds (SD 1.7). For the spinal group, mean baseline score was 7.8 seconds (SD 
2.1) and at session 2 was 8.4 seconds (SD 2.6). The healthy control group mean at 
baseline was 6.0 seconds (SD 1.2) and was 6.0 seconds (1.0) at session 2. The mean 
(standard error) scores at baseline and session 2 for each of the three groups are 
shown in Figure 6.7.
Mean Timed Ten Metere Walk Test Scores at Baseline and 






























Figure 6.7. Baseline and session 2 Timed Ten Metre Walk test scores for the three 
participant groups. Points are raw mean scores. Error bars: Standard error means.
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General linear modelling, with session 2 timed ten metre walk score entered as the 
dependent variable, revealed a significant main effect of the baseline score on this 
measure, F(1,179) = 89.695, p < 0.001, partial η² = 0.334. In the whole sample (i.e. 
all  three participant groups combined), baseline ten metre walk score was positively 
correlated with session 2 ten metre walk score, r(n = 186) = 0.695, p < 0.001. In the 
brain tumour group alone, baseline and session 2 scores on this test were also 
positively correlated, r(n = 56) = 0.731, p < 0.001. This was also the case for the 
spinal control group, r(n = 58) = 0.574, p < 0.001; and also for the healthy control 
group, r(n = 72) = 0.660, p < 0.001. Those patients who had better (i.e. quicker) 
scores on this measure at baseline also performed significantly better at follow-up. 
There was no significant main effect of either of the covariates age, F(1,179) = 
3.112, p = 0.079, partial η² = 0.017; or NART score in the model, F(1,179) = 0.136, p 
= 0.713, partial η² = 0.001. Participant group had a significant main effect in the 
model that included the effects of baseline ten metre walk score, NART and age, 
F(2,179) = 8.257, p < 0.001, partial η² = 0.084. In the presence of the effects of age, 
NART score and baseline ten metre walk score, there was a significant difference 
between the three participant groups on the timed ten metre walk at session 2. To 
explore these differences between groups, pairwise comparisons were used as 
planned.
The estimated marginal mean session 2 timed ten metre walk scores, adjusted for 
age, NART and baseline ten metre walk score, and derived from the general linear 
model described above, were 7.1 (SE 0.2) for the brain tumour group, 7.7 (SE 0.2) 
for the spinal control group and 6.5 (SE 0.2) for the healthy control group. Pairwise 
comparisons using Least Significant Difference tests show that the spinal group 
performed significantly worse than the brain tumour group (p = 0.031). The spinal 
group were also significantly worse than the healthy control group (p < 0.001). The 
brain tumour group were significantly worse than the healthy control group (p = 
0.027) on this measure at session 2. Therefore, the spinal control group showed 
significantly greater deterioration on the timed ten metre walk between baseline and 
session 2 by comparison with both the brain tumour group and the healthy control 
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group. The brain tumour group also deteriorated significantly more between baseline 
and session 2 than the healthy control group. 
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Table 6.1 Estimated marginal mean session 2 test scores, adjusted for age, NART score and baseline test score, and post hoc pairwise comparisons.
Test


















118.1 (1.4) 123.1 (1.3) 124.6 (1.3) 0.008 0.001 0.424
Inspection Time 
(Valid Data)¹
119.3 (1.4) 125.7 (1.3) 127.3 (1.2) 0.001 < 0.001 0.406
Digit Symbol 
Coding¹
65.4 (1.4) 67.7 (1.3) 75.5 (1.3) 0.231 < 0.001 < 0.001
Nine Hole Peg Test 
– Right Hand 
(EFIT)²
13.9 (0.2) 13.5 (0.2) 12.4 (0.2) 0.199 < 0.001 < 0.001
Nine Hole Peg Test 
– Left Hand 
(EFIT)²




9.7 (0.5) 7.5 (0.5) 5.2 (0.5) 0.002 < 0.001 0.001
Timed Ten Metre 
Walk 
(EFIT)²
7.1 (0.2) 7.7 (0.2) 6.5 (0.2) 0.031 0.027 < 0.001
*Estimated marginal mean score, adjusted for age, NART score and test score at baseline. SE = Standard Error.
¹ Higher scores represent better function. ² Higher scores represent worse function.
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6.3 Discussion
Overall, the brain tumour group were found to deteriorate significantly more between 
baseline and session 2 on the inspection time task than both the spinal surgery 
control group and the healthy control group. Neither the spinal surgery group nor the 
healthy control group deteriorated significantly on inspection time between baseline 
and session 2. This was the case when all inspection time data were included in the 
analysis, and the difference between the brain tumour group and the two control 
groups was even larger when only ‘valid’ inspection time scores were included in the 
analysis. The effect size on both occasions was moderate. This suggests that the 
inspection time task a sensitive measure of the effects of brain tumour surgery on 
visual information processing. 
On all of the other tests that comprised the post-operative test battery, (i.e. digit 
symbol coding and the Edinburgh Functional Impairment Tests, EFIT), both the 
brain tumour and spinal surgery groups deteriorated significantly when tested post-
operatively by comparison with the healthy control group who were tested on a 
second occasion. This suggests that surgery in general had a deleterious effect on 
patient function, as measured by these tests. The effect size was moderate – large for 
each of these tests. This suggests that the inspection time task is not unique in its 
ability to detect the effects of surgery in brain tumour patients. However, compared 
with the spinal surgery control group, the brain tumour group deteriorated 
significantly more on only the Williams Delayed Recall Test (WDRT) from the 
EFITs. Thus, inspection time and the WDRT appeared to be particularly sensitive to 
the effects of brain tumour surgery, over and above the general deleterious effects of 
surgery detected by the other measures.
There were a number of advantages associated with enrolling a group of patients who 
were admitted for elective spinal surgery as a control group into the study. Namely, 
the spinal surgery patients provide a control group for general surgery-related 
variables such as anaesthesia and fatigue. A general post-operative cognitive 
dysfunction has been reported in a number of different surgical patient groups, and in 
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particularly in elderly surgical patients (Bekker and Weeks, 2003, Rasmussen, 1999, 
Moller, 1997). Thus, without a matched surgical group for comparison, any post-
operative deterioration in the brain tumour group could simply be explained as the 
result of the general post-operative cognitive dysfunction that is common to many 
different surgical populations. However, since the spinal control group did not show 
the same deterioration in inspection time and WDRT performance post-operatively, 
the post-surgical deterioration following brain tumour surgery on these measures 
cannot simply be attributed solely to the effects of a general post-operative cognitive 
dysfunction. It is more likely that the specific effect of tumour removal or biopsy 
caused a general slowing in processing speed, as measured by the inspection time 
test and also impairment in delayed recall as measured by the WDRT. Certainly, 
previous studies examining the post-operative cognitive function of brain tumour 
patients have shown a post-operative worsening of psychomotor function in low-
grade glioma patients (Reijneveld et al., 2001) and a transient general cognitive 
impairment was observed by Teixidor et al. (2006). However, other studies have also 
found there to be no significant post-operative change in cognition, for example, in 
patients with a meningioma (Tucha et al., 2003). In a study with a methodology that 
broadly reflects that of the present study, Habets et al. (2008) found surgical 
resection to have no negative effect on cognition in a heterogeneous sample of brain 
tumour patients, unless there were specific post-operative complications. Indeed, in 
direct contrast with the findings of our study, these authors observed an improvement 
in mental speed and perceptual abilities in the post-operative period. However, the 
study was limited by a very small sample size (n = 21) and considerable variation in 
the time at which post-operative assessment was carried out (4 – 104 days). 
An additional strength associated with the methodology of the present study is that 
the tests that comprised the battery administered at session 2 were chosen 
specifically because they have either been shown to have minimal practice effects or 
have alternate forms that make the task particularly suitable for repeated assessment. 
However, practice effects may exist to some extent in the tests administered at 
session 2. For example, an improvement in inspection time performance over 
repeated testing has previously been demonstrated in healthy volunteers (Bors et al., 
174
1999b). Therefore, a further strength of the study design was the inclusion of a group 
of non-surgical, healthy volunteer control participants to allow examination of the 
pure effect of practice which is of importance when interpreting cognitive test scores 
following repeated administration of a task. The healthy control group performed 
marginally better at session 2 compared with baseline performance on a number of 
the tests, namely inspection time and digit symbol coding, confirming previous 
studies that have observed practice effects associated with repeated administration of 
the tests (Bors et al., 1999b, Beres and Baron, 1981, Bors et al., 1999a). Thus, even 
in the presence of the potential positive effects of practice on test performance, the 
surgical cohorts deteriorated on a number of the tests at session 2. Overall, the time 
between baseline testing and post-operative (session 2) follow-up was longer for the 
brain tumour group compared with the spinal control group and was longest for the 
healthy control group. Studies have shown that the positive effects of practice on test 
performance are most likely to be seen between the first and second administration of 
a cognitive measure (Benedict and Zgaljardic, 1998, Collie et al., 2003). In fact 
Collie et al. (2003) identify the potential utility of conducting two baseline testing 
sessions, and subsequently excluding of the results from the first baseline session in 
order to minimise the observed practice effects. This methodology would not, 
however, have been feasible in the present study since recruiting patients for even a 
single baseline testing session prior to surgery was problematic due to the time 
constraints associated with recruiting inpatients from a busy hospital ward. The 
results of these aforementioned studies lead us to expect that the participant group 
with the shortest elapsed time between baseline and session 2 testing would be most 
likely to exhibit practice effects. However, since the healthy control group had the 
longest duration between the two sessions, yet exhibited the greatest level of 
improvement at session 2, we can conclude that practice effects had no significant 
impact on the conclusions reached in this study. To control for within group variation 
in terms of the interval between baseline and session 2 testing, one study of 
pulmonary bypass patients employed very strict follow-up criteria whereby only the 
results from patients who completed the second testing session exactly 8 days post-
operatively, as scheduled, were included in the analysis (Pugsley et al., 1994). Given 
the variation in terms of recovery and discharge times for the surgical patients in this 
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study, such a method would not have been feasible and would have lead to the 
exclusion of a very high proportion of patients, many of whom may have 
experienced significant impairment post-operatively. Moreover, this methodology is 
not necessary in the present study given that practice effects were unlikely to have 
had any significant effect on the conclusions made in the study.
The prospective nature of the present study gives the present study an advantage over 
others that report the presence of post-operative impairment in brain tumour patients 
since cognitive test scores were available from the pre-operative period to allow a 
direct comparison with post-operative test scores from the same patients. Thus, a 
direct assessment of the effects of surgery on inspection time, and other, function can 
be made by comparison with the same patient’s test scores in the pre-operative 
period. Several previous studies attempting to elucidate the potential role of surgery 
in causing cognitive deficits have attempted to do so by comparing the test scores of 
patients who have already had surgery with either those of age and sex-matched 
patients who are yet to have surgical intervention (Reijneveld et al., 2001) or with 
age and sex-matched healthy control participants (Klein et al., 2001). However, 
several confounding variables, such as differences in premorbid intelligence and 
differences in terms of tumour size and location limit the conclusions that can be 
drawn from the aforementioned studies. 
It has been suggested that studies of post-operative cognitive dysfunction should aim 
to minimise variability between examiners and within individual participants as 
much as possible (Rasmussen et al., 2001). This study was designed to meet these 
aims as much as was feasibly possible. Firstly, all tests were administered at each 
session and to each group by the same researcher thus minimising potential examiner 
effects and eliminating the need to assess inter-rater reliability. Each testing session 
took place in a controlled testing environment that aimed to minimise external 
distractions, under constant artificial lighting conditions. However, there was 
considerable variability in terms of the time of day during which testing took place. 
Baseline testing often took place later in the day following admission to the hospital 
ward, whereas post-operative testing generally took place in the morning on the day 
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of discharge. Additionally, it was impossible to avoid the potential effects of 
increased fatigue that the surgical cohorts likely experienced post-operatively, 
following an inpatient stay on a hospital ward. However, given that both the brain 
tumour and spinal surgery groups were admitted to the same neurosurgical wards, it 
is likely that the extent of fatigue was similar between the two groups, although no 
formal measure of this variable was made. Therefore, the greater relative post-
operative deterioration on inspection time and the WDRT cannot be attributed to the 
effects of fatigue or to the variation in terms of baseline and session 2 testing times. 
Despite the advantages associated with recruiting both the spinal surgery and healthy 
volunteer control groups into the study, comparing the scores of the brain tumour 
cohort with two control groups raises specific issues associated with data analysis. 
To compare the baseline and session 2 follow-up scores for each participant group 
general linear modelling (analysis of covariance) was used since this allowed us to 
control for important variables that have previously been shown to have a significant 
effect on cognitive test performance. These variables include National Adult Reading 
Test score as a measure of premorbid intelligence and age at the time of testing since 
both variables have been found to correlate with inspection time (Deary and Stough, 
1996) and with cognitive test performance in general (Lezak et al., 2004). Least 
Significant Difference (LSD) pairwise comparisons were specified during analysis in 
order to identify where any specific between-groups differences lie, should a 
significant overall effect of group be found in the model. Running LSD comparisons 
is equivalent to running multiple t-tests between each pair of groups, since there is no 
adjustment made to account for multiple comparisons being made. Thus, the 
probability of obtaining a significant result is increased. However, given that there 
were only three participant groups, and therefore three between-group comparisons 
to run, LSD comparisons were deemed the preferred method of analysis in this 
instance. A potential alternative would have been to use the more conservative 
Bonferroni correction which would have increased the probability of Type II error. 
Given that, based upon the results of a pilot study (Zbinden et al., 2006), it was 
hypothesised that the group of brain tumour patients would show significantly 
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greater post-operative deterioration, LSD comparisons were the most appropriate 
post hoc comparisons to use in this instance.
As highlighted in Chapter 1.5.3, some medications that are commonly prescribed to 
brain tumour patients may have a worsening effect on cognitive function. For 
example, dexamethasone has been shown to have a negative effect on cognition in a 
number of different participant populations, including patients with Alzheimer’s 
disease (Weiner et al., 1997); normal elderly participants (Kalmijn et al., 1998) and 
healthy participants (Kirschbaum et al., 1996). Furthermore, antiepileptic drugs that 
are commonly prescribed to brain tumour patients who present with seizures have 
also been found to result in a deterioration on a number of different tests of cognition
(Kwan and Brodie, 2001). However, since those patients who were prescribed anti-
epileptic medication and/or dexamethasone pre-operatively, were still taking these 
medications post-operatively, the potential for these medications to negatively affect 
cognition cannot explain the post-operative deterioration in the brain tumour group 
compared with baseline performance. Some patients were given a reducing dose of 
dexamethasone following surgery, compared to their pre-operative dose and 
therefore any effect of this reduction in dose might have been to improve cognition. 
For these reasons, the effect of medication is unlikely to explain the observed post-
operative deterioration in inspection time and other test performance in the brain 
tumour group.
The brain tumour and spinal surgery patient groups both showed significant post-
operative deterioration on the Edinburgh Functional Impairment Tests by comparison 
with the healthy control group. The EFITs (i.e. the Nine Hole Peg Tests, Williams 
Delayed Recall Test and Timed Ten Metre Walk) have previously been shown to be 
a potentially useful measure of clinical changes in brain tumour patients, and are 
more sensitive to change than the commonly used disability rating scales, such as the 
Barthel Disability Index (Grant et al., 1994). The findings of the present study 
confirm the sensitivity of the EFIT tests to detect treatment related changes following 
surgery in patients undergoing biopsy or resection of a brain tumour by comparison 
with a healthy volunteer control group who were simply tested on two separate 
178
occasions. However, in this study the EFIT tests also proved to be a sensitive 
measure of the effects of spinal surgery since the spinal surgery group also 
deteriorated post-operatively on these measures, by comparison with the healthy 
control group. That the WDRT was the only subtest from the EFIT on which the 
brain tumour group deteriorated significantly more than the matched spinal surgery 
controls could perhaps be explained by the fact that WDRT performance has been 
found to be independent of intellectual ability. Grant et al. (1994) suggest that the 
test is instead actually more sensitive to the structural effects of a brain tumour than 
are other commonly used cognitive tests that examine digit span or non-verbal 
learning. The effect size of group in the WDRT general linear model was large, and 
the brain tumour patients were significantly more impaired at session 2 than either of 
the control groups. It would therefore appear that the WDRT is potentially as useful 
as the inspection time task as an index of the effects of brain tumour surgery. 
Both surgical groups deteriorated significantly more on the Timed Ten Metre Walk 
EFIT subtest following surgery than the healthy control group.  However, the spinal 
control group deteriorated to a greater degree than the brain tumour patients 
following surgery. This finding was expected, given that many spinal surgery 
patients complained of both pain and an increased level of caution when walking 
following surgery and it was expected that this would impede the speed with which 
the Timed Ten Metre Walk was completed. The other tests administered at follow-up 
that relied heavily on motor function, including digit symbol coding and the Nine 
Hole Peg Tests, failed to distinguish the two surgical groups since both the brain 
tumour and spinal surgery groups deteriorated to a similar degree post-operatively. 
As expected, the healthy control group did not deteriorate on any of these measures 
when tested on the second occasion. This suggests that surgical intervention itself 
had a negative effect on motor function generally, as measured by the 
aforementioned tests. In fact, the extent of the deterioration on these tests that rely on 
intact motor function may be underestimated in the brain tumour group since a 
number of the patients in the brain tumour group who did not complete the initial 
post-operative testing session failed to do so as a result of post-operative 
complications that included hemiparesis. Had these patients completed session 2 
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testing following surgery, it is likely that the extent of the observed post-operative 
deterioration on the tests with a reliance on intact motor function would have been 
greater than that observed in the group of patients who did complete post-operative 
follow-up. 
Since a number of participants in the brain tumour and spinal surgery groups did not 
complete session 2 follow-up, detailed comparisons of the session 2 ‘returners’ and 
‘non-returners’ in each surgical group was carried out in order to determine whether 
those participant who did not complete the initial post-operative follow-up were 
those who exhibited the most severe impairment at the time of baseline. If this were 
found to be the case, it could reasonably be assumed that the extent of post-operative 
deterioration may be underestimated. There were found to be very few significant 
differences between the demographic characteristics and the baseline test 
performance of the returners and non-returners in both surgical groups and this 
therefore suggests that attrition is unlikely to have had any major effect on the results 
presented in this chapter. The results and discussion of the returners vs. non-returners 
analyses are discussed in detail in appendix chapter U. 
Previous studies examining the utility of the Edinburgh Functional Impairment Tests 
in brain tumour patients have found there to be a strong relationship between 
depression, as measured by the Hospital Anxiety and Depression Scale and 
performance on the speeded EFITs, although the direction of causality of this 
relationship is not fully understood (Grant et al., 1994). Thus, given that the brain 
tumour and spinal control groups both reported significantly higher levels of anxiety 
and depression as assessed by the Hospital Anxiety and Depression Scale at baseline 
than did the healthy control group, it may be the case that the levels of depression 
were increased in the two surgical groups post-operatively, following an inpatient 
hospital stay. If this was the case, increased depression could, in part, explain the 
deterioration on the speeded tests of functional impairment seen in the brain tumour 
and spinal surgery groups, but not in the healthy control group. However, no formal 
measure of mood was made post-operatively. In a previous study of anxiety and 
depression in patients with supratentorial intracranial tumours in the pre- and post-
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operative period, Pringle et al. (1999) found that, compared with assessments made 
in the pre-operative period, there was a reduction in levels of both anxiety and 
depression post-operatively. Levels of distress were measured by the Hospital 
Anxiety and Depression Scale and the findings were similar for both male and 
female patients, regardless of tumour location and type of surgery (biopsy or tumour 
resection). The same study also found no significant difference between pre and post-
operative Hospital Anxiety and Depression Scale scores in a cohort of patients who 
underwent elective lumbar spinal surgery. Pringle et al. (1999) conducted their study 
in the same department and recruited patients from the same hospital wards as in the 
present study and patients completed the questionnaire prior to discharge following 
surgery. This reflects the methodology employed in the present study and therefore it 
is reasonable to assume that a  post-operative increase in levels of distress as 
measured by the Hospital Anxiety and Depression Scale was unlikely and is 
therefore unable to account for the observed cognitive decline in neither of the 
surgical patient groups. 
It is perhaps more likely that a surgery-related motor impairment could explain the 
deterioration on these tasks in the brain tumour and spinal control groups. Since 
inspection time, unlike the other measures, does not rely heavily on motor function 
and/or a speeded response, and instead provides a measure of visual processing 
speed, this may explain the lack of relative deterioration on inspection time in the 
spinal surgery patients in comparison with the brain tumour group. The fact that the 
brain tumour group performed significantly less well on inspection time following 
surgery by comparison with both control groups suggests that the task is a sensitive 
measure of the specific effects of brain tumour surgery on visual information 
processing. Therefore inspection time is a potentially useful tool with which to detect 
slowed information processing after surgery that appears to be specific to patients 
with brain tumours. Thus the findings of the present study suggest that brain tumour 
surgery has a negative impact on general processing speed in a cohort of patients 
with a variety of different tumours located in different areas of the brain, when 
compared with a control group of spinal surgery patients and a healthy control group.
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However, the inspection time measure is one that requires a relatively prolonged 
period of concentration for successful completion, by comparison with the other, 
shorter tests administered post-operatively (e.g. Digit Symbol Coding and the 
EFITs). A number of patients in the brain tumour cohort were characterised by 
reduced concentration and disinhibition at presentation and impaired concentration 
may also be a result of emotional distress (Taphoorn and Klein, 2004). Thus, these 
symptoms may not only have influenced performance at baseline but may have 
worsened following surgery and the effect may be particularly evident on inspection 
time and the WDRT both of which have comparatively high attentional demands. 
Therefore, the brain tumour group’s deterioration in inspection time performance 
post-operatively may be the result of reduced concentration as opposed to reflecting 
an intrinsic impairment in visual processing speed that was significantly worsened by 
surgical intervention. If this is the case, it may be that post-operative performance of 
the brain tumour group on any long non-motor cognitive test may have been 
significantly worse than that of the spinal and healthy control groups.
It is generally accepted that cognitive function requires functional interactions 
between a number of distinct neural networks located throughout the brain (Bressler, 
2002). Studies have found that the presence of a brain tumour resulted in a 
significant loss of functional connectivity in the brain as measured by MEG analysis, 
compared with healthy controls and that the loss of connectivity was not only 
associated with those brain regions located near the tumour, but also in brain regions 
further away from the tumour itself. These changes in functional connectivity may, at 
least in part, explain cognitive dysfunction in brain tumour patients (Bartolomei et 
al., 2006a, Bartolomei et al., 2006b). Studies of the functional anatomy of inspection 
time using functional connectivity have revealed two networks that are the likely 
neural correlates of inspection time (see Chapter 2.5). One of these networks 
includes the fronto-opercular area, intrasylvian area, medial frontal gyrus and the 
anterior cingulate cortex and the second is a posterior network that includes sensory 
and associative regions (Deary et al., 2004). The post-surgical deterioration in 
inspection time scores seen in the brain tumour cohort, but not in either the spinal or 
healthy control group, may perhaps be the result of surgical intervention further 
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disrupting functional networks located throughout the brain, particularly those 
networks that are involved in successful inspection time performance. Future work in 
this area could involve pre and post-operative functional MRI scanning during 
inspection time performance in order to determine the functional networks involved 
in inspection time performance in brain invaded by tumour and to examine the 
potential role of surgery in disrupting functional connectivity. 
Given the heterogeneous nature of the brain tumour group who had a variety of 
different tumour types, locations and surgical interventions (biopsy or resection), it is 
of clinical interest to examine the specific effects of these variables on pre and post-
operative inspection time and other tests. The results of these analyses are reported in 
Chapters 7, 8 and 9. Further research should include additional follow-up 
assessments in order to assess whether or not the initial post-operative deterioration 
is transient, and whether this differs between different histological groups (see 
Chapter 9.5 for preliminary analyses).
The cognitive effects of radiotherapy are of particular interest to clinicians and 
patients alike and have been frequently discussed in the literature (see Chapter 1.5.2). 
Since inspection time has been prove as a feasible and sensitive measure of brain 
function in neuro-oncological patients, further research could also involve inspection 
time testing prior to, during and after radiotherapy as a measure of the effects of this 
treatment on brain function. 
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7 The Comparative Effects of Biopsy and
Resection 
7.1 Overview of analysis procedure
To analyse the effect of biopsy or resection on inspection time, digit symbol-coding 
and EFIT test performance, general linear modelling (analysis of covariance) was 
used. The specific test score at session 2 (post-operatively) was specified as the 
dependent variable. Surgery type (biopsy or resection) and sex were fixed effects 
(between-groups factors) in the model. Age at the time of testing and NART score 
were included as covariates for the reasons described in Chapter 5.2.1. The 
corresponding baseline test score for each participant was also included as an 
additional covariate in the models. This effectively allows us to compare the change 
between baseline and session 2 performance on each test between the biopsy and 
resection groups. There was no significant main effect of sex in any of the models for 
each of the test scores detailed below. Therefore, sex was omitted as a fixed effect in 
the analyses reported in this chapter. The models were run again with surgery type 
(biopsy or resection) specified as the only fixed effect.
In each of the sections that follow, mean baseline and session 2 scores for each 
surgery group (biopsy and resection) are presented with standard deviations (SD) in 
brackets.  The results of the general linear modelling analysis are then reported. 
Estimated marginal means (adjusted for age and NART score) are described for each 
of the tests administered to highlight any differences between the groups, adjusted 
for other variables in the models. 
Of the total cohort of brain tumour patients (n = 118), 30 patients (25.4%) had a 
biopsy of their tumour and 86 patients (72.9%) had a resection. The remaining 2 
patients (1.7%) did not subsequently undergo any surgical intervention and their data 
are therefore not included in the following analyses. 
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7.2 Results 
7.2.1 Inspection Time Scores: All Inspection Time Data
To examine the effect of surgery (biopsy vs. resection) on inspection time scores, 
only data from participants who completed inspection time testing at both baseline 
and post-operative follow-up (session 2) were included in the analysis. When all 
inspection data (including ‘invalid) scores were included, there was data from 15 
biopsy patients and 45 resection patients for analysis. 
The mean baseline inspection time score for the biopsy group was 113.0 (SD 21.6) 
and at post-operative follow-up, was 116.3 (SD 22.5). The mean baseline inspection 
time score for the resection group was 119.2 (SD 20.3) and at post-operative follow-
up, was 113.2 (SD 22.7). The mean (standard error) scores at baseline and session 2 
for each of the surgery groups are shown in Figure 7.1.
Mean Inspection Time Scores at Baseline and 































Figure 7.1. Baseline and session 2 inspection time scores for the biopsy and resection 
groups. Points are raw mean scores. Error bars: Standard error means.
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General linear modelling, with inspection time total score at session 2 entered as the 
dependent variable, revealed a significant main effect of the inspection time score at 
baseline, F(1,55) = 32.484, p < 0.001, partial η² = 0.371. That is, in the whole sample 
(i.e. the biopsy and resection groups combined), baseline inspection time score was 
positively correlated with session 2 inspection time score, r(n = 60) = 0.709, p < 
0.001. In the biopsy group, baseline score and session 2 score on inspection time 
were also significantly correlated, r(n = 15) = 0.846, p < 0.001. A similar correlation 
was obtained for the resection group, r(n = 45) = 0.684, p < 0.001. This therefore 
shows that those participants with better baseline inspection time scores generally 
performed significantly better at session 2 follow-up.  
The effect of the covariate age on session 2 inspection time scores approached the 
conventional level of statistical significance, F(1,55) = 3.772, p = 0.057, partial η² = 
0.064. Older participants tended to have lower inspection time scores than younger 
participants. There was no significant main effect of the covariate NART score in the 
model, F(1,55) = 0.621, p = 0.434, partial η² = 0.011. The effect of surgery type did 
not reach significance in the model that included the effects of the covariates age, 
NART and baseline inspection time score, F(1,55) = 3.421, p = 0.070, partial η² = 
0.059. That is, in the presence of the effects of age, NART score and baseline 
inspection time score, there was no significant difference between the performance 
of the biopsy and resection groups on inspection time at session 2 follow-up. 
The estimated marginal mean scores, adjusted for age and NART score, for the 
biopsy group, were 115.3 (SE 4.6) at baseline, and 120.5 (SE 4.1) at post-operative 
follow-up. Corresponding mean scores for the resection group were 117.9 (SE 2.6) at 
baseline, and 111.7 (SE 2.3) at session 2, post-operatively. Thus, despite the fact that 
the mean scores, shown in Figure 7.1, show that the biopsy group tended to improve 
after surgery, whereas the resection group deteriorated, this difference between the 
two surgical groups did not reach statistical significance. 
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7.2.2 Inspection Time Scores: Valid Inspection Time Data
There were 12 brain tumour patients who had a biopsy with ‘valid’ inspection time 
scores at baseline (i.e. at least 17/20 on the longest two durations, see chapter 2.2), 
who also had follow-up inspection time (valid or invalid) scores at session 2. Forty 
patients who had tumour resection also met these criteria. 
The mean baseline inspection time score for the biopsy group was 120.7 (SD 9.5), 
and at post-operative follow-up was 120.4 (SD 11.8). For the resection group, the 
mean baseline score was 124.7 (SD 13.4) and at post-operative follow-up, was 116.6 
(SD 21.6). The mean (standard error) scores at baseline and session 2 for the biopsy 
and resection groups are shown in Figure 7.2.
Mean Inspection Time Scores at Baseline and 






























Figure 7.2. Baseline and session 2 inspection time scores for the biopsy and resection
groups with only valid baseline inspection scores included. Points are raw mean scores. 
Error bars: Standard error means.
General linear modelling, with inspection time total score at session 2 entered as the 
dependent variable, revealed a significant main effect of the inspection time score at 
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baseline, F(1,47) = 15.294, p < 0.001, partial η² = 0.246. In the whole sample (i.e. the 
biopsy and resection groups combined), baseline inspection time score was positively 
correlated with session 2 inspection time score, r(n = 52) = 0.611, p < 0.001. In the 
biopsy group, baseline score and session 2 score on inspection time were also 
significantly correlated, r(n = 12) = 0.740, p = 0.006. A similar correlation was 
obtained for the resection group, r(n = 40) = 0.620, p < 0.001. Those participants 
with better baseline inspection time scores also generally performed significantly 
better at session 2 follow-up.  There was no significant main effect of the covariate 
age on session 2 inspection time scores, F(1,47) = 3.122, p = 0.084, partial η² = 
0.062. There was no significant main effect of the covariate NART score in the 
model, F(1,47) = 1.349, p = 0.251, partial η² = 0.028. The effect of surgery type was 
not significant in the model that included the effects of the covariates age, NART and 
baseline inspection time score, F(1,47) = 2.846, p = 0.098, partial η² = 0.057. In the 
presence of the effects of age, NART score and baseline inspection time score, there 
was no significant difference between the performance of the biopsy and resection 
groups on inspection time at session 2 follow-up.
The estimated marginal mean score, adjusted for age and NART score, for the biopsy 
group at baseline was 122.5 (SE 3.4) and at session 2, post-operatively, was 124.4 
(SE 4.6). The corresponding baseline mean for the resection group on the inspection 
time measure was 124.3 (SE 1.8), and at post-operative follow-up was 115.4 (SE 
2.5). Again, despite the fact that the mean scores, shown in Figure 7.2, suggest that 
when only valid baseline inspection time scores are included in the analysis, the 
biopsy group maintained their baseline performance when tested post-operatively, 
whereas the resection group deteriorated following surgery, this difference between 
the groups was not statistically significant. 
7.2.3 Digit Symbol Coding
There were 15 patients who had a biopsy and completed this test at both baseline and 
post-operative follow-up (session 2). A further 45 patients who had a resection also 
had pre- and post-operative digit symbol-coding scores. 
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The mean baseline digit symbol coding score on this test for the biopsy group was 
54.3 (SD 18.6), and at session 2 was 53.3 (SD 17.5). The resection group scored a 
mean of 64.8 (SD 21.7) at baseline and a mean of 59.9 (SD 22.5) at post-operative 
follow-up. The mean (standard error) scores at baseline and session 2 for each 
surgery type group are shown in Figure 7.3.
Mean Digit Symbol-Coding Scores at Baseline and Session 2 


















Figure 7.3. Baseline and session 2 digit symbol coding scores for the biopsy and resection 
groups. Points are raw mean scores. Error bars: Standard error means.
General linear modelling, with digit symbol coding score at session 2 entered as the 
dependent variable, revealed a significant main effect of the digit symbol coding 
score at baseline, F(1,55) = 141.788, p < 0.001, partial η² = 0.721. In the whole 
sample (i.e. the biopsy and resection groups combined), baseline digit symbol coding 
score was positively correlated with the corresponding session 2 score, r(n = 60) = 
0.892, p < 0.001. In the biopsy group, baseline score and session 2 score on 
inspection time were also significantly correlated, r(n = 15) = 0.953, p < 0.001. A 
similar correlation was obtained for the resection group, r(n = 45) = 0.880, p < 0.001.
This shows that those participants with better baseline scores on the digit symbol 
coding test also tended to perform significantly better on the same test at post-
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operative session 2 follow-up. The effect of the covariate age on session 2 digit 
symbol coding scores was not significant F(1,55) = 0.299, p = 0.587, partial η² = 
0.005. There was no significant main effect of the covariate NART score in the 
model, F(1,55) = 0.899, p = 0.347, partial η² = 0.016. The effect of surgery type was 
not significant in the model that included the effects of the covariates age, NART and 
baseline inspection time score, F(1,55) = 0.851, p = 0.360, partial η² = 0.015. In the 
presence of the effects of age, NART score and baseline digit symbol coding score, 
there was no significant difference between the performance of the biopsy and 
resection groups on digit symbol coding at session 2 follow-up
The estimated marginal mean digit symbol coding scores, adjusted for age and 
NART score, were 56.5 (SE 4.8) at baseline for the biopsy group and 55.3 (SE 4.6) at 
post-operative follow-up. The resection group had a baseline estimated marginal 
mean score of 64.0 (SE 2.7) and a mean of 58.8 (SE 2.8) at session 2 follow-up. 
There was no significant difference in digit symbol coding performance following 
biopsy or resection of the tumour. 
7.2.4 Williams Delayed Recall Test (EFIT)
Fifteen patients who had a biopsy and 47 patients who had a resection completed this 
EFIT subtest at both baseline and session 2 follow-up. 
The biopsy group scored a mean of 10.1 (SD 5.3) at baseline on this measure, and a 
mean of 12.3 (SD 5.8) at session 2 post-operatively. The resection group had a mean 
score of 8.3 (SD 5.2) at baseline and a mean of 11.1 (SD 6.2) at session 2 follow-up. 
The mean (standard error) scores at both baseline and session 2 for the biopsy and 
resection groups are shown in Figure 7.4.
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Mean Scores on Williams Delayed Recall Test at Baseline and 





















Figure 7.4. Baseline and session 2 Williams Delayed Recall Test scores for the biopsy and 
resection groups. Points are raw mean scores. Error bars: Standard error means.
Williams Delayed Recall Test (WDRT) score at session 2 was entered as the 
dependent variable in the general linear model. There was a significant main effect of 
the test score at baseline, F(1,57) = 11.288, p = 0.001, partial η² = 0.165. In the 
whole sample (i.e. the biopsy and resection groups combined), baseline score was 
positively correlated with the corresponding session 2 score, r(n = 62) = 0.495, p < 
0.001. However, in the biopsy group alone, baseline and session 2 WDRT scores 
were not significantly correlated, r(n = 15) = 0.273, p = 0.325. The two scores were 
significantly correlated in the resection group alone, r(n = 47) = 0.552, p < 0.001.
This therefore shows that, overall, those participants with better baseline scores on 
the WDRT also performed significantly better on the same test at post-operative 
session 2 follow-up. The effect of the covariate age on session 2 WDRT scores was 
not significant F(1,57) = 1.103, p = 0.298, partial η² = 0.019. There was no 
significant main effect of the covariate NART score in the model, F(1,57) = 0.538, p 
= 0.466, partial η² = 0.009. The effect of surgery type was not significant in the 
model that included the effects of the covariates age, NART and baseline inspection 
time score, F(1,57) = 0.006, p = 0.937, partial η² < 0.001. In the presence of the 
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effects of age, NART score and baseline WDRT score, there was no significant 
difference between the performance of the biopsy and resection groups on the 
WDRT at session 2 follow-up.
The estimated marginal mean score, adjusted for age and NART score for the biopsy 
group at baseline was 9.6 (SE 1.3), compared with 11.5 (SE 1.4) at post-operative 
testing. The corresponding means for the resection group were 8.5 (SE 0.7) and 11.4 
(SE 0.8), respectively. Figure 7.4 demonstrates that both groups deteriorated 
following surgery, but that the extent of this deterioration did not differ between the 
biopsy and resection groups. 
7.2.5 Nine Hole Peg Test (Right Hand, EFIT)
Fifteen patients who had a biopsy of their tumour completed this measure at both 
baseline and session 2 and 47 patients who underwent a resection also completed the 
task both pre- and post-operatively.
The biopsy group scored a mean of 14.4 (SD 3.4) at baseline, and 15.3 (SD 3.7) at 
session 2, post-operatively. The resection group scored a mean of 13.6 (SD 2.8) at 
baseline and 14.3 (SD 2.5) at post-operative testing. The mean (standard error) scores 
at baseline and session 2 for the biopsy and resection groups are shown in Figure 7.5. 
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Mean Scores on Right Hand Nine Hole Peg Test at Baseline 

















Figure 7.5. Baseline and session 2 right hand nine hole peg test scores for the biopsy and 
resection groups. Points are raw mean scores. Error bars: Standard error means.
Right hand nine hole peg test score at session 2 was entered as the dependent 
variable in the general linear model. There was a significant main effect of the test 
score at baseline, F(1,57) = 45.174, p < 0.001, partial η² = 0.442. In the whole sample 
(i.e. the biopsy and resection groups combined), baseline score was positively 
correlated with the corresponding session 2 score, r(n = 62) = 0.741, p < 0.001. In the 
biopsy group, the baseline score and session 2 score were also significantly 
correlated, r(n = 15) = 0.833, p < 0.001. The two scores were also significantly 
correlated in the resection group, r(n = 47) = 0.692, p < 0.001. This therefore shows 
that those participants with better baseline scores on the digit symbol coding test also 
performed significantly better on the same test at post-operative session 2 follow-up. 
The effect of the covariate age on session 2 right hand nine hole peg test scores was 
not significant F(1,57) = 0.728, p = 0.397, partial η² = 0.013. There was no 
significant main effect of the covariate NART score in the model, F(1,57) = 0.151, p 
= 0.699, partial η² = 0.003. The effect of surgery type was not significant in the 
model that included the effects of the covariates age, NART and baseline score, 
F(1,57) = 1.225, p = 0.273, partial η² < 0.021. In the presence of the effects of age, 
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NART score and baseline inspection time score, there was no significant difference 
between the performance of the biopsy and resection groups on the right hand nine 
hole peg test at session 2 follow-up
The estimated marginal mean scores, adjusted for age and NART score, were 14.1 
(SE 0.6) for the biopsy group at baseline and were 15.0 (SE 0.5) at session 2, post-
operatively. The corresponding means for the resection group were 13.7 (SE 0.3) at 
baseline and 14.4 (SE 0.3) at session 2. Figure 7.5 shows that both the biopsy and 
resection group were slower at post-operative testing compared with baseline. There 
was no significant difference in the extent of decline between the groups. 
7.2.6 Nine Hole Peg Test (Left Hand, EFIT)
Fifteen biopsy patients and 47 resection patients completed this test at both baseline 
and post-operative follow-up (session 2).
The biopsy group had a mean score of 15.6 (SD 3.4) at baseline testing, and 16.0 (SD 
3.9) at session 2. The resection group had a mean score of 15.2 (SD 3.7) at baseline 
and 15.8 (SD 3.4) post-operatively at session 2. The mean (standard error) scores at 
baseline and session 2 for the biopsy and resection groups are shown in Figure 7.6.
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Mean Scores on Left Hand Nine Hole Peg Test at Baseline and 
















Figure 7.6. Baseline and session 2 left hand nine hole peg test scores for the biopsy and 
resection groups. Points are raw mean scores. Error bars: Standard error means.
Left hand nine hole peg test score at session 2 was entered as the dependent variable 
in the general linear model. There was a significant main effect of the test score at 
baseline, F(1,56) = 125.546, p < 0.001, partial η² = 0.692. In the whole sample (i.e. 
the biopsy and resection groups combined), baseline score was positively correlated 
with the corresponding session 2 score, r(n = 61) = 0.859, p < 0.001. In the biopsy 
group, baseline score and session 2 score on the left hand nine hole peg test were also 
significantly correlated, r(n = 15) = 0.797, p < 0.001. The two scores were also 
significantly correlated in the resection group, r(n = 46) = 0.886, p < 0.001. This 
therefore shows that those participants with better baseline scores on the left hand 
nine hole peg test also performed significantly better on the same test at post-
operative session 2 follow-up. The effect of the covariate age on session 2 scores was 
significant F(1,56) = 6.945, p = 0.011, partial η² = 0.110. Older participants took 
significantly longer to complete the test than younger participants. There was no 
significant main effect of the covariate NART score in the model, F(1,56) = 0.553, p 
= 0.460, partial η² = 0.010. The effect of surgery type was not significant in the 
model that included the effects of the covariates age, NART and baseline inspection 
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time score, F(1,57) = 0.355, p = 0.554, partial η² < 0.006. In the presence of the 
effects of age, NART score and baseline score, there was no significant difference 
between the performance of the biopsy and resection groups on the right hand nine 
hole peg test at session 2 follow-up.
The estimated marginal mean score, adjusted for age and NART score, for the biopsy 
group was 15.3 (SE 0.9) at baseline and was 15.6 (SE 0.5) at session 2 testing. The 
estimated marginal mean score for the resection group was 15.3 (SE 0.5) at baseline 
and 15.9 (SE 0.3) at session 2 follow-up. Figure 7.6 shows that neither the biopsy nor 
the resection group deteriorated significantly between baseline and session 2 testing 
on this measure. 
7.2.7 Timed Ten Metre Walk (EFIT)
Fourteen patients in the biopsy group completed this measure at both baseline and 
session 2, post-operatively and 42 patients in the resection group also completed the 
measure on both occasions. 
The mean score for the biopsy group at baseline was 6.8 (SD 1.2) and post-
operatively was 7.2 (SD 1.6). The resection group had a mean score of 6.7 (SD 1.5) 
at baseline, and a mean of 7.1 (SD 1.7) at session 2 follow-up. The mean (standard 
error) scores at baseline and session 2 for the biopsy and resection groups are shown 
in Figure 7.7.
196
Mean Scores on Timed Ten Metre Walk at Baseline and Session 















Figure 7.7. Baseline and session 2 timed ten metre walk test scores for the biopsy and 
resection groups. Points are raw mean scores. Error bars: Standard error means.
Timed ten metre walk test score at session 2 was entered as the dependent variable in 
the general linear model. There was a significant main effect of the test score at 
baseline, F(1,51) = 36.855, p < 0.001, partial η² = 0.419. In the whole sample (i.e. the 
biopsy and resection groups combined), baseline timed ten metre walk score was 
positively correlated with the corresponding session 2 score, r(n = 56) = 0.731, p < 
0.001. In the biopsy group, baseline score and session 2 score on this test were also 
significantly correlated, r(n = 14) = 0.781, p = 0.001. The correlation between the 
two scores in the resection group was also significant, r(n = 42) = 0.721, p < 0.001.
This therefore shows that those participants who completed the timed ten metre walk 
fastest at baseline also performed better on the same test at post-operative session 2 
follow-up. The effect of the covariate age on session 2 scores was significant F(1,51) 
= 4.213, p = 0.045, partial η² = 0.076. Older participants took significantly longer to 
complete the test than younger participants. There was no significant main effect of 
the covariate NART score in the model, F(1,51) = 0.350, p = 0.557, partial η² = 
0.007. The effect of surgery type was not significant in the model that included the 
effects of the covariates age, NART and baseline timed ten metre walk score, F(1,51) 
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= 0.134, p = 0.716, partial η² = 0.003. In the presence of the effects of age, NART 
score and baseline inspection time score, there was no significant difference between 
the performance of the biopsy and resection groups on the time ten metre walk test at 
session 2 follow-up.
The estimated marginal mean scores, adjusted for age and NART effects, were 6.5 
(SD 0.4) for the biopsy group at baseline, and were 7.0 (SD 0.3) at post-operative 
follow-up. The estimated marginal means scores for the resection group were 6.9 
(SD 0.2) at baseline, and 7.1 (SD 0.2) at follow-up. These means, together with 
Figure 7.7 shows that neither the biopsy or resection group deteriorated significantly 
between baseline and post-surgical follow-up.
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7.3 Discussion
Comparison of those patients who had a tumour biopsy and those who underwent
tumour resection revealed no significant differences in terms of the extent of post-
operative deterioration on any of the tests administered at session 2. However, there 
was a clear trend towards maintenance of pre-operative performance in the biopsy 
group and post-operative deterioration in the resection group on the inspection time 
task, although the difference failed to reach the conventional level of statistical 
significance. 
The general cognitive effects of surgical intervention in brain tumour patients are 
discussed in chapter 6.3. Thus, only the specific effects of tumour biopsy vs. 
resection are discussed here. 
This is one of the first studies to specifically compare the cognitive effects of biopsy 
and resection. There was a high rate of attrition in the brain tumour group which 
resulted in only 54% of the brain tumour cohort participating in the initial post-
operative follow-up testing session (session 2). Therefore, there were only 16 
patients in the biopsy group and 48 patients in the resection group who had session 2 
follow-up scores and some of these patients did not complete the entire follow-up 
test battery. As a result, the power to detect any differences in the post-operative 
response of the two brain tumour surgery groups is considerably reduced, making a 
type 2 statistical error likely. This lack of power may explain why, although a clear 
trend towards there being a deleterious effect of resective surgery on inspection time 
performance compared with the lesser effects of biopsy, the difference in 
performance of the two groups did not reach statistical significance. Had a greater 
number of patients completed the post-operative test battery at session 2, the 
difference between the biopsy and resection groups may have been larger and 
statistically significant. That there may have been some bias that resulted in the 
better functioning patients completing follow-up testing must also be considered. 
However, the proportion of patients in each surgery group who did complete session 
2 post-operative follow-up was similar (53% of the biopsy group and 56% of the 
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resection group). This may suggest that a similar proportion of patients in the biopsy 
and tumour groups either declined, were missed or too unwell to take part in the 
initial post-operative testing session, and thus reduces the potential for bias from the 
drop-outs in this instance. 
Very few studies have addressed the question of whether tumour biopsy and 
resection have differential effects on the cognitive function of brain tumour patients.
This question is of interest given the limited survival times of many patients with 
high-grade gliomas in particular. Should resection be proven to increase survival 
times, it is of interest to determine whether this may be at the expense of 
compromised cognitive function and thus likely impairment to quality of life. In the 
present study, patients were classified simply into biopsy or resection groups. Any 
tumour operation where more tissue than necessary for a histopathological diagnosis 
was removed was deemed to be a ‘resection’ (Hart et al., 2000). The potential 
alternative method of classifying patients into more specific groups such as ‘partial 
resection’ and gross total resection’ would have been problematic as this would have 
relied solely on the judgement of the neurosurgeon. Given that a number of different 
neurosurgeons carry out brain tumour surgery in our department, there would have 
been considerable individual differences in terms of assessment regarding the extent 
of resection. Moreover, more specific classification with regards to type of surgery 
would have further reduced the power to detect any differences between the groups.
The potential survival benefits of tumour resection as opposed to biopsy in patients 
with gliomas have received increasing attention in recent years (Smith et al., 2008, 
Stummer et al., 2008). However, whilst in high grade gliomas the evidence is derived 
from a randomised clinical trial (Stummer et al., 2008), answering this question has 
proven to be much more problematic in low grade gliomas given that those patients 
who undergo tumour resection tend to be selected for smaller tumours, more 
accessible tumours and are more likely to be reported than a conservatively managed 
case series. 
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Studies have also evaluated the neurosurgical morbidity and mortality associated 
with biopsy and resection procedures. It is generally accepted that tumour biopsy is a 
relatively lower risk procedure with a low morbidity and mortality rate (Hall, 1998). 
Reported mortality rates and morbidity rates tend to be higher for tumour resections
(Sawaya et al., 1998). However, Vecht et al. (1990) examined neurological function 
in malignant glioma patients in relation to the extent of surgery.  Large resections 
were found to not necessarily result in more neurological impairment than more 
limited surgery. They report that where more extensive surgery was carried out, this 
actually tended to improve the neurological function of the patient. However the 
closer the resection to eloquent brain regions (e.g. somatosensory regions, language 
areas) the more likely a larger resection is to cause a deficit (Peraud et al., 2002).
Therefore, the potentially beneficial effects of tumour resection in terms of 
increasing survival time and the potential for increased functional deficits following 
extensive resection compared with biopsy have received the greatest attention in this 
area. The cognitive effects of biopsy compared to resection are an understudied area 
and future studies could compare inspection time, and other test performance 
between the two groups in a larger cohort than the present study, and including more 
long-term follow-up assessments. This would allow us to determine whether 
inspection time is a sensitive measure of the specific deleterious effects of tumour 
resection by comparison with biopsy. 
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8 Tumour Type, Location and Lateralisation: 
Baseline/Pre-Operative Function
8.1 Overview of Analysis Procedure
To examine the effect of the following tumour-related variables: histological 
subtype, location (lobe) and hemispheric lateralisation, on baseline inspection time 
scores (i.e. prior to any surgical intervention), general linear modelling (ANCOVA) 
was used. The relevant tumour-related variable (i.e. type, lobe or hemisphere) and 
sex were entered as fixed factors in the model. Age and National Adult Reading Test 
(NART) score were entered as covariates for the reasons detailed in Chapter 5.2.1. 
Baseline inspection time score was the dependent variable in each analysis. The 
tumour-related variable by sex interaction was never significant and is therefore not 
reported in the following analyses. Least Significant Difference (LSD) pairwise 
comparisons were specified to examine any differences between subgroups and any 
significant comparisons are reported, where applicable. 
8.2 Histological Tumour Type 
The brain tumour patients were classified into one of the following five main groups, 
according to the histological classification of their brain tumour:
(i) Low-grade glioma (WHO grades I or II)
(ii) High-grade glioma (WHO grades III or IV)
(iii) Metastasis
(iv) Meningioma
(v) Other (including pituitary adenomas)
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The histological diagnoses were obtained from the neuropathology department 
following surgical intervention. Of the total cohort of brain tumour patients (n = 
118), 23 patients were found to have a low-grade glioma. Fifty-one patients had a 
high-grade glioma and 14 had a metastatic brain tumour that had originated from a 
primary cancer elsewhere in the body. A further 17 had a meningioma and 11 
patients had a brain tumour that did not fall into any of the aforementioned categories 
(‘other’). The remaining 2 patients were those patients for whom surgery was 
initially planned but did not subsequently take place. Since six patients did not 
complete the inspection time measure at baseline, the high-grade glioma group fell to 
a total of 46 patients and the meningioma group to 16 patients for this analysis.
In the following analyses where a significant main effect of tumour type was not 
found, post-hoc analyses were carried out to compare the low-grade and high-grade 
tumour type groups only, since it was hypothesised that the performance of these two 
groups was most likely to be significantly different (see Chapter 1.3). 
8.2.1 Inspection Time Scores: All Inspection Time Data
Twenty-three low-grade glioma patients, 46 high-grade glioma patients, 14 patients 
with a metastasis, 16 with a meningioma and 11 with a tumour classified as ‘other’
all completed the inspection time task at baseline.
All inspection time data, including ‘invalid’ scores (see chapter 2.2), were entered 
into the model in the first instance. When all data was included, the group of low-
grade glioma patients scored a mean of 126.1 (SD 11.5) on the task at baseline (i.e. 
pre-operatively). The high-grade glioma group had a mean score of 110.2 (SD 22.2) 
and the group of patients with metastatic tumours scored a mean of 113.8 (SD 18.3). 
The meningioma patients had a mean of 106.4 (SD 22.6) and the group with tumours 
classified as ‘other’ scored a mean of 119.2 (SD 11.6) on the inspection time 
measure at baseline. 
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The covariate ‘age’ had a significant main effect in the general linear model, F(1,98) 
= 26.197, p < 0.001, partial η² = 0.211. The covariate NART score also had a 
significant main effect in the model, F(1,98) = 5.708, p = 0.019, partial η² = 0.055. 
Older patients and patients with higher (poorer) NART scores were more likely to 
have lower (poorer) inspection time scores. Sex had no significant main effect, 
F(1,98) = 2.527, p = 0.115, partial η² = 0.025. Tumour type also had no significant 
main effect in the model that included the effects of age and NART, F(4,98) = 1.280, 
p = 0.283, partial η² = 0.050. Therefore, the type of tumour had no overall effect on 
inspection time scores at baseline.
The estimated marginal mean inspection time scores, adjusted for age and NART 
score and shown in Figure 8.1, for each tumour type were 120.6 (SE 3.8) for the low-
grade glioma group; 111.0 (SE 2.5) for the high-grade glioma group; 118.0 (SE 4.7) 
for the metastasis group; 115.4 (SE 8.9) for the meningioma group and 114.7 (SE 
5.4) for the group of patients with ‘other’ tumours. Pairwise comparisons using Least 
Significant Difference (LSD) tests showed that the high-grade glioma group 
performed significantly worse than the low-grade glioma group (p = 0.040). 


































Figure 8.1. Baseline inspection time scores for each histological tumour type group. Bars are 
estimated marginal mean scores adjusted for age and NART score. Error bars: Standard 
error means.
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8.2.2 Inspection Time Scores: Valid Inspection Time Data
The previous analysis was repeated including only ‘valid’ inspection time scores (i.e. 
data from patients who scored ≥ 17/20 on the longest two durations on the task; see 
Chapter 2.2). This resulted in data from 23 low-grade glioma patients, 37 high-grade 
glioma patients, 12 patients with metastatic tumours, 13 patients with a meningioma 
and 9 patients with tumours classified as ‘other’, being included in the analysis. 
All low-grade glioma patients had valid inspection time date at baseline, thus the 
mean score for this group remained 126.1 (SD 11.5). The high-grade glioma group 
had a mean score of 118.5 (SD 14.2) when only valid inspection time data was 
analysed. The corresponding mean for the metastasis group was 118.7 (SD 14.7) and, 
for the group of patients with a meningioma, was 114.5 (SD 15.8). The patients with 
a tumour type classified as ‘other’ had a mean score of 123.1 (SD 8.0) in this 
instance.
The covariate ‘age’ again had a significant main effect in the model, F(1,82) = 
15.627, p < 0.001, partial η² = 0.160. Older patients had lower inspection time scores 
than younger patients. The covariate NART was not significant on this occasion, 
F(1,82) = 1.821, p =0.181, partial η² = 0.022. Sex had a significant effect in this 
model, F(1,82) = 4.157, p = 0.045, partial η² = 0.048. Female patients tended to have 
lower scores than male patients. Again, tumour type had no significant main effect in 
the model that included the effects of the covariates age and NART score, F(4,82) = 
0.683, p = 0.605, partial η² = 0.032.
The estimated marginal mean scores for the valid inspection time score, adjusted for 
age and NART score and shown in Figure 8.2, for each tumour type were 123.7 (SE 
2.7) for the low-grade glioma group; 118.4 (SE 2.0) for the high-grade glioma group; 
122.3 (SE 3.7) for the metastasis group; 121.6 (SE 6.5) for the meningioma group 
and 120.6 (SE 4.3) for the ‘other’ tumour group. Pairwise comparisons using LSD 
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tests found no significant difference between the performance of the low-grade and 
high-grade glioma groups.
Estimated Marginal Mean Scores on Inspection Time (Valid 
































Figure 8.2. Baseline inspection time scores including only valid data for each histological 
tumour type group. Bars are estimated marginal mean scores adjusted for age and NART 
score. Error bars: Standard error means
8.2.3 Rey Auditory Verbal Learning Test
There were 20 patients with low-grade gliomas, 35 with high-grade gliomas, 10 with 
a metastasis, 10 with a meningioma and 10 with ‘other’ tumour types who completed 
the Rey Auditory Verbal Learning Test at baseline. 
The mean score for the low-grade glioma group on this test was 65.5 (SD 16.1) and 
for the high-grade glioma group was 56.3 (SD 19.1). The metastasis group had a 
mean score of 65.3 (SD 17.2) and the meningioma group had a mean score of 66.5 
(SD 13.0). The group of patients with ‘other’ tumour types scored a mean of 65.3 
(SD 18.2). 
There was a significant main effect of the covariates age, F(1,73) = 11.899, p = 
0.001, partial η² = 0.140; and NART score, F(1,73) = 16.141, p < 0.001, partial η² =
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0.181, in the model. Younger patients and patients with lower (better) NART scores 
were more likely to recall more words on this measure. The effect of sex was not 
significant in the model, F(1,73) = 1.409, p = 0.239, partial η²  = 0.019. The effect of 
tumour type on RAVLT scores did not reach the conventional level of statistical 
significance in the model that included the effects of age and NART score, F(4,73) = 
2.259, p = 0.071, partial η² = 0.110.
The estimated marginal mean scores on the RAVLT, adjusted for age and NART 
score and shown in Figure 8.3, for each tumour type were 62.3 (SE 3.8) for the low-
grade glioma group; 57.8 (SE 2.5) for the high-grade glioma group; 61.6 (SE 5.1) for 
the metastasis group; 76.9 (SE 8.1) for the meningioma group and 71.5 (SE 5.2) for 
the ‘other’ tumour group. Pairwise comparisons using LSD tests revealed no 
significant differences between the low-grade and high-grade glioma groups.
Estimated Marginal Mean Scores on Rey Auditory Verbal 



























Figure 8.3. Baseline Rey Auditory Verbal Learning Test scores for each histological tumour 
type group. Bars are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means
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8.2.4 Trail Making Test Part B
Twenty low-grade glioma patients, 41 high-grade glioma patients, 11 metastasis 
patients, 12 meningioma and 10 patients with ‘other’ tumours completed the trail 
making test part B at baseline.  
The mean score for the low-grade glioma group on this test was 83.1 (SD 21.5). The 
high-grade glioma group scored a mean of 100.2 (SD 32.9), the metastasis group 
scored a mean of 91.9 (SD 33.6) and the meningioma group scored a mean of 99.7 
(SD 34.8). The group of patients with ‘other’ tumours scored a mean of 85.2 (SD 
29.0) on the test at baseline. 
There was a significant main effect of both covariates age, F(1,82) = 13.861, p < 
0.001, partial η² = 0.145; and NART score, F(1,82) = 21.141, p < 0.001, partial η² =
0.205, in the model. Older patients and patients who had higher (poorer) NART 
scores took significantly longer to complete the task. The effect of sex was not 
significant, F(1,82) = 0.001, p = 0.970, partial η² < 0.001. Tumour type had no 
significant main effect on trail making test part B score in the model that included the 
effects of age and NART score, F(4,82) = 0.830, p = 0.510, partial η² = 0.039. 
The estimated marginal mean scores on the trail making test part B, adjusted for age 
and NART score and shown in Figure 8.4, were 90.2 (SE 6.5) for the low-grade 
glioma group; 99.1 (SE 4.2) for the high-grade glioma group; 93.8 (SE 8.7) for the 
metastasis group; 105.6 (SE 14.4) for the meningioma group and 85.4 (SE 8.7) for 
the group of patients with ‘other’ tumours. Pairwise comparisons revealed no 
significant difference between the performance of the low-grade and high-grade 
glioma groups.
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Figure 8.4. Baseline trail making test part B scores for each histological tumour type group. 
Bars are estimated marginal mean scores adjusted for age and NART score. Error bars: 
Standard error means.
8.2.5 Verbal Fluency
Eighteen patients with a low-grade glioma, 39 with a high-grade glioma, 11 
metastasis patients, 11 meningioma patients and 10 patients with ‘other’ tumours all 
completed the verbal fluency test at baseline. 
The low-grade glioma group had a mean score of 34.9 (SD 14.9) on this measure. 
The high-grade glioma group had a mean of 23.9 (SD 8.9), the metastasis group had 
a mean of 37.3 (SD015.7), the meningioma group mean score was 26.4 (SD7.0) and 
the ‘other’ tumour group scored a mean of 29.7 (SD 9.1) on verbal fluency at 
baseline. 
The effect of the covariate age was not significant in the model, F(1,77) = 0.767, p = 
0.384, partial η² = 0.010. The covariate NART did have a significant main effect in 
the model, F(1,77) = 22.581, p < 0.001, partial η² = 0.227, with patients who had 
lower (better) NART scores more likely to produce more words on the verbal fluency 
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task. Sex had no significant effect in the model, F(1,77) = 1.663, p = 0.201, partial η² 
= 0.021. The effect of tumour type was significant in the model that included the 
effects of age and NART score, F(4,77) = 5.700, p < 0.001, partial η²  = 0.228. 
The estimated marginal mean verbal fluency scores, adjusted for age and NART 
score and shown in Figure 8.5, for each tumour group at baseline were 35.8 (SE 2.3) 
for the low-grade glioma group; 24.1 (SE 1.5) for the high-grade glioma group; 33.3 
(SE 2.9) for the metastasis group; 30.7 (SE 5.0) for the meningioma group and 30.7 
(SE 3.0) for the group of ‘other’ tumour patients. Since there was a significant main 
effect of tumour type in the model, post-hoc analyses using LSD pairwise 
comparisons were carried out comparing the performance of each of the tumour type 
groups. These showed that the high-grade glioma group performed significantly less 
well than both the low-grade glioma group (p < 0.001) and the metastasis group 
(p = 0.006).






























Figure 8.5. Baseline verbal fluency test scores for each histological tumour type group.
Bars are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
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8.2.6 Digit Symbol Coding
Twenty-two members of the low-grade glioma group completed digit symbol coding 
at baseline. Forty-six high-grade glioma patients, 14 metastasis patients, 17 
meningioma patients and 10 ‘other’ tumour patients also completed the test at 
baseline.  
The mean baseline digit symbol coding scores for each tumour type groups were as 
follows: 65.7 (SD 14.5) for the low-grade glioma patients; 53.8 (SD 23.3) for the 
high-grade glioma patients; 58.5 (SD 21.5) for the metastasis group; 47.7 (SE 23.7) 
for the meningioma patients and 62.1 (SD 25.5) for the ‘other’ tumour group. 
There was a significant main effect of the covariates age, F(1,97) = 32.250, p < 
0.001, partial η² = 0.250; and NART score, F(1,97) = 27.236, p < 0.001, partial η²   = 
0.219, in the model. Older patients were significantly more likely to score lower on 
this test and patients with higher (poorer) NART scores were also more likely to 
perform less well. The effect of sex was not significant, F(1,97) = 0.055, p = 0.816, 
partial η² = 0.001. The effect of tumour type was not significant in the model that 
included the effects of age and NART score, F(4,97) = 0.549, p = 0.700, partial η²   = 
0.022.
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.6, on digit symbol coding at baseline for each tumour type are as follows: 
60.1 (SE 4.3) for the low-grade glioma group; 54.7 (SE 2.6) for the high-grade 
glioma group; 59.8 (SE 5.0) for the metastasis group; 53.8 (SE 9.4) for the 
meningioma group and 60.6 (SE 5.8) for the ‘other’ tumour group. LSD pairwise 
comparisons showed there to be no significant difference between the low-grade and 
high-grade glioma groups on digit symbol coding.
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Figure 8.6. Baseline digit symbol coding test scores for each histological tumour type group. 
Bars are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
8.2.7 Letter-Number Sequencing
Nineteen low-grade glioma patients completed this test at baseline. Thirty-nine high-
grade glioma patients, 9 metastasis patients, 10 meningioma patients and 10 patients 
with ‘other’ tumours also completed the letter-number sequencing test at baseline.
The mean score for the low-grade glioma group was 10.5 (SD 2.8) and for the high-
grade glioma group was 8.6 (SD 3.6). The mean score for the metastasis group was 
9.3 (SD 3.0), for the meningioma group was 10.3 (SD 4.1) and for the ‘other’ tumour 
group was 9.7 (SD 2.7).
The covariate age had a significant main effect in the model, F(1,75) = 12.627, p = 
0.001, partial η² = 0.144. Younger patients were significantly more likely to have 
better scores on this test. The effect of the covariate NART was also significant, 
F(1,75) = 24.071, p < 0.001, partial η² = 0.243. Lower (better) NART scores were 
significantly associated with better letter-number sequencing scores. Sex had no 
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significant main effect in the model, F(1,75) = 0.096, p = 0.758, partial η² = 0.001. 
There was no significant main effect of tumour type in the model that included the 
effects of age and NART score, F(4,75) = 0.842, p = 0.503, partial η² = 0.043. 
The estimated marginal mean scores for each group, adjusted for age and NART 
score and shown in Figure 8.7, on the letter-number sequencing test at baseline were 
as follows: 9.9 (SE 0.7) for the low-grade glioma group; 8.8 (SE 0.5) for the high-
grade glioma group; 8.3 (SE 1.1) for the metastasis group; 10.8 (SE 1.6) for the 
meningioma group; and 10.1 (SE 0.9) for the ‘other’ tumour group. Pairwise 
comparisons of the low-grade and high-grade glioma groups using LSD tests 
revealed no significant difference between the performance of the two groups. 
Estimated Marginal Mean Scores on Letter-Number 

























Figure 8.7. Baseline letter-number sequencing test scores for each histological tumour type 
group. Bars are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
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8.2.8 Williams Delayed Recall Test (EFIT)
Twenty-two patients with a low-grade glioma and 49 with a high-grade glioma 
completed this test at baseline. A further 14 patients with a metastasis, 17 with a 
meningioma and 11 with ‘other’ tumour types also completed the Williams Delayed 
Recall Test at baseline. 
The mean score for the low-grade glioma group was 7.6 (SD4.4), for the high-grade 
glioma group was 8.9 (SD 4.9) and for the metastasis group was 8.1 (SD 5.6). The 
meningioma group had a mean score of 7.4 (SD 6.4) and the ‘other’ tumour group 
mean score was 7.9 (SD 4.3). 
There was a significant main effect of both of the covariates age, F(1,101) = 11.163, 
p = 0.001, partial η² = 0.100; and NART score, F(1,101) = 4.584, p = 0.035, partial 
η² = 0.043, in the model. Older age and higher (poorer) NART scores were 
significantly associated with higher (poorer) scores on this test. Sex had no 
significant effect in the model, F(1,101) = 1.172, p = 0.281, partial η² = 0.011. 
Tumour type had no significant main effect in the model that included the effects of 
age and NART score, F(4,101) = 0.253, p = 0.907, partial η² = 0.010.
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.8, for each tumour type group on the Williams Delayed Recall Test at 
baseline, were 8.5 (SE 1.2) for the low-grade glioma group; 8.7 (SE 0.7) for the high-
grade glioma group; 7.7 (SE 1.3) for the metastasis group; 7.2 (SE 2.6) for the 
meningioma group and 7.7 (SE 1.5) for the ‘other’ tumour group. LSD pairwise 
comparisons of the low-grade and high-grade glioma groups revealed no significant 
difference in the performance of the two groups on the Williams Delayed Recall 
Test.
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Estimated Marginal Mean Scores on Williams Delayed Recall 


























Figure 8.8. Baseline Williams Delayed Recall Test scores for each histological tumour type 
group. Bars are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
8.2.9 Nine Hole Peg Test (Right Hand, EFIT)
Twenty-two low-grade glioma patients, 49 high-grade glioma patients, 14 metastasis 
patients, 17 meningioma patients and 11 ‘other’ tumour patients completed this 
measure at baseline.
The mean score for the low-grade group was 12.8 (SD 2.0) and for the high-grade 
group was 15.3 (SD 5.6). The metastasis group scored a mean of 13.5 (SD 2.2), the 
meningioma group scored a mean of 15.8 (SD 4.8) and the ‘other’ tumour group 
mean was 15.4 (SD 4.0). 
There was a significant main effect of the covariate age in the model, F(1,101) = 
8.191, p = 0.005, partial η² = 0.075. Younger patients tended to perform faster on this 
test. The covariate NART also had a significant main effect, F(1,101) = 10.372, p = 
0.002, partial η² = 0.093. Patients with lower (better) NART scores also tended to 
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perform more quickly. Sex had no significant main effect in the model, F(1,101) = 
0.497, p = 0.483, partial η² = 0.005. The effect of tumour type was not significant in 
the model that included the effects of age and NART score, F(4,101) = 0.992, p = 
0.416, partial η² = 0.038. 
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.9, for each of the tumour group on the right-hand nine hole peg test were 
13.4 (SE 1.0) for the low-grade glioma group; 15.1 (SE 0.6) for the high-grade 
glioma group; 13.5 (SE 1.2) for the metastasis group; 15.4 (SE 2.2) for the 
meningioma group and 15.6 (SE 1.3) for the ‘other’ tumour group. Pairwise 
comparisons using LSD tests showed no significant difference between the low-
grade and high-grade glioma groups.
Estimated Marginal Mean Scores on Nine Hole Peg Test (Right 

























Figure 8.9. Baseline right hand nine hole peg test scores for each histological tumour type 
group. Bars are estimated marginal mean scores adjusted for age and NART score.
Error bars: Standard error means.
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8.2.10 Nine Hole Peg Test (Left Hand, EFIT)
Twenty-two low-grade glioma patients, 46 high-grade glioma patients, 14 metastasis 
patients, 17 meningioma patients and 11 patients with ‘other’ tumours all completed 
this test at baseline. 
The mean score for the low-grade glioma group was 13.3 (SD 1.9) and for the high-
grade glioma group was 15.5 (SD 3.4). The metastasis group had a mean score of 
15.4 (SD 4.1), the meningioma group had a mean of 17.5 (SD 4.0) and the ‘other’ 
tumour group had a mean score of 15.4 (SD 3.1). 
There was a significant main effect of the covariate age in the model, F(1,98) = 
9.759, p = 0.002, partial η² = 0.091. Older patients were significantly more likely to 
take longer to complete the test. The effect of the covariate NART was not 
significant, F(1,98) = 1.585, p = 0.211, partial η² = 0.016. Sex had no significant 
main effect in the model, F(1,98) = 1.227, p = 0.271, partial η² = 0.012. The effect of 
tumour type was not significant in the model that included the effects of age and 
NART score, F(4,98) = 1.416, p = 0.234, partial η² = 0.055. 
The estimated marginal mean scores for the nine hole peg test (left hand), adjusted 
for age and NART score and shown in Figure 8.10, for each tumour group, were 13.7 
(SE 0.8) for the low-grade glioma group; 15.3 (SE 0.5) for the high-grade glioma 
group; 15.2 (SE 0.9) for the metastasis group; 16.8 (SE 1.7) for the meningioma 
group and 15.9 (SE 1.0) for the ‘other’ tumour group. Pairwise comparisons using 
LSD tests revealed no significant difference between the low-grade and high-grade 
glioma groups.
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Estimated Marginal Mean Scores on Nine Hole Peg Test (Left 


























Figure 8.10. Baseline left hand nine hole peg test scores for each histological tumour type 
group. Bars are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
8.2.11 Timed Ten Metre Walk (EFIT)
There were 21 low-grade glioma patients, 44 high-grade glioma patients, 12 
metastasis patients, 12 meningioma patients and 11 patients with ‘other’ tumours 
who completed the timed ten metre walk at baseline. 
The mean score for the low-grade glioma group was 6.1 (SD 1.0) and for the high-
grade glioma group was 6.8 (SD 1.4). The metastasis group had a mean score of 8.2 
(SD 2.8), the meningioma group scored a mean of 7.9 (SD 1.6) and the ‘other’ 
tumour group scored a mean of 6.8 (SD 2.4).
There was a significant main effect in the model of both covariates age, F(1,88) = 
5.514, p = 0.021, partial η² = 0.059; and NART score, F(1,88) = 4.689, p = 0.033, 
partial η² = 0.051. Older patients and those patients with higher (poorer) NART 
scores were significantly more likely to take longer to complete the test. The effect of 
sex was not significant, F(1,88) = 0.449, p = 0.505, partial η² = 0.005. The effect of 
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tumour type was not significant in the model that included the effects of the 
covariates, F(4,88) = 2.066, p = 0.092, partial η² = 0.086. 
The estimated marginal mean scores on the timed ten metre walk, adjusted for age 
and NART score and shown in Figure 8.11, for each tumour group, were as follows: 
6.4 (SE 0.4) for the low-grade glioma group; 6.7 (SE 0.3) for the high-grade glioma 
group; 8.1 (SE 0.5) for the metastasis group; 7.2 (SE 0.9) for the meningioma group 
and 6.8 (SE 0.5) for the ‘other’ tumour group. Pairwise comparisons using LSD test 
showed no significant difference between the performance of the low-grade and 
high-grade glioma groups.




























Figure 8.11. Baseline timed ten metre walk test scores for each histological tumour type 
group. Bars are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
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8.2.12 Hospital Anxiety and Depression Scale 
There were 23 low-grade glioma patients, 49 high-grade glioma patients, 14 
metastasis patients, 16 meningioma patients and 11 patients with ‘other’ tumours 
who completed the Hospital Anxiety and Depression Scale. 
8.2.12.1 Anxiety Scores
The mean anxiety scores from the scale for each tumour type group were as follows: 
6.5 (SD 3.6) for the low-grade glioma group; 7.9 (SD 4.4) for the high-grade glioma 
group; 8.9 (SD 4.5) for the metastasis group; 9.3 (SD 4.3) for the meningioma group 
and 9.4 (SD 5.2) for the ‘other’ tumour group.
There was no significant main effect in the model of either of the covariates age, 
F(1,101) = 0.360, p = 0.550, partial η² = 0.004; or NART score, F(1,101) = 0.339, p 
= 0.562, partial η² = 0.003. The effect of sex was also not significant, F(1,101) = 
0.209, p = 0.648, partial η² = 0.002. The effect of tumour type was not significant in 
the model that included the effects of age and NART score, F(4,101) = 1.174, p = 
0.327, partial η² = 0.044. 
The estimated marginal mean anxiety scores, adjusted for age and NART score and 
shown in Figure 8.12, were 6.2 (SE 1.0) for the low-grade glioma group, 7.9 (SE 0.6) 
for the high-grade glioma group, 9.0 (SE 1.2) for the metastasis group, 8.7 (SE 2.4) 
for the meningioma group and 9.2 (SD 1.4) for the ‘other’ tumour group. LSD tests 
showed no significant difference in anxiety levels reported by the low-grade and 
high-grade glioma groups.
220
Estimated Marginal Mean Anxiety Scores on the Hospital 


























Figure 8.12. Baseline anxiety scores on the Hospital Anxiety and Depression Scale for each 
histological tumour type group. Bars are estimated marginal mean scores adjusted for age 
and NART score. Error bars: Standard error means.
8.2.12.2 Depression Scores 
The mean depression scores on the Hospital Anxiety and Depression Scale were 3.5 
(SD 3.8) for the low-grade glioma patients, 4.5 (SD 4.3) for the high-grade glioma 
patients, 5.0 (SD 2.9) for the metastasis group, 5.9 (SD 4.5) for the meningioma 
group and 5.8 (SD 4.0) for the ‘other’ tumour group. 
There was no significant main effect in the model of either of the covariates age, 
F(1,101) = 0.705, p = 0.403, partial η² = 0.007; or NART score, F(1,101) = 1.962, p 
= 0.164, partial η² = 0.019. The effect of sex was not significant in the model, 
F(1,101) = 2.586, p = 0.111, partial η² = 0.0.25. The effect of tumour type was not 
significant in the model that included the effects of age and NART score, F(4,101) = 
1.064, p = 0.378, partial η² = 0.040. 
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.13, on the depression scale of the Hospital Anxiety and Depression Scale, 
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were as follows: 3.2 (SE 0.9) for the low-grade glioma patients; 4.6 (SE 0.6) for the 
high-grade glioma patients; 5.4 (SE 1.1) for the metastasis patients; 2.4 (SE 2.2) for 
the meningioma patients and 5.5 (SE 1.3) for the ‘other’ tumour patients. Pairwise 
comparisons using LSD tests revealed no significant differences between the levels 
of depression reported by the low-grade and high-grade glioma groups, as measured 
by the Hospital Anxiety and Depression Scale. 
Estimated Marginal Mean Depression Scores on the Hospital 


























Figure 8.13. Baseline depression scores on the Hospital Anxiety and Depression Scale for 
each histological tumour type group. Bars are estimated marginal mean scores adjusted for 
age and NART score. Error bars: Standard error means.
8.2.12.3 Hospital Anxiety and Depression Scale – Total Score
The mean total score on the Hospital Anxiety and Depression Scale for the low-grade 
glioma group was 10.0 (SD 6.6), for the high-grade glioma group was 12.4 (SD 7.9), 
for the metastasis group was 13.9 (SD 6.3), for the meningioma group was 15.3 (SD 
8.2) and for the ‘other’ tumour group was 15.2 (SD 7.6). 
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The covariate age had no significant main effect in the model, F(1,101) = 0.645, p = 
0.424, partial η² = 0.006; nor did the covariate NART score, F(1,101) = 1.197, p = 
0.277, partial η² = 0.012. Sex had no significant effect in the model, F(1,101) = 
1.281, p = 0.260, partial η² = 0.013. The effect of tumour type was not significant tin 
the model that included the effects of age and NART score, F(1,101) = 1.270, p = 
0.287, partial η² = 0.048.
The estimated marginal mean total scores, adjusted for age and NART score and 
shown in Figure 8.14, were 9.4 (SE 1.7) for the low-grade glioma group, 12.5 (SE 
1.1) for the high-grade glioma group, 14.4 (SE 2.1) for the metastasis group, 11.1 
(SE 4.0) for the meningioma group and 14.7 (SE 2.4) for the ‘other’ tumour group. 
LSD pairwise comparisons revealed no significant difference between the low-grade 
and high-grade glioma groups. 
Estimated Marginal Mean Total Scores on the Hospital Anxiety 

























Figure 8.14. Baseline total scores on the Hospital Anxiety and Depression scales for each 
histological tumour type group. Bars are estimated marginal mean scores adjusted for age 
and NART score. Error bars: Standard error means
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Table 8.1. Comparison of histological groups on cognitive and mood scales at baseline.
Test Effect of tumour type
F Sig. (p) n²*
Inspection Time (All Data) 1.280 0.283 0.050
Inspection Time (Valid Data) 0.683 0.605 0.032
Rey Auditory Verbal Learning Test  (Total) 2.259 0.071 0.110
Trail Making Test Part B (secs) 0.830 0.510 0.039
Verbal Fluency (Total) 5.700 < 0.001 0.228
Digit Symbol Coding (Total) 0.549 0.700 0.022
Letter-Number Sequencing (Total) 0.842 0.503 0.043
EFIT Williams Delayed Recall Test (total) 0.253 0.907 0.010
EFIT Nine Hole Peg Test (Right Hand, secs) 0.992 0.416 0.038
EFIT Nine Hole Peg Test (Left Hand, secs) 1.416 0.234 0.055
EFIT Timed Ten Metre Walk (secs) 2.066 0.092 0.086
Hospital Anxiety and Depression Scale –Anxiety Score 1.174 0.327 0.044
Hospital Anxiety and Depression Scale – Depression Score 1.064 0.378 0.040
Hospital Anxiety and Depression Scale – Total Score 1.270 0.287 0.048
*n² = the proportion of variance accounted for by tumour type. HGG = high-grade glioma; LGG = low-grade glioma
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8.3 Tumour Location – Lobe
The brain tumour cohort were classified into the following seven main subtypes, 









Of the total cohort of brain tumour patients (n = 118), 34 patients had a tumour 
located in the frontal lobes, 16 had a temporal lobe tumour, 8 had a tumour located 
within the limbic system, 19 had a parietal tumour, 5 had an occipital tumour and 23 
had tumour that invaded more than one lobe (‘multiple lobes’). The remaining 13 
had a tumour located in a different region in the brain (‘other’) and this included 
those patients with a pituitary tumour.
8.3.1 Inspection Time Scores: All Inspection Time Data
When all inspection time data was analysed, the group of patients with a frontal 
tumour scored a mean of 118.2 (SD 20.3). The temporal tumour group scored a mean 
of 122.0 (SD 11.9) and the limbic group had a mean score of 120.7 (SD10.8) at 
baseline. The patients with a parietal tumour scored 109.9 (SD 18.7) and the patients 
with an occipital lobe tumour scored a mean of 82.4 (SD 24.0). The ‘multiple lobe’ 
tumour group had a mean score of 109.9 (SD 21.2) and the patients with tumour 
located elsewhere (‘other’) scored 116.7 (SD 16.4) on the inspection time measure at 
baseline testing.
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In this model, there was a significant main effect of the covariates age, F(1,96) =  
39.264, p < 0.001, partial η² = 0.290; and NART score, F(1,96) = 8.645, p = 0.004, 
partial η² = 0.083, were significant. Older patients and those with higher (poorer) 
NART scores had significantly lower inspection time scores. The effect of sex was 
not significant, F(1,96) = 0.690, p = 0.408, partial η² = 0.007. Tumour lobe had a 
significant effect on baseline inspection time scores, in the model that included the 
effects of age and NART score, F(6,96) = 3.732, p = 0.002, partial η² = 0.189.
The estimated marginal mean inspection time scores, adjusted for age and NART 
score and shown in Figure 8.15, for each tumour lobe group were118.1 (SE 2.6) for 
the frontal lobe group; 121.0 (SE 4.0) for the temporal lobe group; 112.1 (SE 6.0) for 
the limbic group; 113.3 (SE 3.7) for the parietal group; 87.7 (SE 7.1) for the occipital 
group; 109.5 (SE 3.5) for the group with more than one lobe affected and 119.4 (SE 
4.3) for the group with tumours located elsewhere (‘other’). Pairwise comparisons 
using LSD tests revealed that the occipital lobe tumour group performed significantly 
worse than each of the other tumour lobe groups (p < 0.001 for the frontal group; p = 
0.001 for the temporal lobe group; p = 0.011 for the limbic group; p = 0.002 for the 
parietal group; p = 0.007 for the multiple lobe group and p < 0.001 for the ‘other’ 
group). The frontal lobe group showed a tendency towards better performance by 
comparison with the multiple lobes tumour group but this difference did not reach 
the conventional level of statistical significance (p = 0.054). 
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Figure 8.15. Baseline inspection time scores for each tumour lobe group. Bars are estimated 
marginal mean scores adjusted for age and NART score. Error bars: Standard error means.
8.3.2 Inspection Time Scores: Valid Inspection Time Data
When only ‘valid’ inspection time scores were entered into the model, this resulted 
in the 29 patients in the frontal tumour group, 15 in the temporal lobe group, 7 in the 
limbic group, 16 in the parietal group, 1 in the occipital group, 16 in the multiple 
lobes group and 12 patients with tumours located in ‘other’ areas.  
The mean baseline inspection time score for the frontal tumour group who met 
validity criteria was 124.7 (SD 12.5). The temporal group had a mean of 122.0 (SD 
11.9) and the limbic group had a mean of 120.7 (SD 10.8). The parietal group had a 
mean score of 113.7 (SD 15.8), the single patient with valid data in the occipital 
group had a score of 100.0 (SD.0.0) and the multiple lobe group had a mean of 118.5 
(SD 12.7). The group of patients with tumours located elsewhere (‘other’) also had a 
mean score of 118.5 (SD 15.8).
227
The covariate age had a significant main effect in this model, F(1,81) = 21.829, p < 
0.001, partial η² = 0.212. Older patients were more likely to have poorer inspection 
time scores. Sex also had a significant effect on valid baseline inspection time scores, 
F(1,81) = 5.180, p = 0.025, partial η² = 0.060. Female patients were significantly 
more likely to have poorer inspection time scores than male participants. NART had 
no significant effect in the model, F(1,81) = 2.842, p = 0.096, partial η² = 0.034. 
Tumour lobe also had no significant overall effect in the model that included the 
effects of age and NART score, F(6,81) = 1.268, p = 0.281, partial η² = 0.086. 
The estimated marginal mean valid inspection time scores, adjusted for age and 
NART score and shown in Figure 8.16, for each tumour lobe group were 124.3 (SE 
2.1) for the frontal lobe tumour group; 122.1 (SE 3.0) for the temporal lobe group; 
116.4 (SE 4.5) for the limbic group, 116.0 (SE 3.0) for the parietal group; 112.6 (SE 
11.8) for the occipital group; 117.6 (SE 3.0) for the group with multiple lobe 
involvement and 120.5 (SE 3.4) for the ‘other’ lobe group. 























Figure 8.16. Baseline inspection time scores including only valid scores for each tumour lobe 
group. Bars are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
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8.3.3 Rey Auditory Verbal Learning Test
Twenty-five frontal lobe tumour patients completed this test at baseline. There were 
13 patients in the temporal lobe group, 5 in the limbic group, 12 parietal lobe 
patients, 4 occipital lobe patients, 17 ‘multiple lobe’ tumour patients and 11 patients 
in the ‘other’ location group who also completed the Rey Auditory Verbal Learning 
Test at baseline. 
The mean score for the frontal lobe group on this measure at baseline was 64.5 (SD 
17.7) and for the temporal lobe group was 57.9 (SD 19.8). The limbic group mean 
score was 53.0 (SD 14.0), the parietal lobe group had a mean score of 64.6 (SD 
21.3), the occipital lobe group had a mean score of 46.3 and the multiple lobe tumour 
group had a mean of 59.5 (SD 14.9). The group of patients with tumours located in 
‘other’ areas scored a mean of 69.5 (SD 14.0).
There was a significant main effect of the covariate age on test scores in this model, 
F(1,71) = 25.646, p < 0.001, partial η² = 0.265. Younger patients were significantly 
more likely to have higher (better) scores. The covariate NART also had a significant 
main effect in the model, F(1,71) = 19.447, p < 0.001, partial η² = 0.215. Better 
NART scores were significantly associated with better RAVLT scores. The effect of 
sex did not reach the conventional level of statistical significance, F(1,71) = 3.418, p 
= 0.069, partial η² = 0.046. The effect of tumour location (lobe) was significant in the 
model that included the effects of age and NART score, F(6,71) = 2.268, p = 0.046, 
partial η² = 0.161.
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.17, for each tumour lobe group on the Rey Auditory Verbal Learning Test, 
were as follows: 62.2 (SE 2.9) for the frontal lobe group; 56.9 (SE 4.0) for the 
temporal lobe group; 47.6 (SE 8.0) for the limbic group; 62.8 (SE 4.4) for the parietal 
lobe group; 49.6 (SE 7.2) for the occipital lobe group; 61.4 (SE 3.5) for the multiple 
lobe group and 72.5 (SE 4.3) for the group of patients with tumours in ‘other’ brain 
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areas. Pairwise comparisons using LSD tests revealed that the ‘other’ tumour 
location group performed significantly better than the temporal lobe group (p = 
0.010); the limbic group (p = 0.008); the occipital lobe group (p = 0.008) and the 
multiple lobe group (p = 0.050). The ‘other’ location group showed a tendency 
towards better performance than the frontal lobe group (p = 0.055). There were no 
other significant differences between the tumour lobe subgroups.
Estimated Marginal Mean Rey Auditory Verbal Learning Test 



























Figure 8.17. Baseline Rey Auditory Verbal Learning Test scores for each tumour lobe group. 
Bars are estimated marginal mean scores adjusted for age and NART score.
Error bars: Standard error means.
8.3.4 Trail Making Test Part B
Thirty patients with frontal tumours and 16 with temporal tumours completed the 
trail making test part B at baseline. Five patients in the limbic group, 12 in the 
parietal group, 3 with occipital tumours, 19 with tumours in ‘multiple lobes’ and 11 
with tumours located elsewhere (‘other’) also completed the test.
The frontal tumour group scored a mean of 96.4 (SD 32.0) and the temporal lobe 
group had a mean score of 90.4 (SD 29.4). The limbic group had a mean of 99.0 (SD 
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20.1), the parietal group scored a mean of 103.2 (SD 39.1) and the mean score for the 
occipital lobe group was 105.9 (SD 67.4). The group of patients with a tumour 
invading multiple lobes scored a mean of 89.4 (SD 30.5) on the trail making test part 
B and the ‘other’ tumour location group had a mean score of 92.4 (SD 24.7).
There was a significant main effect of age in the model, F(1,80) = 18.995, p < 0.001, 
partial η² = 0.192. Older patients were more likely to take longer to complete the test. 
The covariate NART score also had a significant main effect in the model, F(1,80) = 
19.715, p < 0.001, partial η² = 0.198. Those participants with higher (poorer) NART 
scores were significantly more likely to take longer to complete the trail making test 
part B. The effect of sex was not significant in the model, F(1,80) = 3.305, p = 0.073, 
partial η² = 0.040. Tumour lobe had no significant effect on test scores in the model 
that included the effects of the covariates, F(6,80) = 0.846, p = 0.538, partial η² = 
0.060.
The estimated marginal mean scores for each tumour lobe group on the trail making 
test part B, adjusted for age and NART score and shown in Figure 8.18, were as 
follows: 97.3 (SE 5.0) for the frontal lobe group; 89.0 (SE 6.8) for the temporal lobe 
group; 107.7 (SE 12.5) for the limbic group; 101.1 (SE 7.9) for the parietal group; 
111.5 (SE 16.7) for the occipital group; 90.2 (SE 6.3) for the multiple lobe group and
87.1 (SE 8.3) for the ‘other’ location group. 
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Figure 8.18. Baseline trail making test part b scores for each tumour lobe group. Bars are 
estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
8.3.5 Verbal Fluency
Twenty-eight patients in the frontal lobe group, 13 in the temporal lobe group, 7 with 
limbic tumours, 12 with parietal tumours, 4 with occipital lobe tumours, 18 with 
tumours in more than one lobe (‘multiple lobes’) and 9 with tumours elsewhere in 
the brain (‘other’) all completed the verbal fluency measure at baseline. 
The mean score on the verbal fluency test for the frontal lobe group was 28.5 (SD 
11.1) and for the temporal lobe group was 28.0 (SD 9.6). The limbic group had a 
mean score of 26.7 (SD 6.2), the parietal lobe group scored a mean of 34.5 (SD 
18.4), the occipital lobe group mean was 28.8 (SD 5.1), the multiple lobe group 
scored a mean of 25.7 (SD 13.7) and the mean score for the ‘other’ location group 
was 29.9 (SD 9.9).
The covariate age had a significant main effect in the model, F(1,75) = 10.782, p = 
0.002, partial η² = 0.126. Older participants tended to produce more words on the 
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verbal fluency measure. There was a significant main effect of the covariate NART 
score in the model, F(1,75) = 36.864, p < 0.001, partial η² = 0.330. Participants with 
higher (poorer) NART scores tended to perform less well on the verbal fluency 
measure. The effect of sex was not significant in the model, F(1,75) = 0.430, p = 
0.514, partial η² = 0.006. Tumour lobe had no significant effect on test scores in the 
model that included the effects of the covariates, F(6,75) = 1.124, p = 0.357, partial 
η² = 0.083. 
The estimated marginal mean verbal fluency scores, adjusted for age and NART 
score and shown in Figure 8.19, for each tumour lobe group were 27.4 (SE 1.9) for 
the frontal lobe group, 28.3 (SE 2.8) for the temporal lobe group, 23.4 (SE 3.8) for 
the limbic group, 34.1 (SE 3.3) for the parietal group, 29.7 (SE 5.0) for the occipital 
lobe group, 27.4 (SE 2.4) for the multiple lobes group and 32.6 (SE 3.3) for the 
‘other’ location group. 
























Figure 8.19. Baseline verbal fluency test scores for each tumour lobe group. Bars are 
estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
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8.3.6 Digit Symbol Coding
Thirty-four patients with frontal lobe tumours, 16 with temporal lobe tumours, 6 with 
limbic tumours, 17 with parietal lobe tumours, 4 with occipital lobe tumours, 21 with 
tumours in more than one lobe (‘multiple lobes’) and 13 with tumours located 
elsewhere within the brain (‘other’) all completed the digit symbol coding measure at 
baseline testing. 
The mean score for the frontal lobe group was 59.3 (SD 20.7), for the temporal group 
was 65.2 (SD 20.8) and for the limbic group was 61.2 (SD 16.7). The parietal lobe 
group had a mean score of 47.5 (SD 19.8), the occipital lobe group mean was 37.5 
(SD 24.8), the multiple lobe group mean score was 52.8 (SD 25.7) and the ‘other’ 
location group mean score was 58.6 (SD 22.5).
There was a significant main effect of the covariate age in the model, F(1,95) = 
42.733, p < 0.001, partial η² = 0.310. Older participants were more likely to have 
lower (poorer) scores on the digit symbol coding measure. The covariate NART 
score also had a significant main effect in the model, F(1,95) = 35.077, p < 0.001, 
partial η² = 0.270. Those participants with higher (poorer) NART scores were more 
likely to have lower (poorer) digit symbol coding scores. Sex had no significant 
effect in the model, F(1,95) = 0.014, p = 0.906, partial η² < 0.001. The effect of 
tumour lobe approached the conventional level of statistical significance in the model 
that included the effects of the covariates age and NART score, F(6,95) = 2.180, p = 
0.052, partial η² = 0.121. 
The estimated marginal mean scores on the digit symbol coding test at baseline for 
each tumour lobe, adjusted for age and NART score and shown in Figure 8.20, were 
as follows: 58.3 (SE 2.9) for the frontal lobe group; 65.2 (SE 4.3) for the temporal 
lobe group; 50.2 (SE 7.1) for the limbic group; 47.5 (SE 4.2) for the parietal lobe 
group; 47.2 (SE 8.6) for the occipital lobe group; 53.3 (SE 3.7) for the multiple lobes 
group and 62.2 (SE 4.8) for the group of patients with tumours in ‘other’ areas of the 
brain. Since the main effect of tumour lobe approached the conventional level of 
significance, post-hoc analyses were carried out in this instance. Pairwise 
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comparisons, using LSD tests revealed that the frontal lobe group performed 
significantly better than the parietal lobe group (p = 0.037). The temporal lobe group 
and ‘other’ location group also performed significantly better than the parietal lobe 
group (p = 0.004 and p = 0.023, respectively). The temporal lobe group also 
performed significantly better than the multiple lobe group (p = 0.039) and showed a 
tendency towards better performance than the occipital lobe group (p = 0.065).The 
parietal lobe group performed significantly worse than the ‘other’ location group 
(p = 0.023).


























Figure 8.20. Baseline digit symbol coding test scores for each tumour lobe group. Bars are 
estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
8.3.7 Letter-Number Sequencing
Twenty-seven members of the frontal lobe group, 12 in the temporal group, 6 with 
limbic tumours and 13 with parietal lobe tumours completed letter-number 
sequencing at baseline. Four patients with occipital lobe tumours, 18 with multiple 
lobe tumours, and 9 with tumours elsewhere (‘other’) also completed the test.
235
The mean score for the frontal lobe group was 10.2 (SE 3.2) and for the temporal 
lobe group was 10.2 (SE 2.8). The limbic group had a mean score of 8.7 (SE 3.4), the 
parietal lobe group mean was 10.0 (SE 3.6), the occipital lobe group scored a mean 
of 5.0 (SE 3.4), the multiple lobes group mean was 7.6 (SE 3.0) and the ‘other’ 
location group mean was 11.3 (SE 2.3). 
There was a significant main effect of the covariate age on test scores in the model, 
F(1,73) = 24.128, p < 0.001, partial η² = 0.248. Older patients tended to perform less 
well on the letter-number sequencing test at baseline. There was also a significant 
main effect of the covariate NART score in the model, F(1,73) = 31.643, p < 0.001, 
partial η² = 0.302. Patients with lower (better) NART scores tended to have higher 
(better) scores on the test. There was no significant effect of sex in the model, 
F(1,73) = 0.035, p = 0.852, partial η² < 0.001. The effect of tumour lobe was 
significant in the model that included the effects of age and NART score, F(6,73) = 
5.166, p = 0.001, partial η² = 0.298. 
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.21, for each tumour location group on the letter-number sequencing test at 
baseline were as follows: 9.8 (SE 0.5) for the frontal lobe group; 10.2 (SE 0.7) for 
the temporal lobe group; 7.8 (SE 1.1) for the limbic group; 9.6 (SE 0.7) for the 
parietal lobe group; 5.6 (SE 1.2) for the occipital lobe group; 8.0 (SE 0.6) for the 
multiple lobes group and 12.2 (SE 0.8) for the group of patients with tumours located 
elsewhere in the brain (‘other’). Pairwise comparisons, using LSD tests revealed that 
the ‘other’ location group performed significantly better than the frontal lobe group 
(p = 0.018); limbic group (p = 0.002); parietal lobe group (p = 0.021); occipital lobe 
group (p < 0.001) and the multiple lobe group (p < 0.001). The ‘other’ location group 
also showed a tendency towards better performance than the temporal lobe group, 
but this difference did not reach the conventional level of statistical significance (p = 
0.067). The occipital lobe group performed significantly worse than the frontal lobe 
group (p = 0.002), temporal lobe group (p = 0.002) and parietal lobe group (p = 
0.005). The frontal and temporal lobe groups also performed significantly better than 
the multiple lobe group (p = 0.018 and p = 0.022, respectively).
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Estimated Marginal Mean Letter-Number Sequencing Scores 
























Figure 8.21. Baseline letter-number sequencing test scores for each tumour lobe group. Bars 
are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
8.3.8 Williams Delayed Recall Test (EFIT)
Thirty-four patients with frontal lobes tumours, 16 with temporal lobe tumours, 8 
with limbic tumours, 17 with parietal tumours, 5 with occipital lobe tumours, 22 with 
tumours in multiple lobes and 13 with tumours located in ‘other’ brain areas 
completed this subtest from the Edinburgh Functional Impairment Tests. 
The mean score for the frontal lobe group was 8.3 (SD 6.0) and for the temporal lobe 
group was 7.3 (SD 3.1). The limbic group scored a mean of 8.8 (SD 2.9), the parietal 
lobe group mean was 8.1 (SD 4.7), the occipital lobe group mean score was 14.6 (SD 
6.3), the multiple lobes group had a mean score of 8.1 (SD 5.5) and the ‘other’ 
location group had a mean score of 6.5 (SD 3.6). 
There was a significant main effect of the covariate age in the model, F(1,99) = 
13.246, p < 0.001, partial η² = 0.118. Older participants were more likely to have 
higher (poorer) scores on this test. The covariate NART score also had a significant 
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main effect in the model, F(1,99) = 5.336, p = 0.023, partial η² = 0.051. Participants 
with lower (better) NART scores were significantly more likely to have lower 
(better) scores on this subtest. There was no significant effect of sex in the model, 
F(1,99) = 2.532, p = 0.115, partial η² = 0.025. The effect of tumour lobe was not 
significant in the model that included the effects of the covariates age and NART 
score, F(6,99) = 1.740, p = 0.120, partial η² = 0.095. 
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.22, for each tumour lobe group in the Williams delayed recall test, were 8.4 
(SE 0.8) for the frontal lobe tumour group; 7.3 (SE 1.2) for the temporal lobe group; 
9.8 (SE 1.8) for the limbic group; 8.2 (SE 1.2) for the parietal lobe group; 14.0 (SE 
2.2) for the occipital lobe group; 8.1 (SE 1.0) for the multiple lobe group and 6.3 (SE 
1.3) for those patients with tumours located elsewhere in the brain (‘other’). 
Estimated Marginal Mean Williams Delayed Recall Test Scores 
























Figure 8.22. Baseline Williams Delayed Recall Test scores for each tumour lobe group. Bars 
are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
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8.3.9 Nine Hole Peg Test (Right Hand, EFIT)
Thirty-four patients in the frontal lobe tumour group, 16 temporal lobe tumour 
patients, 8 patients with limbic tumours, 17 with parietal tumours, 5 patients with 
occipital lobe tumours, 22 with tumours in multiple lobes and 13 with tumours in 
‘other’ locations in the brain all completed this subtest.
The frontal lobe group had a mean score of 13.7 (SD 2.5) on the test, the temporal 
lobe group had a mean score of 13.4 (SD 2.3) and the limbic group had a mean score 
of 14.5 (SD 2.8). The mean for the parietal lobe group was 18.5 (SD 8.7), for the 
occipital lobe group was 14.8 (SD 4.4) and for the multiple lobe group was 14.2 (SD 
3.4). The ‘other’ location group scored a mean of 15.2 (SE 3.2) on the right hand 
Nine Hole Peg Test. 
There was a significant main effect of age in the model, F(1,99) = 14.891, p < 0.001, 
partial η² = 0.131. Older patients were significantly more likely to take longer to 
complete the subtest than younger patients. There was also a significant main effect 
of the covariate NART score in the model, F(1,99) = 16.020, p < 0.001, partial η² = 
0.139. Participants with lower (better) NART scores were more likely to have lower 
(better) scores on the subtest. There was no significant effect of sex in the model, 
F(1,99) = 0.888, p = 0.348, partial η² = 0.009. The effect of tumour lobe was 
significant in the model that included the effects of age and NART score, F(6,99) = 
3.268, p = 0.006, partial η² = 0.165. 
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.23, for each tumour lobe group on the right hand Nine Hole Peg Test were 
13.4 (SE 0.7) for the frontal lobe group, 13.2 (SE 1.0) for the temporal lobe group, 
15.5 (SE 1.5) for the limbic group, 18.4 (SE 1.0) for the parietal lobe group, 13.8 (SE 
1.8) for the occipital lobe group, 14.0 (SE 0.8) for the multiple lobe group and 14.7 
(SE 1.1) for the ‘other’ location group. Pairwise comparisons using LSD tests 
revealed that the parietal lobe group were significantly slower to complete this test 
than the frontal lobe group (p < 0.001); the temporal lobe group (p < 0.001); the 
occipital lobe group (p = 0.028); the multiple lobe group (p = 0.001) and the ‘other’ 
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location group (p = 0.013). There were no other significant differences between the 
tumour lobe groups. 
Estimated Marginal Mean Nine Hole Peg Test (Right Hand) 























Figure 8.23. Baseline right hand nine hole peg test scores for each tumour lobe group. Bars 
are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
8.3.10 Nine Hole Peg Test (Left Hand, EFIT)
There were 33 patients in the frontal lobe group, 16 in the temporal lobe group, 8 
with limbic tumours, 16 in the parietal lobe group, 5 in the occipital lobe group, 21 
with tumours in multiple lobes and 13 with tumours in ‘other’ brain areas who 
completed this subtest.
The mean score for the frontal lobe tumour group was 15.3 (SD 4.3) and for the 
temporal lobe group was 14.2 (SD 2.3). The mean score for the limbic group was 
14.6 (SD 2.5), for the parietal lobe group was 15.7 (SD 3.2) and for the occipital lobe 
group was 17.7 (SD 2.0). The multiple lobe group scored a mean of 15.5 (SD 3.8) 
and the ‘other’ location group score a mean of 16.3 (SD 3.4). 
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There was a significant main effect of the covariate age on test scores in the model, 
F(1,96) = 18.648, p < 0.001, partial η² = 0.163. Older participants were more likely 
to take longer to complete the subtest. There was no significant main effect of the 
covariate NART score, F(1,96) = 1.889, p = 0.173, partial η² = 0.019. The effect of 
sex was not significant in the model, F(1,96) = 1.324, p = 0.253, partial η² = 0.014. 
The effect of tumour lobe was not significant in the model that included the effects of 
age and NART score, F(6,96) = 0.528, p = 0.786, partial η² = 0.032. 
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.24, for each tumour lobe group on the left hand nine hole peg test were as 
follows: 15.4 (SE 0.6) for the frontal lobe group; 14.2 (SE 0.8) for the temporal lobe 
group; 15.2 (SE 1.2) for the limbic group; 15.7 (SE 0.8) for the parietal group; 16.7 
(SE 1.5) for the occipital group; 15.4 (SE 0.7) for the multiple lobe group and 16.0 
(SE 0.9) for the ‘other’ location group. 
Estimated Marginal Mean Nine Hole Peg Test (Left Hand) 























Figure 8.24. Baseline left hand nine hole peg test scores for each tumour lobe group. Bars 
are estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
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8.3.11 Timed Ten Metre Walk (EFIT)
Thirty-three patients in the frontal lobe tumour group and 15 in the temporal lobe 
group completed this test at baseline. Seven patients in the limbic group, 15 in the 
parietal lobe group, 3 in the occipital lobe group, 17 in the multiple lobe group and 
12 in the ‘other’ location group also completed the subtest.
The frontal lobe group scored a mean of 6.9 (SD 1.4), the temporal lobe group had a 
mean score of 6.1 (SD 0.9) and the limbic group had a mean score of 7.6 (SD 2.9). 
The parietal lobe group had a mean score of 7.4 (SD 1.7), the occipital group mean 
was 6.2 (SD 0.5) and the multiple lobe group mean was 6.8 (SD 1.5). The ‘other’ 
tumour location group had a mean score of 7.9 (SD 2.8) on the timed ten metre walk 
subtest at baseline.
The covariate age had a significant main effect in the model, F(1,86) = 14.032, p < 
0.001, partial η² = 0.140. Older participants were significantly more likely to take 
longer to complete the timed ten metre walk. The effect of the covariate NART did 
not reach the conventional level of statistical significance, F(1,86) = 3.169, p = 
0.079, partial η² = 0.036. Sex had no significant effect in the model, F(1,86) = 0.062, 
p = 0.805, partial η² = 0.001. The effect of tumour lobe was not significant in the 
model that included the effects of the covariates, F(6,86) = 1.879, p = 0.094, partial 
η² = 0.116.
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.25, for each tumour lobe group on the timed ten metre walk subtest were as 
follows: 6.9 (SE 0.3) for the frontal lobe group; 6.1 (SE 0.4) for the temporal lobe 
group; 7.2 (SE 0.6) for the limbic group; 7.3 (SE 0.4) for the parietal lobe group; 5.7 
(SE 0.9) for the occipital lobe group; 6.8 (SE 0.4) for the multiple lobes group and 
7.8 (SE 0.4) for the ‘other’ location group. 
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Figure 8.25. Baseline timed ten metre walk test scores for each tumour lobe group. Bars are 
estimated marginal mean scores adjusted for age and NART score. 
Error bars: Standard error means.
8.3.12 Hospital Anxiety and Depression Scale
There were 33 patients with frontal lobe tumours, 16 with temporal lobe tumours, 8 
with limbic tumours, 18 with parietal lobe tumours, 5 with occipital lobe tumours, 22 
with tumours in multiple lobes and 13 with tumours elsewhere in the brain (‘other’) 
who completed the Hospital Anxiety and Depression Scale at baseline.
8.3.12.1 Anxiety Scores
The frontal lobe group scored a mean anxiety score of 8.7 (SD 5.2) and the temporal 
lobe tumour group scored a mean of 8.2 (SD 5.4). The mean anxiety score for the 
limbic group was 8.0 (SD 4.4), for the parietal lobe group was 7.1 (SD 3.2), for the 
occipital lobe group was 9.6 (SD 3.8), for the multiple lobes group was 7.0 (SD 3.7) 
and for the ‘other’ location group was 8.6 (SD 3.5). 
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There was no significant main effect of the covariate age in the model, F(1,99) = 
0.020, p = 0.889, partial η² < 0.001. The covariate NART score also had no 
significant main effect in the model, F(1,99) = 0.186, p = 0.667, partial η² = 0.002. 
Sex had no significant effect on anxiety scores in the model, F(1,99) =0.225, p = 
0.636, partial η² = 0.002. Tumour lobe had no significant main effect in the model 
that included the effects of the covariates, F(6,99) = 0.807, p = 0.567, partial η² = 
0.047.
The estimated marginal mean scores, adjusted for age and NART score and shown in 
Figure 8.26, for each tumour lobe group on the anxiety measure of the Hospital 
Anxiety and Depression Scale were as follows: 8.7 (SE 0.8) for the frontal lobe 
group; 8.3 (SE 1.1) for the temporal lobe group; 7.4 (SE 1.6) for the limbic group; 
6.9 (SE 1.1) for the parietal lobe group; 10.2 (SE 2.0) for the occipital lobe group; 
7.0 (SE 0.9) for the multiple lobes group and 8.5 (SE 1.2) for the ‘other’ location 
group. 


























Figure 8.26. Baseline anxiety scores on the Hospital Anxiety and Depression Scale for each 
tumour lobe group. Bars are estimated marginal mean scores adjusted for age and NART 
score. Error bars: Standard error means.
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8.3.12.2 Depression Scores
The mean depression score for the frontal lobe group was 5.6 (SD 4.7) and for the 
temporal lobe group was 4.3 (SD 3.9). The limbic group had a mean depression score 
of 3.8 (SD 2.6), the parietal group had a mean of 3.9 (SD 3.8), the occipital group 
had a mean of 4.2 (SD 4.6), the multiple lobes group had a mean of 3.5 (SD 3.3) and 
the ‘other’ location group had a mean score of 6.8 (SD 4.3). 
There was no significant main effect of the covariate age in the model, F(1,99) = 
0.558, p = 0.457, partial η² = 0.006. The covariate NART score also had no 
significant effect, F(1,99) = 1.562, p = 0.214, partial η² = 0.016. Sex had no 
significant effect on depression scores, F(1,99) = 0.059, p = 0.808, partial η² = 0.001. 
The effect of tumour lobe was not significant in the model that included the effects of 
the covariates, F(6,99) = 1.352, p = 0.242, partial η² = 0.076. 
The estimated marginal mean depression scores, adjusted for age and NART score 
and shown in Figure 8.27, for each tumour lobe group were 5.6 (SE 0.7) for the 
frontal lobe group, 4.2 (SE 1.0) for the temporal lobe group, 4.1 (SE 1.4) for the 
limbic group, 3.7 (SE 1.0) for the parietal lobe group, 4.9 (SE 1.8) for the occipital 
lobe group, 3.5 (SE 0.8) for the multiple lobes group and 6.4 (SE 1.1) for the ‘other’ 
location group. 
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Figure 8.27. Baseline depression scores on the Hospital Anxiety and Depression Scale for 
each tumour lobe group. Bars are estimated marginal mean scores adjusted for age and 
NART score. Error bars: Standard error means.
8.3.12.3 Hospital Anxiety and Depression Scale – Total Score
The mean total score on the Hospital Anxiety and Depression Scale was 14.2 (SD 
8.9) for the frontal lobe group, 12.5 (SD 8.2) for the temporal lobe group, 11.8 (SD 
6.1) for the limbic group, 11.0 (SD 6.3) for the parietal lobe group, 13.8 (SD 8.3) for 
the occipital lobe group, 10.5 (SD 6.2) for the multiple lobe group and 15.4 (SD 6.7) 
for the group with tumours located elsewhere in the brain (‘other’).
There was no significant main effect of the covariate age in the model, F(1,99) = 
0.229, p = 0.634, partial η² = 0.002. The covariate NART score also had no 
significant effect in the model, F(1,99) = 0.841, p = 0.361, partial η² = 0.008. Sex had 
no significant effect on total scores in the model, F(1,99) = 0.023, p = 0.879, partial 
η² < 0.001. The effect of tumour lobe was not significant in the model that included 
the effects of age and NART score, F(6,99) = 1.163, p = 0.333, partial η² = 0.066.
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The estimated marginal mean total Hospital Anxiety and Depression Scale scores, 
adjusted for age and NART score and shown in Figure 8.28, for each tumour lobe 
group were 14.4 (SE 1.3) for the frontal lobe group, 12.6 (SE 1.9) for the temporal 
lobe group, 11.5 (SE 2.7) for the limbic group, 10.5 (SE 1.8) for the parietal lobe 
group, 15.1 (SE 3.4) for the occipital lobe group, 10.5 (SE1.6) for the multiple lobe 
group and 14.9 (SE 2.1) for the ‘other’ location group. 
Estimated Marginal Mean Total Hospital Anxiety and 























Figure 8.28. Baseline total scores on the Hospital Anxiety and Depression Scale for each 
tumour lobe group. Bars are estimated marginal mean scores adjusted for age and NART 
score. Error bars: Standard error means.
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Table 8.2. Comparison of tumour lobe groups on cognitive and mood scales at baseline.
Test Effect of tumour lobe Overview of significant pairwise comparisons
F Sig. (p) n²*
Inspection Time (All Data) 3.372 0.002 0.189 Occipital lobe group performed less well than all 
other lobe groups.
Inspection Time (Valid Data) 1.268 0.281 0.086 N/A
Rey Auditory Verbal Learning 
Test  (Total) 
2.268 0.046 0.161 ‘Other’ lobe group performed better than temporal, 
limbic, occipital and multiple lobe groups.
Trail Making Test Part B (secs) 0.846 0.538 0.060 N/A
Verbal Fluency (Total) 1.124 0.357 0.083 N/A
Digit Symbol Coding (Total) 2.180 0.052 0.121 Frontal group performed better than parietal and 
temporal. 
‘Other’ group performed better than parietal. 





5.166 0.001 0.298 ‘Other’ group performed better than frontal, limbic, 
parietal, occipital and multiple lobe groups. 
Occipital group performed less well than temporal, 
parietal, frontal lobe groups. 
Temporal group performed better than multiple lobes 
group. 
EFIT Williams Delayed Recall 
Test (total)
1.740 0.120 0.095 N/A
EFIT Nine Hole Peg Test (Right 
Hand, secs)
3.268 0.006 0.165 Parietal group performed less well than frontal, 
temporal, occipital, multiple and ‘other’ lobe groups.
EFIT Nine Hole Peg Test (Left 
Hand, secs)
0.786 0.786 0.032 N/A
EFIT Timed Ten Metre Walk 
(secs)
1.879 0.094 0.116 N/A
Hospital Anxiety and Depression 
Scale –Anxiety Score
0.807 0.567 0.047 N/A
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Hospital Anxiety and Depression 
Scale – Depression Score
1.352 0.242 0.076 N/A
Hospital Anxiety and Depression 
Scale – Total Score
1.163 0.333 0.066 N/A
n² = the proportion of variance accounted for by tumour lobe.
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8.4 Hemispheric Lateralisation
Of the total cohort of brain tumour patients (n = 118), 53 had a tumour located within 
the left hemisphere and 53 had a tumour located within the right hemisphere. The 
remaining twelve patients had either bi-hemispheric tumours, tumours located on the 
pituitary gland or tumours located between the ventricles, and were not included in 
this analysis.
8.4.1 Inspection Time Scores: All Inspection Time Data
The mean baseline score for the patients with tumours located in the left hemisphere 
was 118.6 (SD 14.9). Patients with tumours in the right hemisphere had a mean 
baseline inspection time score of 109.2 (SD 23.7).
The covariate age had a significant effect in this model, F(1,100) = 43.254, p < 
0.001, partial η² =0.302. Older patients were more likely to have poorer inspection 
time scores. The covariate NART score also had a significant effect, F(1,100) = 
11.525, p = 0.001, partial η² = 0.103. Those participants with lower (better) NART 
scores were significantly more likely to have higher (better) inspection time scores. 
The effect of sex was not significant, F(1,100) = 3.332, p = 0.071, partial η² = 0.032. 
Hemispheric location of tumour had a significant main effect in the model that 
included the effects of the covariates age and NART score, F(1,100) = 10.987, p = 
0.001, partial η² = 0.099.
The estimated marginal mean scores on this test were 119.5 (SE 2.2) for the left 
hemisphere tumour group and 109.0 (SE 2.2) for the right hemisphere tumour group. 
The significant effect of hemisphere in the model therefore suggests that patients 
with a left-sided brain tumour had significantly better inspection time performance 
than the group of patients who had a tumour located in the right hemisphere. 
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8.4.2 Inspection Time Scores: Valid Inspection Time Data
When only data from patients with ‘valid’ inspection time scores was included in the 
analyses, this resulted in the left hemisphere tumour group including data from 50 
patients, with 40 patients with tumours in the right hemisphere.
When only valid scores were included, the left hemisphere tumour group scored a 
mean of 120.2 (SD 13.4) on the inspection time measure at baseline, and the right 
hemisphere group scored a mean of 119.7 (SD 14.7).
There was again a significant effect of age in the model, F(1,84) = 27.763, p < 0.001,
partial η² = 0.248. Older participants had poorer scores on the inspection time 
measure. The effect of the covariate NART score approached the conventional level 
of statistical significance on this occasion, F(1,84) = 3.725, p = 0.057, partial η² = 
0.042. Sex also had no significant effect in the model, F(1,84) = 3.137, p = 0.080, 
partial η² = 0.036. In the model that controlled for the effects of age and NART 
score, hemisphere had no significant effect when only ‘valid’ inspection time data 
was included, F(1,84) = 1.716, p = 0.194, partial η² = 0.020.
The estimated marginal mean score, adjusted for age and NART score, for the left 
hemisphere tumour group was 122.0 (SE 1.7) and for the right hemisphere group was 
118.6 (SE 1.9). When the invalid inspection time scores were removed from the 
model, there were no significant differences between the baseline inspection time 
scores of the left and the right hemisphere tumour groups.
8.4.3 Rey Auditory Verbal Learning Test
Thirty-eight patients with tumours in the left hemisphere and 43 with tumours in the 
right hemisphere completed this measure at baseline. 
The mean score for the left hemisphere group was 57.2 (SD 16.1) and for the right 
hemisphere group was 65.7 (SD 18.3).
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There was a significant main effect of the covariate age in the model, F(1,75) = 
25.180, p < 0.001, partial η² = 0.251. Older patients were significantly more likely to 
have lower scores on this measure. The effect of the covariate NART score was also 
significant, F(1,75) = 11.935, p = 0.001, partial η² = 0.137. Lower (better) NART 
scores were significantly associated with higher (better) scores on the Rey Auditory 
Verbal Learning Test. Sex also had a significant main effect in the model, F(1,75) = 
6.824, p = 0.011, partial η² = 0.083. Female participants tended to have higher scores 
on this test than their male counterparts. The effect of tumour hemisphere was 
significant in the model that included the effects of age and NART score, F(1,75) = 
6.778, p = 0.011, partial η² = 0.083.
The estimated marginal mean scores, adjusted for age and NART score, on the Rey 
Auditory Verbal Learning Test, were 57.4 (SE 2.4)  for the left hemisphere tumour 
group and 65.8 (SE 2.2) for the right hemisphere tumour group. Therefore, the group 
of patients with tumours located within the left hemisphere performed significantly 
less well than the group of patients with right hemisphere tumours. 
8.4.4 Trail Making Test Part B
Forty-six patients with tumours in the left hemisphere and 45 with right hemisphere 
tumours completed the trail making test part B at baseline. 
The mean score for the left hemisphere group was 96.3 (SD 33.2) and for the right 
hemisphere group was 93.0 (SD 28.5).
There was a significant main effect of the covariate age in the model, F(1,85) = 
19.598, p < 0.001, partial η² = 0.187. Older participants were more likely to take 
longer to complete the trial making test part B than younger participants. The 
covariate NART score also had a significant main effect in the model, F(1,85) = 
22.754, p < 0.001, partial η² = 0.211. Poorer performance on the NART was 
significantly associated with slower performance on the trail making test part B. The 
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effect of sex was not significant in the model, F(1,85) = 0.067, p = 0.797, partial η² = 
0.001.  The hemispheric location of the tumour had no significant effect in the model 
that included the effects of age and NART score, F(1,85) = 0.003, p = 0.960, partial 
η² < 0.001.
The estimated marginal mean scores, adjusted for age and NART score, for the trail 
making test part B were 93.8 (SE 3.9) for the left hemisphere group and 94.1 (SE 
3.9) for the right hemisphere group. There was no significant difference between the 
performance of those patients with left hemisphere tumours and those patients with 
right hemisphere tumours on the trail making test part B.
8.4.5 Verbal Fluency
Forty patients with left hemisphere tumours and 46 with right hemisphere tumours 
completed the verbal fluency test at baseline.
The mean score for the left hemisphere tumour group was 28.3 (SD 9.8) and for the 
right hemisphere tumour group was 28.7 (SD 14.1).
There was a significant main effect of the covariate age in the model, F(1,80) = 
6.070, p = 0.016, partial η² = 0.071. Older patients tended to produce fewer words on 
the verbal fluency task than younger participants. There was a significant main effect 
of the covariate NART score in the model, F(1,80) = 24.142, p < 0.001, partial η² = 
0.232. Higher (poorer) NART scores were significantly associated with lower 
(poorer) verbal fluency scores. The effect of sex did not reach the conventional level 
of statistical significance, F(1,80) = 3.315, p = 0.072, partial η² = 0.040. The effect of 
hemispheric location of tumour was not significant in the model that included the 
effects of age and NART score, F(1,80) = 0.079, p = 0.780, partial η² = 0.001.
The estimated marginal mean scores, adjusted for age and NART score, for each 
hemisphere group on the verbal fluency measure were 28.6 (SD 1.7) for the left 
hemisphere tumour group and 29.2 (SD 1.5) for the right hemisphere group. There 
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was no difference between the performance of the two groups on the verbal fluency 
measure.
8.4.6 Digit Symbol Coding
There were 54 patients with a right hemisphere tumour and 52 with a left hemisphere 
tumour who completed the digit symbol coding task at baseline. 
The mean score for the left hemisphere group was 57.4 (SD 21.0) and for the right 
hemisphere group was 54.4 (SD 22.9).
There was a significant main effect of the covariate age in the model, F(1,100) = 
51.387, p < 0.001, partial η² = 0.339. Older participants were significantly more 
likely to have lower (poorer) scores on this test. The covariate NART also had a 
significant main effect in the model, F(1,100) = 34.364, p < 0.001, partial η² = 0.256. 
Those participants with higher (poorer) NART sores were significantly more likely 
to perform less well on the digit symbol coding measure. There was no significant 
effect of sex in the model, F(1,100) = 0.662, p = 0.418, partial η² = 0.007. The effect 
of tumour hemisphere was not significant in the model that included the effects of 
the covariates age and NART score, F(1,100) = 1.177, p = 0.281, partial η² = 0.012. 
The estimated marginal mean scores, adjusted for age and NART score, for each 
hemisphere group on the digit symbol coding test at baseline were 57.7 (SE 2.3) for 
the left hemisphere tumour group and 54.1 (SE 2.4) for the right hemisphere tumour 
group. There was no significant effect of the hemispheric location of the tumour on 
digit symbol coding scores. 
8.4.7 Letter-Number Sequencing
Forty-one patients with left hemisphere tumours and 43 patients with right 
hemisphere tumours completed the letter-number sequencing test at baseline.
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The mean score for the left hemisphere group was 9.3 (SD 3.4) and for the right 
hemisphere group was 9.5 (SD 3.4). 
There was a significant main effect of both covariates age, F(1,78) = 29.787, p < 
0.001, partial η² = 0.276; and NART score, F(1,78) = 26.102, p < 0.001, partial η² = 
0.251, in the model. Older patients and patients with poorer scores on the NART 
were more likely to have poorer scores on the letter-number sequencing test. There 
was no significant effect of sex on test scores in the model, F(1,78) = 0.375, p = 
0.542, partial η² = 0.005. The effect of tumour hemisphere was not significant in the 
model that included the effects of the covariates age and NART score, F(1,78) = 
0.001, p = 0.971, partial η² < 0.001. 
The estimated marginal mean scores, adjusted for age and NART score, on the letter-
number sequencing test at baseline for each tumour hemisphere group were 9.4 (SE 
0.4) for the left hemisphere tumour group and 9.5 (SE 0.4) for the right hemisphere 
tumour group. The hemisphere in which a patient’s tumour was located had no effect 
on letter-number sequencing scores at baseline.
8.4.8 Williams Delayed Recall Test (EFIT)
Fifty-four patients with left hemisphere tumours and 55 patients with right 
hemisphere tumours completed the Williams delayed recall test at baseline.
The mean score for the left hemisphere group was 8.0 (SD 4.4) and the mean score 
for the right hemisphere group was 8.2 (SD 5.9).
There was a significant main effect of both covariates age, F(1,103) = 15.131, p < 
0.001, partial η² = 0.128; and NART score, F(1,103) = 4.251, p = 0.042, partial η² = 
0.040, in the model. Older patients and patients with higher (poorer) NART scores 
were significantly more likely to have higher (poorer) scores on the Williams 
delayed recall test. The effect of sex was not significant, F(1,103) = 0.740, p = 0.392, 
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partial η² = 0.007. Tumour hemisphere had no significant effect in the model that 
included the effects of both covariates, F(1,103) = 0.001, p = 0.975, partial η² < 
0.001.
The estimated marginal mean scores, adjusted for age and NART score, on the 
Williams delayed recall test were 8.1 (SE 0.7) for the left hemisphere group and 8.1 
(SE 0.7) for the right hemisphere group. The hemispheric location of the tumour had 
no effect on how well the patient performed on the Williams delayed recall test.
8.4.9 Nine Hole Peg Test (Right Hand, EFIT)
There were 54 patients with left hemisphere tumours and 55 patients with right 
hemisphere tumours who completed this test at baseline.
The left hemisphere tumour group had a mean score of 15.2 (SD 5.7) and the right 
hemisphere tumour group had a mean score of 14.1 (SD 3.1) on the right-hand nine 
hole peg test. 
There was a significant main effect of the covariate age in the model, F(1,103) = 
16.277, p < 0.001, partial η² = 0.136. Older participants were more likely to perform 
more slowly on this test. The covariate NART score also had a significant main 
effect in the model, F(1,103) = 15.229, p < 0.001, partial η² = 0.129. Higher (poorer) 
NART scores were significantly associated with slower performance on this test. 
There was no significant effect of sex in the model, F(1,103) = 0.996, p = 0.321, 
partial η² = 0.010. There was no significant effect of hemispheric location of tumour 
in the model that included the effects of age and NART score, F(1,103) = 2.126, p = 
0.148, partial η² = 0.020. 
The estimated marginal mean scores, adjusted for age and NART score, on the right 
hand nine hole peg test were 15.3 (SE 0.6) for the left hemisphere tumour group and 
14.1 (SD 0.6) for the right hemisphere tumour group. Therefore, there was no 
significant difference between those patients with left hemisphere tumours and those 
with right hemisphere tumours in terms of right hand nine hole peg test performance. 
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8.4.10 Nine Hole Peg Test (Left Hand, EFIT)
Fifty-four patients with left hemisphere tumours and 52 with right hemisphere 
tumours completed this test at baseline. 
The mean score for the left hemisphere tumour group was 14.6 (SD 2.5) and for the 
right hemisphere tumour group was 16.2 (SD 4.2).
The covariate age had a significant main effect in the model, F(1,100) = 20.376, p < 
0.001, partial η² = 0.169. Older patients were more likely to take longer to complete 
this test than younger patients. The effect of the covariate NART score approached 
the conventional level of statistical significance, F(1,100) = 3.600, p = 0.061, partial
η² = 0.035. Sex had no significant effect in the model, F(1,100) = 1.976, p = 0.163, 
partial η² = 0.019. The effect of tumour hemisphere was significant in the model that 
included the effects of age and NART score, F(1,100) = 5.653, p = 0.019, partial η² = 
0.054. 
The estimated marginal mean scores, adjusted for age and NART score, on the left 
hand nine hole peg test were 14.7 (SE 0.4) for the left hemisphere tumour group and 
16.2 (SE 0.4) for the right hemisphere group. Patients with tumours located in the 
right hemisphere were significantly slower to complete the left hand nine hole peg 
test than those patients with left hemisphere tumours.
8.4.11 Timed Ten Metre Walk (EFIT)
Forty-nine patients with left hemisphere tumours and 47 with right hemisphere 
tumours completed the timed ten metre walk at baseline. 
The mean score for the left hemisphere group was 6.8 (SD 1.9) and for the right 
hemisphere group was 7.0 (SD 1.4). 
There was a significant main effect of age in the model, F(1,90) = 19.775, p < 0.001, 
partial η² = 0.180. Older patients took significantly longer to complete the timed ten 
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metre walk than younger patients. The effect of the covariate NART score almost 
reached the conventional level of statistical significance, F(1,90) = 3.858, p = 0.053, 
partial η² = 0.041. The effect of sex was not significant in the model, F(1,90) = 
2.464, p = 0.120, partial η² = 0.027. The effect of tumour hemisphere was not 
significant in the model that included the effects of age and NART score, F(1,90) = 
0.616, p = 0.435, partial η² = 0.007. 
The estimated marginal mean scores, adjusted for age and NART score, on the timed 
ten metre walk were 6.8 (SE 0.2) for the left hemisphere tumour group and 7.0 (SE 
0.2) for the right hemisphere tumour group. The hemispheric location of tumour had 
no significant effect on timed ten metre walk test performance. 
8.4.12 Hospital Anxiety and Depression Scale
Fifty-five patients with tumours located in the left hemisphere and 54 patients with 
tumours located in the right hemisphere completed the Hospital Anxiety and 
Depression Scale at baseline.
8.4.12.1 Anxiety Scores
The mean anxiety score for the left hemisphere tumour group was 8.0 (SD 4.4) and 
for the right hemisphere tumour group was 7.9 (SD 4.4).
There was no significant effect of either covariates age, F(1,103) = 0.018, p = 0.894, 
partial η² < 0.001; or NART score, F(1,103) = 0.057, p = 0.812, partial η² = 0.001, in 
the model. There was no significant effect of sex, F(1,103) = 1.224, p = 0.271, partial 
η² = 0.012. The effect of tumour hemisphere was not significant in the model that 
included the effects of age and NART score, F(1,103) = 0.010, p = 0.919, partial η² < 
0.001.
The estimated marginal mean anxiety scores, adjusted for age and NART score, were 
7.9 (SE 0.6) for the left hemisphere group and 7.9 (SE 0.6) for the right hemisphere 
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group. Hemispheric location of tumour had no significant effect on anxiety levels, as 
measured by the Hospital Anxiety and Depression Scale. 
8.4.12.2 Depression Scores
The mean depression score for the left hemisphere tumour group was 4.8 (SD 4.4) 
and for the right hemisphere tumour group was 4.4 (SD 3.7). 
There was no significant main effect of either of the covariates age, F(1,103) = 
0.135, p = 0.714, partial η² = 0.001; or NART score, F(1,103) = 0.783, p = 0.378, 
partial η²  = 0.008. The effect of sex approached the conventional level of statistical 
significance, F(1,103) = 3.686, p = 0.0.58, partial η² = 0.035. The effect of tumour
hemisphere was not significant in the model that included the effects of the 
covariates, F(1,103) = 0.016, p = 0.900, partial η² < 0.001.
The estimated marginal mean depression scores, adjusted for age and NART score, 
were 4.5 (SE 0.6) for the left hemisphere tumour group and 4.4 (SE 0.6) for the right 
hemisphere tumour group. Hemispheric location of tumour had no significant effect 
on depression levels, as measured by the Hospital Anxiety and Depression Scale. 
8.4.12.3 Hospital Anxiety and Depression Scale - Total Scores
The left hemisphere group had a mean total score of the Hospital Anxiety and 
Depression Scale of 12.8 (SD 8.0) and the right hemisphere tumour group had a 
mean of 12.3 (SD 7.1). 
There was no significant main effect of either of the covariates age, F(1,103) = 
0.076, p = 0.784, partial η² = 0.001; or NART score, F(1,103) = 0.377, p = 0.541, 
partial η² = 0.004, on total scores in the model. The effect of sex was not significant, 
F(1,103) = 2.821, p = 0.096, partial η² = 0.027. Tumour hemisphere had no 
significant effect on total scores in the model that included the effects of age and 
NART score, F(1,103) < 0.001, p = 0.994, partial η² < 0.001.
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The estimated marginal mean total Hospital Anxiety and Depression Scale scores, 
adjusted for age and NART score, were 12.4 (SE 1.0) for the left hemisphere tumour 
group and 12.3 (SD 1.0) for the right hemisphere tumour group. Therefore, the 
hemispheric location of the tumour has no effect on the levels of distress as measured 
by the Hospital Anxiety and Depression Scale. 
The results detailed in this chapter are discussed in Chapter 9.6.
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Table 8.3. Comparison of the left and right hemisphere groups on cognitive and mood scales at baseline.
Test Effect of tumour 
hemisphere
Estimated marginal mean score
(adjusted for age and NART score)




Inspection Time (All Data) 10.987 0.001 0.099 119.5 (2.2) 109.0 (2.2)
Inspection Time (Valid Data) 1.716 0.194 0.020 122.0 (1.7) 118.6 (1.9)
Rey Auditory Verbal Learning Test  (Total) 6.778 0.011 0.083 57.4 (2.4) 65.8 (2.2)
Trail Making Test Part B (secs) 0.003 0.960 <0.001 93.8 (3.9) 94.1 (3.9)
Verbal Fluency (Total) 0.079 0.780 0.001 28.6 (1.7) 29.2 (1.5)
Digit Symbol Coding (Total) 1.177 0.281 0.012 57.7 (2.3) 54.1 (2.4)
Letter-Number Sequencing (Total) 0.001 0.971 <0.001 9.4 (0.4) 9.5 (0.4)
EFIT Williams Delayed Recall Test (total) 0.001 0.975 <0.001 8.1 (0.7) 8.1 (0.7)
EFIT Nine Hole Peg Test (Right Hand, secs) 2.216 0.148 0.020 15.3 (0.6) 14.1 (0.6)
EFIT Nine Hole Peg Test (Left Hand, secs) 5.653 0.019 0.054 14.7 (0.4) 16.2 (0.4)
EFIT Timed Ten Metre Walk (secs) 0.616 0.435 0.007 6.8 (0.2) 7.0 (0.2)
Hospital Anxiety and Depression Scale –Anxiety 
Score
0.010 0.919 <0.001 7.9 (0.6) 7.9 (0.6)
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Hospital Anxiety and Depression Scale – Depression 
Score
0.016 0.900 <0.001 4.5 (0.6) 4.4 (0.6)
Hospital Anxiety and Depression Scale – Total Score <0.001 0.994 <0.001 12.4 (1.0) 12.3 (1.0)
   * n² = the proportion of variance accounted for by the tumour hemisphere
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9 Tumour Type, Location and Lateralisation:
Post-Operative Function
9.1 Overview of analysis procedure
                                                                            
To investigate the effect of surgery on inspection time, digit-symbol coding and the 
Edinburgh Functional Impairment Tests dependent on tumour histology, location (lobe) 
and hemispheric laterality, general linear modelling (analysis of covariance) was used. 
The post-operative (session 2) test score was entered as the dependent variable and the 
relevant tumour-related variable (type, lobe or hemisphere) and sex were specified as 
fixed effects (between-groups factors) in each model. Age and National Adult Reading 
Test (NART) score were covariates in each model for the reasons highlighted in chapter
5.2.1. The corresponding baseline test score was also included as a covariate in each 
model as this allows us to compare any differences between baseline and session 2 
performance on each test for each histological group, tumour lobe group and 
hemispheric location by controlling for the effects of baseline test score in addition to 
the effects of age and NART score. 
In each of the following sections, mean baseline and session 2 scores for each 
histological, lobe and hemisphere group are presented for each test with standard 
deviations (SD) in brackets. The results of the general linear model are then presented. 
Estimated marginal mean scores and pairwise comparisons are then given for each  
group to highlight any differences between the groups, adjusted for other variables in the 
models when a main effect of the tumour-related variable is found. Least Significant 
Difference (LSD) tests were used to conduct pairwise post-hoc comparisons. Post-hoc 
analyses comparing the low-grade and high-grade tumour groups are carried out for each 
measure, since it was expected that there would be a significant difference between these 
two histological groups (see Chapter 1.3 and 1.5).
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9.2 Histological Tumour Type
Of the total cohort of brain tumour patients who completed both baseline and session 2 
(post-operative) testing, 16 patients were found to have a low-grade glioma, 26 had a 
high-grade glioma, 9 had a metastasis, 10 had a meningioma and 3 had a diagnosis that 
did not fall into the aforementioned categories (‘other’). 
9.2.1 Inspection Time Scores: All Inspection Time Data
Two patients with a high-grade glioma and 2 with a meningioma were tested at session 2 
but did not complete the inspection time task. Therefore, data from 16 low-grade glioma 
patients, 24 high-grade glioma patients, 9 metastasis, 8 meningioma and 3 patients with 
‘other’ tumours were included in the following analysis.
The mean baseline inspection time score for the low-grade glioma group was 127.3 (SD 
10.8) and at session 2 was 118.2 (SD 23.4). The high-grade glioma group had a mean 
score at baseline of 113.3 (SD 22.3) and 113.3 (SD 22.5) at session 2. The baseline mean 
score for the metastasis group was 120.3 (SD 17.0) and at session 2 was 111.0 (SD 
23.0). The meningioma group had a mean baseline score of 106.6 (SD 30.2) and a mean 
of 103.6 (SD 22.5) at session 2. The ‘other’ tumour group mean at baseline was 122.0 
(SD 12.5) and at session 2 was 132.3 (SD 5.8). The mean (standard error) scores at 
baseline and session 2 for each tumour group are shown in Figure 9.1.
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Figure 9.1. Baseline and session 2 inspection time scores for each 
histological group. Points are raw mean scores. Error bars: standard error 
means.
General linear modelling with post-operative (session 2) inspection time score entered as 
the dependent variable revealed a significant main effect of the baseline inspection time 
score, F(1,48) = 28.663, p < 0.001, partial η² = 0.374. In the whole sample (i.e. all 
histology groups combined), baseline inspection time score was positively correlated 
with session 2 inspection time score, r(n = 60) = 0.709, p < 0.001. Similar positive 
correlations were obtained for the high-grade glioma group, r(n = 24) = 0.836, p < 
0.001; the metastasis group, r(n = 9) = 0.849, p = 0.004 and the meningioma group, r(n = 
8) = 0.819, p = 0.013. The two scores were not significantly correlated in the low-grade 
glioma group, r(n = 16) = 0.367, p = 0.162 or in the ‘other’ tumour group, r(n = 3) = 
0.829, p = 0.377. The effect of the covariate age was not significant in the model, 
F(1,48) = 2.201, p = 0.144, partial η² = 0.044. The effect of the covariate NART score 
was also not significant, F(1,48) = 1.088, p = 0.302, partial η² = 0.022. Sex had no 
significant main effect in the model, F(1,48) = 0.207, p = 0.651, partial η² = 0.004. The 
effect of tumour type was not significant in the model that included the effects of the 
covariates age, NART score and baseline inspection time score, F(4,48) = 1.100, p = 
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0.368, partial η² = 0.084. There was no significant interaction between tumour type and 
sex, F(3,48) = 0.321, p = 0.810, partial η² = 0.020. 
The estimated marginal mean session 2 inspection time score, adjusted for age, NART 
and baseline inspection time score—derived from the above-described general linear 
model—was 109.6 (SE 4.3) for the low-grade glioma group; 117.2 (SE 3.5) for the high-
grade glioma group; 111.3 (SE 5.8) for the metastasis group; 116.4 (SE 9.1) for the 
meningioma group and 126.7 (SE 9.4) for the ‘other’ tumour group. Pairwise 
comparisons using Least Significant Difference tests revealed no significant difference
between the low-grade and high-grade glioma patient groups.
9.2.2 Inspection Time Scores: Valid Inspection Time Data
When only data from patients with ‘valid’ inspection time scores at baseline testing were 
included in the analysis, there were 16 low-grade glioma patients, 21 high-grade glioma 
patients, 8 metastasis patients, 5 meningioma patients and 2 patients with ‘other’ 
tumours who also had session 2 inspection time scores. 
The mean baseline score for the low-grade glioma group was 127.3 (SD 10.8) and at 
session 2 was 118.2 (SD 23.4). The high-grade glioma group had a mean score of 119.2 
(SD 15.1) at baseline and 116.8 (SD 17.7) at session 2. The mean baseline score for the 
metastasis group was 125.0 (SD 10.2) and at session 2 was 114.9 (SD 21.2). The 
meningioma group had a baseline mean score of 127.8 (SD 8.7) and 115.6 (SD 20.1) at 
session 2. The ‘other’ tumour type group had a mean baseline score of 128.5 (SD 7.8) 
and 134.0 (SD 7.1) at session 2. The mean (standard error) scores at baseline and session 
2 for each tumour type group are shown in Figure 9.2.
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Figure 9.2. Baseline and session 2 inspection time scores, with only valid 
baseline scores included, for each tumour type group. Points are raw mean scores. 
Error bars: standard error means.
There was a significant main effect of the inspection time score at baseline in the general 
linear model, F(1,40) = 13.473, p = 0.001, partial η² = 0.252. In the whole sample (i.e. 
all tumour type groups combined) valid baseline inspection time scores were positively 
correlated with the inspection time score at session 2, r(n = 52) = 0.611, p < 0.001. 
Similar correlations were obtained for the high-grade glioma group, r(n = 21) = 0.813, p 
< 0.001; the metastasis group, r(n = 8) = 0.886, p = 0.003; and for the ‘other’ tumour 
type group, r(n = 2) = 1.00, p < 0.001. There was no significant correlation between the 
two scores in the low-grade glioma group, r(n = 16) = 0.367, p = 0.162, or in the 
meningioma group, r(n = 5) = 0.675, p = 0.211. There was no significant main effect of 
the covariate age, F(1,40) = 1.077, p = 0.306, partial η² = 0.026. The covariate NART 
also had no significant main effect in the model, F(1,40) = 1.051, p = 0.312, partial η² = 
0.026. Sex had no significant effect in the model, F(1,40) = 0.006, p = 0.938, partial η² < 
0.001. There was no significant main effect of tumour type in the model that included 
the effects of the covariates age, NART and baseline valid inspection time score, F(4,40) 
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= 0.506, p = 0.731, partial η² = 0.048. The interaction between tumour type and sex was 
not significant, F(3,40) = 0.629. p = 0.601, partial η² = 0.045. That is, in the presence of 
the effects of age, NART score and baseline test score there was no significant overall 
difference between the performance of the tumour type groups on inspection time at 
baseline and session 2 follow-up.
The estimated marginal mean session 2 inspection time score, adjusted for age, NART 
and baseline inspection time score—derived from the above-described general linear 
model—was 114.3 (SE 4.3) for the low-grade glioma group; 120.9 (SE 3.9) for the high-
grade glioma group; 115.9 (SE 6.1) for the metastasis group; 117.8 (SE 9.7) for the 
meningioma group and 127.7 (SE 11.6) for the ‘other’ tumour group. Pairwise 
comparisons using Least Significant Difference tests revealed no significant differences 
between the low-grade and high-grade glioma patient groups.
9.2.3 Digit Symbol Coding
Fifteen low-grade glioma patients, 25 high-grade glioma patients, 8 metastasis, 9 
meningioma and 3 patients with ‘other’ tumours all completed the digit symbol coding 
measure at both baseline and session 2. 
The mean score for the low-grade glioma group at baseline was 70.9 (SD 12.2) and at 
session 2 was 64.1 (SD 14.2). The high-grade glioma group scored a mean of 59.4 (SD 
20.8) at baseline and 58.4 (SD 19.6) at session 2. The mean baseline score for the 
metastasis group was 62.6 (SD 23.7) and at session 2 was 54.5 (SD 26.7) and the 
meningioma group baseline mean was 48.2 (SD 24.6) and at session 2 was 42.4 (SD 
22.8). The other tumour group baseline mean was 81.3 (SD 26.0) and at session 2 was 
84.3 (SD 23.0). The mean (standard error) scores on digit symbol coding at baseline and 
session 2 for each tumour type group are shown in Figure 9.3.
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Figure 9.3. Baseline and session 2 digit symbol coding scores for each tumour type 
group. Points are raw mean scores. Error bars: standard error means.
General linear modelling, with digit symbol coding score entered as the dependent 
variable, revealed a significant main effect of baseline digit symbol coding score, 
F(1,48) = 133.269, p < 0.001, partial η² = 0.735. In the whole sample (i.e. the tumour 
type groups combined) baseline digit symbol coding score was positively correlated with 
the same test score at session 2, r(n = 60) = 0.892, p < 0.001. Similar positive 
correlations were obtained for the high-grade glioma group, r(n = 25) = 0.965, p < 
0.001; the metastasis group, r(n = 8) = 0.951, p < 0.001; the meningioma group, r(n = 9) 
= 0.843, p = 0.004 and for the ‘other’ tumour group, r(n = 3) = 0.998, p = 0.044. The 
low-grade glioma group showed a tendency towards a positive correlation between the 
two scores but this did not reach a conventional level of statistical significance, r(n = 15) 
= 0.497, p = 0.060. There was no significant main effect of the covariate age in the 
model, F(1,48) = 0.401, p = 0.530, partial η² = 0.008; or of the covariate NART score, 
F(1,48) = 0.666, p = 0.419, partial η² = 0.014. The effect of sex was significant in the 
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model, F(1,48) = 4.561, p = 0.038, partial η² = 0.087. Female patients were more likely 
to have lower scores than male patients. The effect of tumour type was not significant in 
the model that included the effects of the covariates age, NART score or baseline digit 
symbol coding score, F(4,48) = 1.572, p = 0.197, partial η² = 0.116. There was no 
significant interaction between sex and tumour type, F(3,48) = 1.377, p = 0.261, partial 
η² = 0.079. In the presence of the effects of age, NART score and baseline test score 
there was no significant overall difference between the performance of the tumour type 
groups on digit symbol coding at baseline and session 2 follow-up.
The estimated marginal mean session 2 digit symbol coding score, adjusted for age, 
NART and baseline inspection time score—derived from the above-described general 
linear model—was 57.1 (SE 2.7) for the low-grade glioma group; 60.2 (SE 2.0) for the 
high-grade glioma group; 53.0 (SE 3.5) for the metastasis group; 64.2 (SE 5.3) for the 
meningioma group and 68.3 (SE 5.6) for the ‘other’ tumour group. Pairwise 
comparisons revealed no significant difference between the low-grade and high-grade 
glioma tumour groups.
9.2.4 Williams Delayed Recall Test (EFIT)
Fourteen low-grade glioma patients, 26 high-grade glioma patients, 9 with a metastasis, 
9 with a meningioma and 3 patients with ‘other’ tumours who completed the Williams 
delayed recall test at both baseline and post-operatively during session 2.
The low-grade glioma group scored a mean of 6.4 (SD 3.3) at baseline and 10.9 (SD 7.8) 
at session 2. The high-grade glioma group had a baseline mean score of 9.2 (SD 4.9) and 
a session 2 mean score of 11.1 (SD 4.7). The baseline mean score for the metastasis 
group was 8.9 (SD 6.6) and at session 2 was 12.2 (SD 6.2). The meningioma group 
scored a baseline mean of 10.1 (SD 7.0) and a mean of 11.4 (SD 7.9) at session 2. The 
‘other’ tumour group baseline mean was 10.3 (SD 4.2) and the session 2 mean score was 
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14.3 (SD 2.9) for this group. The mean (standard error) scores at baseline and session 2 
for each tumour type group are shown in Figure 9.4.
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Figure 9.4. Baseline and session 2 Williams Delayed Recall Test scores for each tumour 
type group. Points are raw mean scores. Error bars: standard error means.
General linear modelling, with the session 2 test score entered as the dependent variable 
revealed a significant main effect of the baseline test score, F(1,50) = 16.866, p < 0.001, 
partial η² = 0.252. In the whole sample (i.e. the tumour type groups combined), baseline 
Williams delayed recall test score was positively correlated with session 2 score, r(n = 
62) = 0.495, p < 0.001. The two scores were also positively correlated in the high-grade 
glioma group alone, r(n = 26) = 0.550, p = 0.004, in the metastasis group alone, r (n = 9) 
= 0.805, p = 0.009 and in the meningioma group alone, r(n = 10) = 0.756, p = 0.011. 
There was no significant correlation between the two test scores in neither the low-grade 
glioma group, r(n = 14) = 0.008, p = 0.978; nor in the ‘other’ tumour group, r(n = 3) = -
0.971, p = 0.154. There was a significant main effect of age in the model, F(1,50) = 
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5.795, p = 0.020, partial η² = 0.104. Older participants tended to have higher (poorer) 
scores. The effect of the covariate NART score was not significant, F(1,50) = 2.977, p = 
0.091, partial η² = 0.056. The effect of sex was not significant in the model, F(1,50) = 
0.016, p = 0.901, partial η² < 0.001. The effect of tumour type had no significant main 
effect in the model that included the effects of the covariates age, NART score and 
baseline test score, F(4,50) = 1.560, p = 0.199, partial η² = 0.111. The interaction 
between sex and tumour group was significant in the model, F(3.50) = 4.271, p = 0.009, 
partial η² = 0.204. Female participants in the low-grade glioma and meningioma group 
had significantly higher (poorer) scores on this test at session 2 than their male 
counterparts. 
The estimated marginal mean session 2 Williams delayed recall test score, adjusted for 
age, NART and baseline score—derived from the above-described general linear 
model—was 14.3 (SE 1.5) for the low-grade glioma group; 10.1 (SE 1.0) for the high-
grade glioma group; 11.1 (SE 1.8) for the metastasis group; 10.3 (SE 2.8) for the 
meningioma group and 14.8 (SE 3.0) for the ‘other’ tumour group. Pairwise 
comparisons using Least Significant Difference tests revealed a significant difference 
between the low-grade glioma and high-grade glioma groups (p = 0.031). This suggests 
that the low-grade glioma group deteriorated significantly between baseline and session 
2 testing by comparison with the high-grade glioma group. 
9.2.5 Nine Hole Peg Test (Right Hand, EFIT)
Fifteen patients in the low-grade glioma group, 26 in the high-grade glioma group, 8 
with a metastasis, 10 with a meningioma and 3 ‘other’ tumour patients completed the 
right hand nine hole peg test at both baseline and session 2. 
The low-grade glioma group had a mean baseline score of 12.5 (SD 2.0) and a mean of 
14.2 (SD 2.0) at session 2. The baseline mean score for the high-grade glioma group was 
14.0 (SD 3.0) and at session 2 the group mean was 14.5 (SD 3.1). The metastasis group 
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had a mean score of 13.3 (SD 2.3) at baseline and 13.7 (SD 3.0) at session 2. The 
meningioma group had mean scores of 16.0 (SD 3.6) and 16.2 (SD 2.8) at baseline and 
session 2, respectively. The mean baseline score for the ‘other’ tumour group was 12.4 
(SD 0.2) and at session 2 was 12.3 (SD 0.4). The mean (standard error) scores for each 
tumour type group at baseline and session 2 are shown in Figure 9.5.
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Figure 9.5. Baseline and session 2 right hand nine hole peg test scores for each tumour 
type group. Points are raw mean scores. Error bars: standard error means.
General linear modelling, with right hand nine hole peg test score at session 2 entered as 
the dependent variable revealed a significant main effect of the test score at baseline, 
F(1,50) = 35.156, p < 0.001, partial η² = 0.413. In the whole sample (i.e. all tumour type 
groups combined) baseline right hand nine hole peg test score was correlated with the 
corresponding score at session 2, r(n = 62) = 0.741, p < 0.001. Similar correlations were 
obtained for the two scores in the low-grade glioma group alone, r(n = 15) = 0.673, p = 
0.006; the high-grade glioma group, r(n = 26) = 0.697, p < 0.001; the metastasis group, 
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r(n = 8) = 0.718, p = 0.045; the meningioma group, r(n = 10) = 0.872, p = 0.001. The 
two scores were, however, not significantly correlated in the ‘other’ tumour group alone, 
r(n = 3) = -0.823, p = 0.384. There was no significant effect of either of the covariates 
age, F(1,50) = 1.271, p = 0.265, partial η² = 0.025; or NART score, F(1,50) = 0.024, p = 
0.877, partial η² < 0.001. The effect of sex was not significant, F(1,50) = 0.025, p = 
0.876, partial η² < 0.001. The effect of tumour type was not significant in the model that 
included the effects of the covariates age, NART score and baseline test score, F(4,50) = 
0.622, p = 0.649, partial η² = 0.047. There was no significant interaction between sex 
and tumour type, F(3,50) = 1.843, p = 0.151, partial η² = 0.100.
The estimated marginal mean session 2 right hand nine hole peg test score, adjusted for 
age, NART and corresponding baseline test score—derived from the above-described 
general linear model—was 14.8 (SE 0.6) for the low-grade glioma group; 14.5 (SE 0.4) 
for the high-grade glioma group; 14.3 (SE 0.7) for the metastasis group; 13.8 (SE 1.1) 
for the meningioma group and 13.1 (SE 1.1) for the ‘other’ tumour group. Pairwise 
comparisons using Least Significant Difference tests revealed no significant differences 
between the low-grade and high-grade glioma tumour groups.
9.2.6 Nine Hole Peg Test (Left Hand, EFIT)
Fourteen patients in the low-grade glioma group, 26 in the high-grade glioma group, 8 
patients with a metastasis, 10 with a meningioma and 3 with ‘other’ tumour types 
completed the left hand nine hole peg test at both baseline and session 2. 
The mean baseline score for the low-grade glioma group on the left hand nine hole peg 
test was 13.3 (SD 1.7) and at session 2 was 14.5 (SD 2.4). The high-grade glioma group 
had a mean score of 16.0 (SD 3.5) at baseline and 15.9 (SD 3.5) at session 2. The 
metastasis group had mean scores of 13.8 (SD 1.7) and 15.4 (SD 1.5) at baseline and 
session 2, respectively. The mean baseline score for the meningioma group was 18.5 
(SD 4.6) and at session 2 was 18.7 (SD 4.4). The ‘other’ tumour type group had a mean 
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of 13.1 (SD 2.2) at baseline and 13.3 (SD 2.0) at session 2. The mean (standard error) 
scores for each tumour type group at baseline and session 2 on the left hand nine hole 
peg test are shown in Figure 9.6.
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Figure 9.6. Baseline and session 2 left hand nine hole peg test scores for each tumour 
type group. Points are raw mean scores. Error bars: standard error means.
General linear modelling, with left hand nine hole peg test score entered as the 
dependent variable revealed a significant main effect of the corresponding baseline 
score, F(1,49) = 99.667, p < 0.001, partial η² = 0.670. In the whole sample of all tumour 
type groups combined, baseline left hand nine hole peg test score was positively 
correlated with session 2 left hand nine hole peg test score, r(n = 61) = 0.859, p < 0.001. 
Similar correlations were obtained for the low-grade glioma group, r(n = 14) = 0.696, p 
= 0.006; high-grade glioma group, r(n = 26) = 0.814, p < 0.001; metastasis group, r(n = 
8) = 0.886, p = 0.003 and meningioma group, r(n = 10) = 0.954, p < 0.001. The two 
scores were not significantly correlated in the ‘other’ tumour type group, r(n = 3) = 
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0.658, p = 0.543. There was a significant main effect of the covariate age n the model, 
F(1,49) = 6.642, p = 0.013, partial η² = 0.119. Older patients took significantly longer to 
complete the task. The covariate NART score had no significant effect in the model, 
F(1,49) = 0.812, p = 0.372, partial η² = 0.016. There was also no significant main effect 
of sex, F(1,49) = 1.344, p = 0.252, partial η² = 0.027. The effect of tumour type was not 
significant in the model that included the effects of the covariates age, NART score and 
baseline left hand nine hole peg test score, F(4,49) = 1.098, p = 0.368, partial η² = 0.082. 
The interaction between sex and tumour type was non-significant, F(3,49) = 0.326, p = 
0.807, partial η² = 0.020. That is, in the presence of the effects of age, NART score and 
corresponding baseline test score, there was no significant overall difference between 
the performance of the tumour type subgroups on the left hand nine hole peg test at 
session 2 post-operative follow-up. 
The estimated marginal mean session 2 scores on the left hand nine hole peg test, 
adjusted for age, NART score and baseline left hand nine hole peg test score – derived 
from the above-described general linear model – were 16.4 (SE 0.5) for the low-grade 
glioma group; 15.3 (SE 0.3) for the high-grade glioma group; 16.3 (SE 0.7) for the 
metastasis group; 16.3 (SE 1.0) for the meningioma group and 15.6 (SE 1.0) for the 
‘other’ tumour type group. Pairwise comparisons, using LSD tests, revealed no 
significant differences between the two glioma patient groups (low-grade and high-
grade).
9.2.7 Timed Ten Metre Walk (EFIT)
Fourteen patients in the low-grade glioma group, 25 in the high-grade glioma group, 9 
patients with a metastasis, 5 with a meningioma and 3 with ‘other’ tumour types 
completed the timed ten metre walk test at both baseline and session 2. 
The mean baseline score for the low-grade glioma group was 6.0 (SD 1.0) and at session 
2 was 6.4 (SD 1.0). The high-grade glioma group had a mean score of 6.8 (SD 1.1) at 
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baseline and 7.1 (SD 1.3) at session 2. The metastasis group scored a mean of 7.5 (SD 
1.8) at baseline and 8.5 (SD 2.7) at session 2. The meningioma group scored 7.9 (SD 
1.8) and 7.2 (SD 1.6) at baseline and session 2, respectively. The ‘other’ tumour type 
group scored a mean of 5.2 (SD 1.0) at baseline and 6.3 (SD 0.4) at session 2. The mean 
(standard error) scores at baseline and session 2 for each tumour type group are shown in 
Figure 9.7. 
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Figure 9.7. Baseline and session 2 timed ten metre walk test scores for each tumour 
type group. Points are raw mean scores. Error bars: standard error means.
General linear modelling, with session 2 timed ten metre walk test score entered as the 
dependent variable revealed a significant main effect of the baseline timed ten metre 
walk score, F(1,44) = 34.545, p < 0.001, partial η² = 0.440. In the whole sample of all 
tumour type groups combined, baseline timed ten metre walk score was positively 
correlated with the same score at session 2, r(n = 56) = 0.731, p < 0.001. The two scores 
were similarly correlated in the low-grade glioma group, r(n = 14) = 0.664, p = 0.010; 
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the high-grade glioma group, r(n = 25) = 0.549, p = 0.004 and the metastasis group, r(n 
= 9) = 0.924, p < 0.001. The two scores were not significantly correlated in the 
meningioma group, r(n = 5) = 0.760, p = 0.136 or in the ‘other’ tumour type group, r(n = 
3) = 0.702, p = 0.505. There was no significant main effect of the covariate age, F(1,44) 
= 1.043, p = 0.313, partial η² = 0.023, or the covariate NART score, F(1,44) = 0.032, p = 
0.860, partial η² = 0.001. Sex had no significant effect in the model, F(1,44) = 0.416, p = 
0.522, partial η² = 0.009. There was no significant main effect of tumour type in the 
model that included the effects of the covariates age, NART score and baseline timed ten 
metre walk score, F(4,44) = 0.975, p = 0.431, partial η² = 0.081. The interaction between 
tumour type and sex was not significant, F(3,44) = 1.163, p = 0.334, partial η² = 0.073. 
That is, in the presence of the effects of age, NART score and baseline test score, there 
was no significant overall difference between the performance of the tumour type 
subgroups on the timed ten metre walk at session 2, post-operatively. 
The estimated marginal mean session 2 timed ten metre walk scores, adjusted for age, 
NART score and baseline timed ten metre walk score – derived from the above-
described general linear model – were 7.2 (SE 0.3) for the low-grade glioma group; 7.0 
(SE 0.2) for the high-grade glioma group; 7.8 (SE 0.4) for the metastasis group; 6.5 (SE 
0.7) for the meningioma group and 7.6 (SE 0.7) for the ‘other’ tumour type group. 
Pairwise comparisons using LSD tests revealed no significant difference between the 
low-grade and high-grade glioma groups.
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Table 9.1. Overview of comparisons of post-operative test performance in each histological group
Test Effect of tumour type
F Sig. (p) n²*
Inspection Time (All Data) 1.100 0.368 0.084
Inspection Time (Valid Data) 0.506 0.731 0.048
Digit Symbol Coding (Total) 1.572 0.197 0.116
EFIT Williams Delayed Recall Test (total) 1.560 0.199 0.111
EFIT Nine Hole Peg Test (Right Hand, secs) 0.622 0.649 0.047
EFIT Nine Hole Peg Test (Left Hand, secs) 1.098 0.360 0.082
EFIT Timed Ten Metre Walk (secs) 0.975 0.431 0.081
*n² = the proportion of variance accounted for by the covariate (tumour lobe).
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9.3 Tumour Lobe 
Of the total cohort of brain tumour patients who were tested at baseline and also post-
operatively at session 2, 21 patients had a tumour located in the frontal lobes, 10 had a 
temporal lobe tumour, 2 had a limbic tumour, 9 had a parietal lobe tumour, 4 had an 
occipital lobe tumour, 12 patients had tumours that infiltrated more than one lobe of the 
brain (‘multiple lobes’) and 6 patients had tumours located elsewhere (e.g. pituitary 
gland).
9.3.1 Inspection Time Scores: All Inspection Time Data
Of the cohort of brain tumour patients who completed both baseline and session 2 
testing, 3 patients with tumours located in ‘multiple lobes’ and 1 patient with a tumour 
located elsewhere (‘other’) did not complete inspection time testing. Therefore, data 
from 21 patients with frontal tumours, 10 with temporal lobe tumours, 2 with limbic 
tumours, 9 with parietal lobe tumours, 4 with occipital lobe tumours, 9 with tumours in 
multiple lobes and 5 with ‘other’ tumours were included in the analysis. 
The mean baseline inspection time score for the frontal lobe group was 119.0 (SD 21.0) 
and at session 2 was 117.5 (SD 20.2). The temporal lobe group scored a baseline mean 
of 124.2 (SD 11.4) and a session 2 mean score of 119.6 (SD 14.8). The limbic group 
scored 119.5 (SD 20.5) and 110.5 (SD 27.6) at baseline and session2, respectively. The 
baseline mean for the parietal lobe group was 115.8 (SD 22.3) and the session 2 mean 
was 107.9 (SD 21.0). The group of patients with occipital lobe tumours had a baseline 
mean score of 78.0 (SD 25.3) and a session 2 mean score of 89.3 (SD 34.7). The 
multiple lobe tumour group had a baseline mean of 120.9 (SD 12.0) and a session 2 
mean of 110.9 (SD 29.1) and the group of patients with tumours located elsewhere 
(‘other’) had mean scores of 127.4 (SD 9.1) and 125.0 (SD15.9) at baseline and session 
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2, respectively. The mean (standard error) scores at baseline and session 2 for each 
tumour group are shown in Figure 9.8.
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Figure 9.8. Baseline and session 2 inspection time scores (all data) for each tumour 
lobe group. Points are raw mean scores. Error bars: standard error means.
Post-operative (session 2) inspection time score was entered as the dependent variable in 
the general linear model. There was a significant main effect of baseline inspection time 
score in the model, F(1,44) = 15.783, p < 0.001, partial η² = 0.264. Participants with 
higher baseline inspection time scores were significantly more likely to have higher 
scores at session 2. The effect of the covariate age did not reach significance in the 
model, F(1,44) = 3.404, p = 0.072, partial η² = 0.072. NART score also had no 
significant main effect, F(1,44) = 0.953, p = 0.334, partial η² = 0.021. The effect of sex 
was not significant in the model, F(1,44) = 0.081, p = 0.778, partial η² = 0.002. There 
was no significant main effect of tumour lobe in the model that included the effects of 
the covariates age, NART score and baseline inspection time score, F(6,44) = 0.495, p = 
282
0.808, partial η² = 0.063. The interaction between tumour lobe and sex was not 
significant, F(5,44) = 0.471, p = 0.796, partial η² = 0.051.
The estimated marginal mean session 2 inspection time score, adjusted for age, NART 
score and baseline inspection time score – derived from the above-described general 
linear model – were 117.0 (SE 3.7) for the frontal lobe group; 114.3 (SE 5.8) for the 
temporal lobe group; 103.6 (SE 12.2) for the limbic group; 110.1 (SE 6.0) for the 
parietal lobe group; 118.1 (SE 10.0) for the occipital lobe group; 108.5 (SE 5.6) for the 
multiple lobe group and 116.5 (SE 7.8) for the ‘other’ location group. 
9.3.2 Inspection Time Scores: Valid Inspection Time Data
When data from only patients with ‘valid’ baseline inspection time scores were included 
in the analysis, there were 18 frontal lobe tumour patients, 10 temporal, 2 limbic, 8 
parietal, 9 ‘multiple lobe’ and 5 ‘other’ location patients who also had inspection time 
scores at session 2. 
The mean score at baseline for the frontal lobe group was 125.5 (SD 13.5) and at session 
2 was 121.3 (SD 17.2). The temporal lobe group had a baseline mean of 124.2 (SD 11.4) 
and a mean at session 2 of 119.6 (SD 14.8). The mean scores for the limbic group were 
119.5 (SD 20.5) and 110.5 (SD 27.6) at baseline and session 2, respectively. The parietal 
lobe group had a baseline mean of 121.4 (SD 15.7) and a session 2 mean score of 110.8 
(SD 20.5). The mean scores for the multiple lobe group were 120.9 (SD 12.0) and 110.9 
(SD 29.1) for baseline and session 2, respectively. The baseline mean for the ‘other’ 
location group was 127.4 (SD 9.1) and was125.0 (SD 15.9) at session 2. The occipital 
group who returned for session2 follow-up all had invalid baseline inspection time 
scores. The mean (standard error) scores at baseline and session 2 for each tumour lobe 
group are shown in Figure 9.9. 
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Figure 9.9. Baseline and session 2 inspection time scores (valid baseline data) for 
each tumour lobe group. Points are raw mean scores. Error bars: standard error means.
Session 2 inspection time score was entered as the dependent variable in the general 
linear model. There was a significant main effect of the baseline inspection time score, 
F(1,38) = 5.105, p = 0.030, partial η² = 0.118. Patients with higher scores at baseline 
were significantly more likely to have higher scores at session 2. The effects of the 
covariate age did not reach statistical significance, F(1,38) = 3.563, p = 0.067, partial η² 
= 0.086. The covariate NART score also had no significant main effect, F(1,38) = 3.200, 
p = 0.082, partial η² = 0.078. Sex also had no significant effect in the model, F(1,38) < 
0.001, p = 0.993, partial η² < 0.001. The effect of tumour lobe was not significant in the 
model that included the effects of the covariates age, NART score and baseline 
inspection time score, F(5,38) = 0.759, p = 0.585, partial η² = 0.091. There was no 
significant interaction between sex and tumour lobe, F(4,38) = 0.514, p = 0.726, partial 
η² = 0.051.
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The estimated marginal mean scores, adjusted for age, NART score and baseline 
inspection time score – derived from the above-described general linear model – were 
121.8 (SE 4.0) for the frontal lobe group; 118.9 (SE 5.6) for the temporal lobe group; 
106.0 (SE 12.2) for the limbic group; 111.2 (SE 6.2) for the parietal group; 113.4 (SE 
5.5) for the multiple lobe group and 122.5 (SE 7.6) for the ‘other’ location group. 
9.3.3 Digit Symbol Coding
There were 21 frontal lobe patients, 10 temporal lobe patients, 2 patients with limbic 
tumours, 7 parietal lobe patients, 3 occipital, 11 multiple lobe and 6 patients with 
tumours located elsewhere (‘other’) who completed digit symbol coding at both baseline 
and session 2, post-operatively.
The mean baseline digit symbol coding score for the frontal lobe group was 59.8 (SD 
16.7) and at session 2 was 58.8 (SD 18.2). The temporal lobe group had a baseline mean 
score of 70.7 (SD 21.5) and a session2 mean score of 64.3 (SD 24.6). The limbic group 
scored a mean of 72.0 (SD 7.1) at baseline and 64.0 (SD 12.7) at session 2. The mean 
scores for the parietal group were 54.0 (SD 21.4) and 48.1 (SD 17.6) at baseline and 
session 2, respectively. The occipital lobe tumour group had a baseline mean digit 
symbol coding score of 38.0 (SD 30.3) and a mean of 36.3 (SD 30.7) at session 2. The 
mean baseline score for the multiple lobe group was 65.4 (SD 22.5) and at session 2 was 
59.2 (SD 19.9). The ‘other’ location group score means of 68.7 (SD 27.2) and 65.3 (SD 
29.4) at baseline and session 2, respectively. The mean (standard error) scores at 
baseline and session 2 for each tumour lobe group are shown in Figure 9.10.
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Figure 9.10. Baseline and session 2 digit symbol coding scores for each tumour lobe 
group. Points are raw mean scores. Error bars: standard error means.
General linear modelling, with session 2 digit symbol coding score as the dependent 
variable revealed a significant main effect of the corresponding baseline test score, 
F(1,44) = 110.451, p < 0.001, partial η² = 0.715. There was no significant effect of either 
covariate age, F(1,44) = 0.018, p = 0.893, partial η² < 0.001; or NART score, F(1,44) = 
0.036, p = 0.851, partial η² = 0.001. Sex had a significant main effect in the model, 
F(1,44) = 7.067, p = 0.011, partial η² = 0.138. Female participants had significantly 
lower session 2 scores than their male counterparts. There was no significant main effect 
of tumour lobe in the model that included the effects of the covariates age, NART score 
and baseline digit symbol coding score, F(6,44) = 0.792, p = 0.581, partial η² = 0.097. 
The interaction between sex and tumour lobe was not significant, F(5,44) = 1.753, p = 
0.143, partial η² = 0.166.
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The estimated marginal mean scores, adjusted for age, NART score and baseline test 
score – derived from the above-described general linear model – were 60.7 (SE 2.1) for 
the frontal lobe group; 54.7 (SE 3.3) for the temporal lobe group; 55.5 (SE 6.9) for the 
limbic group; 55.9 (SE 3.7) for the parietal group; 55.3 (SE 6.2) for the occipital group; 
56.7 (SE 2.9) for the multiple lobe group and 59.9 (SE 3.9) for the ‘other’ location 
group. 
9.3.4 Williams Delayed Recall Test (EFIT)
Twenty-one patients in the frontal lobe group, 10 in the temporal lobe group. 2 in the 
limbic group, 8 with parietal tumours, 4 with occipital lobe tumours, 11 with tumours in 
multiple lobes and 6 patients with tumours elsewhere (‘other’) completed the Williams 
delayed recall test at both baseline and session 2. 
The mean baseline Williams delayed recall test score for the frontal lobe tumour group 
was 8.5 (SD 6.2) and at session 2, the mean score was 10.1 (SD 5.4). The temporal lobe 
group scored a mean of 7.9 (SD 2.6) at baseline and 13.2 (SD 7.5) at session 2. The 
limbic group baseline mean score was 7.0 (SD 4.2) and at session 2 was 5.5 (SD 2.1). 
The occipital lobe tumour group mean scores were 17.0 (SD 3.9) and 18.0 (SD 8.1) at 
baseline and session 2, respectively. The multiple lobe tumour group had a baseline 
mean score of 7.8 (SD 5.3) and a session 2 mean score of 13.9 (SD 5.3). The ‘other’ 
location group mean score was 7.0 (SD 3.2) at baseline and 9.2 (SD 5.4) at session 2. 
The mean (standard error) scores at baseline and session 2 for each tumour lobe group 
are shown in Figure 9.11.
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Figure 9.11. Baseline and session 2 Williams Delayed Recall Test scores for each 
tumour lobe group. Points are raw mean scores. Error bars: standard error means.
General linear modelling, with session 2 test score specified as the dependent variable 
revealed a significant main effect of the Williams delayed recall test score at baseline, 
F(1,46) = 8.455, p = 0.006, partial η² = 0.155. Patients with lower (better) scores at 
baseline were significantly more likely to have lower scores at session 2 testing. There 
was no significant effect of either covariate age, F(1,46) = 1.261, p = 0.267, partial η² = 
0.027; or NART score, F(1,46) = 0.060, p = 0.808, partial η² = 0.001. Sex had no 
significant main effect in the model, F(1,46) = 0.129, p = 0.721, partial η² = 0.003. The 
effect of tumour lobe was not significant in the model that included the effects of age, 
NART score and baseline test score, F(6,46) = 2.091, p = 0.073, partial η² = 0.214. 
There was no significant interaction between sex and tumour lobe location, F(5,46) = 
1.942, p = 0.106, partial η² = 0.174.
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The estimated marginal mean scores, adjusted for age, NART score and baseline 
Williams delayed recall test score – derived from the above-described general linear 
model – were 10.2 (SE 1.1) for the frontal lobe tumour group; 15.0 (SE 1.7) for the 
temporal lobe tumour group; 7.1 (SE 3.6) for the limbic group; 9.0 (SE 1.9) for the 
parietal lobe tumour group; 13.8 (SE 2.8) for the occipital lobe tumour group; 13.8 (SE 
1.6) for the multiple lobes group and 10.1 (SE 2.1) for the ‘other’ location group. 
9.3.5 Nine Hole Peg Test (Right Hand, EFIT)
Twenty-one patients in the frontal lobe tumour group, 10 in the temporal lobe tumour 
group, 2 in the limbic group, 7 in the parietal lobe group, 4 in the occipital lobe group, 
12 in the multiple lobe group and 6 with tumours elsewhere in the brain (‘other’) 
completed this test at both baseline and session 2. 
The mean score for the frontal lobe tumour group at baseline was 13.8 (SD 2.2) and at 
session 2 was 14.5 (SD 2.5). The temporal lobe tumour group had a mean score of 13.2 
(SD 2.8) at baseline and 13.7 (SD 2.5) at session 2. The limbic tumour group had mean 
scores of 13.0 (SD 0.2) and 15.7 (SD 0.5) at baseline and session 2, respectively. The 
parietal lobe tumour group had a baseline mean score of 15.2 (SD 3.9) and a session 2 
mean of 14.9 (SD 2.5). The mean scores for the occipital lobe tumour group were 15.5 
(SD 4.7) and 15.1 (SD 3.8) at baseline and session 2, respectively. The multiple lobe 
tumour group scored a mean of 13.5 (SD 3.7) at baseline and 14.9 (SD 4.2) at session 2 
and the ‘other’ location group had a mean of 13.3 (SD 1.7) at baseline and 13.7 (SD 1.5) 
at session 2. The mean (standard error) scores at baseline and session 2 for each tumour 
lobe group are shown in Figure 9.12.
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Figure 9.12. Baseline and session 2 nine hole peg test (right hand) scores for each 
tumour lobe group. Points are raw mean scores. Error bars: standard error means.
General linear modelling revealed a significant main effect of baseline score on session 
2 nine hole peg test (right hand) scores, F(1,46) = 43.448, p < 0.001, partial η² = 0.486. 
Those patients who performed more quickly at baseline were significantly more likely to 
perform more quickly at session 2 on this measure. There was no significant main effect 
of the covariate age, F(1,46) = 1.252, p = 0.269, partial η² = 0.027. The covariate NART 
also had no significant main effect in the model, F(1,46) = 0.024, p = 0.878, partial η² = 
0.001. Sex had no significant main effect in the model, F(1,46) = 0.011, p = 0.918, 
partial η² < 0.001. Tumour lobe had no significant main effect in the model that included 
the effects of the covariates age, NART score and baseline right hand nine hole peg test 
score, F(6,46) = 0.641, p = 0.697, partial η² = 0.077. There was no significant interaction 
between sex and tumour lobe, F(5,46) = 0.815, p = 0.545, partial η² = 0.081. 
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The estimated marginal mean scores, adjusted for age, NART score and baseline test 
score – derived from the above described general linear model – were 14.6 (SE 0.4) for 
the frontal lobe tumour group; 14.5 (SE 0.7) for the temporal lobe tumour group; 16.0 
(SE 1.5) for the limbic group; 13.9 (SE 0.8) for the parietal lobe tumour group; 13.9 (SE 
1.0) for the occipital lobe tumour group; 15.2 (SE 0.6) for the multiple lobe tumour 
group and 14.1 (SE 0.8) for the ‘other’ location tumour group
9.3.6 Nine Hole Peg Test (Left Hand, EFIT) 
Twenty patients in the frontal lobe group, 10 in the temporal lobe group, 2 in the limbic 
group, 4 in the occipital lobe group, 12 in the multiple lobe group and 6 in the ‘other’ 
group all completed this test at both baseline and session 2 follow-up. 
The mean baseline score for the frontal lobe tumour group was 15.5 (SD 3.7) and at 
session 2 was 15.7 (SD 3.5). The temporal lobe tumour group had a baseline mean score 
of 13.9 (SD 2.7) and a mean score of 14.6 (SD 2.0) at session 2. The limbic tumour 
group had mean scores of 12.8 (SD 1.3) and 14.7 (SD 0.3) at baseline and session 2, 
respectively. The parietal lobe tumour group had a mean baseline score of 16.0 (SD 3.0) 
and a session 2 mean score of 16.2 (SD 3.0). The mean scores for the occipital lobe 
tumour group were 18.3 (SD 1.9) and 20.1 (SD 3.6) at baseline and session 2, 
respectively. The group of patients with multiple lobe tumours scored a mean of 15.8 
(SD 4.8) at baseline and 16.3 (SD 4.4) at session 2. The ‘other’ tumour location group 
scored a mean of 14.4 (SD 3.1) at baseline and at session 2 had a mean score of 14.8 
(SD 2.7). The mean (standard error) scores at baseline and session 2 for each tumour 
lobe group are shown in Figure 9.13.
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Figure 9.13. Baseline and session 2 nine hole peg test (left hand) scores for each 
tumour lobe group. Points are raw mean scores. Error bars: standard error means.
General linear modelling revealed a significant main effect of baseline test score on left 
hand nine hole peg test scores, F(1,45) = 92.662, p < 0.001, partial η² = 0.673. Those 
participants who had faster scores on the test at baseline were significantly more likely 
to have faster scores at session 2. The covariate age also had a significant main effect in 
the model, F(1,45) = 6.296, p = 0.016, partial η² = 0.123. Older participants were 
significantly more likely to take longer to complete the task. NART score had no 
significant main effect in the model, F(1,45) = 0.697, p = 0.408, partial η² = 0.015. Sex 
also had no significant main effect in the model, F(1,45) = 0.168, p = 0.684, partial η² = 
0.004. Tumour lobe had no significant main effect in the model that included the effects 
of the covariates age, NART score and baseline test score, F(6,45) = 0.919, p = 0.491, 
partial η² = 0.109. The interaction between sex and tumour lobe was not significant, 
F(5,45) = 0.105, p = 0.991, partial η² = 0.012. 
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The estimated marginal mean scores, adjusted for age, NART score and baseline test 
score – derived from the above described general linear model – were 15.6 (SE 0.4) for 
the frontal lobe tumour group; 15.8 (SE 0.6) for the temporal lobe tumour group; 17.3 
(SE 1.3) for the limbic tumour group; 15.6 (SE 0.7) for the parietal lobe tumour group; 
17.6 (SE 0.9) for the occipital lobe tumour group; 15.8 (SE 0.5) for the multiple lobes 
tumour group and 15.6 (SE 0.7) for the ‘other’ location group. 
9.3.7 Timed Ten Metre Walk (EFIT)
This test was completed at both baseline and session 2 by 20 patients in the frontal lobe 
tumour group, 9 patients in the temporal lobe tumour group, 2 in the limbic group, 7 in 
the parietal lobe tumour group, 2 in the occipital lobe tumour group, 11 in the multiple 
lobes tumour group and 5 patients in the ‘other’ location group.
The frontal lobe tumour group scored a mean of 7.0 (SD 1.4) at baseline and 7.2 (SD 
1.6) at session 2. The temporal lobe tumour group had a mean baseline score of 6.2 (SD 
1.2) and a mean session 2 score of 6.5 (SD 1.2). The limbic tumour group has mean 
scores of 7.4 (SD 2.0) and 6.7 (SD 1.1) at baseline and session 2, respectively. The 
baseline mean score for the occipital lobe tumour group was 6.1 (SD 0.7) and at session 
2 was 7.1 (SD 1.4). The multiple lobes tumour group had a baseline mean score of 6.4 
(SD 1.2) and a session 2 mean score of 7.6 (SD 1.8). The ‘other’ tumour location group 
scored means of 6.5 (SD 2.2) and 6.5 (SD 1.5) at baseline and session 2, respectively. 
The mean (standard error) scores at baseline and session 2 for each tumour lobe group 
are shown in Figure 9.14.
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Figure 9.14. Baseline and session 2 timed ten metre walk scores for each tumour 
lobe group. Points are raw mean scores. Error bars: standard error means.
General linear modelling revealed a significant main effect of the timed ten metre walk 
test score at baseline, F(1,41) = 42.022, p < 0.001, partial η² = 0.506. The covariate age 
had no significant main effect in the model, F(1,41) = 3.204, p = 0.081, partial η² = 
0.072. The covariate NART also had no significant main effect, F(1,41) = 0.569, p = 
0.455, partial η² = 0.014. Sex had no significant effect in the model, F(1,41) = 0.190, p = 
0.665, partial η² = 0.005. Tumour lobe had no significant main effect in the model that 
included the effects of the covariates age, NART score and baseline timed ten metre 
walk score, F(6,41) = 1.318, p = 0.271, partial η² = 0.162. There was a significant 
interaction between tumour lobe and sex, F(4,41) = 2.680, p = 0.045, partial η² = 0.207. 
Female participants in the multiple lobes and ‘other’ location group took longer to 
complete the timed ten metre walk than the male participants. 
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The estimated marginal mean scores for each tumour lobe group, adjusted for age, 
NART score and baseline timed ten metre walk score – derived from the above 
described general linear model – were 7.0 (SE 0.2) for the frontal lobe tumour group; 7.0 
(SE 0.4) for the temporal lobe tumour group; 6.2 (SE 0.8) for the limbic tumour group; 
6.8 (SE 0.4) for the parietal lobe tumour group; 7.6 (SE 0.7) for the occipital lobe 
tumour group; 7.8 (SE 0.3) for the multiple lobes tumours group and 6.7 (SE 0.5) for the 
‘other’ location tumour group.
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Table 9.2. Overview of comparisons of post-operative test performance in each tumour lobe group.
Test Effect of tumour lobe
F Sig. (p) n²*
Inspection Time (All Data) 0.495 0.808 0.063
Inspection Time (Valid Data) 0.759 0.585 0.091
Digit Symbol Coding (Total) 0.792 0.581 0.097
EFIT Williams Delayed Recall Test (total) 2.091 0.073 0.214
EFIT Nine Hole Peg Test (Right Hand) 0.641 0.697 0.077
EFIT Nine Hole Peg Test (Left Hand) 0.919 0.491 0.109
EFIT Timed Ten Metre Walk (secs) 1.318 0.271 0.162
n² = the proportion of variance accounted for by the covariate (tumour lobe).
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9.4 Hemispheric Lateralisation
Thirty-one patients with left hemisphere tumours and 31 patients with right hemisphere
tumours were tested at both baseline and session 2, post-operatively. 
9.4.1 Inspection Time Scores: All Inspection Time Data
Data from 29 patients with left hemisphere tumours and 29 with right hemisphere 
tumours was available for analysis. 
The left hemisphere tumour group had a mean score of 122.3 (SD 14.4) at baseline and 
117.3 (SD 20.6) at session 2. The right hemisphere tumour group scored a baseline mean 
of 112.2 (SD 25.0) and a mean score at session 2 of 109.5 (SD 24.1). The mean 
(standard error) scores at baseline and session 2 for each hemisphere group are shown in 
Figure 9.15.
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Figure 9.15. Baseline and session 2 inspection time scores for each tumour hemisphere 
group. Points are raw mean scores. Error bars: standard error means.
General linear modelling revealed a significant main effect of baseline inspection time 
score in the model, F(1,51) = 21.401, p < 0.001, partial η² = 0.296. Participants who 
scored higher on inspection time at baseline were significantly more likely to also score 
better at session 2. The effect of the covariate age approached significance in the model, 
F(1,51) = 3.730, p = 0.059, partial η² = 0.068. The covariate NART score had no 
significant main effect in the model, F(1,51) = 1.192, p = 0.280, partial η² = 0.023. Sex 
had no significant main effect in the model, F(1,51) = 0.600, p = 0.442, partial η² = 
0.012. The effect of tumour hemisphere was not significant in the model that included 
the effects of the covariates age, NART score and baseline inspection time score, 
F(1,51) = 0.197, p = 0.659, partial η² = 0.004. There was no significant interaction 
between tumour hemisphere and sex, F(1,51) = 0.008, p = 0.928, partial η² < 0.001. 
Thus, in the presence of the effect of the covariates, there was no significant difference 
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in the extent of post-operative deterioration between the left and right hemisphere 
tumour groups. 
9.4.2 Inspection Time Scores: Valid Inspection Time Data
Twenty-seven patients with left hemisphere tumours and 23 with right hemisphere 
tumours had valid baseline inspection time scores and also completed session 2 post-
operative testing. 
The mean baseline score for the left hemisphere group was 124.4 (SD 11.7) and at 
session 2 was 117.7 (SD 20.3). The right hemisphere group had a baseline mean score of 
122.6 (SD 14.2) and a mean score of 115.7 (SD 19.7) at session 2. The mean (standard 
error) scores at baseline and session 2 for each hemisphere group are shown in Figure 
9.16.
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Figure 9.16. Baseline and session 2 inspection time scores (valid baseline data) for 
each tumour hemisphere group. Points are raw mean scores. Error bars: standard error 
means.
General linear modelling again revealed a significant main effect of the baseline 
inspection time score, F(1,43) = 11.077, p = 0.002, partial η² = 0.205. Participants with 
higher inspection time scores at baseline were significantly more likely to have higher 
scores at session 2. There was no significant main effect of the covariates age, F(1,43) = 
2.229, p = 0.143, partial η² = 0.049; or NART score, F(1,43) = 2.406, p = 0.128, partial 
η² = 0.053. Sex had no significant main effect in the model, F(1,43) = 0.035, p = 0.851, 
partial η² = 0.001. Tumour hemisphere had no significant effect in the model that 
included the effects of the covariates age, NART score and baseline inspection time 
score, F(1,43) = 0.445, p = 0.508, partial η² = 0.010. The interaction between tumour 
hemisphere and sex was not significant, F(1,43) = 1.345, p = 0.253, partial η² = 0.030. 
Thus, in the presence of the effects of the covariates, there was no significant difference 
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between the left and right hemisphere groups in terms of post-operative inspection time 
performance when only valid baseline scores were included in the analysis. 
9.4.3 Digit Symbol Coding
There were 29 patients in the left hemisphere tumour group and 29 in the right 
hemisphere tumour group who completed the digit symbol coding score at both baseline 
and session 2, post-operatively. 
The mean baseline score for the left hemisphere tumour group was 61.4 (SD 20.3) and at 
session 2 was 57.2 (SD 19.6). The right hemisphere tumour group had a mean score of 
60.7 (SD 21.3) at baseline and 56.6 (SD 21.7) at session 2. The mean (standard error) 
scores at baseline and session 2 for each hemisphere group are shown in Figure 9.17.
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Figure 9.17. Baseline and session 2 digit symbol coding scores for each tumour 
hemisphere group. Points are raw mean scores. Error bars: standard error means.
General linear modelling revealed a significant main effect of the baseline digit symbol 
coding score, F(1,51) = 114.215, p < 0.001, partial η² = 0.691. Patients with higher 
scores at baseline were significantly more likely to have higher scores when tested at 
session 2. There was no significant effect of either of the covariates age, F(1,51) = 
0.016, p = 0.899, partial η² < 0.001; or NART score, F(1,51) = 0.245, p = 0.623, partial 
η² = 0.005. Sex had no significant main effect in the model, F(1,51) = 2.851, p = 0.097, 
partial η² = 0.053. The effect of tumour hemisphere was not significant in the model that 
included the effects of the covariates age, NART score and baseline test score, F(1,51) = 
0.054, p = 0.817, partial η² = 0.001. The interaction between sex and tumour hemisphere 
was not significant, F(1,51) = 0.049, p = 0.826, partial η² = 0.001. Thus, in the presence 
of the effects of age, NART score and baseline score, there was no significant difference 
between the left and right hemisphere groups in terms of performance on digit symbol 
coding at session 2. 
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9.4.4 Williams Delayed Recall Test (EFIT)
Twenty-nine patients with left hemisphere tumours and 31 with right hemisphere 
tumours completed the Williams delayed recall test at both baseline and post-operatively 
at session 2. 
The mean score at baseline for the left hemisphere tumour group was 8.5 (SD 4.9) and at 
session 2 was 11.3 (SD 6.8). The right hemisphere tumour group had a baseline mean 
score of 9.0 (SD 5.8) and a session 2 mean score of 11.2 (SD 5.6). The mean (standard 
error) scores at baseline and session 2 for each hemisphere group are shown in Figure 
9.18.
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Figure 9.18. Baseline and session 2 Williams delayed recall test scores for each tumour 
hemisphere group. Points are raw mean scores. Error bars: standard error means.
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General linear modelling revealed a significant main effect of the baseline tests score in 
the model, F(1,53) = 10.766, p = 0.002, partial η² = 0.169. There was no significant main 
effect of either of the covariates age, F(1,53) = 1.213, p = 0.276, partial η² = 0.022; or 
NART score, F(1,53) = 0.712, p = 0.403, partial η² = 0.013. Sex had no significant effect 
in the model, F(1,53) = 0.007, p = 0.931, partial η² < 0.001. Tumour hemisphere had no 
significant main effect in the model that included the effects of the covariates age, 
NART score and baseline Williams delayed recall test score, F(1,53) = 0.017, p = 0.897, 
partial η² < 0.001. The interaction between sex and tumour hemisphere was not 
significant, F(1,53) = 0.081, p = 0.777, partial η² = 0.002. Thus, in the presence of the 
effects of the covariates, there was no significant difference between the performance of 
the left and right hemisphere tumour groups at session 2 post-operatively. 
9.4.5 Nine Hole Peg Test (Right Hand, EFIT)
Twenty-nine left hemisphere tumour patients and 31 right hemisphere tumour patients 
completed this test at both baseline and post-operatively at session 2.
The mean score for the left hemisphere tumour group at baseline was 13.8 (SD 2.6) and 
at session 2 was 14.3 (SD 1.9). The left hemisphere tumour group had a baseline mean 
score of 14.0 (SD 3.3) and at session 2 had a mean score of 14.9 (SD 3.5). The mean 
(standard error) scores at baseline and session 2 for each hemisphere group are shown in 
Figure 9.19.
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Figure 9.19. Baseline and session 2 right hand nine hole peg test scores for each tumour 
hemisphere group. Points are raw mean scores. Error bars: standard error means.
General linear modelling revealed a significant main effect of the baseline right hand 
nine hole peg test score, F(1,53) = 41.854, p < 0.001, partial η² = 0.441. Participants 
with faster scores at baseline were significantly more likely to also have faster scores at 
session 2. There was no significant main effect of either of the covariates age, F(1,53) = 
1.005, p = 0.321, partial η² = 0.019; or NART score, F(1,53) = 0.035, p = 0.853, partial 
η² = 0.001. Sex had no significant main effect in the model, F(1,53) = 0.089, p = 0.766, 
partial η² = 0.002. The effect of hemispheric location of the tumour had no significant 
main effect in the model that included the effects of the covariates age, NART score and 
baseline score, F(1,53) = 0.666, p = 0.418, partial η² = 0.012. The interaction between 
sex and hemisphere was also not significant, F(1,53) = 1.342, p = 0.252, partial η² = 
0.025. Thus, in the presence of the effect of the aforementioned covariates, there was no 
significant difference between the extent of post-operative deterioration on this test in 
the left and right hemisphere tumour groups.  
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9.4.6 Nine Hole Peg Test (Left Hand, EFIT)
Thirty patients with left hemisphere tumours and 29 with right hemisphere tumours 
completed the left hand nine hole peg test at both baseline and session 2. 
The mean baseline score for the left hemisphere tumour group on this test was 14.6 (SD 
2.6) and at session 2, post-operatively, was 14.9 (SD 2.7). The right hemisphere tumour 
group scored a mean of 16.3 (SD 4.2) at baseline and 17.0 (SD 3.8) at session 2. The 
mean (standard error) scores at baseline and session2 for each hemisphere group are 
shown in Figure 10.20.
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Figure 9.20. Baseline and session 2 left hand nine hole peg test scores for each tumour 
hemisphere group. Points are raw mean scores. Error bars: standard error means.
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There was a significant main effect of the baseline test score in the general linear model, 
F(1,52) = 99.183, p < 0.001, partial η² = 0.656. Those participants who had faster scores 
at baseline were significantly more likely to have faster scores at session 2. The 
covariate age also had a significant main effect in the model, F(1,52) = 7.215, p = 0.010, 
partial η² = 0.122. The covariate NART score had no significant main effect in the 
model, F(1,52) = 1.228, p = 0.273, partial η² = 0.023. The effect of sex was not 
significant, F(1,52) = 0.778, p = 0.382, partial η² = 0.015. The effect of hemispheric 
location of tumour did not reach significance in the model that included the effects of the 
covariates age, NART score and baseline left hand nine hole peg test score, F(1,52) = 
3.377, p = 0.072, partial η² = 0.061. The interaction between sex and hemisphere was not 
significant, F(1,52) = 0.015, p = 0.904, partial η² < 0.001. In the presence of the effects 
of the covariates, there was no significant difference in the extent of post-operative 
deterioration on this measure in the left and right hemisphere tumour groups. 
9.4.7 Timed Ten Metre Walk (EFIT)
There were 27 patients with left hemisphere tumours and 27 patients with right 
hemisphere tumours who completed the timed ten metre walk at both baseline and 
session 2, post-operatively.
The mean baseline score for the left hemisphere tumour group was 6.7 (SD 1.5) and the 
mean score at session 2 was 6.9 (SD 1.7). The right hemisphere tumour group had a 
baseline mean score of 6.9 (SD 1.3) and a session 2 mean score of 7.4 (SD 1.7). The 
mean (standard error) scores at baseline and session 2 for each hemisphere group are 
shown in Figure 9.21.
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Figure 9.21. Baseline and session 2 timed ten metre walk test scores for each tumour 
hemisphere group. Points are raw mean scores. Error bars: standard error means.
There was a significant main effect of the timed ten metre walk test score at baseline in 
the general linear model, F(1,47) = 28.629, p < 0.001, partial η² = 0.379. Those 
participants with faster scores on the test at baseline were significantly more likely to 
have faster scores at session 2 testing. The effect of the covariate age was also 
significant in the model, F(1,47) = 5.548, p = 0.023, partial η² = 0.106. Older 
participants were more likely to take longer to complete the test. The covariate NART 
score had no significant min effect in the model, F(1,47) = 0.668, p = 0.418, partial η² = 
0.014. Sex had no significant effect in the model, F(1,47) = 0.113, p = 0.738, partial η² = 
0.002. The effect of tumour hemisphere was not significant in the model that included 
the effects of the covariates age, NART score and baseline test score, F(1,47) = 1.162, p 
= 0.287, partial η² = 0.024. The interaction between sex and tumour hemisphere was not 
significant, F(1,47) = 1.519, p = 0.224, partial η² = 0.031. Thus, in the presence of the 
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effects of the covariates, there was no significant difference between the post-operative 
performance of the left and right hemisphere tumour groups. 
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Table 9.3. Overview of comparisons of post-operative test performance in the left and right hemisphere groups. 
Test Effect of tumour hemisphere
F Sig. (p) n²*
Inspection Time (All Data) 0.197 0.659 0.004
Inspection Time (Valid Data) 0.445 0.508 0.010
Digit Symbol Coding (Total) 0.054 0.817 0.001
EFIT Williams Delayed 
Recall Test (total)
0.017 0.897 < 0.001
EFIT Nine Hole Peg Test 
(Right Hand, secs)
0.666 0.418 0.012
EFIT Nine Hole Peg Test
(Left Hand, secs)
3.377 0.072 0.061
EFIT Timed Ten Metre 
Walk (secs)
1.162 0.287 0.024
   * n² = the proportion of variance accounted for by the tumour hemisphere.
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9.5 Session 3 Follow-Up: Low-Grade Glioma vs. High-
Grade Glioma
9.5.1 Rationale and Overview of Analysis Procedure
Only patients with either a low-grade or high-grade glioma participated in session 3 
follow-up testing and many patients completed only inspection time testing at this 
time due to time constrains (see Chapter 3.4). Therefore, a preliminary analysis was 
carried out to examine whether or not the deterioration in inspection time 
performance in the immediate post-operative period was transient, and whether the 
performance of the low-grade and high-grade glioma groups differed. The following 
analysis was carried out by Mike Allerhand, Statistician in the Department of 
Psychology, University of Edinburgh. 
9.5.2 Results
The mean (standard deviation) inspection time score for the low-grade glioma group 
was 126.1 (SD 11.5) at baseline, 118.2 (SD 23.4) at session 2 and was 129.1 (SD 9.2)
at the time of session 3 follow-up. The mean inspection time score for the high-grade 
glioma group was 110.0 (SD 21.8) at baseline, 113.3 (SD 22.5) at session 2 testing, 
and 116.0 (SD 20.5) at session 3. 
To compare the performance of the low-grade and high-grade glioma cohorts across 
the three testing sessions, the difference in trajectories of the mean inspection time 
scores over the three measurement occasions between the two groups (low grade and 
high grade glioma) was tested using a quadratic multi-level growth model (using the 
lme4 package in R), since this allowed inclusion of inspection time scores from all 
participants, not only scores from those patients who had been tested across all three 
sessions:
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The level-2 model is conditioned on a dichotomy TUMOURTYPE, (low and
high-grade). The parameter of interest is the fixed effect that describes the 
difference in the second-order growth parameter (effectively the curvature of the 
growth curve) between the two groups (low and high). The estimate is significant
(p=.024). Figure 9.22 shows that the low-grade glioma group has a curved trajectory, 
with session 2 scores lower than both baseline and session 3, whereas the high-grade 
glioma group has a straight trajectory. The significant p-value suggests that the 
difference between the performance of the two groups is different: the low-grade 
glioma group deteriorated in the initial post-operative period, but maintained their 
baseline performance when tested at session 3, whereas the high-grade glioma group 
did not show this pattern of transient deterioration. The implications of this are 
discussed in the following section.
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Figure 9.22. Baseline, session 2 and session 3 inspection time scores for the 
low-grade and high-grade glioma groups. Points are raw mean scores. 
Error bars: standard error means.
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9.6 Tumour Characteristics: Discussion
9.6.1 Tumour Histology
Overall, there was no significant main effect of tumour type on any of the baseline 
(pre-operative) test scores. However, post-hoc analyses revealed that, when all 
inspection time data was included in analysis, the performance of the high-grade 
glioma group was significantly worse than that of the low-grade glioma group, 
although this difference was eliminated when invalid inspection time scores were 
excluded. No other significant differences between the performance of the low-grade 
and high-grade glioma groups were found. 
Following surgery, at the initial post-operative testing session, there was no main 
effect of tumour type on follow-up test performance. However, post-hoc tests 
revealed that the low-grade glioma group deteriorated significantly more than the 
high-grade glioma group on the Williams Delayed Recall Test. On the inspection 
time measure, there was a trend towards greater deterioration in the low-grade 
glioma group following surgery when all data was included in the analysis and also 
when only valid data was included. However, these differences were not statistically 
significant. Preliminary analysis of the performance of the low-grade and high-grade 
glioma tumour groups on the inspection time task across all three testing sessions 
suggested that the initial post-operative deterioration observed in the low-grade 
glioma group may be transient, with the low-grade glioma group exceeding baseline 
inspection time scores when tested on a third occasion.
That there were so few differences between the baseline performance of the tumour 
type groups on any of the cognitive measures is somewhat surprising. It has 
generally been reported that high-grade glioma patients tend to present with more 
severe neurological impairment than their low-grade counterparts, given the more 
aggressive nature of their tumour (DeAngelis, 2001). Thus, it was expected that the 
high-grade glioma group would exhibit more severe cognitive impairment in the pre-
operative period than the low-grade glioma group. However, since the majority of 
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studies examining cognition in brain tumour patients tend to focus on a single, 
specific histological group, this prevents direct comparison of the extent of 
impairment in different histological groups as measured by the same tests, at the 
same point in the disease journey. In one of the few studies that directly compare 
different tumour types, patients with rapidly growing tumours (i.e. high-grade 
gliomas) were found to exhibit more severe cognitive impairment than patients with 
more slowly-growing tumours (Hom and Reitan, 1984). Conversely, in a comparison 
of a group of patients with an anaplastic astrocytoma with a group of patients with a 
glioblastoma multiforme, no significant differences between the two groups on a 
battery of tests assessing five domains of cognition were found (Kayl and Meyers, 
2003). This finding suggests that patients with more malignant disease do not suffer 
more severe cognitive deficits than those with less aggressive tumours, although the 
study did not a directly compare high and low-grade glioma patients. In the present 
study, the high-grade glioma group did perform significantly less well than the low-
grade glioma group on inspection time at baseline, but only when all data was 
included in analyses. That this difference was eliminated when invalid scores were 
removed from the data set suggests that high-grade glioma patients were significantly 
more likely to have invalid scores than the low-grade glioma group. The relatively 
high proportion of high-grade glioma patients who failed to achieve validity criterion 
on the inspection time test may not only reflect poorer concentration and 
comprehension of the task demands in the high-grade glioma group but could also 
reflect a slowing of visual information processing in this group to such an extent that 
validity criterion could not be met despite full comprehension of the task. Thus, the 
difference between the two glioma groups when all inspection time data is analysed 
may accurately reflect a greater extent of visual information processing slowing in 
high-grade glioma patients in particular. It is for this reason that an alternative 
version of the inspection time task using an adaptive staircase procedure (as 
discussed in Chapter 5.7) may prove particularly useful since this would allow us to 
determine whether visual information processing is slowed to such an extent in high-
grade glioma patients that validity criterion on the more commonly used version of 
the task cannot be met in some patients with highly aggressive tumours. Moreover, 
the poorer performance of the high-grade glioma group on verbal fluency (by
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comparison with the low-grade glioma and metastasis groups) and on the Rey 
Auditory Verbal Learning Test (by comparison with the meningioma and ‘other’ 
tumour groups) suggests that the extent of cognitive impairment was greater in the 
patients with highly aggressive tumours. As highlighted in Chapter 4, a significantly 
lower proportion of high-grade glioma patients than expected were entered into the 
study and, conversely, the majority of low-grade glioma patients did take part. This 
selection bias must be taken into account when interpreting the results comparing the 
performance of the different tumour type groups at baseline. Since those patients 
who had the most severe impairment and were unable to consent or unwilling to take 
part in the study were more likely to have a high-grade glioma, the cognitive 
impairment in the high-grade glioma group as a whole is likely to be greater than that 
observed in the present study, as a result of inclusion bias. 
Comparatively few studies have examined cognition in patients with meningiomas 
and brain metastases and the present study provides further insight into this under-
studied area. There was no consistent pattern of either greater impairment or superior 
performance in either of these tumour type groups on the baseline cognitive test 
battery by comparison with the other tumour type groups. In one of the few studies 
of cognition in patients with brain metastases, a specific impairment on tests of recall 
and delayed memory was found (Herman et al., 2003). However, in the present 
study, the metastasis group were no more impaired on the baseline measures of 
memory and recall (e.g. Rey Auditory Verbal Learning Test and Williams Delayed 
Recall Test) than the other tumour type groups. In contrast with glial tumours, 
meningiomas tend to be benign, non-infiltrating tumours and it was expected that 
patients with a meningioma would therefore exhibit less severe impairment than 
those patients with gliomas, particularly those of a high-grade. The only baseline test 
on which the meningioma group significantly outperformed any other tumour group 
was the Rey Auditory Verbal Learning Test, yet these patients showed a similar 
degree of impairment as the other tumour type groups on the other baseline tests. In 
one of the few studies to specifically examine cognition in meningioma patients prior 
to surgery, Tucha et al. (2003) report significant impairment in several cognitive 
domains in a group of patients assessed pre-operatively by comparison with a 
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matched group of healthy control participants. Thus, the finding that meningioma 
patients showed similar levels of impairment as the other tumour type groups in the 
present study lends support to Tucha et al.’s (2003) conclusions that suggest 
cognitive impairment is common to meningioma patients prior to surgical 
intervention.
There were no differences between any of the tumour type groups with respect to the 
levels of anxiety and depression as measured by the Hospital Anxiety and 
Depression Scale (HADS). Thus, it can be reasonably assumed that the potential for 
emotional distress to negatively impact cognitive test performance was similar in 
each tumour type group. However, this finding is inconsistent with a study that found 
patients with a meningioma had higher levels of both anxiety and depression pre-
operatively, as measured by the HADS (Pringle et al., 1999). 
At the initial post-operative testing session (session 2), there was no significant 
overall effect of tumour type on patient performance on any of the follow-up 
measures. This suggests that there is no single group of patients with a specific 
tumour type who have an increased risk of suffering greater cognitive impairment 
following surgical intervention. However, although there was no statistically 
significant effect, the low-grade glioma group did show a trend towards greater 
deterioration following surgery by comparison with the high-grade glioma group on 
a number of measures, including inspection time, digit symbol coding and the 
Williams Delayed Recall Test. Although studies have examined post-operative 
cognitive impairment in low-grade glioma patients specifically, no studies have 
assessed the risk of impairment by comparison with other tumour type groups. The 
present results suggest that there may be a tendency for low-grade glioma patients to 
deteriorate to a greater extent than high-grade glioma patients following surgery The 
lack of significant main effect in these analyses may be a result of reduced power to 
detect differences due to relatively high levels of post-operative attrition in the brain 
tumour group that makes type 2 statistical error more likely. Although the low-grade 
glioma group appeared to be at greater risk of deterioration at the time of the initial 
post-operative testing, that the low-grade group exceeded their baseline scores on 
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inspection time testing when assessed for a third time, 10-14 days later, suggests that 
any post-operative deterioration may be transient. Future studies could specifically 
compare the relative risk of impairment in low and high-grade glioma patients in a 
larger cohort to overcome the problems associated with high levels of attrition in the 
present study. Previous studies examining post-operative neurological and cognitive 
complications in low-grade glioma patients have found evidence to suggest that, 
three months after surgery, patients may actually exceed their pre-operative function
(Duffau et al., 2003, Teixidor et al., 2006) and this is supported by the findings of the 
present study. However, further investigation is necessary, with a larger battery of 
tests administered at session 3 given that it was only possible to analyse inspection 
time scores at session 3 due to failure of the majority of patients to complete the 
remaining follow up measures. Moreover, those glioma patients who were assessed 
at session 3 are likely to have been those patients who had a more positive outcome 
following surgery.
The finding that the group of patients with a meningioma did not deteriorate to a 
lesser extent post-operatively than the other tumour type groups contradicts the 
results of the aforementioned study (Tucha et al., 2003). These authors found that the 
cohort of meningioma patients actually improved post-operatively on some tests 
assessing several aspects of cognition, and maintained their pre-operative 
performance on many other measures. However, the cohort of meningioma patients 
recruited into the present study had tumours located throughout the brain, as opposed 
to only frontal lobe tumours. Additionally, there was no adequate control group 
recruited into the study by Tucha et al., (2003) which questions the validity of their 
findings. Thus, since no direct comparison with other tumour type groups was 
carried out and the test battery comprised measures that were perhaps less suitable 
for repeated assessment than those used in the present study, the findings reported in 
this thesis question the conclusions made by Tucha et al. (2003).
Future studies could seek to confirm the present findings in a larger cohort of 
patients with meningiomas. Moreover, since the group of patients with ‘other’ 
tumours was relatively small and consisted primarily of patients with pituitary 
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adenomas, it would be of interest to specifically examine cognition in patients with 
pituitary tumours. Little research had been directed towards this area and given that,
in this very small sample of patients with these relatively benign pituitary tumours, 
cognition appeared to be disrupted in both the pre- and post-operative periods, future 
research could seek to confirm this finding in a much larger sample of patients. 
9.6.2 Hemispheric Location
Very few significant differences between the left and right hemisphere tumour 
groups on the baseline measures were found. When all inspection time data was 
analysed, the left hemisphere group significantly outperformed the right hemisphere 
group, however this difference was eliminated when invalid scores were removed 
from the model. The left hemisphere group were significantly impaired by 
comparison with the right hemisphere tumour group on the RAVLT and the right 
hemisphere group were impaired on the left hand nine hole peg test compared with 
the left hemisphere group. There were no other significant differences between the 
left and right hemisphere tumour groups on any of the other baseline tests and the 
two groups did not differ at all in terms of the extent of post-operative decline. The 
number of patients in each hemisphere group was evenly distributed, and any 
patients with bi-hemispheric tumours, or tumours located elsewhere (e.g. on the 
pituitary gland) were excluded from the analyses in this instance. 
The literature to date has been somewhat conflicting regarding the effect of 
hemispheric location on cognitive function in patients with brain tumours. Studies 
have generally reported that right hemisphere lesions are associated with impairment 
on tests that rely on visual-perceptual skills (Scheibel et al., 1996, Klein et al., 2001),
whereas left hemisphere tumours tend to result in poorer performance on verbal 
learning and language tasks (Hom and Reitan, 1984, Scheibel et al., 1996). Thus, 
based upon this evidence, it was expected that the left hemisphere group would 
perform significantly less well on verbal fluency and the Rey Auditory Verbal 
Learning Test (RAVLT) since both measures involve language function and the 
RAVLT is a measure of verbal learning. However, relative impairment in the left 
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hemisphere group was observed on the RAVLT only, with no significant difference 
found between the two hemisphere groups on the verbal fluency measure. Patients 
with tumours in the right hemisphere were significantly more likely to have invalid 
inspection time scores, given that the group were significantly impaired by 
comparison with the left hemisphere group when all inspection time data was 
included in the analysis. This may not simply reflect a lack of comprehension of task 
instructions but could again be the result of impaired visual perceptual skills that 
precluded successful completion of even the longest stimulus presentation trials. 
However, studies of the functional anatomy of the inspection time task have found 
that both left and right hemispheric brain regions are involved in carrying out the 
task (Deary et al., 2001). Therefore, given that both sides of the brain are involved in 
inspection time task performance, this cannot explain the poorer performance of the 
right hemisphere group on the test. 
That there was no significant difference between the left and right hemisphere groups 
in terms of the extent of impairment on the Williams Delayed Recall Test contrasts 
with the findings of an initial investigation into the utility of the EFIT tests in neuro-
oncological patients. Grant et al. (1994) found that, in a cohort of patients with 
cerebral gliomas, left hemisphere tumours were associated with poorer memory 
function on this measure. However, the heterogeneous nature of the brain tumour 
group in the present study contrasts with the glioma cohort recruited into the 
aforementioned study. This may have contributed to the lack of differences between 
the two hemisphere groups, since the brain tumour group recruited into the present 
study included patients with benign and less invasive tumours. As expected, the right 
hemisphere group were significantly slower to complete the nine hole peg test using 
the left hand at baseline. However, there were no significant differences between the 
two groups on the right hand version of the test. In their study, Grant et al. (1994)
found that the nine hole peg test could detect minor differences between each hand 
that reflect the lateralisation of the tumour. Thus patients with right hemisphere 
tumours were significantly slower on the left hand nine hole peg test and vice versa. 
The present study supports this finding, for the left hand subtest at least. That no 
320
difference on the right hand subtest was found may also be the result of the inclusion 
of non-glioma patients in the study cohort. 
Post-operatively, the extent of decline did not differ between the left and right 
hemisphere tumour groups on inspection time and other tests, suggesting that there is 
no increased risk of neither left nor right hemisphere tumour surgery in terms of 
increasing the extent of cognitive impairment as assessed by the post-operative test 
battery. There has been little attention directed towards the comparative post-
operative cognitive outcome in patients with right vs. left hemisphere tumours. 
Studies of survival in high-grade glioma patients have reported no significant effect 
of tumour hemisphere (Jeremic et al., 1994, Kreth et al., 1993) and therefore it is 
perhaps unsurprising that neither hemisphere group were found to be at greater risk 
of increased cognitive deterioration following surgery.
9.6.3 Tumour Location: Lobe
There was no consistent pattern of either greater impairment or better performance 
on the baseline test battery in any of the tumour lobe groups. The occipital lobe 
group performed significantly less well than each of the other groups on inspection 
time when all data was included. These differences were only observed when all 
inspection time scores, including invalid ones, were included in the analysis. When 
only valid data was examined, the frontal lobe group performed significantly better 
than the parietal lobe group. There was a significant overall effect of tumour lobe in 
the model for the RAVLT and Letter-Number Sequencing task, with the group of 
patients with tumours located elsewhere (‘other’) performing significantly better on 
both measures than the majority of the other lobe groups. The parietal lobe group 
were significantly slower to complete the right hand nine hole peg test than each of 
the other lobe groups and the occipital lobe group were significantly impaired on the 
Williams Delayed Recall Test. The effect of tumour lobe approached significance in 
the model for the digit symbol coding test, with the parietal lobe group performing 
significantly less well than the majority of the other lobe groups. 
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Post-operatively, there was no main effect of tumour lobe for any of the test models. 
However, the temporal lobe group deteriorated to a significantly greater extent than 
the frontal and parietal lobe groups on the Williams Delayed Recall Test. The group 
of patients with a tumour invading more than one lobe (‘multiple lobes’) showed 
greater relative deterioration than the frontal, parietal and ‘other’ location groups on 
the timed ten metre walk. No other significant differences were observed between the 
different lobe groups.
Few studies have explicitly assessed the comparative cognitive effects of brain 
tumours dependent upon the lobe in which it is located in both the pre- and post-
operative periods. It must be highlighted, however, that the number of patients in the 
limbic and occipital lobe groups was relatively small, likely as a result of the 
comparative rarity of tumours located in the limbic system and the increased 
likelihood of severe visual impairment in patients with occipital tumours that would 
have rendered these patients ineligible. Therefore, the power to detect any 
differences dependent upon tumour location is likely to have been reduced. However, 
these results provide interesting preliminary results upon which future studies could 
be based. 
There were no consistent findings with regard to the effect of tumour lobe on 
baseline test scores. That the occipital lobe group were significantly worse than all 
other lobe groups on inspection time, only when all data was included in the analysis, 
is not unexpected. Given that tumours located within the occipital lobes often result 
in visual impairment (quadrantanopia or hemianopia), the occipital lobe group were 
more likely to have difficulty in discriminating between the two inspection time 
stimulus shapes. As such, these patients were more likely to have invalid inspection 
time scores. This may also explain the poorer Williams Delayed Recall Test scores in 
the occipital lobe tumour group since some patients may have had greater difficulty 
seeing the images to be memorised, resulting in poorer recall. The absence of any 
other significant differences in the performance of the tumour lobe groups on 
inspection time testing is likely because relative activation and deactivation in a 
number of different brain areas have been shown in fMRI studies to be involved
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during task performance (Deary et al., 2001, Deary et al., 2004). Therefore, since the 
neural correlates of inspection time performance are not confined to a single region, 
this may explain why the different tumour location groups exhibited a similar degree 
of impairment on the inspection time measure. 
Frontal lobe tumours are often associated with a better prognosis, at least in high-
grade glioma patients and by comparison with temporal and parietal lobe tumours
(Simpson et al., 1993). Since studies have found cognitive function to be a predictor 
of survival in patients with recurrent gliomas (Meyers et al., 2000), it may be 
reasonable to expect that those patients with tumours located within the frontal lobes 
may have outperformed those patients with tumours located elsewhere in the brain at 
the time of baseline testing. However, several studies that have investigated the 
neural correlates of different cognitive measures have often reported frontal lobe 
involvement during task performance. For example, numerous studies have found 
that the prefrontal cortex is specifically involved in verbal fluency tasks (Parks et al., 
1988, Hirshorn and Thompson-Schill, 2006) and studies have found poorer scores on 
this measure to be associated with frontal lesions, and left frontal lesions in particular 
may cause greater impairment (Miceli et al., 1981). Increased frontal lobe activity 
has also been observed during the digit-symbol coding test (Nakahachi et al., 2008), 
although performance on this measure has also been reported to be negatively
affected by the presence of a tumour, regardless of lesion location (Lezak et al., 
2004). Studies of trail making test performance in brain-injured populations have 
found evidence to suggest that frontal lobe activation occurs during task performance 
(Segalowitz et al., 1992). These findings, coupled with the fact that frontal lobe 
damage is commonly reported to have a negative impact on executive functioning, 
would suggest that frontal lobe patients may have been more likely to experience 
greater impairment on the baseline test battery, compared with patients with tumours 
located in different lobes throughout the brain. However, the present study does not 
confirm this theory, given that the frontal lobe tumour group were no more or less 
impaired on the majority of baseline tests, with the exception of digit symbol coding, 
on which they outperformed a number of other lobe groups. This therefore questions 
the proposal that the frontal lobes are specifically involved during performance of the 
323
digit symbol coding test (Nakahachi et al., 2008). Future studies could involve fMRI 
scanning in brain tumour patients during performance of cognitive tests in order to 
provide greater insight into the disruptive effect of a tumour on the brain’s functional 
anatomy. 
Post-operatively, there were very few significant differences in the extent of 
deterioration dependent upon the location of the tumour, by lobe. This suggests that 
the cognitive risks of brain tumour surgery are generally no greater for any specific 
lobe group. However, the temporal lobe tumour group did exhibit greater 
deterioration on the Williams Delayed Recall Test when compared with the frontal 
and parietal lobe groups, suggesting that surgery for temporal lobe tumours may be 
associated with greater risk of delayed memory impairment than surgery for frontal 
and parietal lobe tumours, although this may be transient. This finding can likely be 
explained by the fact that short term memory is related to temporal lobe function, 
with previous studies reporting that visual recognition memory is mediated by a 
neural system that included the medial temporal lobe structures and the 
inferotemporal cortex (Owen et al., 1995).
Thus, overall there were found to be very few significant differences between the 
different tumour lobe groups on the cognitive measures in neither the pre, nor post-
operative period. Future studies involving fMRI scanning in this patient group during 
performance of the inspection time, and other cognitive measures could provide 
information regarding the specific brain areas involved in performance of different 
cognitive tasks. Additionally, further research could also provide greater insight into 
the extent of disturbance to functional brain networks that occurs as a result of the 
presence of a tumour that may explain cognitive deficits in neuro-oncological 
patients that cannot simply be explained as resulting from the location of the tumour 
(see Chapters 1.4 and 6.3).
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10 Quality of Life 
10.1 Method of Scoring
The brain tumour and spinal surgery cohorts were administered the European 
Organisation for the Research and Treatment of Cancer Quality of Life 
Questionnaire Core-30 version 3.0 (EORTC QLQ-C30) at the time of baseline (pre-
operative) testing. One hundred and two patients in the brain tumour group and 77 
patients in the spinal surgery group completed the questionnaire at baseline. The 
EORTC QLQ-C30 comprises five functional scales – physical, role, emotional, 
cognitive and social; three symptom scales - fatigue, nausea and vomiting and pain; 
six single-item scales – dyspnoea (shortness of breath), insomnia, appetite loss, 
constipation, diarrhoea and financial impact of disease; and an overall global health
scale (health-related quality of life). There are a total of 30 questions in the EORTC 
QLQ-C30.  The questionnaire items were scored according to the procedures 
recommended by the EORTC Quality of Life Group (Fayers et al., 2001). Briefly, an 
average score for each scale was calculated (raw score). Each raw score was 
converted using a linear transformation to a scale that standardises the raw score. 
Scores ranged from 0 to 100 with higher scores either representing a ‘better’ level of 
functioning on the functional and global health scales, or a ‘worse’ level of 
symptoms on the symptom and single-item scales.
Both the brain tumour and spinal surgery groups were also administered the Brain 
Cancer Module (QLQ-BN20), a 20 item questionnaire, intended primarily for brain 
tumour patients undergoing chemotherapy and/or radiotherapy. It includes four 
scales assessing future uncertainty, visual disorder, motor dysfunction and 
communication deficit, and seven single items that measure other disease symptoms 
(headache, seizures, daytime drowsiness, hair loss, itching, weakness of both legs 
and bladder control). One hundred and one brain tumour patients and 77 spinal 
patients completed the QLQ-BN20. Standardised scores were calculated from raw 
scores, using a linear transformation in the same manner as described for the EORTC 
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QLQ-C30, with higher scores representing a higher (‘worse’) level of symptoms
(Fayers et al., 2001). 
This chapter compares the brain tumour and spinal surgery patient groups on the 
EORTC QLQ-C30 and QLQ-BN20 in order to determine whether quality of life is 
significantly worse in patients with brain tumours by comparison with matched 
surgical controls. Scores on both questionnaire scales are then correlated with 
inspection time scores at baseline for each group in order to determine whether 
impairment in specific aspects of quality of life are significantly related to poorer 
visual information processing. 
Given that the scores for several of the EORTC QLQ C30 and QLQ-BN20 were 
found to be either positively or negatively skewed, non-parametric comparisons were 
run to compare the brain tumour and spinal surgery groups on each scale. 
10.2 Quality of Life: Brain tumour patients vs. spinal 
surgery controls
The scores for the brain tumour and spinal surgery control group on each scale of the 
EORTC QLQ-C30 were compared using the Mann-Whitney test. The mean 
(standard deviation) and median (range) baseline scores for the two groups along 
with relevant p-values, are shown in Table 10.1 for each scale on the questionnaire. 
The brain tumour patients did not differ significantly from the spinal surgery patients 
on the emotional and cognitive function scales, U = 3496.500, z = -1.264, p = 0.206 
and U = 3709.000, z = -0.648, p = 0.517, respectively.  There was also no significant 
difference between the levels of nausea and/or vomiting, U = 3876.500, z = -0.173, p 
= 0.862; dyspnoea, U = 3887.000, z = -0.151, p = 0.880; or diarrhoea, U = 3590.000, 
z = -1.474, p = 0.140, experienced in the two groups.
However, the brain tumour group had significantly better physical functioning than 
the spinal surgery patients, U = 2130.000, z = -5.454, p < 0.001. They also had 
significantly better role (i.e. daily life) function, U = 2573.000, z = -3.993, p < 0.001 
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and significantly better social function than the spinal surgery patients, U = 
2189.000, z = -5.137, p < 0.001. 
In terms of symptoms, the spinal surgery group reported significantly more fatigue, 
U = 2178.000, z = -5.143, p < 0.001; pain, U = 776.500, z = -9.334, p < 0.001; 
insomnia, U = 3019.000, z = -2.736, p = 0.006; appetite loss, U = 3243.000, z = -
2.329, p = 0.020; constipation, U = 3350.500, z = - 2.117, p = 0.034, and financial 
difficulties, U = 3125.000, z = -2.624, p = 0.009, than the brain tumour cohort. 
The brain tumour group had significantly better self-rated overall health-related 
quality of life than the spinal surgery patients, U = 2915.000, z = -2.976, p = 0.003. 
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Table 10.1. Mean scores and comparisons of the brain tumour and spinal surgery groups on each EORTC QLQ-C30 scale. p-value from Mann-Whitney 
test. ¹ = higher scores indicate better function. ² = higher scores indicate greater symptom burden.
Brain Tumour Spinal Surgery 
Mean (SD) Median (range) Mean (SD) Median (range) p value for 
difference













































































10.3 Brain Cancer Module: Brain tumour patients vs. 
spinal surgery controls
The scores on the QLQ-BN20 scales were compared between the brain tumour and 
spinal surgery groups using the Mann-Whitney test. The descriptive data and p-
values for comparison on each scale are shown in Table 10.2. The two groups did not 
differ significantly on the future uncertainty scale, U = 3810.500, z = -0.230, p = 
0.818. There was also no significant difference between the two groups on the visual 
disorder scale, U = 3459.000, z = -1.592, p = 0.111. On the single items in the 
questionnaire, the two groups did not differ significantly on the daytime drowsiness 
item, U= 3670.000, z = -0.699, p = 0.484; the itching item, U = 3737.500, z = -0.633, 
p = 0.527; or the bladder control item, U = 3535.000, z = -1.595, p = 0.111. 
However, the spinal surgery group reported significantly higher levels of motor 
dysfunction than the brain tumour group, U = 3018.500, z = -2.601, p = 0.009 and 
also reported a higher incidence of weakness of both legs than the brain tumour 
group, U = 3060.500, z = -3.082, p = 0.002. The brain tumour group had higher 
scores on the communication deficit scale than the spinal surgery patients, U = 
3011.000, z = -2.746, p = 0.006 and also had higher scores on the following single 
items: headache, U = 2880.000, z = -3.180, p = 0.001; seizures, U = 3321.000, z = -
3.269, p = 0.001; and hair loss, U = 3564.000, z = -2.113, p = 0.035.
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Table 10.2. Mean scores and comparisons of the brain tumour and spinal control groups on the QLQ-BN20 scales. p-value from Mann-Whitney test. 
Higher scores indicate greater symptom burden. 
Brain Tumour Spinal Surgery
Mean (SD) Median (range) Mean (SD) Median (range) p value for 
difference










Motor Dysfunction 18.8 (21.1) 11.1



















Daytime Drowsiness 24.8 (26.5) 33.3 
(0 – 100)
26.4 (24.4) 33.3 
(0 – 100)
0.484
Hair Loss 5.0 (15.9) 0.0
(0 – 100)














Bladder Weakness 9.2 (20.6) 0.0
( 0 – 100) 
5.2 (17.2) 0.0
(0 – 100) 
0.111
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10.4 Quality of Life and Inspection Time
Since the scores for several scales on the EORTC QLQ-C30 were found to be 
positively or negatively skewed, non-parametric correlations (Spearman’s rho) of 
total baseline inspection time scores and scores on each EORTC QLQ-C30 scale 
were carried out to determine whether specific aspects of Quality of Life were related 
to inspection time performance in the brain tumour and spinal surgery groups. The 
correlations are shown in Table 10.3. 
In the brain tumour group, poorer inspection time scores were significantly 
correlated with poorer physical function scores, rho(n = 98) = 0.374, p < 0.001; 
poorer role functioning scores, rho(n = 98) = 0.264, p = 0.009 and poorer social 
functioning scores, rho(n = 98) = 0.206, p = 0.042. There were no significant 
correlations between any of the symptom scale scores and inspection time 
performance in the brain tumour group (see Table 11.3). Inspection time scores were 
positively correlated with global health scale scores in the brain tumour group, rho(n 
= 98) = 0.264, p = 0.009. Patients with higher total inspection time scores were more 
likely to have better self-perceived global health scores on the questionnaire. 
Conversely, there were no significant correlations between total baseline inspection 
time scores and any of the physical, symptom or global health scales in the spinal 
surgery control group (see Table 10.3). 
10.5 Brain Cancer Module and Inspection Time
Non-parametric correlations of baseline total inspection time scores and each 
scale/item on the QLQ-BN20 were also carried out for both the brain tumour and 
spinal surgery groups. The correlations are shown in Table 10.4. 
In the brain tumour group, the motor dysfunction scale was significantly correlated 
with total inspection time score, rho(n = 98) = -0.275, p = 0.006. Patients who 
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reported greater motor impairment on the QLQ-BN20 were significantly more likely 
to have poorer inspection time scores. Inspection time was also significantly 
correlated with the ‘headache’ item in the brain tumour group, rho(n = 98) = 0.211, p 
= 0.037. Patients who reported greater effects of headache were more likely to have 
higher inspection time scores at baseline. No other significant correlations between 
baseline inspection time total score and any of the other QLQ-BN20 scales were 
obtained. 
In the spinal surgery group, scores on the visual disorder scale were significantly 
correlated with baseline inspection time score, rho(n = 76) = -0.336, p = 0.003. 
Patients who reported higher levels of visual disorder were more likely to have lower 
(poorer) total inspection time scores at baseline. There was also a significant 
correlation between scores on the ‘itching’ item and baseline inspection time scores, 
rho(n = 76) = -0.304, p = 0.008. Patients in the spinal surgery group who had higher 
ratings on the itching item were more likely to have lower (poorer) inspection time 
scores. There were no other significant correlations between total scores on 
inspection time at baseline and any of the other QLQ-BN20 scales. 
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Table 10.3. Non-parametric (spearman’s rho) correlations between total baseline inspection time scores and the functional, symptom and global health 
scales of the EORTC QLQ-C30. * denotes significant correlation. 
Brain Tumour Group Spinal Surgery Control Group
Correlation coefficient 
(with baseline total 
inspection time score)
p value for significance Correlation coefficient 
(with baseline total 
inspection time score)
p value for significance
Physical Function 0.374 < 0.001* 0.142 0.221
Role Function 0.264 0.009* -0.158 0.173
Emotional Function -0.005 0.958 -0.209 0.069
Cognitive Function 0.096 0.347 0.216 0.060
Social Function 0.206 0.042* -0.189 0.102
Fatigue -0.196 0.054 -0.073 0.529
Nausea/Vomiting 0.037 0.721 0.030 0.796
Pain 0.208 0.040* 0.055 0.635
Dyspnoea -0.073 0.472 0.139 0.231
Insomnia -0.060 0.556 0.015 0.895
Appetite Loss 0.050 0.623 -0.028 0.810
Constipation -0.003 0.976 -0.008 0.947
Diarrhoea 0.047 0.647 -0.170 0.142
Financial Difficulties -0.163 0.110 0.161 0.165
Global Health 0.264 0.009* -0.100 0.392
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Table 10.4. Non-parametric (spearman’s rho) correlations between total baseline inspection time scores and the symptom scales/items on the QLQ-
BN20. * denotes significant correlation. 
Brain Tumour Group Spinal Surgery Control Group
Correlation coefficient 
(with baseline total 
inspection time score)
P value for significance Correlation coefficient 
(with baseline total 
inspection time score)
P value for significance
Future Uncertainty -0.016 0.877 0.007 0.950
Visual Disorder 0.022 0.830 -0.336 0.003*
Motor Dysfunction -0.275 0.006* -0.081 0.487
Communication Deficit 0.066 0.517 -0.086 0.459
Headache 0.211 0.037* 0.018 0.875
Seizures 0.121 0.235 0.198 0.087
Daytime Drowsiness -0.163 0.109 -0.072 0.536
Hair Loss 0.034 0.740 -.0.096 0.411
Itching 0.036 0.723 -0.304 0.008*
Weakness of Both Legs <0.001 0.997 <0.001 0.997
Bladder Control -0.050 0.628 0.049 0.677
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10.6 Discussion
10.6.1 Brain Tumour vs. Spinal Surgery Patients
Comparing the brain tumour patient group with the matched group of spinal surgery 
control patients revealed significant differences on a number of the EORTC QLQ-
C30 scales. The spinal surgery group had significantly worse physical, role and 
social function than the brain tumour patients. They also reported significantly more 
fatigue, pain, insomnia, appetite loss, constipation and financial difficulties. The 
spinal surgery group also reported significantly poorer global health than the brain 
tumour patient group. There were also a number of significant differences between 
scores on the QLQ-BN20 in the two groups. The spinal surgery patients reported 
significantly more motor dysfunction and weakness of both legs on this scale. The 
brain tumour patients reported significantly more communication deficit, headache, 
seizures and concerns about hair loss than the spinal surgery group. 
Several studies have assessed health-related quality of life (QoL) using a number of 
different self-report questionnaires in brain tumour patients. The majority of studies 
focus specifically on patients with high-grade gliomas and examine the changes in 
QoL throughout the course of the disease journey, and as a measure of the 
comparative effects of different treatments (Taphoorn et al., 2005). However, few 
studies have examined QoL in brain tumour patients by comparison with other 
patient groups. That the spinal surgery patient group had significantly worse 
physical, role and social function compared with the brain tumour patients is 
somewhat unexpected given the relative severity of disease in the latter group. 
However, this may be explained by the fact that the spinal surgery cohort may have 
been more physically symptomatic given the disabling effects of their disease. The 
majority of the brain tumour cohort likely had minimal physical impairment due to 
the ameliorating effects of dexamethasone. The physical effects of degenerative 
spinal disease likely resulted in poorer role and social functioning. Moreover, given 
that the spinal patients were more likely to have experienced symptoms over a 
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significantly longer period of time than the brain tumour cohort who tended to 
present on a much more urgent basis, this may explain the greater financial 
difficulties in the spinal surgery group given that they may have been unable to work 
for a longer period of time than the brain tumour patients. Furthermore, the increased 
pain in the spinal surgery group is unsurprising and this may also explain the 
increased levels of insomnia and fatigue due to pain. Again, the increased reports of 
motor dysfunction and weakness in both legs in the QLQ-BN20 in the spinal surgery 
group are common symptoms in this group of patients. 
The brain tumour group had a higher symptom level on only the communication 
deficit, headache, seizures and hair loss items on the QLQ-BN20, suggesting that 
QoL was no worse in this patient group than in the matched spinal surgery cohort.
In one of the few studies to compare the QoL of brain tumour patients with another 
patient group, Giovagnoli (1999) compared a group of glioma patients with stable 
disease following surgery, radiotherapy and chemotherapy with a group of control 
patients who had other chronic neurological disease. All patients completed the 
Functional Living Index-Cancer (FLIC) as a measure of QoL and there were no 
significant differences between the two groups on any of the FLIC scales. Therefore, 
although the brain tumour patients were at a different stage of disease and a different 
measure of QoL was used, the finding of the present study that suggest the brain 
tumour patients did not have significantly worse QoL than matched surgical control 
patients is supported by Giovagnoli (1999). 
It must again be considered that the group of brain tumour patients who were entered 
into the study were a select cohort who likely had less severe symptoms than those 
who declined to participate, or were excluded for medical reasons. Therefore, 
although the brain tumour cohort did not appear to have a poorer health-related QoL 
by comparison with the spinal surgery patient group, this may not reflect the entire 
newly-presenting group of patients. 
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10.6.2 Quality of Life and Inspection Time Scores
In the brain tumour group, a number of EORTC QLQ-C30 scales were correlated 
with inspection time scores. Patients with poorer physical function, role function and 
social function were all significantly more likely to have lower (poorer) inspection 
time total scores. Increased pain and lower (poorer) global health score were also 
significantly associated with poorer inspection time total scores in the brain tumour 
group. Higher levels of motor dysfunction, as assessed by the QLQ-BN20, were also 
significantly associated with poorer inspection time scores in the brain tumour group. 
Interestingly, greater symptoms of headache were associated with higher (better) 
inspection time scores in the brain tumour group. Conversely, there were no 
significant correlations between any of the scales on the EORTC QLQ-C30 and total 
inspection time scores in the spinal surgery control group. The visual disorder and 
itching items in the QLQ-BN20 were, however, correlated with total baseline 
inspection time scores in the spinal surgery group, with greater reported symptoms 
associated with poorer inspection time scores. 
Correlating the different scales on the two QoL questionnaires was carried out in 
order to determine whether, in addition to providing information regarding the 
presence and extent of visual information processing slowing that reflects the extent 
cognitive impairment, inspection time performance also reflects specific aspects of 
quality of life. It is well recognised that impaired cognition can have a significantly 
detrimental effect on an individual’s quality of life (Weitzner and Meyers, 1997) and 
this study gives an insight into the specific areas of quality of life that may be 
affected by slowed information processing in brain tumour patients. 
The brain tumour and spinal surgery groups differed with respect to the quality of 
life scales that were significantly related to total baseline inspection time scores, with 
poorer physical, role and social functioning reflected in poorer inspection time scores 
in the brain tumour group. This may be the result of increased levels of depression 
resulting from impairment in these aspects of daily function, since previous studies 
have reported slowed information processing in unmedicated depressed patients, as 
measured by the visual inspection time task (Tsourtos et al., 2002). However, given 
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that the spinal surgery group actually had significantly poorer physical, role and 
social function by comparison with the brain tumour group and that levels of anxiety 
and depression, as measured by the Hospital Anxiety and Depression Scale, did not 
differ, depression is unlikely to explain these correlations in the brain tumour group. 
Motor dysfunction was significantly associated with poorer inspection time scores in 
the brain tumour group, but not in the spinal surgery group. Although a small 
minority of patients who experienced motor weakness as a result of the tumour 
location chose to voice their responses, with the researcher recording the responses, 
the majority of patients were able to use the computer keyboard to respond 
independently. However, it may be that those patients with some form of motor 
weakness were also more likely to experience more severe cognitive symptoms. 
Conversely, motor dysfunction in the spinal surgery group was related only to the 
physical effects of degenerative spinal disease and this may explain why there was 
no significant correlation between the motor function scale and inspection time 
performance in the spinal surgery cohort. Surprisingly, complaints of headache were 
significantly related to better inspection time scores in the brain tumour cohort and 
this finding is somewhat difficult to explain. It may be that those patients who 
complain of headache are those for whom headache is the primary symptom. In 
patients with more severe symptoms such as impaired physical and/or mental 
function, the effects of headache may seem relatively minor and are therefore rated 
as less severe in these patients. Those patients for whom headache is the only 
symptom would therefore likely be better functioning since they are relatively 
unaffected by other complaints and this could, in part, explain the correlation 
between increased report of headache and better inspection time performance. 
It is also of interest that the visual disorder scale in the QLQ-BN20 was correlated 
with inspection time scores in the spinal surgery control group only, with greater 
visual disorder significantly related to poorer inspection time scores. This was 
despite the fact that there was no difference between the levels of visual disorder 
reported in the two groups. It would be expected that a higher symptom burden on 
this scale would be reflected in poorer scores on inspection time since it relies 
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heavily on the participant having intact visual function and it is unclear why this was 
not observed in the brain tumour cohort. 
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11 Conclusions and Future Work
This thesis has shown that newly-presenting patients with supratentorial brain 
tumours experience tumour-related cognitive impairment in a number of different
domains at the time of presentation and prior to any treatment, by comparison with 
age and sex-matched surgical and healthy controls. Few studies have assessed 
cognition in patients with brain tumours prior to any surgical intervention and this 
thesis has given insight into the role of the tumour itself in causing impairment in 
cognition. Moreover, the inclusion of patients with meningiomas and metastases in 
the study cohort has shown the feasibility of carrying out such assessments in these 
patient groups and shows that cognitive impairment is common to patients with these 
types of tumours. This has been an understudied area to date. Surgical intervention, 
in the form of either biopsy or resection, results in general worsening of these
deficits, although this may be transient, at least for those patients with a low-grade 
glioma. Initial post-operative deterioration was also observed on several cognitive 
measures in a matched surgical control cohort. 
In this large cohort of brain tumour patients, there was a clear trend towards greater 
post-operative deterioration in those patients who had undergone a resection by 
comparison with those patients who had biopsy only, although the difference did not 
reach statistical significance. This was likely due to relatively high levels of attrition 
that occurred in the brain tumour cohort in particular. Chapters 8 and 9 show that 
there was no trend towards greater impairment in a single histological group on the 
baseline test measures, nor was there any specific histological group that was at 
greater risk of impairment following surgery. However, the high-grade glioma group 
showed greater impairment on inspection time, a measure of memory and a measure 
of verbal fluency in the pre-operative period. Post-operatively, the low-grade glioma 
group deteriorated significantly more than the high-grade glioma group on the 
Williams Delayed Recall Test and there was a trend towards greater post-operative 
deterioration in the low-grade glioma group by comparison with the high-grade 
glioma patients, although this did not reach significance. Inspection time testing on a 
second occasion post-operatively (session 3) suggested that the observed initial post-
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operative deterioration in the low-grade cohort was transient, whereas this pattern of 
initial deterioration followed by a significant improvement on inspection time was 
not evident in the group of patients with a high-grade glioma. There were few 
significant differences in terms of test performance dependent upon the location of 
the tumour, by hemisphere or lobe.
Research has expanded in recent years and the cognitive effects of treatments and 
interventions in brain tumour patients are now being addressed in addition to 
measurements of neurological function and objective response on CT or MRI 
scanning. Thus, neurocognitive function is becoming an increasingly important 
outcome measure in clinical trials in neuro-oncology and as a result there is a need 
for short, repeatable tests that are sensitive to change and measure an important 
function (Weitzner and Meyers, 1997). This thesis primarily aimed to evaluate the 
utility of the inspection time task, a measure of visual information processing, as a 
clinical tool for use in neuro-oncological patients. The task was found to be a useful 
tool with which to measure and quantify the extent of slowing in visual information 
processing in brain tumour patients at the time of presentation, and as an indicator of 
response to treatment. It was as sensitive as a number of commonly-used 
standardised measures at baseline and was able to distinguish post-operative 
deterioration in the brain tumour group specifically from the general post-operative 
deterioration observed in both the brain tumour and surgical controls on other 
follow-up tests. Given that the task has a number of specific advantages for use in 
neuro-oncology: it is not confounded by motor or speech impairments; is suitable for 
repeated assessment and is a relatively short and simple measure, it could usefully be 
incorporated into neurocognitive test batteries in order to provide meaningful 
information that is not confounded by focal neurological deficits, emotional distress 
or practice effects. Moreover, minimal staff training is required for the administration 
of the inspection time task and it therefore could easily be administered in a clinic 
setting, with minimal demands on resources.
In addition to detailing the cognitive status of brain tumour patients in the pre- and 
post-operative period and evaluating the utility of inspection time testing in this 
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patient cohort, this thesis also raises important issues surrounding the potential for 
bias when carrying out cognitive testing with brain tumour patients. Low-grade 
glioma patients were over-represented in the study cohort and high-grade glioma 
patients were under-represented when compared with the total number of potentially 
eligible patients. As such, previous and future studies of cognition in brain tumour 
patients may actually under-estimate the extent of impairment, given that patients 
with high-grade gliomas tend to exhibit the most severe symptoms. Thus, the 
importance of recording and reporting the representative nature of the sample 
obtained in similar studies is highlighted (Scotland et al., 2009). 
There are a number of directions for future research into the use of this measure of 
visual information processing in neuro-oncology. Given its proven utility as a 
measure in neuro-oncology that is tolerated by the majority of patients, the visual 
inspection time task could usefully be employed as a measure of brain changes that 
occur during and for many years following radiotherapy in patients with brain 
tumours. Inspection time testing during functional MRI scanning could give insight 
into the specific brain processes and networks that are disrupted as a result of the 
presence of a tumour. Future studies could also expand upon the methodology used 
in the present study to include other version of the inspection time that use an 
adaptive staircase procedure in order to determine whether those brain tumour 
patients who fail to meet validity criteria on the more commonly-used version of the 
test do so as a result of severe slowing to visual information processing ability, or 
because of reduced attentional function. Finally, given that low-grade glioma patients 
appeared to show greater deterioration than those patients with high-grade gliomas in 
the initial post-operative period, it is of particular interest to determine whether or 
not this deterioration is transient, as indicated by preliminary analysis of data from 
the small number of patients who completed testing on a second post-operative 
occasion. Therefore, further studies of cognition in glioma patients could evaluate 
inspection time changes post-operatively as described in this thesis, but could also 
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Appendix A. Recruitment poster
Principal Investigator: Prof. Ian R. Whittle
I am currently recruiting brain tumour patients for the 
above study and would really appreciate your help. I 
need to see patients prior to surgery for up to an hour 
and during this time they will complete a number of 
different tasks. I will then see them post-surgery for
around 25 minutes. I am also recruiting healthy patients 
who are undergoing spinal surgery as controls. If you 
could contact me with information about any suitable 
patients, this would be a great help. I am based in ECNO 
and my contact details are below. 
Tel: ext 33267
E-mail: jscotla2@staffmail.ed.ac.uk
We are also looking for healthy volunteers to take part in the 
study as controls. Please pass this information to anyone who may be 
willing to participate. 
Thank you!
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Appendix B. Patient Information Sheet
Patient Information Form       
Assessment of Information Processing and the Effects of Therapy
You are being invited to take part in a research study that provides information about 
how the brain copes with new information. We wish to determine whether the brain 
is slowed down by the presence of a tumour and if treatments improve the speed at 
which the brain processes information. The tasks you complete will not influence 
your normal course of treatment in any way. 
If you choose to participate in this study, you will be required to complete a number 
of thinking tasks. Some of the tasks involve remembering things, some involve 
working things out, and some look at how fast your brain is working on that day. 
Each task is short. One of the tasks is performed in front of a computer. You will be 
asked to make a simple decision about a pattern that appears on the screen. You will 
be given further, precise instructions before each task to ensure you understand 
completely what is involved. 
You will be asked to complete these tasks before therapy (surgery). This should take 
about 1 hour. You will also be asked to complete a shorter session which will take up 
to 30 minutes a few days after therapy (surgery). If you have a brain tumour, you will 
also be asked to take part in a third session which will take place when you attend 
your outpatient appointment. The tests you complete will not influence your normal 
course of treatment in any way. 
The information we gain from these results will help to determine whether certain 
therapies improve patient functioning.
All the information that is obtained is entirely confidential and stored in protected 
databanks. Your data will not be identifiable to any other person. As part of this 
research programme, we shall let your GP know that you have participated in the 
study.
Please feel free to ask questions if anything is not clear or if you would like more 
information. 
If you require further information on these tests and why they are performed you or 
your family can contact Dr. Robin Grant, Consultant Neurologist, Western General 
Hospital (0131 537 2084). He is not involved in the study and so will be able to give 
you independent advice.
Yours sincerely
IAN R. WHITTLE MD PhD FRACS FRCSE (SN) FRCPE
Forbes Professor of Surgical Neurology
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Appendix C. Healthy volunteer information sheet
Participant Information Form       
Assessment of Information Processing and the Effects of Therapy
Principal Investigator: Professor Ian R. Whittle, Department of Clinical 
Neurosciences, Western General Hospital, Edinburgh.
You are being invited to take part in a research study that provides information about 
how the brain copes with new information. We wish to determine whether the brain 
is slowed down by the presence of a tumour and if treatments improve the speed at 
which the brain processes information. You have been asked to take part in this study 
as part of a group of healthy volunteers. By comparing your results with those of a 
group of patients who have a brain tumour, we hope to learn more about this group 
of patients. 
If you choose to participate in this study, you will be required to complete a number 
of thinking tasks. Some of the tasks involve remembering things, some involve 
working things out, and some look at how fast your brain is working on that day. 
Each task is short. One of the tasks is performed in front of a computer. You will be 
asked to make a simple decision about a pattern that appears on the screen. You will 
be given further, precise instructions before each task to ensure you understand 
completely what is involved. 
Taking part in this study will involve two separate sessions. The first of these should 
take up to 1 hour. The second session will take place three to seven days after the 
first session and will be shorter, lasting around 25-30 minutes. These sessions can 
take place at any time convenient to you. 
The information we gain from these results will help to determine whether certain 
therapies improve patient functioning.
All the information that is obtained is entirely confidential and stored in protected 
databanks. Your data will not be identifiable to any other person.
Please feel free to ask questions if anything is not clear or if you would like more 
information. 
Yours sincerely
IAN R. WHITTLE MD PhD FRACS FRCSE (SN) FRCPE
Forbes Professor of Surgical Neurology
Consultant Neurosurgeon
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Appendix D. Letter to recruitment panel
Edinburgh Centre of Neuro-Oncology






As a registered member of the recruitment panel for the Department of Psychology, 
University of Edinburgh, we are writing to ask you to participate as a healthy volunteer in a 
study currently being carried out at the Western General Hospital, Edinburgh. 
The study is being carried out in order to examine how patients with a brain tumour perform 
on a number of different thinking tasks carried out on two separate occasions - before and 
after surgery to remove the tumour. Your participation will allow us to compare the group of 
patients with a brain tumour with a group of healthy volunteers. 
Participating in this study will involve two separate testing sessions both of which will take 
place at the hospital:
The first session will last up to an hour and during this time, you will complete a number of 
short thinking tasks.
The second session will take place 3-7 days later and will last around 20-30 minutes. Here 
you will be given some of the tasks you completed during session 1. 
Both sessions will take place at a pre-arranged time convenient to you and can take place 
during the day, in the evening or at the weekend depending on your preference. We can 
reimburse your travel to and from the hospital.
We are looking for people who speak English as a first language and who have never had
any kind of brain disorder.
Your participation in this study would be greatly appreciated. If you are willing to take part 
or if you require any further information about what taking part would involve please email 
me at jscotla2@staffmail.ed.ac.uk or telephone me on 0131 537 3267.  





Appendix E. Patient consent form
Patient Consent Form
Assessment of Information Processing
Principal Investigator: Professor Ian R. Whittle, Department of Clinical Neurosciences, Western 
General Hospital, Edinburgh.
 I have read the information sheet that has been provided to me, and this 
Consent Form, and have been given the opportunity to ask questions about 
them. I am satisfied that I have all the information that I need to provide 
informed consent. 
 I understand that my doctor will be informed of my participation in this study 
and know that he/she will be provided with a routine clinical report. 
 I know that I am under no obligation to take part in this study and can 
withdraw at any time without my care being compromised. 
 I agree that any test results obtained during assessment may be stored and 
processed using computers and after the study is complete they may be 
copied onto a permanent record and may be studied again at a later time.
 I agree that information gathered during this study may be shared with other 
medical and scientific researchers, subject to laws and University policies 
intended to safeguard my privacy. 
 I agree to participate in this study.
Signature of patient:
Name of patient (please print in block capitals):
Witnessed by:
Name of witness (please print in block capitals):
Date:
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Appendix F. Healthy control group consent form
Consent Form
Assessment of Information Processing
Principal Investigator: Professor Ian R. Whittle, Department of Clinical 
Neurosciences, Western General Hospital, Edinburgh.
 I have read the information sheet that has been provided to me, and this 
Consent Form, and have been given the opportunity to ask questions about 
them. I am satisfied that I have all the information that I need to provide 
informed consent. 
 I know that I am under no obligation to take part in this study and can 
withdraw at any time without giving a reason for doing so.
 I agree that any test results obtained during assessment may be stored and 
processed using computers and after the study is complete they may be 
copied onto a permanent record and may be studied again at a later time.
 I agree that information gathered during this study may be shared with other 
medical and scientific researchers, subject to laws and University policies 
intended to safeguard my privacy. 
 I agree to participate in this study.
Signature of participant:
Name of participant (please print in block capitals):
Witnessed by:
Name of witness (please print in block capitals):
Date:
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Appendix G. Order of administration of test battery
ORDER OF TEST ADMINISTRATION 
Session 1 -Baseline
No. Test
1 Rey Auditory-Verbal Learning Test (I – VI)
2 Inspection Time*
3 Rey Auditory-Verbal Learning Test (VII)
4 National Adult Reading Test (NART)
5 Trail Making Test Part B
6 Verbal Fluency
7 Hospital Anxiety and Depression Scale 
8 Letter-Number Sequencing
9 Quality of Life Questionnaire
10 EFIT Williams Delayed Recall Test (Part 1)*
11 EFIT Nine Hole Peg Test*
12 Digit Symbol-Coding*
13 EFIT Williams Delayed Recall Test (Part 2)*
14 EFIT Boston Aphasia Severity Rating Scale*
15 Barthel Disability Index
16 Karnofsky Performance Scale
17 EFIT Timed Ten Metre Walk*
* denotes tests completed at session 2. 
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Appendix H. Rey Auditory Verbal Learning Test Word Lists
























































































Appendix J. Trail Making Test Part B Test Sheet
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Appendix L. Digit Symbol Coding Test Sheet
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Appendix M. Letter-Number Sequencing Test Sheet
Trial Item Response TrialScore 
(0 or 1)
Item Score 
(0, 1, 2,or 3)
1 1 L – 2 2 – L
2 6–P 6 – P
3 B – 5 5 – B
2 1 F – 7 – L 7 – F – L
2 R – 4 – D 4 – D – R 
3 H – 1 – 8 1 – 8 – H
3 1 T – 9 – A – 3 3 – 9 – A – T
2 V – 1 – J – 5 1 – 5 – J- V
3 7 – N – 4 – L 4 – 7 – L – N
4 1 8 – D – 6 – G – 1 1 – 6 - 8 – D – G
2 K – 2 – C – 7 – S 2 – 7 – C – K – S
3 5 – P – 3 – Y – 9 3 – 5 – 9 – P –Y
5 1 M – 4 – E – 7 – Q – 2 2 – 4 – 7 – E – M – Q 
2 W – 8 – H – 5 – F – 3 3 – 5 – 8 – F – H – W 
3 6 – G – 9 – A  - 2 – S 2 – 6 – 9 – A – G – S 
6 1 R – 3 – B - 4- Z – 1– C 1 – 3 – 4 – B – C – R – Z 
2 5 – T – 9 – J – 2 – X- 7 2 – 5 – 7 – 9 - J – T – X
3 E – 1 – H –8 – R– 4- D 1 – 4 – 8 – D – E – H – R 
7 1 5 – H –9- S- 2- N- 6–A 2 – 5 –6 – 9 –A –H –N –S 
2 D –1 –R –9- B- 4- K- 3 1 –3– 4 –9 –B –D –K – R 
3 7 –M –2 –T -6- F- 1- Z 1 –2 –6 –7 – F –M –T – Z 
                                                             TOTAL RAW SCORE (MAX. = 21)
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Appendix N. Hospital Anxiety and Depression Scale
HAD Scale
This questionnaire is designed to help us know how you feel. Read each item and 
place a firm tick in the box opposite the one that comes closest to how you have been 
feeling in the past week.
Try not to take too long over your replies; your immediate reaction to each item will 
probably be more accurate than a long thought out response. 
Tick only one box in each section. 
I feel tense or ‘wound up’: TICK I feel as if I am slowed down: TICK
Most of the time Nearly all the time
A lot of the time Very often
Some of the time, occasionally Sometimes
Not at all Not at all
I still enjoy the things I 
used to enjoy:
TICK I get a sort of frightened 
feeling like ‘butterflies’ in the 
stomach:
TICK
Definitely as much Not at all
Not quite as much Occasionally
Only a little Quite often
Hardly at all Very often
I get a sort of frightened 
feeling as if something 
awful is about to happen:
TICK I have lost interest in my 
appearance:
TICK
Very definitely and quite badly Definitely
Yes, but not too badly I don’t take so much care as I 
should
A little, but it doesn’t worry me I may not take quite as much care
Not at all I take just as much care as ever
I can laugh and see the 
funny side of things:
TICK I feel restless as if I have to 
be on the move:
TICK
As much as I always could Very much indeed
Not quite so much now Quite a lot
Definitely not so much now Not very much
Not at all Not at all
Worrying thoughts go 
through my mind:
TICK I look forward with 
enjoyment to things:
TICK
A great deal of the time As much as I ever did
A lot of the time Rather less than I used to
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From time to time, but not too 
often
Definitely less than I used to
Only occasionally Hardly at all
I feel cheerful: TICK I get sudden feelings of 
panic:
TICK
Not at all Very often indeed
Not often Quite often
Sometimes Not very often
Most of the time Not at all
I can sit at ease and feel 
relaxed:
TICK I can enjoy a good book or 




Not often Not often









Appendix P. Boston Aphasia Severity Rating Scale ‘Cookie Theft’ Picture
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Appendix Q. European Organisation for the Research and Treatment of Cancer Quality of    
Life Questionnaire and Brain Cancer Module
EORTC QLQ-C30 (version 3)
We are interested in some things about you and your health. Please answer all of the 
questions yourself by circling the number that best applies to you. There are no 
“right” or “wrong” answers. The information that you provide will remain strictly 
confidential.
Please fill in your name: ___________________________________
Your birth date (Day, Month, Year): ________________________
Today’s date (Day, Month, Year): __________________________
Did you fill in the questionnaire yourself?       No           Yes  
No Yes
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase? 1 2
2. Do you have any trouble taking a long walk?
1 2
3. Do you have any trouble taking a short walk 
outside of the house? 1 2
4. Do you need to stay in a bed or a chair during the 
day? 1 2
5. Do you need help with eating, dressing, washing 
yourself or using the toilet? 1 2
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During the past week: Not at 
All




6. Were you limited in doing either your 
work or other daily activities? 1 2 3 4
7. Were you limited in pursuing your 
hobbies or other leisure time activities? 1 2 3 4
8. Were you short of breath?
1 2 3 4
9. Have you had pain?
1 2 3 4
10. Did you need to rest?
1 2 3 4
11. Have you had trouble sleeping?
1 2 3 4
12. Have you felt weak? 
1 2 3 4
13. Have you lacked appetite?
1 2 3 4
14. Have you felt nauseated?
1 2 3 4
15. Have you vomited?
1 2 3 4
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During the past week: Not at 
All




16. Have you been constipated?
1 2 3 4
17. Have you had diarrhoea?
1 2 3 4
18. Were you tired?
1 2 3 4
19. Did pain interfere with your daily 
activities? 1 2 3 4
20. Have you had difficulty in 
concentrating on things, like reading a 
newspaper or watching television?
1 2 3 4
21. Did you feel tense?
1 2 3 4
22. Did you worry?
1 2 3 4
23. Did you feel irritable?
1 2 3 4
24. Did you feel depressed?
1 2 3 4
25. Have you had difficulty 
remembering things? 1 2 3 4
26. Has your physical condition or 
medical treatment interfered with your 
family life? 
1 2 3 4
27. Has your physical condition or
medical treatment interfered with your 
social activities?
1 2 3 4
28. Has your physical condition or 
medical treatment caused you financial 
difficulties?
1 2 3 4
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For the following questions please circle the number between 1 and 7 that best
applies to you:
29. How would you rate your 
overall health during the past 
week?
1         2         3         4         5         6         7
Very Poor                                            Excellent
30. How would you rate your 
overall quality of life during the 
past week?
1         2         3         4         5         6         7
Very Poor                                            Excellent
During the past week: Not at 
All




31. Did you feel uncertain about the 
future? 1 2 3 4
32. Did you feel you had setbacks in 
your condition? 1 2 3 4
33. Were you concerned about 
disruption of family life? 1 2 3 4
34. Did you have headaches?
1 2 3 4
35. Did your outlook on the future 
worsen? 1 2 3 4
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During the past week: Not at 
All




36. Did you have double vision?
1 2 3 4
37. Was your vision blurred?
1 2 3 4
38. Did you have difficulty reading 
because of your vision? 1 2 3 4
39. Did you have seizures?
1 2 3 4
40. Did you have weakness on one side 
of your body? 1 2 3 4
41. Did you have trouble finding the 
right words to express yourself? 1 2 3 4
42. Did you have difficulty speaking?
1 2 3 4
43. Did you have trouble communicating 
your thoughts? 1 2 3 4
44. Did you feel drowsy during the 
daytime? 1 2 3 4
45. Did you have trouble with your 
co-ordination? 1 2 3 4
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During the past week: Not at 
All




46. Did hair loss bother you?
1 2 3 4
47. Did itching of your skin bother you?
1 2 3 4
48. Did you have weakness of both legs?
1 2 3 4
49. Did you feel unsteady on your feet?
1 2 3 4
50. Did you have trouble in controlling 
your bladder? 1 2 3 4
389
EUROQOL
To help people say how good or bad a health state is, we have drawn a scale (rather 
like a thermometer) on which the best state you can imagine is marked ‘100’ and the 
worst state you can imagine is marked by ‘0’.
We would like you to indicate on this scale how good or bad your health is today, in 
your opinion. Please do this by ticking a box on the scale indicating how good or bad 















Appendix R. Barthel Disability Index
BARTHEL DISABILITY INDEX
Feeding
2 = Independent Able to use any necessary device: eats in a reasonable time: 
able to butter on his/her own.
1 = Needs help Cutting or spreading butter.
0 = Dependent Needs to be fed.
Bathing
1 = Independent Able to wash self all over; maybe by using a shower, full bath 
or stable getting in or out of shower room.
0 = Dependent Needs some help.
Dressing
2 = Independent Includes tying shoelaces, 7 buttons.
1 = Needs help Able to dress by self but needs help tying shoes, 7 fasteners.
0 = Dependent Needs to be dressed.
Grooming
1 = Independent Washing hands/face, combing hair, brushing teeth.
0 = Dependent Needs some help.
Mobility
3 = Independent Can walk 50m. May use aid except roller, speed not 
important.
2 = Needs help Needs help of one person, including help standing.
1 = In 
wheelchair
Independent.
0 = Immobile Including being wheeled by another. 
Stairs
2 = Independent Must carry walking aid if used; needs no help.
1 = Needs help Manages with help. Physical or verbal supervision, carrying 
aid.
0 = Dependent Unable. Cannot negotiate stairs, needs lift. 
Toilet
2 = Independent Able to handle clothes, wipe self, flush toilet, empty 
commode completely.
1 = Needs help Able to manage with minor help balancing, handling clothes 
or toilet.
0 = Dependent Needs major assistance. 
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Bed Chair
3 = Independent Needs no help in moving from bed to (wheel)chair and vice 
versa. In wheelchair if necessary.
2 = Minimal 
help
Verbal supervision, minor physical help from spouse. 
1 = Major help Able to sit unaided but needs much help of one/two persons.
0 = Dependent Unable to sit. Needs hoist or lift by two persons.
Bowels 
2 = No accidents.
1 = Occasional accidents/help with enema.
0 = Incontinent.
Bladder
2 = No accidents.




Appendix S. Karnofsky Performance Scale
KARNOFSKY PERFORMANCE SCALE
Able to carry on normal activity. No 
special care needed.    
Unable to work. Able to live at home 
and care for most personal needs; a 
varying amount of assistance needed.
Unable to care for self; requires 
equivalent of institutional or hospital 
care. Disease may be progressing 
rapidly.
100 Normal, no complaints or evidence 
of disease.
90 Normal activity, minor signs and 
symptoms.
80 Normal activity with effort, signs 
and symptoms of disease.
70 Cares for self: unable to do normal 
activity or work.
60 Requires occasional assistance, able 
to care for most needs.
50 Requires considerable assistance and 
frequent medical care.
40 Disabled; requires special medical 
care and assistance.
30 Severely disabled. Hospitalisation 
indicated.
20 Very sick. Hospitalisation necessary. 









Appendix U. Returners vs Non-Returners: Analyses and Discussion
Returners vs Non-Returners: Comparison of Baseline 
Scores
U.1 Overview of Analysis Procedure
Before examining the effects of surgical intervention on cognitive test performance, 
the baseline test scores of those participants in each group (brain tumour and spinal 
surgery control) who completed session 2 follow-up were compared with those who 
did not complete follow-up at session 2 using univariate general linear modelling 
(analysis of covariance). This was done in order to determine whether those 
participants who were not followed up post-operatively were those patients who had 
the most severe impairment prior to surgery. Participants were classified as 
‘returners’ if they completed session 2 testing and as ‘non-returners’ if they were not 
tested at session 2. The data was analysed separately for each of the participant 
groups. Follow-up status (i.e. returner or non-returner) and sex were entered as fixed 
effects (between-subjects factors) in the models. Age and NART score were included 
as covariates for the reasons described in Chapter 5.2.1.
In each of the sections that follow, mean scores for the returners and non-returners in 
the brain tumour group and the spinal control group are presented with standard 
deviations (SD) in brackets. The results of the general linear modelling analysis are 
then reported. Estimated marginal means (adjusted for age and NART score) are 
reported for the returner and non-returner groups and for the male and female 
participants in each group where applicable. Since the number of non-returners in the 
healthy group was too small to allow for any meaningful comparisons (n = 4), only 
comparisons of the returners and non-returners in each of the two surgical groups 
(brain tumour and spinal surgery control) are presented below. An overview of the 






Thirty-two members of the returner group were male and 32 were female. Twenty-
eight members of the non-returner group were male and 26 were female. Pearson 
chi-square analysis showed there were no significant differences between the two 
groups with respect to sex, χ²(1) = 0.040, p = 0.841.
Spinal Surgery Group
In the spinal surgery group, 34 returners were male and 33 were female. In the non-
returner group, there were 5 males and 13 females. Pearson chi square analysis 
showed there were no significant differences between the two groups with respect to 
sex, χ²(1) = 3.014, p = 0.083.
Age
Brain Tumour Group
The mean age of the returners in the brain tumour group was 49.6 years (SD 14.2) 
and the mean age of the non-returners was 50.5 years (SD 11.5). The independent 
samples t-test revealed no significant differences in the age of the returners and non-
returners, t(116) = -0.398, p = 0.691.
Spinal Surgery Group
The mean age of the returners in the spinal control group was 46.9 (SD 10.7) and the 
mean age of the non-returners was 51.1 (SD 12.9). The independent samples t-test 
revealed no significant differences in the age of the returner and non-returners, t(83) 




In the returner group, 56 patients were right handed and 8 were left handed. In the 
non-returner group, 46 patients were right handed and 7 were left handed. Pearson 
chi square analysis revealed no significant difference between the two groups with 
respect to handedness, χ²(1) = 0.013, p = 0.909. 
Spinal Surgery Group
In the returner group, 60 patients were right handed, 6 were left handed and 1 patient 
was ambidextrous. In the non-returner group there were 18 right handed patients and 
no left handed patients. Pearson chi square analysis revealed no significant difference 
between the returners and non-returners with respect to handedness, χ²(1) = 2.049, p 
= 0.359.
Highest Levels of Qualification Achieved
Brain Tumour Group
Pearson chi square analysis of the highest levels of qualification achieved by 
participants in each of the returner and non-returner groups revealed no significant 
difference between the two groups, χ²(6) = 8.307, p = 0.216.
Spinal Surgery Group
Pearson chi square analysis of the highest levels of qualification achieved by 
participants in the returner and non-returner groups revealed no significant difference 
between then two groups, χ²(5) = 1.439, p = 0.920.
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National Adult Reading Test Score
Brain Tumour Group
The mean NART score for the returners in the brain tumour group was 18.8 (SD 8.5) 
and for the non-returners was 22.8 (SD 10.0). The independent samples t-test 
revealed a significant difference between the NART scores of the two groups, t(114) 
= -2.338, p = 0.021. Although there were no significant differences between the 
highest levels of qualification achieved in the returners and non-returners, the non-
returners in the brain tumour group had significantly higher (poorer) NART scores 
than the returners. 
Spinal Control Group
The returners in the spinal control group had a mean NART score of 19.7 (SD 9.2) 
and the non-returners had a mean score of 21.7 (SD 10.0). The independent samples 
t-test showed there to be no significant difference between the NART scores of the 
two groups, t(81) = -0.880, p = 0.382. 
Tumour Type
Brain Tumour Group
In the returner group, 26 patients had a high-grade glioma; 16 had a low-grade 
glioma; 9 had a metastasis; 10 had a meningioma and 3 had ‘other’ tumour types. 
The non-returner group comprised 25 high-grade glioma patients; 7 low-grade 
glioma patients; 5 patients with a metastasis; 7 with a meningioma and 8 patients 
with ‘other’ tumour types. Pearson chi-square analysis was carried out to compare 
the histological diagnoses of those participants who were returners and those who 
were non-returners at session 2. There was no significant difference between the two 
groups, χ²(5) = 8.701, p = 0.122.
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U.3 Baseline Test Comparisons
Inspection Time: All Inspection Time Scores
Brain Tumour Group
Sixty two patients in the brain tumour cohort completed inspection time testing at 
baseline and session 2 (‘returners’) and 50 patients in the brain tumour cohort 
completed baseline testing but did not return for session 2 follow-up (‘non-
returners’). The mean baseline inspection time score for the returner group was 116.6 
(SD 21.2) and for the non-returner group was 111.5 (SD 17.9).
General linear modelling, with inspection time total (i.e. score /150) as the dependent 
variable revealed a significant main effect of the covariates age, F(1,106) = 37.711, p 
< 0.001, partial η² = 0.262; and NART score, F(1,106) = 6.563, p  = 0.012, partial η² 
= 0.058, in the model. Older patients, and those with higher (i.e. poorer) NART 
scores tended to perform less well on inspection time at baseline. There was no 
significant main effect of sex in the model, F(1,106) = 2.621, p = 0.108, partial η² = 
0.024. There was no significant main effect of follow-up status (returner or non-
returner) on baseline inspection time scores, in the model that included the effects of 
age and NART score, F(1,106) = 0.494, p = 0.484, partial η² = 0.005. The interaction 
between sex and follow-up status was not significant, F(1,106) = 0.639, p = 0.426, 
partial η² = 0.006.
The estimated marginal mean baseline inspection time scores for the brain tumour 
group, adjusted for age and NART score, were 115.4 (SE 2.2) for the returners and 
113.1 (SE 2.4) for the non-returners. Therefore, there was no significant difference 
between the returners and non-returners in the brain tumour group on baseline 




Sixty-six patients in the spinal cohort completed inspection time testing at baseline 
and session 2 (returners) and a further 16 were classified as ‘non-returners’ since 
they were not tested on inspection time at session 2. 
The mean baseline inspection time score for the returner group in the spinal control 
cohort was 122.2 (SD 13.8), and the mean score for the non-returner group was 
118.0 (SD 13.0). 
General linear modelling was carried out with inspection time total entered as the 
dependent variable. There was a significant main effect of the covariate age in the 
model, F(1,76) = 11.836, p = 0.001, partial η² = 0.135. The covariate NART score 
also had a significant main effect in the model, F(1,76) = 9.041, p = 0.004, partial η² 
= 0.106. Older patients and those who scored less well on the NART measure tended 
to have poorer inspection time scores. There was no significant main effect of sex, 
F(1,76) = 0.768, p = 0.384, partial η² = 0.010. Follow-up status (returner or non-
returner) had no significant main effect on baseline inspection time scores in the 
model that included the effects of age and NART score, F(1,76) = 0.001, p = 0.974, 
partial η² < 0.001. There was no significant interaction between sex and follow-up 
status, F(1,76) = 2.693, p = 0.105, partial η² = 0.034.
The estimated marginal mean baseline inspection time scores for the spinal group, 
adjusted for age and NART score, were 121.7 (SE 1.5) for the returner group and 
121.9 (SE 3.4) for the non-returner group. This shows that, when all baseline 
inspection time scores were included in the model, there was no significant 
difference in inspection time performance between those participants in the spinal 
control group who completed session 2 follow-up and those who completed baseline 
testing only in the spinal group.
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Inspection Time: Valid Inspection Time Scores
Brain Tumour Group
Fifty-three patients in the brain tumour cohort had ‘valid’ inspection time scores at 
baseline and follow-up scores at session 2 (‘returners’) and 43 patients in the brain 
tumour group had valid inspection time scores at baseline but did not complete 
session 2 testing (‘non-returners’). Valid inspection time scores are scores from those 
patients who scored at least 17/20 on the two longest durations, as described in 
chapter 2.2. 
The mean baseline score for the brain tumour returner group with valid baseline 
inspection time data was 123.3 (SD 13.1) and for the non-returner group was 116.2 
(SD 13.5).
General linear modelling revealed a significant main effect of the covariate age on 
valid baseline inspection time scores, F(1,90) = 23.888, p < 0.001, partial η² = 0.210. 
Older participants tended to have lower inspection time scores. The covariate NART 
score had no significant main effect on the model when only valid inspection time 
scores were included, F(1,90) = 2.123, p = 0.149, partial η² = 0.023. The effect of sex 
approached the conventional level of statistical significance in the model, F(1,90) = 
3.918, p = 0.051, partial η² = 0.042. Follow-up status (returner or non-returner) had a 
significant main effect in the model that included the effects of age and NART score 
on valid baseline inspection time scores, F(1,90) = 4.855, p = 0.030, partial η² = 
0.051. There was a significant interaction between sex and follow-up status, F(1,90) 
= 4.288, p = 0.041, partial η² = 0.045.
The estimated marginal mean baseline inspection time scores for brain tumour 
patients with valid data, adjusted for age and NART score, were 122.6 (SE 1.6) for 
the returner group and 117.3 (SE 1.8) for the non-returner group. Therefore, in this 
group of patients with valid baseline scores, those brain tumour patients who were 
returners performed significantly better at baseline than those who did not complete 
follow-up (non-returners). 
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The estimated marginal mean score for the female returners was 122.5 (SE 2.2) and 
for the female non-returners was 112.3 (SE 2.4). The corresponding mean score for 
the male returners was 122.8 (SE 2.4) and for the male non-returners was 122.2 (SE 
2.7). The female non-returners performed significantly worse than the female 
returners on inspection time at baseline, when only valid data was included in the 
analysis. 
Spinal Surgery Group
When only ‘valid’ baseline inspection time scores were included, 62 members of the 
spinal control group were classified as ‘returners’ and 16 patients had valid baseline 
inspection time scores but did not complete session 2 testing (‘non-returners’). 
The mean baseline score for the returner group was 124.7 (SD 10.1) and for the non-
returner group was 118.0 (SD 13.0).
General linear modelling revealed a significant main effect of age on baseline 
inspection time scores when only valid data was entered into the model, F(1,72) = 
17.767, p < 0.001, partial η² = 0.198. Older patients were again more likely to 
perform less well on this test. The covariate NART score had no significant main 
effect on baseline inspection time scores on this occasion, F(1,72) = 2.558, p = 0.114, 
partial η² = 0.034. Sex also had no significant main effect in the model, F(1,72) = 
1.366, p = 0.246, partial η² = 0.019. There was no significant main effect of follow-
up status (returner or non-returner) on baseline valid inspection time scores in the 
model that included the effects of age and NART score, F(1,72)  = 0.822, p = 0.368, 
partial η² = 0.011. There was however a significant interaction between follow-up 
status and sex in the model, F(1,72) = 5.322, p = 0.024, partial η² = 0.069. 
The estimated marginal mean valid baseline inspection time scores, adjusted for age 
and NART score were 124.2 (SE 1.2) for the returner group and 121.6 (SE 2.6) for 
the non-returner group. There was no significant difference between the performance 
of the returners and non-returners with valid baseline inspection time scores in the 
spinal group. 
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The estimated marginal mean score for the female returners was 125.8 (SE 1.7), 
compared with 116.6 (SE 2.9) for the female non-returners. The corresponding mean 
score for the male returners was 122.6 (SE 1.7) and for the male non-returners was 
126.5 (SE 4.3). Therefore, the significant interaction between follow-up status and 
sex suggests that female non-returners scored significantly worse in inspection time 
at baseline than the female returners when only valid scores were included. 
Rey Auditory Verbal Learning Test
Brain Tumour Group
There were 51 brain tumour patients who completed the Rey Auditory Verbal 
Learning Test (RAVLT) at baseline and also completed session 2 (‘returners’) and 
36 brain tumour patients who completed this test at baseline but did not complete the 
follow-up testing session (‘non-returners’).
The returners scored a mean of 62.7 (SD 19.0) on this measure at baseline and the 
non-returners score a mean of 60.3 (SD 15.4). 
General linear modelling, with RAVLT total score entered as the dependent variable, 
revealed a significant main effect of the covariate age on test score, F(1,81) = 24.731, 
p < 0.001, partial η² = 0.234. NART score also had a significant main effect in the 
model, F(1,81) = 15.382,  p < 0.001, partial η² = 0.160. Participants with better 
(lower) NART scores and younger participants were significantly more likely to have 
higher (better) RAVLT scores. Sex also had a significant main effect in the model, 
F(1,81) = 4.897, p = 0.030, partial η² = 0.057. Follow-up status (returner or non-
returner) had no significant main effect on RAVLT scores in the model that included 
the effects of age and NART score, F(1,81) = 0.503, p = 0.480, partial η² = 0.006. 
There was also no significant interaction between sex and follow-up status, F(1,81) = 
0.469, p = 0.496, partial η² = 0.006.
Estimated marginal mean scores, adjusted for age and NART score were 60.9 (SE 
2.1) for the returner group and 63.3 (SE 2.5) for the non-returner group. There was 
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no significant difference between the performance of the returners and non-returners 
in the brain tumour group on the RAVLT at baseline.
Spinal Surgery Group
There were 60 patients in the spinal group who completed the RAVLT at baseline 
and also completed session 2 testing (‘returners’). Fourteen members of the spinal 
group completed this test at baseline but did not complete any follow-up testing 
(‘non-returners’).
The mean RAVLT score for the returners in the spinal group was 72.5 (SD 15.6) and 
for the non-returners was 64.8 (SD 15.5).
General linear modelling revealed a significant main effect of the covariates age, 
F(1,68) = 36.006, p < 0.001, partial η² = 0.346; and  NART score, F(1,68) = 19.868, 
p < 0.001, partial η² = 0.226 in the model. Older patients, and those with higher 
(poorer) NART scores were significantly more likely to have lower scores on the 
RAVLT. There was no significant main effect of sex in the model, F(1,68) = 0.642, p 
= 0.426, partial η² = 0.009. Follow-up status (returner or non-returner) had no 
significant main effect in the model that included the effects of age and NART score, 
F(1,68) = 0.152, p = 0.698, partial η² = 0.002. There was however a significant 
interaction between follow-up status and sex in the model, F(1,68) = 4.858, p = 
0.031, partial η² = 0.067. 
Estimated marginal mean RAVLT scores, adjusted for age and NART scores, for the 
spinal control group were 71.5 (SE 1.5) for the returners and 70.1 (SE 3.3) for the 
non-returners. There was therefore no significant overall difference between the 
performance of the returners and the non-returners on the RAVLT. 
The estimated marginal mean scores for the female returners was 74.1 (SE 2.1) and 
for the female non-returners, was 64.6 (SE 4.0). The male returners had a 
corresponding mean score of 69.0 (SE 2.2) and the male non-returners had a mean of 
64.6 (SE 4.0). It would therefore appear that the female non-returners performed 
significantly worse on the RAVLT than the female returners.
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Trail Making Test Part B
Brain Tumour Group
Fifty-three patients in the brain tumour group completed the Trail Making Test Part 
B and also completed session 2 (‘returners’). Forty-three brain tumour patients were 
classified as ‘non-returners’ who completed the test at baseline but did not participate 
in session 2 follow-up.
General linear modelling, with Trail Making Test Part B score entered as the 
dependent variable, revealed a significant main effect of the covariate age in the 
model, F(1,90) = 19.000, p < 0.001, partial η² = 0.174. Younger patients were 
significantly more likely to be faster to complete the test than older participants. The 
effect of the covariate NART score was also significant in the model, F(1,90) = 
17.894, p < 0.001, partial η² = 0.166. Those participants in the brain tumour group 
who had better (lower) NART scores were also significantly more likely to have 
better (faster) scores on the Trail Making Test Part B. Sex had no significant main 
effect in the model, F(1,90) = 0.075, p = 0.784, partial η² = 0.001. The effect of 
follow-up status (returner or non-returner) approached the conventional level of 
statistical significance in the model that included the effects of age and NART score, 
F(1,90) = 3.375, p = 0.069, partial η² = 0.036. There was no significant interaction 
between follow-up status and sex in the model, F(1,90) = 0.767, p = 0.383, partial η² 
= 0.008.
The estimated marginal mean scores, adjusted for age and NART score, were 90.1 
(SE 3.7) for the returner group and 100.5 (SE 4.2) for the non-returner group on the 
TMT Part B. Therefore, in the brain tumour group, the returners had faster scores 
than the non-returners on this test. However, the difference failed to reach the 
conventional level of statistical significance. 
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Spinal Surgery Group
Sixty-five patients in the spinal control group completed the Trail Making Test Part 
B at baseline and also took part in session 2 testing (‘returners’). Seventeen spinal 
control patients were classified as ‘non-returners’.
The returners in the spinal group had a mean score of 79.8 (SD 25.6) and the non-
returners had a mean score of 86.6 (SD 16.2).
General linear modelling, with Trail Making Test Part B score entered as the 
dependent variable, revealed a significant main effect of the covariates age, F(1,76) = 
21.199, p < 0.001, partial η² = 0.218; and NART score, F(1,76) = 21.082, p < 0.001, 
partial η² = 0.217, in the model. Again, those patients in the spinal group who were 
older or had higher (poorer) scores on the NART were significantly more likely to 
take longer to complete this test. There was no significant main effect of sex on test 
scores in this model, F(1,76) = 0.070, p = 0.792, partial η² = 0.001. The effect of 
follow-up status (returner or non-returner) was not significant in the model that 
included the effects of age and NART score, F(1,76) = 0.003, p = 0.955, partial η² < 
0.001. The interaction between sex and follow-up status was also non-significant, 
F(1,76) = 0.039, p = 0.843, partial η² < 0.001. 
The estimated marginal mean scores on the TMT Part B, adjusted for age and NART 
score, were 81.3 (SE 2.5) for the spinal group returners and 80.9 (SE 5.5) for the 
spinal group non-returners. Therefore, there was no significant difference between 
the performance of the returners and non-returners in the spinal group on this test.
Verbal Fluency 
Brain Tumour Group
Forty-nine patients in the brain tumour group were classified as returners who 
completed the verbal fluency test at baseline and also completed session 2 testing and 
42 patients were ‘non-returners’ who completed the test at baseline only. 
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The mean verbal fluency total score for the returners in the brain tumour group was 
31.4 (SD 13.6) and for the non-returners was 25.5 (SD 9.2).
General linear modelling, with total verbal fluency score as the dependent variable, 
revealed a significant main effect of the covariates age, F(1,85) = 8.589, p = 0.004, 
partial η² = 0.092; and NART score, F(1,85) = 38.086, p < 0.001, partial η² = 0.309, 
in the model. Participants who performed better on the NART and older participants 
tended to perform better on the test. Sex had no significant main effect in the model, 
F(1,85) = 2.560, p = 0.113, partial η² = 0.029. Follow-up status had no significant 
main effect in the model that included the effects of age and NART score, F(1,85) = 
2.275, p = 0.135, partial η² = 0.026. The interaction between sex and follow-up status 
was significant in the model, F(1,85) = 13.267, p < 0.001, partial η² = 0.135.
The estimated marginal mean score, adjusted for age and NART, for the returner 
group on the verbal fluency measure was 30.2 (SD 1.4) and for the non-returner 
group was 27.1 (SD 1.5). There was no significant overall difference between the 
two follow-up groups on this measure at baseline. 
The estimated marginal mean score for the female returners was 35.8 (SE 2.0) and 
for the female non-returners was 24.8 (SE 2.1). The corresponding mean for the male 
returners was 24.6 (SE 2.0) and for the male non-returners was 29.4 (SE 2.3). 
Therefore, in the brain tumour group, the female returners performed significantly 
better than the female non-returners on the verbal fluency measure. 
Spinal Surgery Group
In the spinal control group, 64 patients were classified as returners who completed 
the verbal fluency test at baseline and also completed session 2 follow-up. Fourteen 
spinal patients were classified as non-returners who completed verbal fluency testing 
at baseline but did not complete session 2 follow-up.
The mean verbal fluency score for the returners in the spinal group was 35.3 (SD 
13.6) and for the non-returners was 33.4 (SD 11.0).
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General linear modelling with verbal fluency total score for each spinal group 
patient, revealed that the effect of the covariate age approached the conventional 
level of statistical significance, F(1,72) = 3.807, p = 0.055, partial η² = 0.050. This 
suggests that older patients tended to perform better on the verbal fluency test than 
younger patients. The effect of the covariate NART was significant in the model, 
F(1,72) = 33.966, p < 0.001, partial η² = 0.321. Those patients with better scores on 
the NART tended to perform better on the verbal fluency measure. The effect of sex 
was significant in the model, F(1,72) = 6.018, p = 0.017, partial η² = 0.077. Female 
patients performed significantly better than male patients. The effect of follow-up 
status was not significant in the model that included the effects of age and NART 
score, F(1,72) = 0.454, p = 0.503, partial η² = 0.006. There was also no significant 
interaction between age and follow-up status, F(1,72) = 0.623, p = 0.433, partial η² = 
0.009. 
The estimated marginal mean score, adjusted for age and NART score, for the 
returners in the spinal control group was 35.2 (SE 1.4) and for the non-returners was 
32.9 (SE 3.1). There was no significant difference between the returners and non-
returners in the spinal group on the verbal fluency test.
Digit Symbol Coding
Brain Tumour Group
Sixty-two members of the brain tumour group completed this measure at baseline 
and also completed session 2 follow-up (returners) and 49 patients had baseline digit 
symbol coding data but did not complete follow-up (non-returners).
The returner group had a mean score of 61.5 (SD 22.4) on digit symbol coding at 
baseline and the non-returner group had a mean score of 49.9 (SD 20.3).
General linear modelling, with baseline digit symbol coding score entered as the 
dependent variable, revealed a significant main effect of the covariate age on the test 
scores, F(1,105) = 42.265, p < 0.001, partial η² = 0.287. Older patients tended to 
perform less well on the digit symbol coding measure. The covariate NART score 
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also had a significant main effect in the model, F(1,105) = 23.547, p < 0.001, partial 
η² = 0.183. Patients with higher (poorer) NART scores were more likely to have 
lower (poorer) digit symbol coding scores. There was no significant main effect of 
sex in the model, F(1,105) = 0.485, p = 0.488, partial η² = 0.005. There was a 
significant main effect of follow-up status in the model that included the effects of 
the covariates, F(1,105) = 5.164, p = 0.025, partial η² = 0.047. The interaction 
between follow-up status and sex was not significant, F(1,105) = 1.307, p = 0.256, 
partial η² = 0.012. 
The estimated marginal mean score for the returners in the brain tumour group was 
59.6 (SE 2.2) and for the non-returners was 52.0 (SE 2.5). The non-returners in the 
brain tumour group performed significantly less well on the digit symbol coding 
measure than those who returned to take part in session 2.
Spinal Surgery Group
There were 66 spinal patients who were classified as ‘returners’ who completed digit 
symbol coding at baseline and also returned for session 2 follow-up. There were 17 
spinal patients who completed the test at baseline but did not complete session 2 
(‘non-returners’).
The mean baseline digit symbol coding score for the returner group was 69.4 (SD 
17.2) and for the non-returner group was 59.6 (SD 13.9). 
General linear modelling, with digit symbol coding score at baseline entered as the 
dependent variable, revealed a significant main effect of the covariate age in the 
model, F(1,77) = 38.621, p < 0.001, partial η² = 0.334. Older patients were 
significantly more likely to have lower scores on the measure. The effect of the 
covariate NART was also significant, F(1,77) = 27.503, p < 0.001, partial η² = 0.263. 
Patients with better NART scores were significantly more likely to perform better on 
the digit symbol coding test. The effect of sex was not significant in the model, 
F(1,77) = 1.212, p = 0.274, partial η² = 0.016. There was also no significant main 
effect of follow-up status (returner or non-returner) on baseline digit symbol coding 
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scores in the model that included the effects of age and NART score, F(1,77) = 
1.066, p = 0.305, partial η² = 0.014. There was no significant interaction between sex 
and follow-up status in the model, F(1,77) = 1.584, p = 0.212, partial η² = 0.020. 
The estimated marginal mean score, adjusted for age and NART score, for the 
returners in the brain tumour group on the digit symbol coding test was 68.2 (SD 1.6) 
and for the non-returners was 64.3 (SD 3.4). The difference between the baseline 
scores was not significant. 
Letter-Number Sequencing
Brain Tumour Group
There were 47 ‘returners’ in the brain tumour group who completed letter-number 
sequencing at baseline and who also returned for follow-up testing at session 2. 
Forty-two brain tumour patients were ‘non-returners’ who completed the test at 
baseline but did not complete session 2 follow-up.
The mean letter-number sequencing score for the returners in the brain tumour group 
was 9.6 (SD 3.4) and for the non-returners was 9.2 (SD 3.3). 
General linear modelling, with baseline letter-number sequencing test score as the 
dependent variable, revealed a significant main effect of age on test scores, F(1,83) = 
19.548, p < 0.001, partial η² = 0.191. Older patients were significantly more likely to 
have lower scores on this test. The covariate NART score also had a significant main 
effect in the model, F(1,83) = 19.364, p < 0.001, partial η² = 0.189. Those 
participants with higher (worse) scores on the NART were more likely to have lower 
(worse) scores on letter-number sequencing. There was no significant main effect of 
sex in the model, F(1,83) = 0.235, p = 0.629, partial η² = 0.003. Follow-up status 
(returner or non-returner) had no significant main effect in the model that included 
the effects of age and NART score, F(1,83) = 0.726, p = 0.397, partial η² = 0.009. 
There was no significant interaction between sex and follow-up status, F(1,83) = 
1.545, p = 0.217, partial η² = 0.018.
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The estimated marginal mean score, adjusted for age and NART score, for this 
measure was 9.2 (SE 0.4) for the returners in the brain tumour group and was 9.7 (SE 
0.4) for the non-returners. There was no significant difference between the 
performance of the returners and the non-returners on the letter-number sequencing 
measure. 
Spinal Surgery Group
In the spinal group, there were 63 patients who completed the letter-number 
sequencing test at baseline and returned for session 2 follow-up (returners). Fifteen 
spinal patients completed the test at baseline but did not complete session 2 follow-
up (non-returners). 
The mean score for the returners in the spinal group on this test was 11.3 (SD 2.7) 
and for the non-returners was 10.9 (SE 2.5). 
General linear modelling, with letter-number sequencing test score as the dependent 
variable, revealed a significant main effect of the covariates age, F(1,72) = 23.436, p 
< 0.001, partial η² = 0.246; and NART score, F(1,72) = 16.779, p < 0.001, partial η² 
= 0.189 in the model. Older patients and those with poorer scores on the NART were 
significantly more likely to have poorer letter-number sequencing test scores. There 
was no significant main effect of sex in the model, F(1,72) = 0.283, p = 0.596, partial 
η² = 0.004. The effect of follow-up status (returner or non-returner) was not 
significant in the model that included the effects of age and NART score, F(1,72) = 
0.265, p = 0.596, partial η² = 0.004. There was no significant interaction between sex 
and follow-up status, F(1,72) = 0.002, p = 0.961, partial η² < 0.001.
The estimated marginal mean score, adjusted for age and NART score, for the 
returners in the spinal group on this test was 11.1 (SE 0.3) and for the non-returners 
was 11.5 (SE 0.6). The returners did not perform significantly differently from the 
non-returners on the letter-number sequencing test at baseline.
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Williams Delayed Recall Test (EFIT)
Brain Tumour Group
Sixty-three patients in the brain tumour group completed the Williams Delayed 
Recall Test (WDRT) at baseline and also completed session 2 follow-up 
(‘returners’), compared with 52 patients who completed the test at baseline only, and 
did not complete session 2 (‘non-returners’).
The mean score for the returners on this measure was 8.8 (SD 5.2) and for the non-
returners was 7.5 (SD 4.9).
General linear modelling, with WDRT score as the dependent variable, revealed a 
significant main effect of age on test scores, F(1,109) = 14.550, p < 0.001, partial η² 
= 0.118. Older patients were significantly more likely to have higher (poorer) scores 
on this test. The covariate NART score also had a significant main effect in the 
model, F(1,109) = 4.102, p = 0.045, partial η² = 0.036. Patients who had lower 
(better) NART scores were significantly more likely to have lower (better) scores on 
this test. There was no significant main effect of sex in the model, F(1,109) = 1.521, 
p = 0.220, partial η² = 0.014. The effect of follow-up status approached a 
conventional level of significance in the model that included the effects of age and 
NART score, F(1,109) = 3.889, p = 0.051, partial η² = 0.034. There was no 
significant interaction between the sex of the participant and follow-up status, 
F(1,109) = 1.379, p = 0.243, partial η² = 0.012. 
The estimated marginal mean score, adjusted for age and NART score, on the 
WDRT, was 9.0 (SE 0.6) for the returners in the brain tumour group and for the non-
returner group was 7.2 (SE 0.7). The returner group performed better than the non-
returner group on this test at baseline, and the difference between the groups 
approached the conventional level of statistical significance.
Spinal Surgery Group
A total of 66 patients in the spinal control group were classified as ‘returners’ who 
completed the WDRT at baseline and also completed session 2 testing. Seventeen 
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patients were classed as ‘non-returners’ who completed the test at baseline but did 
not complete follow-up.
The mean score for the returners in the spinal group on the WDRT was 5.0 (SD 3.7) 
and for the non-returners in the spinal group was 6.6 (SD 3.8).
WDRT score at baseline was the dependent variable in the general linear modelling 
analysis. There was a significant main effect of age in the model, F(1,77) = 5.715, p 
= 0.019, partial η² = 0.069. Older participants were significantly more likely to have 
higher (poorer) scores on the test. There was also a significant main effect of NART 
score on WDRT scores, F(1,77) = 4.337, p = 0.041, partial η² = 0.053. Lower (better) 
NART scores were significantly related to lower (better) WDRT scores. There was 
no significant main effect of sex in the model, F(1,77) = 0.229, p = 0.634, partial η²= 
0.003. Follow-up status (returner or non-returner) had no significant effect in the 
model that included the effects of age and NART score, F(1,77) = 0.646, p = 0.424, 
partial η² = 0.008. There was no significant interaction between participant sex and 
follow-up status, F(1,77) = 0.777, p = 0.381, partial η² = 0.010.
The estimated marginal mean score, adjusted for age and NART score, on the 
WDRT was 5.1 (SD 0.4) for the returner group and 6.0 (SD 1.0) for the non-returner 
group.  There was no significant difference between the performance of the returners 
and the non-returners in the spinal group on this test at baseline.
Nine Hole Peg Test – Right Hand
Brain Tumour Group
A total of 63 patients in the brain tumour group completed the right hand Nine Hole 
Peg Test (NHPT)  at baseline and also completed session 2 follow-up (‘returners’) 
and 52 patients completed the test at baseline only and did not complete session 2 
(‘non-returners’).
The mean score on the right hand NHPT for the returners in the brain tumour group 
was 13.8 (SD 2.9) and for the non-returners was 15.8 (SD 5.8). 
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Right hand NHPT score was the dependent variable in the general linear modelling 
analysis. There was a significant main effect of the covariate age in the model, 
F(1,109) = 13.095, p < 0.001, partial η² = 0.107. Older participants were more likely 
to perform less well on this measure. The effect of the covariate NART score was 
also significant in the model, F(1,109) = 9.743, p = 0.002, partial η² = 0.082. Those 
participants who scored less well on the NART were more likely to have poorer 
scores on the right hand NHPT. The effect of sex was not significant in the model, 
F(1,109) = 0.754, p = 0.387, partial η² = 0.007. Follow-up status (returner or non-
returner) had no significant main effect in the model that included the effects of age 
and NART score, F(1,109) = 3.003, p = 0.086, partial η² = 0.027. There was no 
significant interaction between sex and follow-up status, F(1,109) = 0.002, p = 0.964, 
partial η² < 0.001. 
The estimated marginal mean score, adjusted for age and NART score, for the 
returners in the brain tumour group on the right hand NHPT was 14.1 (SE 0.5) and 
for the non-returners was 15.5 (SE 0.6). The non-returners were slower to complete 
this test than the returners, however, the difference between the two groups was not 
significant.
Spinal Surgery Group
Sixty-six patients in the spinal group were classed as ‘returners’ who completed the 
right hand NHPT at baseline and also completed session 2 follow-up. There were 17 
‘non-returners’ in the spinal group who completed the test at baseline but did not 
complete follow-up.
The mean score for the returners was 13.0 (SD 2.9) and for the non-returners was 
12.9 (SD 1.8).
General linear modelling, with right hand NHPT score as the dependent variable, 
revealed a significant main effect of age on test scores, F(1,77) = 9.875, p = 0.002, 
partial η² = 0.114. Older patients were significantly more likely to take longer to 
complete the test at baseline. The effect of the covariate NART score was not 
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significant in the model, F(1,77) = 3.208, p = 0.077, partial η² = 0.040. There was no 
significant main effect of sex in the model, F(1,77) = 0.133, p = 0.716, partial η² = 
0.002. The effect of follow-up status (returner or non-returner) was not significant in 
the model that included the effects of age and NART score, F(1,77) = 0.628, p = 
0.430, partial η² = 0.008. The interaction between sex and follow-up status was not 
significant, F(1,77) = 0.285, p = 0.595, partial η² = 0.004. 
The estimated marginal mean score, adjusted for age and NART score, on the right 
hand nine hole peg test was 13.1 (SE 0.3) for the returners in the spinal control group 
and was 12.5 (SE 0.7) for the non-returners. There was no significant difference 
between the returners and the non-returners in terms of performance on this test at 
baseline.
Nine Hole Peg Test
Brain Tumour Group 
Sixty-three patients in the brain tumour group completed the left hand Nine Hole Peg 
Test (NHPT) at baseline and also completed session 2 follow-up (‘returners’) and 49 
patients completed the test at baseline but did not complete session 2 (‘non-
returners’).
The mean score for the returners on the left hand NHPT was 15.5 (SD 3.9) and for 
the non-returners was 15.3 (SD 3.0). 
General linear modelling, with left hand NHPT score as the dependent variable 
revealed a significant main effect of the covariate age in the model, F(1,106) = 
21.188, p < 0.001, partial η² = 0.167. Older participants were significantly more 
likely to take longer to complete the left hand NHPT. The effect of the covariate 
NART was not significant in the model, F(1,106) = 2.119, p = 0.148, partial η² = 
0.020. Sex had no significant main effect in the model, F(1,106) = 2.864, p = 0.093, 
partial η² = 0.026. The effect of follow-up status (returner or non-returner) was not 
significant in the model that included the effects of age and NART score, F(1,106) = 
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0.362, p = 0.549, partial η² = 0.003. There was also no significant interaction 
between sex and follow-up status, F(1,106) = 0.008, p = 0.929, partial η² < 0.001.
The estimated marginal mean score, adjusted for age and NART, for the returners in 
the brain tumour group was 15.6 (SE 0.4) and for the non-returners was 15.2 (SE 
0.5). There was no significant difference between the performance of the returners 
and the non-returners in the brain tumour group on the left hand NHPT at baseline. 
Spinal Surgery Group
Sixty-six members of the spinal control group were ‘returners’ who completed the 
left hand nine hole peg test at baseline and also completed session 2 testing. 
Seventeen members of the spinal control group were ‘non-returners’ who completed
the test at baseline but did not complete session 2 follow-up.
The mean score for the returners on the brain tumour group was 14.2 (SD 3.3) and 
for the non-returners was 14.8 (SD 4.8).
General linear modelling, with left hand NHPT score as the dependent variable, 
revealed a significant main effect of the covariate age on test scores, F(1,77) = 
15.259, p < 0.001, partial η² = 0.165. Older participants tended to have slower scores 
on the test. The covariate NART score also had a significant main effect in the 
model, F(1,77) = 8.524, p = 0.005, partial η² = 0.100. Participants with higher 
(poorer) NART scores were more likely to take longer to complete the left hand 
NHPT. The effect of sex was not significant in the model, F(1,77) = 0.081, p = 
0.776, partial η² = 0.001. Follow-up status (returner or non-returner) had no 
significant main effect in the model that included the effects of age and NART score, 
F(1,77) = 0.222, p = 0.638, partial η² = 0.003. There was no significant interaction 
between sex and follow-up status, F(1,77) = 0.057, p = 0.812, partial η² = 0.001.
The estimated marginal mean score, adjusted for age and NART, for the returners in 
the brain tumour group was 14.4 (SE 0.4) and for the non-returners was 13.9 (SE 
0.9). There was no significant difference between the performance of the returners 
and non-returners in the brain tumour group on the left hand nine hole peg test.
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Timed Ten Metre Walk (EFIT)
Brain Tumour Group
Fifty-six members of the brain tumour group were ‘returners’ who completed the 
time ten metre walk at baseline and also completed session 2. There were 46 ‘non-
returners’ who completed the test at baseline but did not take part in session 2.
The returners scored a mean of 6.7 (SD 1.4) and the non-returners scored a mean of 
7.3 (SE 2.1) on the timed ten metre walk at baseline. 
General linear modelling, with timed ten metre walk as the dependent variable, 
revealed a significant main effect of age on test scores, F(1,96) = 11.050, p = 0.001, 
partial η²  = 0.103. Older participants were significantly more likely to take longer to 
complete the time ten metre walk. The covariate NART score had no significant 
main effect in the model, F(1,96) = 2.000, p = 0.160, partial η²  = 0.020. There was 
no significant effect of sex in the model, F(1,96) = 1.335, p = 0.251, partial η² = 
0.014. The effect of follow-up status (returner or non-returner) was not significant in 
the model that included the effects of age and NART score, F(1,96) = 0.480, p = 
0.490, partial η²  = 0.005. The interaction between sex and follow-up status was not 
significant, F(1,96) = 0.188, p = 0.666, partial η² = 0.002.
The estimated marginal mean, adjusted for age and NART score, for the returners in 
the brain tumour group on the timed ten metre walk, was 6.9 (SE 0.2) and for the 
non-returners was 7.1 (SE 0.3). There was no significant difference between the 
performance of the returners and non-returners on the time ten metre walk at 
baseline.
Spinal Surgery Group
There were 63 spinal control patients who completed the timed ten metre walk at 
baseline and also completed session 2 follow-up (‘returners’). Fourteen spinal control 
patients were ‘non-returners’ who completed this test at baseline but did not take part 
in session 2.
421
The mean score for the returners in the spinal group on the timed ten metre walk was 
7.9 (SD 2.3) and for the non-returners the mean score was 8.4 (SD 2.4). 
General linear modelling, with timed ten metre walk score as the dependent variable, 
revealed a significant main effect of the covariate age, F(1,71) = 8.344, p = 0.005, 
partial η² = 0.105. Older patients were significantly more likely to take longer to 
complete the test than younger patients. There was no significant main effect of the 
covariate NART score, F(1,71) = 1.247, p = 0.268, partial η² = 0.017. The effect of 
sex was not significant in the model, F(1,71) = 0.528, p = 0.470, partial η² = 0.007. 
Follow-up status (returner or non-returner) had no significant main effect in the 
model that included the effects of age and NART score, F(1,71) = 0.030, p = 0.863, 
partial η² < 0.001. The interaction between sex and follow-up status was not 
significant, F(1,71) = 0.003, p = 0.955, partial η² < 0.001.
The estimated marginal mean score on the timed ten metre walk, adjusted for age and 
NART, was 7.9 (SE 0.3) for the returners in the spinal control group and was 8.0 (SE 
0.7) for the non-returners. There was no significant difference between the 
performance of the returners and the non-returners on the timed ten metre walk at 
baseline.
Hospital Anxiety and Depression Scale – Anxiety Score
Brain Tumour Group
There were 63 patients in the brain tumour group who completed the Hospital 
Anxiety and Depression Scale (HADS) at baseline and also completed session 2 
follow-up (‘returners’) and 52 patients who completed the questionnaire at baseline 
but did complete session 2 testing (‘non-returners’).
The mean anxiety score for the returners was 7.9 (SD 4.6) and for the non-returners 
was 8.1 (SD 4.2). 
General linear modelling, with anxiety scores as the dependent variable, revealed no 
significant main effect of either the covariate age, F(1,109) = 0.088, p = 0.768, 
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partial η² = 0.001; or NART score, F(1,109) = 0.079, p = 0.779, partial η² = 0.001. 
Sex had no significant main effect in the model, F(1,109) = 0.816, p = 0.368, partial 
η² = 0.007. The effect of follow-up status (returner or non-returner) was not 
significant in the model that included the effects of the covariates age and NART 
score, F(1,109) = 0.043, p = 0.837, partial η² = 0.007. The interaction between sex 
and follow-up status was not significant, F(1,109) = 1.518, P = 0.221, partial η² = 
0.014.
The estimated marginal mean score, adjusted for age and NART score, for the 
returners in the brain tumour group was 7.9 (SE 0.6) and for the non-returners was 
8.1 (SE 0.6). There was no significant difference in anxiety levels, as measured by 
the Hospital Anxiety and Depression Scale, between the returners and non-returners 
in the brain tumour group. 
Spinal Surgery Group
There were 65 patients in the spinal control group who completed the Hospital 
Anxiety and Depression Scale at baseline and also completed session 2 follow-up 
(‘returners’) and 17 patients who completed the questionnaire at baseline but did not 
complete follow-up testing (‘non-returners’).
The mean anxiety score for the returners in the spinal control group was 8.1 (SD 4.0) 
and for the non-returners was 7.2 (SD 3.1).
General linear modelling, with anxiety scores at the dependent variable, revealed no 
significant main effect of either of the covariates age, F(1,76) = 0.031, p = 0.860, 
partial η² < 0.001; or NART score, F(1,76) = 1.044, p = 0.310, partial η² = 0.014, in 
the model. There was no significant main effect of sex in the model, F(1,76) = 0.017, 
p = 0.897, partial η² < 0.001. The effect of follow-up status (returner or non-returner)
was not significant in the model that included the effects of age and NART score, 
F(1,76) = 0.582, p = 0.448, partial η² = 0.008. There was no significant interaction 
between sex and follow-up status, F(1,76) = 0.220, p = 0.640, partial η² = 0.003.
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The estimated marginal mean anxiety score, adjusted for age and NART score, was 
8.1 (SE 0.5) for the returners and for the non-returners was 7.2 (SE 1.0). The anxiety 
levels of the returners and non-returners in the spinal control group, as measured by 
the Hospital Anxiety and Depression Scale at baseline, did not differ significantly.
Hospital Anxiety and Depression Scale – Depression Score
Brain Tumour Group
The mean depression score for the 63 returners in the brain tumour group on the 
Hospital Anxiety and Depression Scale was 4.4 (SD 4.3) and for the non-returners 
was 5.0 (SD 3.9).
General linear modelling, with the depression score entered as the dependent 
variable, revealed no significant main effect of either of the covariates age, F(1, 109) 
= 0.008, p = 0.927, partial η² < 0.001; or NART score, F(1,109) = 0.813, p = 0.369, 
partial η² = 0.007. Sex had no significant main effect in the model, F(1,109) = 2.443, 
p = 0.121, partial η² = 0.022. Follow-up status (returner or non-returner) had no 
significant main effect in the model that included the effects of the covariates age 
and NART score, F(1,109) = 0.287, p = 0.593, partial η² = 0.003. There was no 
significant interaction between sex and follow-up status, F(1,109) = 0.804, p = 0.372, 
partial η² = 0.007.
The estimated marginal mean depression scores, adjusted for age and NART score, 
were 4.5 (SE 0.5) for the returners in the brain tumour group and 4.9 (SE 0.6) for the 
non-returners. The levels of depression, as measured by the Hospital Anxiety and 
Depression Scale at baseline, did not differ significantly between the returners and 
non-returners in the brain tumour group. 
Spinal Surgery Group
The 65 returners in the spinal group scored a mean of 5.3 (SD 3.7) on the depression 
scale of the questionnaire and the 17 non-returners scored a mean of 5.4 (SD 3.2).
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The general linear model, with depression score as the dependent variable, revealed 
no significant main effect of the covariate age on depression scores, F(1,76) = 0.444, 
p = 0.507, partial η² = 0.006. The covariate NART score had a significant main effect 
in the model, F(1,76) = 4.712, p = 0.033, partial η² = 0.058. Participants with lower 
NART scores were more likely to have lower depression scores. Sex had no 
significant main effect in the model, F(1,76) = 0.299, p = 0.586, partial η² = 0.004. 
The effect of follow-up status (returner or non-returner) had no significant effect in 
the model that included the effects of age and NART score, F(1,76) = 0.043, p = 
0.837, partial η² = 0.001. There was no significant interaction between sex and 
follow-up status, F(1,76) = 0.239, p = 0.626, partial η² = 0.003.
The estimated marginal mean depression score, adjusted for age and NART score, 
for the returners in the brain tumour group was 5.4 (SE 0.4) and for the non-returners 
was 5.1 (SE 1.0). There was no significant difference between the depression levels 
of the returners and non-returners in the spinal surgery group, as measured by the 
Hospital Anxiety and Depression Scale at baseline. 
Hospital Anxiety and Depression Scale – Total Score
Brain Tumour Group
The 63 returners in the brain tumour group scored a mean of 12.3 (SD 7.8) on the 
Hospital Anxiety and Depression Scale, and the 52 non-returners scored a mean of 
13.2 (SD 7.2). 
General linear modelling, with total score on the Hospital Anxiety and Depression 
Scale as the dependent variable, showed there to be no significant main effect of the 
covariate age, F(1,109) = 0.015, p = 0.902, partial η² < 0.001; or the covariate NART 
score, F(1,109) = 0.424, p = 0.516, partial η² = 0.004 in the model. Sex had no 
significant main effect in the model, F(1,109) = 1.881, p = 0.173, partial η² = 0.017. 
The effect of follow-up status (returner or non-returner) was not significant, F(1,109) 
= 0.168, p = 0.683, partial η² = 0.002 in the model that included the effects of the 
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covariates. There was no significant interaction between sex and follow-up status, 
F(1,109) = 1.449, p = 0.231, partial η² = 0.013.
The estimated marginal mean score, adjusted for age and NART score, for the 
returners in the brain tumour group on the Hospital Anxiety and Depression Scale, 
was 12.5 (SE 1.0) and for the non-returners was 13.0 (SE 1.1). There was no 
significant difference between the total scores of those who completed session 2 
follow-up and those who did not.
Spinal Surgery Group
The 65 returners in the spinal group had a mean total score of 13.3 (SD 6.9) on the 
Hospital Anxiety and Depression Scale and the 17 non-returners had a mean score of 
12.6 (SD 4.6). 
Total score on the Hospital Anxiety and Depression Scale was entered as the 
dependent variable in the general linear model. There was no significant main effect 
of the covariates age, F(1,76) = 0.066, p = 0.797, partial η² = 0.001; or NART score, 
F(1,76) = 3.238, p = 0.076, partial η² = 0.041 in the model. The effect of sex was not 
significant in the model, F(1,76) = 0.142, p = 0.707, partial η² = 0.002. Follow-up 
status (returner or non-returner) also had no significant main effect in the model that 
included the effects of the covariates, F(1,76) = 0.326, p = 0.570, partial η² = 0.004. 
There was no significant interaction between sex and follow-up status, F(1,76) = 
0.301, p = 0.585, partial η² = 0.004. 
The estimated marginal mean total score, adjusted for age and NART score, on the 
Hospital Anxiety and Depression Scale was 13.4 (SE 0.8) for the returners in the 
spinal control group and 12.3 (SE 1.7) for the non-returners. There was no significant 
difference between the returners and non-returners in the spinal group in terms of 
levels of distress measured by the Hospital Anxiety and Depression Scale. 
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Table U.1. Overview of comparisons between the performance of the returners and non-returners in the brain tumour group and spinal surgery group on 
each of the baseline tests. 
Test



















p value for 
difference
Inspection Time (All 
Data)
115.4 (2.2) 113.1 (2.4) 0.484 121.7 (1.5) 121.9 (3.4) 0.974
Inspection Time 
(Valid Data)
122.6 (1.6) 117.3 (1.8) 0.030* 124.2 (1.2) 121.6 (2.6) 0.368
Rey Auditory Verbal 
Learning Test 
60.9 (2.1) 63.3 (2.5) 0.480 71.5 (1.5) 70.1 (3.3) 0.152
Trail Making Test 
Part B
90.1 (3.7) 100.5 (4.2) 0.069 81.3 (2.5) 80.9 (5.5) 0.955
Verbal Fluency 30.2 (1.4) 27.1 (1.5) 0.135 35.2 (1.4) 32.9 (3.1) 0.503
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Digit Symbol Coding 59.6 (2.2) 52.0 (2.5) 0.047* 68.2 (1.6) 64.3 (3.4) 0.014*
Letter-Number 
Sequencing
9.2 (0.4) 9.7 (0.4) 0.726 11.1 (0.3) 11.5 (0.6) 0.596
Williams Delayed 
Recall Test (EFIT)
9.0 (0.6) 7.2 (0.7) 0.051 5.1 (0.4) 6.0 ( 1.0) 0.424
Nine Hole Peg Test –
Right Hand (EFIT)
14.1 (0.5) 15.5 (0.6) 0.086 13.1 (0.3) 12.5 (0.7) 0.430
Nine Hole Peg Test –
Left Hand (EFIT)
15.6 (0.4) 15.2 (0.5) 0.362 14.4 (0.4) 13.9 (0.9) 0.638
Timed Ten Metre 
Walk (EFIT)
6.9 (0.2) 7.1 (0.3) 0.490 7.9 (0.3) 8.0 (0.7) 0.863
Hospital Anxiety and 
Depression Scale –
Anxiety Score
7.9 (0.6) 8.1 (0.6) 0.837 8.1 (0.5) 7.2 (1.0) 0.448
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Hospital Anxiety and 
Depression Scale –
Depression Score
4.5 (0.5) 4.9 (0.6) 0.593 5.4 (0.4) 5.1 (1.0) 0.837
Hospital Anxiety and 
Depression Scale –
Total Score 
12.5 (1.0) 13.0 (1.1) 0.683 13.4 (0.8) 12.3 (1.7) 0.570
¹ Estimated marginal mean scores, adjusted for and National Adult Reading Test score and derived from general linear models. 
* Indicates significant difference between returners and non-returners. 
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U.4 Discussion
Comparisons of the baseline test scores of those patients in the brain tumour group 
who completed session 2 (‘returners’) with those who did not complete session 2 
(‘non-returners’) revealed no significant differences between the two groups in terms 
of the demographic variables sex, age, handedness and highest level of qualification 
achieved. The non-returners in the brain tumour group did however have 
significantly poorer scores on the National Adult Reading Test (NART) than the 
returners. The histological diagnoses of the two groups were not significantly 
different. The returners had significantly higher scores than the non-returners on 
inspection time, but this was only the case when valid inspection time data alone was 
included in the analysis. Specifically, it was the female non-returners who performed 
significantly worse than the female returners. When all inspection time data was 
included, there was no significant difference between the returners and non-returners 
in the brain tumour group. The returners had higher (worse) scores on the Williams 
Delayed Recall Test from the Edinburgh Functional Impairment Tests than the non-
returners, although the difference did not quite reach the conventional level of 
statistical significance (p = 0.051). The non-returners in the brain tumour group also 
had significantly poorer scores than the returners on the digit symbol coding 
measure. Comparisons of the returner and non-returners in the brain tumour group on 
the other baseline tests revealed no significant overall differences between the two 
groups. However, the female returners significantly outperformed the female non-
returners on the verbal fluency test, despite no overall difference between the 
returners and non-returners being found. 
The returners and non-returners in the spinal surgery control group were also 
compared. There was no significant difference between the two groups on any of the 
demographic variables, including age, sex, handedness, highest level of qualification 
achieved and NART score. In the spinal control group, there were no significant 
overall differences between the returners and non-returners on any of the baseline 
measures. However, the female returners outperformed the female non-returners on 
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the Rey Auditory Verbal Learning Test (RAVLT) and also on the inspection time 
task when only valid data was included. 
Comparing the performance of the returners and non-returners in each group is 
important as it gives an indication of whether differential attrition may have 
confounded the results and conclusions drawn regarding the effects of surgical 
intervention. If those patients who completed session 2 follow-up (returners) were 
more likely to be higher functioning patients who were less symptomatic, with better 
scores at baseline, they may have been less likely to have worsening of existing 
deficits following surgery. Therefore, the results detailed in the following chapters 
may under-estimate the prevalence of post-operative dysfunction as measured by the 
test battery. Since only 54.2% of the brain tumour group and 78.8% of the spinal 
control group completed session 2 testing post-operatively, it is therefore particularly 
important to consider potential differences between those who were followed up and 
those who were not. Certainly, in the brain tumour cohort, 31.6% of those who 
received no follow-up at all (at session 2 or session 3) were not assessed as they were 
unable to complete the testing sessions as a result of either cognitive impairment or 
physical impairment post-operatively. Therefore, those individuals in the brain 
tumour group who had the most severe post-operative complications were not taken 
into account in our analyses. That the returners in the brain tumour group performed 
significantly better at baseline on inspection time when only valid inspection time 
data was included suggests that the extent of deterioration on this measure at least 
may have been underestimated. Since only 4 members of the healthy control group 
failed to complete follow-up, comparisons of the returners and non-returners were 
not carried out as the very small number of non-returners in this group meant that no 
meaningful comparisons could be made.
In both the brain tumour and spinal control groups, there were no significant 
differences between the returners and non-returners in terms of sex or age. This 
finding contradicts other studies that have found predictors for drop out to be 
increased age and being male (Matthews et al., 2004). However, a study of older 
adults in a disability prevention trial found no significant differences between those 
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who did and did not return for follow-up in terms of age, sex or self-perceived health 
at baseline assessment (Minder et al., 2002). In general, the results of studies 
examining the effect of sex on attrition have been inconsistent. Our finding that the 
sex of the participant had no effect on whether or not the participant returned for 
follow-up is consistent with the findings of Mihelic and Crimmins (1997) who also 
found no significant effect of sex on returner status in a study detailing factors 
associated with loss to follow-up in a cohort of participants older than 70 years. The 
spinal returners and non-returners did not differ significantly in terms of their 
performance on the National Adult Reading Test (NART) which was administered as 
a measure of premorbid intelligence (see Chapter 3.5.2.2). The brain tumour 
returners, however, had significantly better NART scores than the non-returners, 
suggesting that the returners had better premorbid ability than the non-returners in 
this group. This likely reflects the tendency for better educated individuals and those 
with higher intelligence test scores to not only participate in but to be more likely to 
complete clinical trials. For example, van Beijsterveldt et al. (2002) report predictors 
of drop out to be older age and being less well educated. That the spinal surgery 
returners did not have significantly better NART scores than the non-returners in this 
group could be explained by the fact that 44% of the non-returning spinal surgery 
cohort were classified as ‘missed’ (see Figure 5.1), compared with only 13% of the 
non-returners in the brain tumour group. Thus, a significant proportion of the non-
returners in the spinal surgery group were not approached and as such they 
essentially did not choose to withdraw from further participation.  
The returners in the brain tumour group significantly out-performed the non-
returners on inspection time testing when valid data only was included and also on 
the digit symbol coding measure. There was a trend towards poorer performance in 
the non-returner brain tumour group on the Williams Delayed Recall Test from the 
EFITs. However, no significant differences between the two groups on any of the 
other measures were found. It is would therefore appear that those brain tumour 
patients who completed session 2 follow-up were broadly representative of the total 
cohort tested at baseline and this finding is inconsistent with the findings of many 
studies that detail selective attrition in longitudinal studies that include cognitive 
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assessment. In a review of such studies of elderly participants, Chatfield et al. (2005)
report that people with poorer functioning and greater cognitive impairment are 
consistently found to be more likely to drop out. Levin et al. (2000) also found that, 
in a sample of patients with Parkinson’s disease, patients who performed less well on 
a number of neuropsychological measures were the least likely to return for follow-
up. More specifically, in one of the few neuro-oncological, longitudinal studies of 
cognition that specifically detail attrition, Correa et al. (2007) have reported that, in a 
cohort of low-grade glioma patients, those patients who did not return for follow-up 
were significantly impaired on non-verbal recall measures at baseline by comparison 
with those patients who completed follow-up. These authors highlight the importance 
of recruiting large cohorts and employing sensitive measures of cognition in future 
studies in an attempt to overcome this problem. 
In the brain tumour group, histological diagnosis had no significant effect on whether 
the participant was a returner or non-returner at session 2. This is perhaps surprising 
given that previous studies have found patients with more malignant tumours tend to 
be more symptomatic than those with less aggressive disease, for example low-grade 
glioma patients who are often asymptomatic (Whittle, 2004). On this basis, it could 
be hypothesised that high-grade glioma patients would be less likely to complete 
follow-up due to more severe cognitive and/or physical impairment. However, 
Scheibel et al. (1996) report no significant effect of histology on neuropsychological 
test performance of brain tumour patients in the post-operative period. Patients were 
classified into a ‘glioblastoma’ and ‘non-glioblastoma’ group however, and this 
differs from the low and high-grade glioma groups in the present and other similar 
studies. If the low and high-grade glioma groups did not differ broadly in terms of 
likelihood of experiencing severe post-operative impairment, this could explain why 
that those patients with more aggressive tumours were no less likely to be returners 
than those patients with more benign lesions in the present study. Moreover, as 
detailed in chapter 4, high-grade glioma patients were under-represented in the total 
recruited brain tumour cohort. Thus, the high-grade group who did take part were 
likely to be a select group who had less severe cognitive impairments than did the 
total cohort of newly presenting high-grade glioma patients. 
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It is of interest that, in both the brain tumour and the spinal surgery groups, female 
non-returners had significantly lower inspection time scores than female returners 
when only valid data was included for comparison. This was also the case for the 
verbal fluency measure in the brain tumour group and the RAVLT in the spinal 
control group. In both cases, the female returners significantly outperformed the 
female non-returners, although there was no significant overall difference between 
the returners and non-returner groups as a whole. Although several studies have 
reported that male participants are more likely to be non-returners than female 
participants, no interaction between participant sex, follow-up status and baseline 
performance has been reported in the literature. 
Given the potential for attrition to negatively affect the representative nature of
results and subsequent conclusions drawn in the study, a number of steps were taken 
to minimise participant drop-out in the present study. Where possible, the 
neurosurgeon involved with the patient’s care encouraged him/her to complete post-
operative follow-up prior to discharge, the researcher was flexible and available out 
of hours wherever possible to carry out follow-up testing and the medical staff on the 
relevant wards were encouraged to contact the researcher when a patient was planned 
for discharge. However, the majority of the non-returners either declined follow-up 
or were too unwell post-operatively to participate further at the time of discharge (in 
such cases, the patient was often transferred to another hospital for further 
rehabilitation). Thus, despite the detailed recruitment plan, the majority of 
participants who were non-returners in the brain tumour group were not recruited for 
reasons outwith our control. However, those patients who declined and a small 
proportion of those who were too unwell at the time of discharge may have been 
willing to participate a few days later. Therefore, had the researcher been able to visit 
the patient in their own home to carry out the post-operative testing session this 
could have reduced attrition rates to some extent. It is therefore recommended that 
future studies should consider conducting more flexible follow-up testing sessions, 
preferably in a location convenient to the patient. This methodology could not be 
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employed in the present study however, since the inspection time task requires a 
specific computer monitor that is not easily portable.
Thus, although the returners and specifically the female returners in both the brain 
tumour and spinal surgery groups outperformed the non-returners on a small 
proportion of the baseline tests, there were few significant differences between the 
two groups in terms of demographic variables and baseline test performance. It is 
therefore reasonable to assume that the observed attrition in both surgical groups is 
unlikely to have affected the results to a great extent. In fact, the post-operative 
deterioration in the brain tumour group specifically may actually be under-estimated, 
given that several patients who did not complete session 2 follow-up did not do so as 
a result of post-operative complications that resulted in physical and/or cognitive 
dysfunction.
